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ABSTRACT
Dietary-derived lipoproteins, chylomicrons (CM) and CM remnants (CMR), have been 
implicated in the progression of cardiovascular disease. Retinyl esters are currently the 
most widely used method for monitoring CM metabolism. The availability, however, of 
a specific antisera to apo B-48, the protein uniquely associated with dietary-derived 
lipoproteins, has allowed more extensive investigation of CM and CMR metabolism.
The effect of habitual, moderate levels of exercise (3 to 4 exercise sessions a week) on the 
lipaemic response to meals of varying fat content was assessed in young male subjects. 
Apo B-48, triacylglycerol (TAG) and retinyl ester were used as markers for CM particles. 
Active subjects had a lower response than an inactive group in all parameters measured 
over time after the meals. Lipoprotein lipase (LPL) activity levels measured at the end of 
the postprandial period were higher in the active group. The area under the time-response 
curwes (AUC) for apo B-48 in the inactive group increased with increasing fat content of 
the meals, whereas the AUC for apo B-48 was the same after each meal in the active 
group.
Validation of a specific ELISA for apo B-48 was carried out. Cross-reactivity of the 
antisera with low levels of apo B-lOO, the protein present on endogenous lipoproteins, 
was ruled out. The assay was specific and sensitive for measuring apo B-48 
concentrations in the CM-enriched fractions. The use of the assay in the current format 
for plasma samples could not be fully assessed due to difficulties with isolating a pure, 
concentrated sample of apo B-lOO and problems with reactivity between the secondary 
antibody used in the assay and plasma proteins. The assay was useful for showing 
postprandial patterns of changes in apo B-48 levels in plasma.
The effects of meal frequency on the lipaemic response to a high fat test meal challenge 
were assessed in an intervention study. A nibbling diet was found to cause differences 
between the response of various parameters after the meal (NEFA-AUC, LPL activity, 
infranatant-TAG AUC and time to peak) compared with the normal meal frequency.
The size and density distribution of CMR in plasma were investigated. Apo B-48 was 
found in the IDL and LDL fractions in both the postabsorptive and postprandial states. A 
comparison between the retinyl ester and apo B-48 responses in the postprandial studies 
showed that the time to peak retinyl ester level was delayed compared to apo B-48 and 
TAG. The importance of apo B-48 for studying the metabolism of CM and CMR 
metabolism was demonstrated.
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CHAPTER ONE GENERAL INTRODUCTION
1.1 LIPOPROTEIN CLASSIFICATION
Lipid molecules need to be transported between tissues to supply the needs of individual 
cells, however triacylglycerol (TAG), cholesterol and cholesterol ester (CE) are virtually 
insoluble in water. Their transport through the aqueous medium of the blood requires 
stabilisation with a coat of amphiphilic molecules. Lipids are thus incorporated into 
soluble, macromolecular particles called lipoproteins. These particles have a 
hydrophobic lipid core containing TAG and CE and a polar surface monolayer consisting 
of phospholipid (PL), specialised proteins (apolipoproteins) and cholesterol, all of which 
have their polar regions facing outwards and apolar regions directed inwards interacting 
with the lipid core (Lewis, 1990).
Several different types of lipoproteins can be isolated and these have been classified in 
various ways according to their differences in origin, function, composition or physical 
properties. A historical overview of the discovery and classification of lipoproteins is 
presented in a review by Alaupovic (1972). A brief account of this history is described 
here. All references used in this section aie cited in Alaupovic (1972).
At the beginning of this century, Nerking (1901) postulated that plasma lipids are 
chemically bound to proteins. In 1929 Machebouef isolated a lipoprotein of constant 
composition (59.1% protein, 22.7% PL and 17.9% CE) from horse plasma, thus 
confirming tliis suspicion. The protein moiety of the lipoprotein was found to differ from 
any known globulin. Several lines of evidence over the next few yeais indicated that the 
plasma lipids were combined with specific proteins to form two major groups of 
lipoproteins. The difference was seen in the characteristic mobilities of the lipoproteins 
in an electric field. They migrated with either a i-  or p- globulin fractions (Blix et al., 
1941).
The first practical procedure for the isolation of lipoproteins involved the fractionation of 
human plasma in ethanol-water mixtures. This resulted in two lipoprotein classes 
differing in physical and chemical properties as well as in their characteristics in an 
electric field. In view of these latter properties they were designated a i -  and 
P-lipoproteins. Later, with the advent of zonal electrophoresis, two more classes of 
lipoproteins were described; one with the band remaining at the origin and the other with 
a band migrating to the pre-P position.
The association of proteins with lipids gives them a low hydrated density, a unique 
physical property of lipoproteins which has been used for their isolation and 
characterisation. In 1945, Pederson isolated a lipid-protein complex with p-globulin
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mobility by flotation ultracentrifugation. Gofman (1949) established that plasma 
lipoproteins had a wide range of particle sizes and hydrated densities by using fractional 
ultracentrifugation of lipoproteins in salt solutions of increasing densities. From these 
results lipoproteins were classified according to their density ranges. This gave four 
major classes of circulating lipoproteins which are, in order of increasing density (d), 
chylomicrons (CM) (d <0.94 g/ml), very low density lipoproteins (VLDL) (d <1.006 
g/ml), low density lipoproteins (LDL) (d <1.063 g/ml) and high density lipoproteins 
(HDL) (d <1.22 g/ml). These lipoprotein classes corresponded to bands forming after 
electrophoresis at the origin, pre-p-, p- and a l -  positions respectively. This is still the 
most common nomenclature used for the classification of lipoproteins (Gurr and 
Harwood, 1991). CM remnants (CMR) and VLDL remnants, known as intermediate 
density lipoproteins (IDL) (d <1.019 g/ml), are also included in the classification.
More recently, with the aid of density gradient ultracentrifugation, a further nomenclature 
has been adopted which describes the lipoprotein classes with respect to their flotation 
coefficients. The flotation coefficient is defined by a Svedberg flotation (Sf) rate. Each 
lipoprotein class covers a range of Sf values with the largest, TAG-rich lipoproteins 
having the largest Sf rate as follows: Sf >400 (CM), Sf 60-400 (large VLDL or VLDLi), 
Sf 20-60 (small VLDL or VLDLz), Sf 12-20 (IDL), Sf 0-12 (LDL). As with the 
sequential flotation density ranges, the use of Sf ranges is an operational definition for 
separating the endogenous and exogenous lipoproteins, however there is much evidence 
that endogenous large VLDL and exogenous CM and CMR may have substantially 
overlapping distributions in tenus of their Sf rates and density (Lindgren et al, 1972).
In the early 1950's the significance of circulating lipids in the development of 
atherosclerotic lesions was realised. This focused much research on the lipid content of 
each lipoprotein class. Towards the end of that decade there was considerable interest in 
the protein moiety of the lipoprotein, with the recognition that these apolipoproteins are 
very important in the structure and stability of the lipoprotein, as well as having important 
functions in their metabolism. Initially, only two apolipoproteins had been defined, 
apolipoprotein (apo) A the major protein of HDL and apo B the major protein of LDL. 
Subsequently apo C was discovered on VLDL of hypertriglyceridaemic patients. Furtlier 
work showed that each apolipoprotein was not confined to a single lipoprotein type. This 
led Alaupovic and colleagues (1971) to propose a classification system for lipoproteins 
based on their distinct chemical components, the apolipoproteins. This resulted in three 
classes; LP-A (predominantly HDL), LP-B (predominantly LDL) and LP-C 
(predominantly VLDL). The structure, function and genetic code for several 
apolipoproteins has now been discovered and, because of their importance in lipoprotein 
metabolism, the major apolipoproteins are described here.
1.2 STRUCTURE AND FUNCTION OF THE MAJOR APOLIPOPROTEINS
Apolipoproteins aie identified by letters, with various subclasses within each type being 
denoted by numbers. The genes for the ten major apolipoproteins were isolated and 
sequenced during the 1980s. The main apolipoproteins, their sites of formation and 
functions aie shown in Table 1.1.
APOLIPOPROTEIN MOLECULAR 
WEIGHT (kDa)
FUNCTION SITE OF 
SYNTHESIS
A-I 28 Activates LCAT liver/intestine
A-II 17 Activates hepatic lipase liver/intestine
A-IV 44.5 Activates LCAT intestine
B-48 264 CM assembly intestine
B-lOO 550 IDL/LDL uptake liver
C-I 6 .6 Activates LCAT? liver
c-n 8.9 Activates LPL liver
C-III 8.8 Inhibits CMR receptor 
binding
liver
D 2 2 Cholesterol tr ansport 7
E 34 Ligand for receptor- 
mediated uptake
liver
Abbreviations: LCAT, lecithin cholesterol acyl transferase; LPL, hpoprotein hpase; 
IDL, intermediate density lipoprotein.
1.3 LIPOPROTEIN METABOLISM
Lipoproteins vary greatly in composition and thus in function. The triglyceride-rich 
lipoproteins (TGRL), including CM and VLDL, transport TAG from the intestine and 
liver respectively to sites for their storage or use. The cholesterol-rich lipoproteins fall 
into two categories: LDL transport cholesterol to the tissues for use in membranes and 
metabolite synthesis. HDL transport cholesterol from peripheral tissues to the liver for 
catabolism in a process known as reverse cholesterol transport. The lipid transport 
system can be divided into an exogenous (CM and CMR) and an endogenous (VLDL, 
IDL, LDL and HDL) cycle. The properties of the lipoproteins are shown in Table 1.2. 
Although the metabolism of individual lipoproteins can be described separately (Section
1.3.1 to 1.3.4), their metabolic pathways are linked so that most of the processes involve 
inter-change of components between different types of lipoprotein (Figure 1.1).
Table 1.2. Properties of the lipoproteins (modified from Lewis, 1990)
CM VLDL IDL LDL HDL
DENSITY RANGE 
(g/ml)
<0.95 0.95-1.006 1.006-1.019 1.019-1.063 1.063-1.210
DIAMETER (nm) >70 30-90 25-35 18-22 5-15
SITE OF 
SYNTHESIS
Gut liver Peripheral
tissue
capillaries
Peripheral
tissue
capillaries
Gut/liver
MAJOR
FUNCTION
Transport 
dietary fat
Transport 
endogenous fat
Metabolic
intermediate
Transport 
cholesterol to 
periphery
Reverse 
transport of 
cholesterol
APOLIPOPROTEIN
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1.3.1 CHYLOMICRON METABOLISM
1.3.1.1 CHYLOMICRON SYNTHESIS AND SECRETION
The main function of CM is to transport TAG of exogenous origin around the body. CM 
are formed in the enterocyte of the small intestine during the digestion and absorption of a 
fat-containing meal. It is assumed that a low level of CM are also secreted in the fasting 
state when they probably contain fatty acids of biliai y PLs or lipids of cells shed from the 
intestinal mucosa (Gotto et al, 1986). After a meal, free fatty acids (FFA) and 2- 
monoacylglycerol (2-MAG) ai*e produced in the lumen of the intestine by the action of 
pancreatic lipase on dietary lipids. Medium and short-chain fatty acids are absorbed into 
the enterocyte and pass directly into the hepatic portal vein. Long chain fatty acids are 
absorbed into the enterocyte and used for re-esterification of 2-MAG in the formation of 
TAG, CE and PL. The absorption of FFA is facilitated by maintenance of an inward 
diffusion gradient. A fatty-acid binding protein (FABP) in the brush-border membrane 
enables the fatty acids to enter the cell and they are then re-esterified in the smooth 
endoplasmic reticulum (SER) by enzymes of the monoacylglycerol pathway to form 
TAG. FABP is believed to bind preferentially to long-chain unsaturated fatty acids, 
rather than to saturated fatty acids (SFA) (Gurr and Harwood, 1991). 
Monoacylphosphatidylcholine is the main precursor of PL absorbed into the enterocyte. 
It is re-esterified with FFA to fonn phosphatidylcholine by the enzyme acyl transferase. 
The main function of the PL is to stabilise the CM. Cholesterol is absorbed more slowly 
than TAG (Gurr and Harwood, 1991) and is re-esterified by the enzyme acyl CoA; 
cholesterol acyltransferase (ACAT). Both CE and free cholesterol are present on the CM. 
Apo B-48 and apo A-I, A-II and A-IV are synthesised in ribosomes associated with the 
enterocyte rough endoplasmic reticulum (RER). The proteins are joined with the TAG 
and PL at the junction of the SER and RER to form a nascent CM which is transported to 
the Golgi apparatus (Gotto et a l, 1986) where the apo B-48 is glycosylated (Dumngton, 
1991).
Only one apo B-48 molecule is believed to be present on each CM (Young, 1990). Apo- 
B48 is unique to CM and CMR and remains associated with the CM paiticle throughout 
its residence time in the blood. Apo B-48 is thought to be essential for CM assembly and 
secretion (Gotto et a l, 1986). Evidence for this was provided from studies on patients 
with the genetic disorder abetalipoproteinaemia who do not produce apo B. These 
individuals have no apo B-containing lipoproteins and have an accumulation of lipid in 
the enterocytes. The abetalipoproteinaemic patients do, however, have circulating HDL 
which contain all the other apolipoproteins normally found in lipoproteins (Malloy and 
Kane, 1982, cited in Lewis, 1990).
Most data suggests that the supply of apo B-48 is not the rate-limiting step for the 
formation of CM. Hayashi et a l  (1990) showed that the absorption of a physiological 
load of lipid did not affect the level of synthesis or secretion of apo B in the enterocyte of 
rats, and therefore postulated that the number of CM paiticles released from the intestine 
remains constant whilst the size increases. Other investigators have suggested that the 
main response to increasing dietary fat content is to increase the size of the CM but, to a 
lesser extent, there is also an increase in the number of CM particles released after a high 
fat meal (Gotto et a l, 1986). It was suggested that the increase in particle number was 
accomplished by additional cells being recmited into the absorptive process.
Golgi vesicles containing CM migrate to the lateral membrane of the enterocyte. The CM 
particles are released into the intercellular' space via exocytosis, from where the CM are 
secreted into the lymph. CM enter the bloodstream via the thoracic duct where apo C-I, 
C-n, C-III and apo E are immediately transferred to the CM from HDL in exchange for 
some of the apo A components of the CM (Patsch, 1987).
1.3.1.2 CHYLOMICRON METABOLISM
The enzyme lipoprotein lipase (LPL) is associated with the endothelial lining of 
capillaries in peripheral tissues which have a high requirement for TAG i.e. adipose 
tissue, muscle and lactating breast. The enzyme is produced in parenchymal cells and 
secreted onto the endothelium where it is bound by heparan sulphate proteoglycans 
(Lewis, 1990). LPL hydrolyses 1-and 3- ester bonds of TAG in the CM core to produce 
FFA and 2-MAG. The FFA are taken up by the cells, the 2-MAG are further hydrolysed 
to produce FFA and glycerol which are then taken up into the tissues. It is thought that 
apolipoproteins have heparin-binding sites which bind the CM to the capillary surface 
near the LPL. Apo C-II on the CM surface is known to be a cofactor for LPL. Apo C-II 
binds to the LPL and thus activates the enzyme by increasing the LPL-CM interaction 
(Nestel, 1987). The level of apo C-II in plasma is normally in excess of levels needed to 
activate LPL (Kane and Malloy, 1991).
LPL is also regulated by dietary and hormonal factors, most notably insulin which has 
tissue-specific effects. An increase in insulin occurring after a meal activates the LPL in 
adipose tissue but suppresses the LPL in muscle, so that FFA from the meal can be taken 
up and stored in adipose tissue. Conversely, in the fasting state, LPL in muscle becomes 
active so that FFA from VLDL can be taken up and used as a source of energy by muscle 
cells (Eckel, 1989). At the same time, in the fasting state, LPL in the adipose tissue 
becomes inactive to prevent uptake and storage of VLDL-FFA.
During the catabolism of the CM, surface components released during the action of LPL, 
apo A, apo C-II, apo C-in and PLs, are transfened to HDL. Also in the circulation some 
TAG is transferred to HDL in exchange for CE. This process is catalysed by the 
cholesterol ester transfer protein (CETP). After 70-90% of the TAG is removed a CMR 
is foraied. The resulting CMR can no longer compete for LPL due to the loss of apo C H. 
The remodelling is believed to stabilise the CMR or enhance the hepatic uptake.
1.3.1.3 CHYLOMICRON REMNANT UPTAKE
Once in the liver the CMR may undergo further hydrolysis by hepatic lipase (HL) (Shafi 
et al., 1994). Uptake of the CMR involves three parts; sequestration into the space of 
Disse, binding of the CMR to the receptor and internalisation of the particle. The CMR is 
taken up by the liver cells due to the interaction of apo E with a specific remnant receptor 
on the hepatic cells. The receptor binds to CMR, IDL and apo-E enriched HDL. The 
presence of apo C-III inhibits the binding of the CM to the remnant receptor, thus 
preventing premature uptake of the CM before all its TAG has been hydrolysed, or from 
very small CM released into the circulation by the enterocyte. The loss of apo C-III 
during CM hydrolysis allows the resultant CMR to bind to the remnant receptor in the 
liver. Some investigators suggest that the apo C-III obscures the apo E receptor binding 
domain whilst on the CM and therefore its release allows the CMR to bind to the E 
receptor (Durrington, 1989). Other studies suggest that it is the hydrolysis of the TAG 
which exposes the binding site of the apo E (Brasaemle et al, 1993).
It has been established that CMR are rapidly cleared by the liver and that apo E is 
essential for this process. Currently there is some controversy over the nature of the 
CMR receptor, an overview of the current opinions and evidence for an independent 
CMR receptor is presented in a review by van Berkel et al. (1994). Evidence began to 
grow in the 1980s for uptake of CMR by a receptor independent of the LDL receptor. In 
vitro evidence suggested that the CMR receptor is distinct from the LDL apo B/E 
receptor in dogs, humans and pigs (Mahley et a l, 1981). In vivo studies using 
homozygous Watanabe hereditary hyperlipidaemic (WHHL) rabbits (Kita et a l, 1982b) 
and studies of patients with homozygous familial hypercholesterolemia (Brown and 
Goldstein, 1976; Rubinsztein et a l, 1990) showed that clearance of CMR was normal 
despite the complete lack of LDL receptors in both cases. Demacker et al. (1992) later 
confirmed that apo B-48 removal is normal in WHHL rabbits. Choi et al. (1991) have 
presented evidence against the complete uptake of CMR by an independent CMR 
receptor. They found that anti-LDL receptor antibodies reduced the uptake of iodinated 
CMR by the liver by 50 %. These results agree with the suggestion that CMR can be
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taken up by both the LDL receptor and an LDL-independent receptor (Brown et a l, 
1981).
A candidate protein for the CMR receptor was identified by Herz et al. (1988). This 
group found a protein in the liver, similar to the LDL receptor, which binds to CMR. The 
protein was named the LDL receptor-related protein (LRP). The LRP has since been 
described as a multi-functional receptor as it binds to various ligands including 
lactoferrin, a2-macroglobulin, apo E and LPL. Lactoferrin was found to completely 
inhibit CMR uptake but not to block the LDL receptor. Using cross-linking studies, 
Beisegel et al. (1989) verified that the LRP was the protein responsible for CMR uptake 
and showed that the presence of LPL enhanced the binding (Beisegel et al., 1991). 
Skottova et al. (1995) demonstrated that LPL acts as a ligand for CMR binding to 
receptors. Heparan sulphate proteoglycans have been shown to be important for CMR 
clearance (Zhong-Sheng et al., 1995). The function of these proteoglycans may be to 
mediate the effect of LPL in the uptake process by increasing the CMR binding in the 
receptor region.
Despite this body of evidence for an independent CMR receptor, other groups suggest 
that the remnant receptor and the LDL receptor are the same protein (Durrington, 1989). 
They contend that the difference in uptake is achieved by different affinities of the LDL 
receptor for apo E and apo B. If the affinity of the receptor were much greater for apo E 
than fro apo B, this could explain much of the above evidence.
Uptake of dietary cholesterol from CMR by the liver reduces both the hepatic synthesis of 
cholesterol and LDL receptor activity. The CMR receptor is resistant to feed-back 
inhibition and therefore continues to take up dietaiy cholesterol when required even if the 
hepatocyte is full (Nestel, 1987). The CMR can also interact with receptors on 
macrophages, overloading the cells with cholesterol and TAG (Nestel et al., 1985). This 
uptake is not down-regulated by cholesterol (van Lenton etal., 1985).
1.3.2 VLDL METABOLISM
VLDL transport TAG of endogenous origin to ensure a supply of TAG to the tissues in 
the fasting as well as the postprandial state. VLDL are synthesised primarily in the liver 
in a manner similar to that of CM in the intestine. The main differences between the two 
pathways is that, in the human liver, the cholesterol for transport is not usually esteiified 
before secretion (Durrington, 1989), so VLDL contain free cholesterol which is 
transferred to HDL for estérification in the circulation. This process will be described
later (Section 1.3.4). In contrast to nascent CM, VLDL contain most of their complement 
of apo C before release into the circulation. Also, all VLDL secreted by the liver contain 
the form of apo B known as apo B-lOO (Edge 1985). This protein is approximately twice 
the size of the apo B-48 in CM. Further details of the apo B structure and metabolism can 
be found in Section 1.6. VLDL particles contain only one apo B-lOO molecule (Elovson 
et al., 1988) but have vaiying amounts of apo C and E (Lewis, 1990).
The components of endogenous TAG are derived from various sources: during the 
postprandial period, long-chain FFA from the most recent meal are delivered to the liver 
bound to albumin after lipolysis of TAG in CM particles by LPL; short-chain FFA are 
delivered directly to the liver bound to albumin after entry into the hepatic portal vein. 
FFA are also obtained after uptake of the CMR and hydrolysis of TAG. In the fasting 
state, FFA are mobilised from the adipose tissue and transported to the liver for re- 
esterification (Gotto et al, 1986). Nascent VLDL are secreted directly into the 
bloodstream via the sieve-plate fenestrae of the sinusoidal epithelium. Unlike CM, 
VLDL receive all their constituent apolipoproteins in the hepatocyte, but additional apo E 
and C are added in the bloodstream by transfer from HDL (Lewis, 1990). The VLDL 
population exhibits a high degree of heterogeneity in relation to size and composition 
(Gotto et al, 1986) and this fact may alter the resultant metabolic fate of a VLDL par ticle 
(Nestel, 1987).
Initial metabolism of VLDL is similar to that of CM as the TAG core is subjected to 
hydrolysis by LPL in peripheral tissues. After 90% of the VLDL-TAG is hydrolysed and 
apo A and C, PLs and some cholesterol have been transferred to HDL, only apo B-lOO, 
apo E and some CE obtained from HDL remain. This remnant particle is known as an 
IDL and has one of two possible fates: it can either be taken up directly by the liver or it 
can be further metabolised to produce a LDL. Kinetic studies of this lipoprotein cascade 
have suggested that the metabolic fate of the VLDL remnant may be determined by its 
size (Packard et al., 1984). It appears that large VLDL give rise to larger IDL which are 
directly removed by receptors in the liver, whereas small VLDL produce smaller IDL 
which are more likely to be further metabolised to LDL before uptake (Stalenhoef et al, 
1984).
IDL and LDL are taken up by LDL receptors in the liver which were first discovered by 
Goldstein and Brown (1973). Evidence for LDL receptor-mediated uptake of IDL comes 
from studies of WHHL rabbits which have no LDL receptors and an accumulation of IDL 
(Kita et a l, 1982a). The LDL receptor is also known as the B-100/E receptor due to its 
recognition of receptor-binding sites on apo E and apo B-lOO (Nestel, 1987). The LDL 
receptor is an 839 amino-acid transmembrane protein. The lipoprotein binding site is
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situated at the amino-end and is composed of 7 repeat sequences of 40 amino acids each. 
Each of the 7 sequences contains 6  cysteine residues which allows extensive cross-linking 
to occur within this region There is also a cluster of acidic amino-acids in each of the 7 
sequences and the region is thus negatively charged. Both apo E and apo B-lOO have a 
single binding site for the LDL receptor. The binding sites on the two proteins are 
homologous. These binding site regions are rich in positively-charged arginine and lysine 
residues and thus interact with the negatively-charged binding site on the receptor (Brown 
and Goldstein, 1986).
The binding affinity of the LDL receptor has been shown to be greater for apo E- 
containing lipoproteins, such as IDL, than for LDL (Brown et al, 1981) as apo E, not apo 
B-lOO, is the major determinant mediating the receptor binding activity of VLDL and 
IDL (Hui et a l, 1984). It has been proposed that, if the lipoprotein contains several apo E 
(as is the case with IDL), there is an opportunity to interact with multiple binding sites on 
several receptors thus forming a strong interaction between the receptors and the 
lipoprotein (Innerarity et a l, 1980). If, however, apo B-lOO is the only protein on the 
lipoprotein (as in an LDL particle) it can only bind to a single binding site and therefore 
produces a weaker interaction between the lipoprotein and the receptor. Large IDL 
presumably have more apo E than smaller particles and therefore may produce more 
effective interactions with the receptor (Gotto et al, 1986; Lewis, 1990) leading to uptake 
rather than catabolism to LDL.
Despite their apo B-lOO and apo E content, VLDL directly released from the liver are not 
taken up by LDL receptors. It has been suggested that, as with CM, the presence of apo 
C-III prevents the premature uptake of these large particles. An alternative theory 
proposed by a Japanese group suggests that stiiictural changes in apo E on the lipoprotein 
are required before the protein can be recognised by the receptor (Ito et a l, 1994).
1.3.3 LDL METABOLISMl
The final catabolism of IDL to fonn LDL occurs in the hepatic circulation (Lewis, 1990). 
The enzyme HL hydrolyses most of the remaining TAG during formation of LDL. HL 
appears to preferentially hydrolyse TAG of small, TAG-poor lipoproteins and PLs of 
HDL2 (Section 1.3.4). PL and apo E are transferred to HDL leaving only apo B-lOO, CE 
and some cholesterol. The LDL is then taken up by LDL receptors in both the liver and 
extra-hepatic tissues by interaction of the apo B-lOO with the receptor (Gotto et a l,
1986). After internalisation the CE is hydrolysed and the protein degraded in lysosomes. 
Thus LDL particles transfer cholesterol to the extra-hepatic tissues for use in membrane
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biosynthesis and repair. In specialised tissues cholesterol is used for steroid hormone 
formation. In extra-hepatic tissues cholesterol elicits three regulatory responses (Salter 
and Brindley, 1988): a) inhibition of de novo cholesterol synthesis by suppression of 
HMG-CoA reductase; b) activation of cholesterol ester transferase to produce CE for 
storage and c) down-regulation of the LDL receptor. In the liver cholesterol can be re­
secreted in VLDL and HDL or secreted in the bile.
IDL are primarily taken up by B/E receptors on the liver, whereas a proportion of the 
LDL are taken up by extra-hepatic tissues. This may be due to the different 
apolipoprotein content of the two species. LDL contain only apo B-lOO which is believed 
to bind less effectively to the receptor than apo E as described previously. Unsuccessful 
competition for the hepatic receptors therefore enables the LDL to enter the extra-hepatic 
tissues where it is taken up by peripheral apo B/E receptors.
In hyperlipidaemia it is possible that LDL is secreted directly by the liver. This may 
occur in disorders chaiacterised by over-production of apo B (Nestel, 1990). A high 
carbohydrate diet stimulates the synthesis of TAG and apo B and their release in VLDL. 
A high cholesterol diet stimulates apo B production and its release in small, TAG-poor, 
cholesterol-enriched IDL and LDL.
There are two other mechanisms by which LDL can be taken-up into cells. Chemically- 
modified LDL can be taken up by macrophages by a high-affinity 'scavenger receptor' 
mechanism (Kelley et al., 1991). This scavenger receptor is not subject to feedback 
control and therefore uncontrolled cholesterol accumulation in macrophages occurs 
(Babiak and Rudel, 1987). LDL can also be taken up by many cells by a low-affinity, 
receptor-independent process (Spady et al., 1985)
1.3.4 HDL METABOLISM
HDL remove unesterified cholesterol from the peripheral tissues and carry it in its 
esterified form to the liver, the main organ of cholesterol utilisation, where it is either 
degraded or used for synthesis of bile acids. Extra-hepatic tissues obtain cholesterol from 
LDL and therefore need to maintain a constant cholesterol content by the efflux of excess 
unesterified cholesterol (Reichl, 1994). It is thought that HDL particles bind to cells and 
stimulate the mobilisation and efflux of cholesterol through the plasma membrane to be 
accepted by the HDL (Schmitz and Lackner, 1993).
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Unlike the other lipoprotein classes, which have a range of overlapping particle sizes, 
there are several discrete forms of HDL; the major ones being HDL2 and HDL3. The 
core diameter of HDL2 is 50% larger than in HDL3, so that HDL2 contains almost four 
times as much CE and TAG as HDL3 (Eisenberg, 1984). Formation of HDL is not 
unidirectional; nascent HDL particles are secreted by the intestine or the liver and consist 
of a bilayer of PL mixed with apo A-I and A-II which forms a discoid-shape. Once in the 
bloodstream HDL acquire more surface components from CM and VLDL during their 
hydrolysis by LPL, and cholesterol from peripheral tissues, and so become spherical, 
mature hpoproteins (Miller, 1990)
The metabolism of HDL is closely interrelated with that of the TGRL (Figure 1.2). HDL 
can be seen as acting as a reservoir for lipids and apolipoproteins and thus interact with 
most of the enzymes and transfer proteins involved in lipoprotein metabolism (Nestel,
1987). Apolipoproteins, PLs and free cholesterol transfer from TGRL surfaces and 
membrane surfaces to the small HDL3 during lipolysis. Once in the HDL3 the cholesterol 
is converted to CE by the action of lecithin xholesterol acyl transferase (LCAT) which is 
associated with the HDL particle. This enzyme is secreted by the liver with apo A-I and 
apo D. LCAT catalyses the transfer of a fatty acid from phosphatidylcholine to 
cholesterol to form a CE (Gotto et al, 1986). Apo A-I is a co-factor for this process. The 
CE is sequestered in the core of the HDL thus generating a gradient to take up more 
cholesterol. This formation of CE causes the HDL3 to increase in size and be converted 
into an HDL2 particle. The CE of HDL2 can be transferred to TGRL in exchange for 
TAG by the action of cholesterol ester transfer protein (CETP). The CE which originated 
from cell membranes or endogenous lipoproteins can thus be taken up by the liver in the 
TGRL remnants (CMR and IDL) by the E or B/E receptor.
Unlike the other lipoproteins HDL appears to have several modes of interaction with cells 
(Eisenberg, 1984). It has been proposed that the HDL paiticle itself can be taken up by 
cells (Miller, 1990), although this is probably not a quantitatively important mechanism 
for the delivery of cholesterol. Most tissues, including the liver, appear to possess 
binding sites different from the CMR or LDL receptors which bind to HDL, although 
HDL also bind to apo E receptors. After binding to these receptors either the entire HDL 
particle can be internalised and degraded or the CE can be transferred to the cell leaving 
the HDL particle intact (Miller, 1990).
The uptake of the CE in both TGRL and HDL, for its use or catabolism, completes the 
process known as reverse cholesterol transport (Eisenberg, 1984). The TAG-rich HDL 
produced by the action of CETP is a good substrate for HL. The TAG is thus hydrolysed 
and the smaller, denser HDL3 particle is reformed (Shepherd, 1992). Recent studies have
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Figure 1.2 Simplified scheme showing the relationship between 
Chylomicrons and High Density Lipoproteins
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identified that the apo A content is important in the metabolic function of the HDL 
(Fruchart and Ailhaud, 1991). Particles containing only apo A-I may be the main 
acceptors of cellular cholesterol and HDL2 containing both apo A-I and A-II are better 
substrates for HL than HDL2 containing only apo A-I (Mowri et al., 1994)
1.4 RELATIONSHIP OF CHYLOMICRON METABOLISM TO CORONARY 
HEART DISEASE
1.4.1 THE MECHANISM OF ATHEROGENESIS
Cardiovascular disease has become one of the major causes of death in Western 
countries. The reason appears to be that some aspects of modern life are increasing the 
incidence of atherosclerosis. The development of an atherosclerotic plaque in the artery 
wall is a significant event in the initialisation of coronary artery disease (CAD). This 
plaque reduces the diameter of the aiteiy lumen and renders the aiea more susceptible to 
thrombosis.
The development of atherosclerosis is a complex phenomenon, characterised by 
progressive cellular proliferation and accumulation of lipoprotein lipids in the artery wall. 
In the past, two independent theories for the genesis of atherosclerosis were proposed 
(Benditt, 1977). The 'lipid hypothesis' stated that increased levels of LDL resulted in an 
increased rate of LDL infiltration into the artery wall. This deposition of cholesterol acts 
as an irritant and causes inflammation and the proliferation of cells. On the other hand 
the 'endothelial injury hypothesis' states that endothelial damage causes platelets to 
adhere to the arterial wall and aggregate causing the release of platelet-derived growth 
factor (PDGF). PDGF stimulates the proliferation of smooth muscle cells and secretion 
of connective tissue matrix elements including collagen. Steinberg (1983) proposed a 
'unified theory' suggesting that interactions between these two pathways make them 
inseparable. The proposed unified hypothesis for atherosclerosis is shown in Figure 1.3. 
In brief, the hypothesis states that atherogenesis occurs when the endothelial cells lining 
artery walls are damaged, increasing the permeability of the endothelium and allowing 
lipoproteins to infiltrate the artery wall. Monocytes and platelets begin to adhere to the 
injured endothelium. Platelets aggregate and release mitogenic agents that cause the 
proliferation of smooth muscle cells (SMC) in the artery wall. Monocytes are then 
converted to macrophages which take up lipid from lipoproteins to form a cholesterol­
laden foam cell. The causes of the various stages in this process are dependent on a 
number of factors; disturbances in lipid and lipoprotein metabolism appear to play an 
important role (Kostner, 1991).
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Figure 1.3. The proposed unified hypothesis for the genesis of atherosclerosis showing 
the links between the lipid infiltration and the endothelial damage hypotheses (taken from Steinberg, 1983).
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1.4.2 RISK FACTORS FOR THE DEVELOPMENT OF ATHEROSCLEROSIS
1.4.2.1 LDL METABOLISM
It has been known for many years that high levels of LDL particles are highly correlated 
with CAD. As described previously (Section 1.3.3), there are two classes of receptor that 
bind to LDL: i) the LDL (B/E) receptor which recognises sites on apo B-lOO and apo E 
and causes the uptake of LDL, IDL and VLDL; ii) the scavenger receptors found on 
monocytes, SMC and endothelial cells which bind to and take up modified LDL paiticles 
(Kostner, 1991). If the activity of the B/E receptor is low, for example due to the 
consumption of a diet rich in cholesterol and saturated fats which causes a down- 
regulation of the receptor, then there will be an increase in the level of LDL circulating in 
the plasma.
The usual residence time of an LDL particle in the bloodstream is 2-3 days (Kostner,
1991). The longer an apo B-containing lipoprotein is in the plasma, the more prone it is
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to chemical modification such as lipid peroxidation or masking of the receptor-binding 
site by auto-antibodies. The modified LDL can then be taken up by the scavenger 
receptor and CE is deposited in the monocyte. Unlike the normal LDL receptor the 
scavenger receptor on the monocyte is not regulated by cholesterol uptake, thus causing 
accumulation of excess CE and the production of a foam cell (Kostner, 1991).
1.4.2.2 HDL METABOLISM
High levels of HDL have consistently been shown to be inversely correlated with the 
development of CAD (Miesenbock and Patsch, 1992). High levels of the HDL2 particle 
seem to be the most important predictor. There have been several mechanisms suggested 
for the protective effect of HDL. Originally it was proposed that the HDL may bind to 
lipid-laden cells, including macrophages, via HDL receptors, picking up excess CE and 
transporting it to the liver in the process of reverse cholesterol transport (Eisenberg, 
1984). Other theories suggested that HDL may compete for the scavenger receptor to 
prevent LDL uptake (Eisenberg, 1984), or inhibit LDL-mediated cytotoxicity (Schmitz 
and Lackner, 1993). It has been demonstrated that the lipid species in HDL are more 
susceptible to oxidation than those in LDL, which contain efficient anti-oxidants, and that 
HDL cholesterol ester hydroperoxides are cleared more rapidly than HDL cholesterol 
esters. In the light of these findings Schmitz and Lackner (1993) suggested that HDL 
lipids are preferentially oxidised and rapidly cleared from the circulation by hepatic cells 
and that this is another protective function of HDL.
A more recent proposal is that HDL may be involved in CAD due to its close metabolic 
interrelationship with the TGRL as described earlier (Section 1.3.4) (Grundy and Vega,
1992). This theory suggests that high levels of HDLs do not provide protection against 
atherosclerosis independently, but are a result of an anti-atherogenic metabolic process 
involving association with low levels of circulating TGRL (Miesenbock and Patsch, 
1991). This relationship is described below.
1.4.2.3 THE LINK BETWEEN ATHEROSCLEROSIS AND DIETARY-DERIVED 
LIPOPROTEINS
The direct link
There is increasing evidence for the involvement of TGRL, especially CMR, in the 
atherogenic process (Zilversmit, 1979), This hypothesis was initially suggested by 
Zilversmit in view of the fact that the site of TGRL metabolism by LPL is on the
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endothelium of artery walls. CMR ai'e thus produced in close proximity to possible sites 
of injury and, if enriched in CE, they possess the potential to cause cholesterol deposition 
in die ar terial wall.
Evidence from cholesterol-fed rabbits suggests that CMR and VLDL can be taken up into 
the artery wall in a similar manner to LDL (Zilversmit, 1979). Apo B and apo C 
(characteristic of TGRL) have been found in human arterial lesions (Hoff et a i, 1975, 
cited in Zilversmit, 1979). Further direct evidence for a link between postprandial 
lipaemia and atherosclerosis was provided by Floren and coworkers (1981) who showed 
that, in vitro, CMR can gain access to human arterial SMC if endothelial injury has 
occuiTed. Chung and Segrest (1990) showed that TGRL remnants can cause both foam 
cell formation and cell death in the endothelial cells. Mamo and Wheeler (1994) showed 
that CM harvested from rat thoracic ducts and injected into rabbits were deposited in the 
arterial wall at the same level as LDL particles. However this data has been criticised 
(Karpe and Hamsten, 1995) as the dose of CM was very lai'ge and it is unclear whether 
rat apo B and apo E interact properly with rabbit LDL or CMR receptors.
Evidence for the direct uptake of TGRL into atherosclerotic plaques was provided by 
Rapp et al. (1994), but no mention was made of the contribution of dietary-derived 
lipoprotein remnants. The group isolated intact TGRL from human atherosclerotic 
plaques using selected affinity anti apo B immunosorption. The content of apo B in 
VLDL and IDL fractions was measured by immunoblotting with a sheep anti-human apo 
B antiserum. The results appeared to show no apo B-48 present in the fractions, but this 
was not discussed by the authors.
Karpe and Hamsten (1995) and Nordestgard and Nilson (1994) have suggested that CM 
and CMR are removed from plasma before they attain a paiticle size that will allow them 
to penetrate the vascular' endothelium. On the basis of this theory, Karpe and Hamsten 
(1995) suggested that the results of Rapp et al. (1994) may mean that CMR are not 
directly important in atherosclerosis but that CM metabolism may induce atherogenic 
alterations in other cholesterol-containing lipoproteins. However an alternative 
explanation for the results of Rapp et al. (1994) was that the method was not sensitive 
enough to detect potentially low levels of apo B-48.
The indirect link
Currently there are two theories which describe the link between CAD and postprandial 
lipaemia. The 'Zilversmit hypothesis' described above suggests a direct role of CMR 
uptake into the arterial lesion. A more recent theory, the TAG intolerance' hypothesis, 
suggests that CAD is linked to impairment of TAG transport rather than a direct effect of
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the CMR particles. The theory, proposed initially by Miesenbock and Patsch (1991), was 
based on a large body of work throughout the 1980s showing a strong relationship 
between CM and HDL metabolism (Grundy and Vega, 1992). In this theory the tiansport 
of TAG is a potentially atherogenic process. The postprandial state provides a challenge 
to this transport system and a low TAG metabolic capacity impaits susceptibility to CAD.
Patsch and co-workers (1983) showed that subjects with a high fasting HDLz level have 
an increased ability to clear a standard fat load. Further studies also showed that subjects 
with a high postprandial lipaemia, indicating a decreased ability to metabolise or clear 
CM, showed a high level of TAG in postprandial HDL2 particles. This in turn invoked an 
increase in the activity of HL to form an HDL3 particle (Patsch et al., 1984). It was then 
shown that subjects with lower LPL activity had both higher postprandial lipaemia and 
high postprandial HDL2-TAG levels (Patsch et al., 1987). The result of this was 
increased HL activity and a lower fasting HDL2-cholesterol level, a known predictor of 
high CAD risk. Furthermore Groot et al. (1991) showed that, in normolipidaemic men 
who had suffered from CHD, the cleaiance of postprandial lipoproteins was delayed 
when compared to a control group of healthy men. The CHD group also had lower 
fasting HDL2 levels.
In view of these apparent correlations between HDL-cholesterol, HDL2-cholesterol, CM 
and CAD, it was suggested that low production or efficient clearance of TGRL decreases 
the amount of transfer by CETP of TAG to HDL in exchange for CE to TGRL. This 
keeps CE in HDL and allows their transport to the liver, at the same time reducing the 
amount of CE in potentially atherogenic TGRL (Miesenbock and Patsch, 1991). As there 
is less TAG in the HDL2 under these conditions, there will be less metabolism by HL and 
thus higher HDL2 levels in plasma. In this scenaiio, the high levels of HDL2 are seen as a 
result of a more efficient TGRL metabolism. It appears therefore that high HDL2 levels 
may be indicators of potentially anti-atherogenic metabolic processes rather than anti­
atherogenic particles in themselves (Miesenbock and Patsch, 1991).
The TAG level measured at late time-points (6 -8  hours) after a standardised oral fat load 
has been identified as a potential discriminator of CAD in multivariate analysis (Patsch et 
al, 1992a; Nikkila, 1994), whereas the fasting TAG level tends to be eliminated as a risk 
factor for CAD by HDL-cholesterol. It could be argued that postprandial 
hypertriglyceridemia at late time-points after a meal might reflect a type of TAG 
intolerance of clinical significance. This reaffirms the importance of postprandial studies 
for investigation of potentially atherogenic lipid abnormalities.
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The indirect evidence showing a link between postprandial lipaemia and atherosclerosis is 
accumulating. Karpe et al. (1994) measured apo B-48 and apo B-lOO in postprandial 
TGRL from patients with CAD and showed that the apo B-48 level in the Sf 20-60 size 
range was significantly conelated with the rate of progression of CAD. Levels of apo B- 
48 in the Sf 20-60 fraction also correlated with levels of small, dense LDL. In other 
postprandial studies, CAD patients have been shown to have higher postprandial lipaemia 
than healthy controls (Simons et al., 1987; Sünpson et al, 1990; Groot et a l, 1991).
In familial combined hyperlipidaemic (FCH) patients, impaired CMR metabolism has 
been shown to be implicated in the development of premature atherosclerosis (Castro- 
Cabazas et a l, 1993). The authors proposed that the FCH patients had evidence of 
slower CMR clearance, as measured by higher TAG AUC after a meal (Section 1.5.1), 
even after the fasting TAG levels were lowered by treatment.
There is increasing evidence from clinical, angiographic, animal and cell culture studies 
that CMR may contribute as much to the atherogenic process as VLDL and LDL. In 
general, current data suggest that repeated episodes of exaggerated or perturbed 
alimentary lipaemia are linked to disturbances in lipoprotein metabolism which are in 
turn related to premature CAD. These disturbances may include formation of small, 
dense TAG-rich LDL, cholesterol-enrichment of VLDL and increased susceptibility of 
postprandial LDL to oxidation. If this is the case then studies investigating lipoprotein 
responses to a meal should reveal factors which are potentially atherogenic through their 
adverse effects on postprandial lipaemia.
1.5 POSTPRANDIAL LIPAEMIA
Most of the original studies on lipoproteins looked at levels in fasting (postabsorptive) 
plasma, as this was believed to be the most accurate reflection of the 24 hour mean levels. 
However, due to the consumption of three regular meals a day, the human body spends 
over 80% of the time in the postprandial state (Patsch, 1987). After eating a meal there is 
a rise in plasma TAG levels due to the synthesis and secretion of TGRL. Postprandial 
lipaemia appears to occur in two stages, the first stage being characterised by TAG 
release from the intestine in the foim of CM and their subsequent metabolism by LPL to 
form CMR which are taken up by the liver. It was initially suggested that this phase lasts 
for 6 - 8  hours after the meal (Patsch, 1987). More recent evidence suggests that the 
effects of a meal are still evident in exogenous lipoproteins 12-14 hours later (Sethi et al, 
1993). The second phase of postprandial lipaemia involves the production of VLDL
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containing endogenously synthesised TAG as a result of the meal and lasts from 8-24 
hours after the meal (Cohn et aL, 1989).
The quantification of this postprandial lipaemia considers both the magnitude and 
duration of the TAG elevation. Observations by Patsch et a l (1992) demonstrated that 
the 6  and 8  hour postprandial TAG levels are a better predictor of CAD than fasting 
levels. Measurement of postprandial lipaemia has become a convenient tolerance test for 
investigating the effects of various factors on TAG metabolic capacity. Initial studies 
measured the plasma-TAG response to a meal but this gives only limited infomiation on 
processes occurring postprandially. Various methods for more detailed study of TAG 
metabolism have been developed including oral and intravenous fat tolerance tests and 
duodenal perfusion (Cohen, 1989a). Methods to study postprandial lipoprotein 
metabolism using maikers for dietai'y-derived lipoproteins have also been described.
1.5.1 METHODS FOR STUDYING POSTPRANDIAL LIPAEMIA
1.5.1.1 TAG LEVELS
i) Oral fa t tolerance test
An oral fat tolerance test described by Patsch et a l (1983) has frequently been used in 
studies on postprandial lipaemia. The test involves studying subjects following a 12 -14 
hour overnight fast. The subjects eat a meal consisting of whipping cream (65 g of fat) 
and blood samples aie taken for 8-12 hours after the meal. The amount of fat in the test 
meal is intended to elicit postprandial TAG values showing the highest degree of 
variability between normolipidaemic subjects. Smaller fat loads will not exhaust and 
larger fat loads will exceed the digestive and metabolic capacities of the body (Foger and 
Patsch, 1993). The subjects aie not allowed to consume any alcohol tlie day before the 
test meal.
The simplest method for measuring postprandial lipaemia after an oral fat load is to 
analyse TAG levels in the plasma and identify the peak. In order to give a more detailed 
view of dietary-derived lipids, CM-TAG levels have been measured after isolation of a 
CM-enriched fraction by ultracentrifugation (Weintraub et a l, 1987b). The area under 
the curve (AUC) for the time-response curve also gives an indication of postprandial 
TAG metabolic capacity.
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ii) Intravenous fa t tolerance test
A  disadvantage of the oral fat tolerance test is that the rate of fat absorption is not 
controlled and therefore CM-TAG metabolism cannot be quantitatively determined. The 
principle of an intravenous fat tolerance test was first used by Nestel (1964) to obtain a 
direct measurement of CM-TAG clear ance. In these studies an isolated, radiolabelled 
CM fraction was re-injected into the cubital vein of volunteers. This eliminates TAG 
absorption as a confounding factor. Although the use of isolated CM is the most logical 
way to measure CM-TAG kinetics, this technique has ethical and practical limitations.
An artificial lipid emulsion (usually Intralipid) is often used to model the intravenous 
decay kinetics of CM-TAG. After injection of a bolus of Intralipid, blood samples are 
taken every 2.5 to 5 minutes for a 30 minute period. The Intralipid half-life is calculated 
from the slope of the cuiwe of TAG concentration versus time. Although an early study 
demonstrated that Intralipid and CM-TAG showed qualitatively similar kinetic behaviour, 
more usually studies using Intralipid have found a mean half-Mfe of Intialipid to be longer 
than that of CM-TAG (15 minutes compared to 6  minutes) (Cohen, 1989a). The use of 
an artificial emulsion probably gives a more accurate representation of endogenous TAG 
metabolism rather than exogenous TAG.
Hi) Duodenal perfusion
This method was devised in 1976 by Grundy and Mok to directly measure the half-life of 
CM-TAG. The procedure involves calculating CM-TAG clearance from steady-state 
plasma TAG concentrations reached after constant infusion of fat into the duodenum for 
several hours. The CM half-life is calculated from the rate of input of perfused TAG and 
the plasma pool of TAG. This procedure relies on two assumptions; a) the rate at which 
CM-TAG enters the blood is equal to the rate of influx of perfused fat into the duodenum 
and b) the CM fraction isolated by ultracentrifugation (Sf >1000) contains all the CM 
particles and no endogenous VLDL-TAG.
Extensive work suggests that absorption of fat from the intestine is complete and Cohen 
(1989a) showed a strong correlation between the half-life obtained by duodenal perfusion 
and intravenous fat tolerance tests. These results suggest that the first assumption of 
equivalent rates of absorption and perfusion is acceptable. Grundy and Mok (1976) 
found no apo B-lOO in the CM-fraction using agarose gel suggesting that no endogenous 
lipoproteins are present after an ultracentrifugal spin of 1.6 x lOg g.min. This was 
confirmed by Cohen (1989a) who found only 7 % non CM-TAG in this fraction. 
However Cohen (1989a) also found 30 % of the perfusion-induced increment in TAG 
was in the Sf <1000 fraction, suggesting that the Sf >1000 fraction did not contain all 
CM-TAG. Therefore the second assumption of the method remains controversial.
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Using this method the residence time of CM-TAG in the circulation in normolipidaemic 
individuals was determined to be approximately 4.5 minutes (Grundy and Mok, 1976). 
This half-hfe reflects the rate of CM-TAG hydrolysis by LPL to form a CMR and is not a 
measure of CMR clear ance. Early work by Brunzell et al. (1973) suggested that the CM- 
TAG removal mechanism by LPL was a saturable process. The duodenal perfusion 
method utilised by Grundy and Mok (1976) did not provide any evidence for saturation of 
the process.
1.5.1.2 POSTPRANDIAL LIPOPROTEIN LEVELS
i) Retinyl ester
CMR clear ance can only be studied by using a marker which will remain in the CMR 
until its uptake by the liver. A convenient exogenous marker for CM particles is retinyl 
ester (RE). Vitamin A (retinol), usually esterified with palmitate, can be taken orally and 
is metabolised in a similar way to CE in the lumen of tire intestine. The retinol is re- 
esterified in the enterocyte, most usually with palmitate to form retinyl palmitate (RP), 
and incorporated into the CM core as RE. In the circulation the RE is treated similarly to 
CE and is not hydrolysed by LPL. The RE thus remain in the CM and CMR core until 
the particle is removed via the CMR receptor in the liver and therefore can be used to 
follow CMR clearance (Berr, 1992).
Originally reverse phase high perfoimance liquid chromatography (HPLC) incorporating 
silver nitrate was the main method used to separate RP from other RE and retinol (De 
Ruyter and De Leenheer, 1978). This method has two major disadvantages in that it takes 
20 to 80 minutes to separate all the RE components and the lifespan of a column is short 
due to deposition of AgNOg. There are four commonly circulating forms of RE in 
humans (palmitate, oleate, stearate and linoleate) (Bankson et al., 1986) and therefore a 
potentially more accurate and convenient measure of CM paiticles is to measure total RE. 
A normal phase HPLC method was developed in which the four major RE co-elute as a 
single peak (Ruotolo et a l, 1992). The method has the added advantage that it takes only 
10 minutes to separate RE from the retinol.
Studies in the early 1980s showed that less than 10 % of the RE was transferred to 
lipoproteins of higher density (Wilson et a l, 1983; Berr and Kern, 1984). However at 
that time Zilversmit et al. (1982) reported the transfer of RE to lipoproteins of 
density >1.019 g/ml in rabbits. More recently Demacker et al. (1992) reaffirmed these 
observations in WHHL rabbits. Krasinski et al. (1990a) have shown in humans that a 
significant amount of RP is found in LDL (19-33 %) and a small proportion in HDL
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(2-7 %) nine or more hours after the meal. This is presumably caused by neutral transfer 
of the RP from the CM via CETP. Thus this method is not completely reliable for 
measuring absolute levels of CMR when studying subjects for more than 9 hours.
Krasinski et al. (1990a) also showed that the time-course of RP does not follow that of 
apo B-48 or TAG. They found a delay in the time to the RP peak compared with TAG 
and apo B-48, which was also observed in other postprandial studies (Krasinski et aL, 
1990b; Cohn et al., 1993). The number and rate of incorporation of RP molecules into 
each CM particle at different times after the meal is unclear. This causes further 
problems for the quantification of dietary-derived lipoproteins with the use of RP as a 
marker. In addition a review of all the studies using RP suggests that the type of RP used 
may influence the time-course of the response. Studies using oil-based preparations of 
RP show a delay in the RP peak relative to TAG and apo B-48, whereas most studies 
using the aqueous form generally show a good comparison between the time-courses 
(Wilson et al., 1985; Brown and Roberts, 1991a; Ruotolo et a l, 1992; de Bruin et a l, 
1993).
In many postprandial studies, the concentrations of RE have been used to provide a 
measure of the level of dietary-derived lipoproteins after a meal in a similar manner to the 
measurement of plasma-TAG after an oral fat tolerance test. Berr and Kern (1984) 
developed a method to measure the clearance rate of CMR particles. Blood samples were 
taken five hours after oral administration of RP and CM were isolated from plasma by 
ultracentrifugation. These CM were reinjected into the donor 42 hours after the meal. 
Blood samples were taken every 3 minutes for 30 minutes and then every 10 minutes for
3.5 hours. The RP plasma clearance was determined from the curve of RP concentration 
against time. A variation on this method to measure the half-life of CMR particles has 
been developed (Cortner et a l, 1987) whereby oral administration of RE is followed by 
measurement of RE levels. The half-life is determined using a multicompartmental 
model which removes the need to isolate, store and reinject lipoproteins. Detennination 
of the clearance rates of CMR showed the half-life of a CMR to vary from 10 to 53 
minutes depending on a number of factors (BeiT, 1992). The same study also showed that 
CMR catabolism by the liver appears to be saturated by 70 g of lipid intake in humans.
Recently new doubt has been cast upon the effectiveness of RP as a measure of CMR 
uptake because studies have shown significant uptake of RP by tissues other than the 
liver. In particular, a study by Blaner et al. (1994) demonstrated that a significant amount 
of RE is hydrolysed by LPL and the retinol taken up into the adipocyte. The use of RP as 
a mai'ker for CM particles may provide useful information on processes such as rate of
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RP/CE uptake under different conditions but, in light of the potential problems, care 
should be used in the interpretation of results obtained using RP as a mai'ker for CMR.
ii) Apo B-48
In view of the potential problems with RE it would be preferable to use an endogenous, 
non-transferable marker for dietary-derived lipoproteins. Apo B-48 is a suitable 
candidate as a marker for CM and CMR particles. This protein is essential for CM 
assembly and it is believed that there is only one apo B-48 on each CM particle (Young, 
1990). Unlike other apolipoproteins, apo B-48 is not transferred to other lipoproteins in 
the circulation due to the very high lipid-binding capacity of the molecule. Apo B-48 
thus remains with CMR until it is taken up by the liver. Some studies have measured apo 
B-48 levels postprandially and these will be discussed in more detail in Sections 1.6 and 
4.1.
1.5.2 FACTORS AFFECTING POSTPRANDIAL LIPAEMIA
As the extent of postprandial lipaemia is affected by a variety of physiological and 
nutritional factors, various studies have begun to investigate these processes. There is a 
wide var iation between individual responses to a standard fat intake. Postprandial studies 
should provide vital information on those factors which are potentially atherogenic 
through their adverse effects on postprandial metabolic processes.
1.5.2.1 PHYSIOLOGICAL FACTORS
i) Postabsorptive lipid status
Several correlations have been noted between the extent of postprandial lipaemia and 
postabsorptive lipid status. Fasting TAG levels have been demonstrated to be positively 
correlated with postprandial TAG levels (Lewis et a i, 1990; Patsch et a l,  1992a; 
O'Meara et a l, 1992). It has also been shown, however, that some people with normal 
fasting lipid levels show unexpectedly large responses which may indicate increased 
atherogenic risk (Schrezenmeir et a l, 1992).
Normolipidaemic obese patients show a greater postprandial lipaemia than normal weight 
subjects (Lewis et al, 1990). The very small increase in RP levels observed in the obese 
subjects suggested that the main contribution to the higher postprandial lipaemia in this 
group was from hepatic lipoproteins. Despite their fasting lipid levels falling within the 
normal range, the obese subjects in this study did have significantly higher fasting TAG 
than the normal-weight controls. This introduces a confounding factor in assessing
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whether obesity is a direct cause of the high postprandial response or whether the 
response is due to the fasting TAG levels.
As discussed in Section 1.4.2.3, HDL levels have been found to be negatively coiTelated 
with postprandial lipaemia (Lewis et ah, 1990; Patsch eta l, 1992a). Fasting LPL activity 
has been shown to be inversely coiTelated with postprandial lipaemia (Weintraub et a l, 
1987b). Patients with genetically-determined LPL deficiency have exaggerated 
postprandial lipaemic responses (Miesenbock et al, 1993)
ii) Effect o f  age and gender
In studies of postprandial lipoprotein metabolism in a wide range of healthy people, older 
subjects showed a greater triglyceridaemia after a meal than younger subjects (Cohn et 
a l, 1988b) and CMR remained in plasma longer in elderly subjects (Kiasinski et a l, 
1990b). Subjects older than 50 years had higher RE responses than subjects under 50 
years (Johnson et a l, 1992). Weintraub et a l (1992) investigated the postprandial 
lipoprotein metabolism in healthy octogenarian subjects (mean age 84 ±4.2 yeai's) using 
RP as a marker. They found that the octogenarians had significantly lower CMR-RP 
levels than younger controls (mean age 50 ±4.8 years), but there was no significant 
difference between the CM-RP levels. The authors proposed that the high capacity of 
these subjects to metabolise TAG was a possible reason for them having reached their 
ninth decade.
In studies investigating the influence of gender on postprandial lipaemia, females showed 
a lower lipaemic response than males as measured by plasma-TAG levels (Redai'd et a l, 
1990; Cohn e ta l, 1988b) and by plasma-RE concentrations (Johnson e ta l,  1992). In the 
latter study the investigators also found that the peak postprandial RE concentration 
occurred 1 hour earlier for the female subjects.
in) Effect o f  apo E polymoiphism
Studies on apo E polymorphism have shown that an individual’s apo E phenotype can 
affect postprandial lipaemia. There are three isoforms of apo E which differ by a single 
amino-acid substitution, apo E2, E3 and E4. Apo E3 is the most common isoform, with 
the homozygous phenotype (E3/E3) found in 56 % of the population.
Apo E2 has been shown to have impaired binding to the hepatic receptor. The presence 
of the E2 isoform, either in heterozygous or homozygous form, has consistently been 
shown to be associated with a higher postprandial lipaemia than the more common E3/E3 
phenotype (Weintraub e ta l, 1987a; Brown and Roberts, 1991a; Boer winkle e ta l,  1994). 
The effects of apo E4 have been less consistent. Apo E4 has been shown to have similar
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receptor-binding affinity to the E3 isoform, however eaily studies in humans showed that 
subjects with the E4 isoform (heterozygous E3/E4 or homozygous E4/E4) have a lower 
TAG response than those with the E3/E3 phenotype (Weintraub et al., 1987a). 
Conversely Brown and Roberts (1991a) showed an increased postprandial response 
associated with the presence of apo E4 and Boeiwinkle et al. (1994) showed no effect.
iv) Effects o f exercise
In a limited study on two individuals, Patsch etal. (1983) showed that increased exercise 
caused a decrease in postprandial lipaemia. More recent studies have shown that active 
people have lower postprandial lipaemia, and that training decreases the postprandial 
lipaemic response. These studies will be discussed in more detail in Chapter 3.
v) Effects o f  coronary artery disease
The ratio of apo B-48 to apo B-lOO in the Sf >60 fraction 4 hours postprandially was 
found to be a significant predictor of CAD (Simons et al., 1987). In a comparison of 
normolipidemic patients with and without CAD, RE and TAG levels remained elevated in 
CAD patients for a prolonged period compared with the controls (Groot et al., 1991). 
The authors interpreted these results as delayed clearance of postprandial lipoproteins in 
the CAD group. This effect was evident in both TAG and RP levels, thus the authors 
suggested that delayed clearance of postprandial lipoproteins could play a role in 
atherosclerosis. The same effect was observed in CAD patients by Simpson et al. (1990) 
and fenofibrate treatment was found to reduce alimentary lipaemia in both 
normolipidaemic and hyperlipidaemic CAD patients. It is not clear, however, from this 
type of study whether the longer residence time of CM and CMR was a result of CAD 
already present, or whether defects in postprandial lipoprotein metabolism precede and 
aie of pathological significance in CAD.
This question was addressed in a study by Uiterwaal et al. (1994) who looked at 
postprandial TAG responses in young men with a familial risk of CAD. The subjects had 
no evidence of disease. The results of the study confirmed that the men at risk of CAD 
had a higher, prolonged lipaemia after a meal compared with a normal control group, 
suggesting a causal relationship between postprandial lipaemia and CAD. It would be 
necessary to follow up the incidence of CAD in the 'at risk' group in later years to provide 
more solid evidence for this effect.
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1.5.2.2 DIETARY FACTORS
i) Effects o f  Fatty acids
The effects of polyunsaturated fatty acids (PUFA) on postprandial lipaemia have been 
investigated because of the beneficial effects of these fatty acids on other metabolic 
processes. The results with n-3 PUFA have generally been more clear-cut than those with 
n- 6  PUFA. The acute effect of fatty acids has been demonstrated, as the type of fatty 
acids in a single meal has been shown to affect postprandial lipaemia. Zampelas et al. 
(1994) showed that consumption of n-3 PUFA produced a significantly lower 
postprandial lipaemia than a mixed oil meal, whereas there was no significant difference 
when comparing the response after a corn oil meal with that after a mixed oil meal. 
Harris et a l (1988) showed no difference in the TAG response after a meal rich in SFA 
compared with a meal rich in n-3 PUFA. Salomaa et a l (1993) showed no difference in 
postprandial lipaemia after meals containing SFA or n-6  PUFA.
Several studies have shown that chronic intake of n-3 PUFA for a period of 3-4 weeks 
reduces the postprandial lipaemic response to a single test meal (Hauls et a l, 1988; 
Weintraub e ta l, 1988; Williams e ta l, 1992). There are various possible reasons for this 
effect; Levy (1991) suggested that the larger size of PUFA-rich CM compared with SFA- 
rich CM may give them an increased ability to compete with VLDL for LPL. 
Alternatively, the study by Zampelas et a l (1994) observed increased LPL activity after a 
meal containing n-3 PUFA. The long-term effects of n-3 PUFA consumption may be 
mediated by the up-regulation of LPL gene expression. This has been demonstrated in 
the rat (Murphy et a l, 1993) but effects of fish oils on gene expression have not so-far 
been shown in humans.
The results of studies on the effects of n- 6  PUFA have been inconsistent. A study by 
Weintraub et a l  (1988) showed that, following 2 weeks on an n- 6  PUFA diet, the 
postprandial TAG response was lower after consuming a meal rich in n-6  PUFA 
compared with a meal rich in SFA. In the same study, however, after 2 weeks on a 
saturated fat diet no difference was found between the postprandial responses to a high 
SFA or high PUFA meal. Demacker et a l (1991) also showed that the 24 hour TAG and 
apo B-48 levels were lower during a period on an n-6  PUFA enriched diet compared with 
a period on a SFA-enriched diet.
Few studies have been carried out on the effects of MUFA on postprandial lipaemia. 
Brouwer et a l (1993) compared the response to intravenous infusions of olive oil and 
soybean oil. They found that TAG clearance rates were slower and HL activity was 
lower following olive oil infusion. An oral fat tolerance test by de Bruin et al. (1993)
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showed that the RP concentrations in CM after an olive oil meal were higher than after a 
soybean oil meal. They also showed that apo B-48 concentrations in CMR (d 1.006- 
1.019 g/ml) were higher after the olive oil meal compared to the soybean oil. The slower 
removal of CMR was correlated with HL activity. This study also showed that 
postprandial levels of HDL were conserved after olive oil consumption but decreased 
following soybean oil. They suggested that the higher postprandial lipaemia reflected an 
HDL-conserving effect through competition for HL between olive oil-CMR and HDL.
ii) Effects o f  other nutnents
The effects of dietary sugars on postprandial lipoprotein metabolism have recently been 
reviewed (Frayn, 1995). Cohen and Schall (1988) studied the effect of 50 g of either 
fructose, glucose, sucrose, or no carbohydrate in a 40 g fat meal. Fructose increased the 
response compared with the control meal; sucrose had no effect and glucose diminished 
the response. The same group suggested that the effects of glucose may be due to 
osmotic effects and delayed gastric emptying rather than increased cleaiance of TAG 
(Cohen and Berger, 1990). Cohen (1989b) also investigated the effects of protein on 
postprandial lipaemia and found that ingestion of protein with fat had no effect on 
postprandial TAG levels compared with fat alone.
The effects of fibre on postprandial lipaemia have not been extensively studied. Redard 
et a l (1990) found no effect of guar gum on the postprandial TAG response in males but, 
in females, guar gum increased both the extent and duration of lipaemia. A small study in 
which 1 0  g of guar gum was added to a normal meal showed a delay in the time to peak 
plasma-TAG suggesting attenuation of TAG digestion or absorption by fibre (Lovegrove 
et al, 1993)
1.5.3 CONTRIBUTION OF LIVER-DERIVED LIPOPROTEINS TO 
POSTPRANDIAL LIPAEMIA
Increases in plasma-TAG after a meal are not solely a reflection of the presence of 
intestinally-derived lipoproteins. A major limitation in understanding postprandial 
lipaemia has been the limited ability to quantify the relative contribution of the intestinal 
and liver-derived lipoproteins to the increase in TAG concentrations. The density ranges 
of CM and VLDL overlap and therefore they cannot be adequately separated by 
ultracentrifugation. Structural similarities between the two forms of apo B have also 
hampered the attempts to raise a specific antibody to apo B-48. Several groups have set 
out to investigate the relative contributions of endogenous and exogenous lipoproteins in 
postprandial lipaemia and their work is detailed below. The methods used for the
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measurement of apo B-48 and B-lOO in these studies are described in more detail in 
Section 1.6.
Cohn et a l (1988a) demonstrated that both apo B-48 and apo B-lOO in TGRL increased 
after a fat-containing meal. A further study showed that lipoproteins from the liver and 
intestine are involved in both the early and late peaks of the postprandial response and 
that there is a 50 % increase in the apo B-lOO concentration and a 5 to 6  fold increase in 
the level of apo B-48 in the TGRL fraction (Cohn et al., 1989). A more recent study by 
the same laboratory suggested that, because of the relatively low initial concentration of 
apo B-48, 80 % of the increase in the total paiticle number was accounted for by VLDL 
(Cohn et a l, 1993). Despite this, 80 % of the increase in TAG was carried in the apo 
B-48 containing lipoproteins. Similar results were seen by Schneeman et al. (1993). 
Taken together these results show that a relatively low number of CM carry the bulk of 
the TAG during postprandial lipaemia.
There are several possible reasons for the postprandial increase in apo B-lOO: the liver 
may increase production and secretion of VLDL; apo B-lOO may be produced by the 
intestine; or CM may prevent the hydrolysis of VLDL-TAG. The latter possibility has 
been examined in the most detail since CM and VLDL share a common lipolytic pathway 
(Hazzard and Bierman, 1976). Several groups have proposed that CM and VLDL 
compete for LPL and that CM are the favoured substrate which results in an accumulation 
of VLDL paiticles during the postprandial period (Kai'pe et al., 1993a; Schneeman et al,
1993). Furthermore Karpe et al. (1993a) showed that there was an increase in apo B-lOO 
in the large VLDL fraction and a decrease in the apo B-lOO concentration in the IDL 
fraction, thus reinforcing the hypothesis that the postprandial increase in TGRL apo 
B-lOO was caused by reduced clearance of VLDL as a result of competition of CM for 
LPL.
1.6 APOLIPOPROTEIN B
Apo B is the major stmctural protein of LDL, IDL, VLDL and CM and has a central role 
in lipoprotein metabolism. Work by Kane et al. (1980) showed that apo B occurs in two 
main forms. Apo B-lOO is the larger form and is synthesised primarily in the liver in 
humans. Apo B-48 is approximately half the size of apo B-lOO and is synthesised only in 
the intestine in humans. Apo B has three important functions: it is essential for the 
assembly and secretion of VLDL and CM; it maintains the structural integrity of the 
particles in the circulation as it is not transferred to other lipoproteins; apo B-lOO also acts 
as a ligand for the uptake of LDL by the receptor. There has been much progress in
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understanding apo B over the last ten years and aspects including primary structure, 
important functional domains, details of synthesis, secretion and catabolism are now 
known. Some of these aspects are detailed below.
1.6.1 APOLIPOPROTEIN B-lOO
In 1986 four groups reported the nucleotide sequence of apo B complementary DNA 
(cDNA) (Chen e ta l ,  1986; Cladaras et a l, 1986; Knott e ta l,  1986; Law e ta l,  1986). 
From this they determined the amino acid sequence. Apo B-lOO is a glycoprotein 
consisting of 4536 amino acids. Apo B-lOO contains several hydrophobic domains 
throughout its sequence which are believed to be important in lipid binding. Nine 
amphipathic ot-helices are found in apo B-lOO, particularly in the region from amino acid 
2 0 0 0  to 2600, and several |3-sheet structures are found throughout the protein. Both these 
types of structure are believed to have very high lipid-binding potential and explain why 
apo B is not transferred to other lipoproteins. Other apolipoproteins do not have such 
extensive hpid-binding sites and therefore are more readily transferred (Chan, 1992).
The LDL receptor binding region was found to be in the carboxy-half of the apo B-100. 
Work by Milne et a l (1989) using monoclonal antibodies showed that the receptor 
binding domain was between amino acids 2980 and 3780. This region contains many 
positively charged residues that are necessary to interact with the negatively charged, 
cysteine-rich repeats of the ligand binding domain of the LDL receptor (Brown and 
Goldstein, 1986). There are two highly basic regions in the sequence of araino-acids 
from 3147-3157 and 3359-3367. These two regions are brought together during the 
folding of the apo B-100 on the LDL particle by the formation of a disulphide link 
between cysteine 3167 and cysteine 3297 and may form the receptor binding site (Law 
and Scott, 1990).
1.6.2 APOLIPOPROTEIN B-48
The discovery that there are two distinct forms of apo B was made in the early 1980s by 
Kane et a l  (1980). They showed that apo B-48 was found only in CM particles in 
humans and thus was probably only produced in the intestine. The same group suggested 
that apo B-100 was found in both VLDL, LDL and CM. At that point there were three 
theories for the mechanism by which apo B-48 is produced. Firstly it was thought that 
there were two different genes for apo B-100 and B-48, secondly that apo B-48 was 
produced by proteolytic cleavage of fully-translated apo B-100 or, thirdly, that there was
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a single apo B gene which produced both apo B-100 and B-48. The first two theories 
were rejected in 1986: studies of a genetic polymorphism in apo B-48 and apo B-100 
showed that apo B-48 and B-100 were produced from the same gene (Young et al, 1986) 
and Glickman et a l  (1986) ruled out post-translational cleavage of apo B-100. In 1987 
three groups showed that apo B-48 is produced from the apo B-100 gene by a novel 
mRNA editing mechanism (Chen et a l, 19877; Hospattanker et a l, 1987; Powell et a l, 
198). This editing mechanism was found to be tissue-specific, occurring only in the 
intestine in humans. In the rat the editing mechanism occurs in both intestine and liver 
(Tennyson et a l, 1989). This agreed with earlier studies in the rat by Van't Hooft et a l
(1982) which showed that the apo B-48 of rat CM was not a precursor of apo B-48 in 
LDL of hepatic origin.
Since the preliminary discovery of the mechanism for the synthesis of apo B-48 there has 
been some dispute as to the tissue-specific nature of the editing process. Higuchi et a l  
(1988) showed that in humans both liver and intestine contain apo B-48 and apo B-100 
mRNA. Furthermore, from the results of immunochemical studies both Levy et a l 
(1990) and Hoeg et a l  (1990) proposed that apo B-100 is synthesised in the intestine. 
However, the likelihood of the presence of apo B-100 in the intestine being due to uptake 
of endogenous lipoproteins from the lymph was discussed in the former study and this 
possibility has not been adequately investigated.
Hodges et a l (1991) showed that the mRNA editing mechanism was a site-specific 
cytidine tiansaminase which caused the conversion of the C of codon 6 6 6 6  (CAA) to a T 
(TAA) converting the sense of the codon from encoding a glutamine amino acid at 
position 2153 of the protein to a stop codon. This produces a protein consisting of 2152 
amino acids. Sequencing studies by Hardman et a l (1987) confinned that the amino acid 
sequence of apo B-48 corresponds to the amino-terminal half of apo B-100.
One question which remains difficult to answer is why there is a need to make two forms 
of apo B when apo B-100 seems to be capable of forming very large TGRL. Young 
(1990) proposed that apo B-48-containing lipoproteins may be able to accommodate more 
apo E molecules, resulting in more efficient and rapid delivery of dietary fats to the liver. 
Scott et a l  (1989b), on the other hand, proposed that removal of the apo B-100 receptor 
binding domain in apo B-48 facilitated rapid delivery of dietary fats and lipid-soluble 
vitamins and anti-oxidants to the liver. He further postulated that, if apo B-100 were the 
CM carrier protein, few antioxidant molecules would reach the liver and therefore 
endogenous VLDL and LDL would contain no anti-oxidants and be rapidly destroyed.
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1.6.3 APOLIPOPROTEIN B SYNTHESIS AND SECRETION
Davis et al. (1990) suggested that there were two functionally distinct pools of apo B 
from which the apo B is either secreted or degraded. This led to further work to elucidate 
the mechanism for apo B synthesis. The pathways for synthesis of apo B-100 and apo 
B-48 are essentially similar. During the first phase of apo B synthesis on polyribosomes, 
a 27 amino acid signal sequence is formed which binds to a signal recognition particle on 
the ER membrane and opens an aqueous channel within the membrane. As the synthesis 
process continues the nascent protein is translocated through the channel into the ER 
lumen. There are two fates for the apo B at this stage: if the apo B is translocated 
through the membrane close to a region of TAG and PL synthesis, lipid becomes 
associated with the protein to form a lipoprotein. If the lipid content is large enough to 
permit the correct folding of the apo B the lipoprotein can enter the secretory pathway. 
Alternatively, if there is no TAG synthesis occurring the lipoprotein formed is too small 
to allow correct folding of the apo B and the protein is directed into a degradation 
pathway. In addition, if the apo B is not fully translocated across the membrane it also 
enters an intracellular degradative pathway (Boren et al, 1991).
There are some parts of this process where the fate of an apo B-48 molecule is believed to 
be different from an apo B-100. Whereas apo B-100 particles cannot fold correctly in 
HDL sized particles and are thus degraded, it is believed that apo B-48 can be folded in 
the correct configuration in these HDL-sized particles. These small lipoproteins are 
stored in the ER lumen until they are converted to CM-sized particles by addition of lipid. 
Another different fate has been established for the apo B-48 protein compared to apo 
B-100; after completion of synthesis the translocation channel can close and trap the 
C-teiminal of the apo B-48 in the membrane thus creating a pre-formed pool of apo B-48 
in the ER (Sparks and Sparks, 1994a). Although the evidence for the existence of a 
degradation pathway for the regulation of the level of apo B-100 in the hepatocyte is 
convincing, the full extent of a degradative pathway for the regulation of apo B-48 levels 
in the enterocyte has not been established.
Both apo B-100 and apo B-48 are secreted as phosphoproteins (Jackson et a l, 1990) 
which are mainly phosphorylated on serine residues. However the number of 
phosphorylation sites and the nature of hormonal and dietary effects on the 
phosphoiylation process are not clear (Spaiks and Sparks, 1994b).
Dietary and hormonal control o f  apo B-48 synthesis and secretion
Most of the studies on apo B mRNA editing and apo B synthesis and secretion have been
carried out using animal models, despite the differences between human and rodent
33
lipoprotein metabolism. Mazur et al. (1991) showed that a high fibre diet decreased 
levels of apo B mRNA in the rat ileum. Srivatstava et al. (1992) investigated the effects 
of sex hormones and diet on apo B mRNA editing in mice and found that both 
17 p-estradiol and testosterone caused an increase in apo B-100 mRNA, whereas a high 
fat diet caused an increase in apo B-48 mRNA. Conversely no effects on hepatic apo B 
mRNA levels were observed in rats fed a high fat diet (Osada et a l, 1994). In studies of 
high sucrose diets on regulation of apo B in the rat liver, Baum et al. (1990) showed that 
a high carbohydrate diet increased the editing of apo B mRNA in the liver, whereas after 
a 48 hour fast no apo B synthesis could be measured. These results were interpreted to 
mean that apo B mRNA editing is modulated by changes in hepatic lipogenesis.
The differences between rodent and human lipoprotein metabolism created difficulties in 
the interpretation of results. In order to overcome this problem a cell-culture model of 
human enterocytes, the CaCo-2 cell-line, was established in 1977 (Fogh e ta l, 1977) from 
a human colonic adenocarcinoma. This has been used extensively to study apo B 
synthesis and secretion. Jiao et al. (1990) showed that, when CaCo-2 cells are allowed to 
differentiate on filters, the in-frame stop-codon is introduced into the apo B-100 mRNA 
leading to the synthesis of apo B-48. CaCo-2 cells can therefore also be used to study 
apo B mRNA editing.
Although CaCo-2 cells do not contain the MAG pathway usually found in human 
enterocytes, results of studies using these cells have begun to provide some insight into 
the mechanisms involved in fatty acid regulation of lipoprotein secretion but the situation 
is far from clear. Studies on the effects of fatty acids have consistently shown an increase 
in apo B secretion in response to incubation with oleic acid (Dashti et al., 1991; Mobeiiy 
et al., 1990; Murthy et al., 1990). Oleate may protect the nascent apo B from inhacellular 
degradation eaiJy in the secretory pathway (Dixon et a l, 1991) by binding to the protein 
but this has not been conclusively proved. Conversely eicosopentanoic acid (EPA) has 
been shown to decrease apo B secretion, although the mechanism for this is controversial. 
Murthy et a l  (1992) suggested that EPA inhibits apo B synthesis by decreasing mRNA 
levels in CaCo-2 cells, whilst Wang et al. (1993) suggested that EPA enhanced 
intracellular degradation of apo B in rat hepatocytes.
Several studies have shown that insulin inhibits hepatic apo B secretion (Jackson et a l, 
1990; Sparks and Sparks, 1990). This may be via insulin-mediated degradation of apo B 
or an effect on phosphorylation of the protein. The effects of insulin seem to be limited 
to apo B-100 only as apo B-48 appears to be insensitive to the effects of insulin. This is 
presumably to ensure that exogenous lipid carried by apo B-48-containing lipoproteins
34
can be efficiently utilised without competition from endogenous VLDL (Sparks and 
Spai'ks, 1994a).
African green monkeys have a similar lipoprotein system to humans as they produce apo 
B-48 only in the intestine and apo B-100 only in the liver. Sorci-Thomas et al. (1989) 
studied the effects of dietary fatty acids and cholesterol on apo B mRNA expression in 
the liver of these monkeys. They found that total cholesterol, LDL-cholesterol and apo B 
levels were higher in the monkeys on higher cholesterol diets and on the saturated fat 
diet. However no dietary fat or cholesterol effects on apo B mRNA levels in the liver or 
on apo B secretion were observed. They did find a 50 % decrease in LDL receptor 
mRNA in the liver on a higher cholesterol diet. Therefore these results suggest that 
increased plasma-cholesterol caused by high dietary cholesterol is due to a decrease in the 
uptake of apo B-containing particles rather than an increase in their production.
1.7. MEASUREMENT OF APO B
Measurement of total apo B is clinically relevant due to the association between LDL and 
CAD and, more importantly, apo B and CAD (Anon, 1990). The most commonly used 
methods for the analysis of total apo B have been immunoassay techniques. Some 
examples of the types of immunoassays used have been reviewed by Rosseneu et al.
(1983) and Labeur et al. (1990). There are various disadvantages associated with all 
potential immunoassay formats for measuring apo B on intact lipoproteins. 
Electroimmunoassay and radial immunodiffusion are not suitable for lai'ge numbers of 
samples and have been shown to be affected by lipoprotein size. Immunoturbidometry 
and immunonepholometry require the formation of an antigen-antibody lattice and 
require pre-treatment for the removal of lipid. Draw-backs with radioimmunoassays 
(RIA) are that the method is expensive and involves the use of potentially hazaidous 
radioactive substances.
Enzyme immunoassay techniques have frequently been used for the measurement of 
apo B as their sensitivity is very high but they have the added advantage of no 
radioactivity being required (Labeur et a l, 1990). Several formats for enzyme-linked 
immunosorbent assays (ELISA) to measure both total apo B or apo B-100 have been 
successfully developed. These have been either direct or competitive and have used 
either monoclonal antibodies (Albers e ta l,  1989; Bojanovski et a l, 1987) or polyclonal 
antibodies (Kandoussi et al, 1991) to apo B-100, or antibodies directed to LDL particles 
(Ordovas et al., 1987). These methods have been used to investigate the effects of 
valions drugs, or other intervention measures, on apo B levels.
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Some drawbacks with the use of immunological techniques for measuring apo B have 
been reported. It has been shown that different sized LDL particles react differently with 
monoclonal antibodies (Tikkanen et a l, 1983) and polyclonal antibodies (Schonfeld et 
al., 1979). This was suggested to be due to differences in lipid masking of the epitopes. 
The immunoreactivity of apo B was found to increase on storage (La Belle et a l, 1990). 
Even at -20 “C there was a 5 % increase in the level of apo B measured in an LDL 
fraction after storage for 3 months (Evans et a l, 1995). These changes were attributed to 
changes in the conformation of the apo B during storage which may have decreased the 
lipid masking of the epitopes. Therefore it would seem important when designing an 
ELISA or measuring samples to take these storage problems into consideration.
Apo B-100 is present in relatively high concentrations in the plasma (range 0.4 -2.0 g/1) 
and thus the sensitivity of each of these methods is adequate to allow the accurate 
quantification of the protein in plasma.
1.8. MEASUREMENT OF APO B-48
Early work by Zilversmit (1979) suggested a direct involvement of CMR in the 
atherogenic process. Work by Patsch throughout the 1980s also suggested a link between 
CM and CMR and HDL metabolism. In light of the potential importance of dietary- 
derived lipoproteins in atherogenesis it is essential to investigate CM and CMR 
metabolism. CMR cleaiance can only be studied by using a marker which will remain in 
the CMR until its uptake by the liver. As described in Section 1.5.1 there are drawbacks 
with using TAG and RE for measuring postprandial lipoprotein levels. A preferable 
marker for dietaiy-derived lipoproteins is an endogenous, non-transferable component for 
which apo B-48 is the only suitable candidate.
Since the discovery of two major forms of apo B, apo B-48 and apo B-100 (Kane et a l, 
1980), comparatively little work on the measurement of apo B-48 has been carried out. 
One of the main reasons for this is that apo B-48 is present in very low concentration in 
plasma relative to apo B-100, ranging from 1 % of the total apo B concentration in the 
fasting state to 3-4 % postprandially. This is equivalent to an approximate absolute 
concentration of less than 5 pg/ml. Various methodological problems have also 
hampered the investigation including the very large size and insolubility of the protein, 
the impossibility of completely separating apo B-48 containing lipoproteins from apo B- 
1 0 0  containing lipoproteins by ultracentrifugation due to their overlapping densities, and 
the fact that the stmcture of apo B-48 is identical to the N-teiminal 48 % of apo B-100.
36
The most sensitive and convenient method for distinguishing between endogenous and 
exogenous lipoproteins would appear to be via an immuno-based assay. However the 
similarities between the two forms of apo B has hindered the development of an 
immunoassay for apo B-48 as antibodies raised to any section of apo B-48 would also 
cross-react with apo B-100. In view of these difficulties the most commonly used method 
for the measurement of apo B-48 has been densitometric scanning of stained protein 
bands after separation of apolipoproteins using gel electrophoresis (Kane et a l, 1980; 
Poapst et a i, 1987; Zilversmit and Shea, 1989; Karpe and Hamsten, 1994). The basis of 
this method is described in Section 2.4. There are many variations to the method which 
are employed by different groups for individual requirements. Initially Kane et a l (1980) 
used a 3 % SDS polyacrylamide gel to investigate the apo B content of CM. A single 
concentration gel of 4 % was used by Demacker et a l (1991) and of 5 or 7.5 % by 
Zilversmit and Shea (1989). A linear gradient polyacrylamide gel of a 4-20 % gradient 
was described by Cohn et a l (1988b) and was subsequently used in postprandial studies 
(Cohn et a l, 1989; Krasinski et a l, 1990). A 3-10 % gradient polyacrylamide gel was 
used in the study by Kotite et a l (1995) and a 3-20 % lineai' gradient was used by Kai'pe 
and his group (1994).
SDS-PAGE has provided useful information but the method is not entirely suitable for 
analysing large numbers of samples from a postprandial study and the technique is 
susceptible to a high degree of variation. The stained gels have very low sensitivity and 
require the removal of the majority of plasma proteins other than apolipoproteins by 
ultracentrifugation. Despite the problems with the stained SDS-PAGE procedure several 
studies have been described which have used this method to analyse apo B-48. These are 
described further in Chapter 4.
In order to increase the sensitivity of the method, two groups have transferred the 
separated proteins to a nitrocellulose membrane following electrophoresis and then 
immunoblotted with a specific antiserum against apo B. This has enabled quantitation of 
apo B-48 and apo B-100 (Myserth et a l, 1989; Cartwright and Higgins, 1992). In the 
former study, even with the proposed added sensitivity, the apo B-48 band could not be 
detected or quantified any better than on a Coomassie-stained gel. In the second study 
the immunoblotting method was a very long and complicated procedure and required the 
use of izsf. The method would therefore not be suitable for laige postprandial studies.
Other techniques have been used less frequently to sepaiate and measure apo B-48 levels. 
In the early 1980s two groups used radiolabelling techniques to investigate the kinetics of 
apo B-48 metabolism (Nestel et a l, 1983; Stalenhoef et a l, 1984). Isolated TGRL
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fractions were radiolabelled with and re-injected into fasted volunteers. After re­
isolation of the lipoproteins, the proteins were separated by SDS-PAGE and specific 
radioactivities were measured in the bands. Lichtenstein et al. (1992) used stable isotope 
labelling to measure apo B-48 and apo B-100 kinetics. After a constant infusion of 
deuterated leucine, isotopic enrichment in each protein was measured by gas 
chromatography-mass spectrometry. Labelling techniques are invasive, complicated, 
potentially hazardous and have not been extensively used.
Gel permeation chromatography HPLC was used to separate apo B-48 and apo B-100 
according to their size (Schwandt et a l, 1986; Wagner et a l, 1987; Hidaka et a l, 1990) 
and allowed the proteins to be collected. This method has been criticised due to the very 
high ratio of apo B-48 to apo B-100 obtained compaied with other methods (Karpe and 
Hamsten, 1995) and has not subsequently been used in studies.
A recent advance in the measurement of apo B-48 was the production and application of a 
specific antisera to apo B-48 (Peel et a l, 1993). The antisera was raised to a negatively- 
chai'ged heptapeptide sequence consisting of the carboxyl terminal 6  amino acids of apo 
B-48 attached to an N-terminal cysteine residue for conjugation. The negatively charged 
carboxyl group on the terminal amino acid of this peptide corresponds to ile-2152, the 
terminal amino acid on the carboxyl end of the apo B-48 molecule. In the apo B-100 
molecule this ile-2152 is part of a peptide bond and thus the antisera takes advantage of 
the charged nature of the amino acid (Peel et a l, 1992). Initially an immunoblotting 
method using the antisera had been developed and used in a postprandial study. However 
this method was only semi-quantitative due to high coefficients of variation and the lack 
of a suitable standar d curve. The production of a specific, quantitative immunoassay had 
yet to be fully developed, but is considered essential for following the metabolism of 
dietary-derived lipoproteins under different conditions.
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1.9. AIMS OF THIS STUDY
The main objective of this research was to investigate the metabolism of intestinally- 
derived lipoproteins by using apo B-48 as a marker for CM and CMR. There were two 
aims to achieve this objective. Firstly to continue to use the existing immunoblotting 
technique for apo B-48, and to assist with tire validation of a specific, quantitative ELISA 
for apo B-48. Secondly to apply both the methods in studies of postprandial lipaemia to 
investigate the impact of nutritional and physiological factors on CM and CMR levels. In 
pursuit of this objective a comparison was made between the use of RE and apo B-48 as 
markers for intestinally-derived lipoproteins.
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CHAPTER TWO 
MATERIALS AND METHODS
2.1 TREATMENT OF BLOOD SAMPLES
2.1.1 Materials
Blood samples were obtained from healthy volunteers. Aprotinin (kallikrein inactivator), 
benzamidine, gentamicin sulphate and chloramphenicol were obtained from Sigma 
Chemical Co. Ltd., Poole, Dorset. Sodium azide, sodium chloride, sodium hydroxide and 
ethylenediaminetetraacetic acid (disodium salt) (EDTA) ("Analar" grade) were from 
BDH Laboratory Supplies, Merck Ltd., Lutteiivorth, Leics.
2.1.2 Procedure
A preservative solution was prepared, following the method of Edelstein & Scanu (1986), 
for plasma, CM-enriched fractions and infranatant fractions which were to be analysed 
for apo B-48. First, 1.2 g of EDTA was added to 40 ml of water and the pH adjusted to 
pH 7.4 with 3.0 M sodium hydroxide to aid solubilisation. Then 0.1 g of sodium azide,
1 0 ,0 0 0  units of aprotinin, 8 .8  g of sodium chloride, 0.16 g of benzamidine, 80 mg of 
chloramphenicol and 80 mg of gentamicin sulphate were added and the total volume was 
made up to 50 ml. This was stored at room temperature (RT).
For most of the studies (Chapters 3, 4 and 5) blood was collected into heparinised tubes 
and centrifuged at 3,000 rpm for 10 minutes (3,000 g.min) to separate plasma from red 
blood cells. For the lipoprotein distribution study in Chapter 6  the blood was collected 
into EDTA tubes and centrifuged as usual. The plasma was removed and aliquotted into 
separate tubes for each analysis. Preservative was added to the samples for analysis of 
apo B-48 to give a final concentration of 5 % (v/v). All samples were stored at -20 °C 
unless otherwise stated in the relevant Sections.
40
2.2 ULTRACENTRIFUGATION METHODS
2.2.1 Principle
Ultracentiifugation is central to investigating lipoprotein metabolism. There are two 
main variations of this method which aie used throughout this thesis and are briefly 
outlined below. All of these techniques are discussed in much greater detail in Lindgren 
et al. (1972) and Mills et al. (1984).
i) Sequential flotation ultracentrifugation
Sequential flotation ultracentrifugation (SFUC) is used to sub-fractionate the individual 
lipoprotein classes according to the density of the lipoproteins. In this method the solvent 
density of plasma (or other solution of lipoproteins) is adjusted to the lower limit of the 
fraction that is to be isolated and then centrifuged at about 1 0 0  0 0 0  g for several hours. 
The lipoproteins of density less than that to which the solution was adjusted float to the 
top of the tube, while other substances sediment towards the bottom. The floating 
lipoproteins are removed. However, no matter how carefully the experiment is 
performed, fractions always overlap because paiticles with a density close to that of the 
solvent migrate very slowly into (or out of) the upper part of the tube. This technique has 
the drawback that it cannot be used to separate CM from VLDL as both species are less 
dense than physiological salt solution (d <0.94 and d <1,006 g/ml respectively).
A modified version of this technique is used to sub-fractionate CM from plasma, although 
the fraction is always contaminated with very large VLDL. The plasma is overlayered 
with 0.196 M NaCl (d = 1.006 g/ml at 20 °C) and centrifuged for a short, precise time at 
constant temperature. The resolution of this process is low because slow-moving 
particles that start from the top of the sample layer will reach the top of the tube at the 
same time as faster particles that travel from the bottom of the tube.
ii) Density gradient ultracentrifugation
Density gradient ultracentrifugation (DGUC) depends on floating the lipoprotein particles 
through a gradient formed by layering salt solutions of decreasing density above a layer 
of plasma adjusted to a density greater than the solution above it. Lipoproteins are 
separated according to their Svedberg flotation (Sf) rate. This technique allows more 
accurate sub-fractionation of the lipoprotein species as the density gradients can be 
manipulated to produce narrow Sf ranges. Centrifugation in a swinging bucket rotor 
causes the lipoprotein particles to float through the gradient. The gradient can either be 
continuous or discontinuous and the fractions can be removed from either the top or the 
bottom of the tube. Again, CM and VLDL cannot be completely sepaiated, however, for
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this method, CM and VLDL are usually separated on the basis of an operational 
definition whereby CM are defined as having an Sf rate greater than 400 and VLDL have 
an Sf range of 20-400.
The overlapping nature of the lipoprotein classes means that it is important to follow 
published methods exactly and to beai* in mind that any CM preparation will produce a 
heterogeneous population with a significant VLDL content.
2.2.2 Preparative ultracentrifugation of CM-enriched fractions
Two slightly different methods were used to isolate CM-enriched fractions in the two 
studies described in this thesis (Chapters 3 and 5). The variation was due to the 
availability of different ultracentrifuges. The CM-enriched fractions in both studies were 
prepared by a modification of the method described by Grundy & Mok (1976) with 
further modifications from Mills et a l (1984).
2.2.2.1 Preparation of a CM-enriched fraction using the Beckman ultracentrifuge 
Materials
The ultracentrifuge was a Beckman L7-65 model. The polycarbonate ultracentrifuge 
tubes and 50,2 Ti rotor were also supplied by Beckman RIIC Ltd., High Wycombe, 
Bucks. Sodium chloride ("Analar" grade) was from BDH Laboratory Supplies, Merck 
Ltd., Lutteiworth, Leics.
Procedure
Sodium chloride solution of density (d) 1.006 g/ml was prepared by dissolving 10.49 g of 
NaCl in 1 L of water. The density was accurately adjusted with the aid of a hydrometer.
3.5 g of plasma was weighed into a 32 ml thick-walled ultracentrifuge tube and 
overlayered with 3.5 g of the sodium chloride solution (d=1.006 g/ml). The tubes were 
centrifuged at 45,000 rpm in a 50.2 Ti rotor at 24 °C for 16.5 minutes (plus 13.5 minutes 
acceleration and 9 minutes deceleration). The cumulative 'g' force for this spin was 
4.99 X 10  ^gmax-niin. Using a U-shaped fine bore glass pipette, the upper supernatant 
layer, which will be termed "CM-enriched fraction", was removed by aspiration with a 
modified glass pasteur pipette and treated in one of two ways: in the fasting or early 
samples where there were very few CMs and thus a very thin supernatant layer, 0.4 ml of 
supernatant was removed into a tube and mixed. 0 .2  ml of this was removed into another 
tube for analysis of apo B-48. 0.6 ml of 0.9% (w/v) NaCl solution was added to the
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remaining 0.2 ml, mixed and aliquotted. At all other time-points where the CM layer was 
greater than 0.4 ml, the entire supernatant CM layer was removed into a tube and the 
volume made up to 1.2 ml with 0.9% (w/v) NaCl. This sample was mixed and then 
aliquotted into 3 tubes. If the volume of CM was greater than 1.2 ml the entire CM layer 
was removed, the volume measured, mixed and aliquotted as before. Preservative was 
added to all tubes which were then stored at - 2 0  °C until analysis.
The infranatant remaining after removal of the CM-enriched fraction was made up to
7.0 ml with NaCl (0.9 %) aliquotted, preservative added and stored at - 20 °C until 
analysis.
2.2.2.2 Preparation of a CM-enriched fraction using the Camiab ultracentrifuge 
Materials
The centrifuge was a Camiab refrigerated high speed centrifuge (4239R) (Camiab Pic., 
Cambridge) and the polycaibonate ultracentrifuge tubes were from Fisons Scientific 
Equipment, Loughborough, Leics. Sodium chloride ("Analar" grade) was from BDH 
Laboratoiy Supplies, Merck Ltd., Luttei*worth, Leics.
Procedure
The NaCl solution (d=1.006 g/ml) was made up as in Section 2.2.2.1. 3.5 ml of plasma 
was accurately pipetted into a 12 ml ultracentrifuge tube and overlayered with 3.5 ml of 
NaCl. The tubes were centrifuged at 20,000 rpm in a Camiab rotor at 24 °C for 
99 minutes (including acceleration and deceleration). The cumulative 'g' force for this 
spin was 4.31 x 10  ^gmax min. Using a straight fine bore glass pipette, the CM-enriched 
fraction was carefully removed into a tube and the volume made up to 1 .2  ml. 
Preservative was added and the fraction was aliquotted and stored at -20 °C.
The infranatant (5.8 ml) remaining after removal of the CM-enriched fraction (the volume 
was made up to 5.8 ml with NaCl (0.9 %) if greater than 1.2 ml of CM-enriched fraction 
had been removed) was aliquotted, preservative added and stored at - 2 0  ®C until analysis.
The methods for preparation of CM-enriched fractions in other rotors and from other 
volumes of plasma are outlined in the relevant chapters.
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2.2,3 Sequential flotation ultracentrifugation (SFUC)
The method described below was modified from a published technique using a fixed 
angle rotor (Mackness and Durrington, 1992) to allow for lipaemic postprandial samples.
Materials
NaCl, NaBr and KBr were obtained from Fisons Scientific Equipment, Loughborough, 
Leics. Thick-walled polycarbonate 10 ml ultracentrifuge tubes were from Beckman UK. 
The ultracentrifuge was a Beckman L7-65 model.
Procedure
Density solutions
Solutions of varying density were made up as indicated in Table 2.1 and the density 
tested using a digital density-meter at 15 “C. The initial stock solutions were NaCl 
(d =1.006 g/ml) as described in Section 2.2.3.1 and a stock 'heavy solution’ of KBr/NaCl 
(d = 1.27 g/ml). The heavy solution was made from 76.5 g NaCl and 111 g KBr in 500 ml 
of water and the density measured with a density meter. The intermediate density 
solutions were made up using different volumes of these two stock solutions determined 
from the following equation:
Equation 2.1. V2 = Vi x D - Di
D2-D
where Vi = volume of NaCl d =1.006 g/ml
y 2 -  volume of NaCl/KBr d =1.27 g/ml 
D = density of solution required 
Di = 1.006 g/ml (density of NaCl)
D2 = 1.27 g/ml (density of NaCI/KBr)
Density required Volume of KBr/NaCl Volume of NaCl
(g/ml) d =1.27 g/ml (ml) d =1.006 g/ml (ml)
1.019 5.2 1 0 0
1.063 27.5 1 0 0
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VLDL + CM (d <1.006 g/ml)
3.5 ml of each plasma sample containing 5 % (v/v) preseiwative was mixed with 3.0 ml of 
NaCl (d = 1.006 g/ml) in a Beckman polycarbonate 10 ml tube. The samples were 
centrifuged at 35,000 rpm for 17 hours 46 minutes (1.2 x 10  ^ g.min) in a 70.1 Ti fixed 
angle rotor at 15 “C. The VLDL fraction was removed in the top 1.2 ml using a glass 
pasteur pipette.
IDL (d <1.019 g/ml)
The density of the remaining infranatant was raised to 1.019 g/ml by adding 0.27 ml of 
heavy solution (calculated from equation 2.1 where Vi = volume of infranatant 
remaining, V% = volume of heavy solution to add, D = density required for IDL spin, 
Di = density of infranatant and D2 = density of heavy solution). This was thoroughly 
mixed to resuspend the pellet. The volume of the solution was made up to 6.5 ml with 
0.93 ml of NaCl/KBr (d =1.019 g/ml) and mixed. If the sample was very lipaemic more 
than 1.2 ml was removed, ensuring no lipid remained on the tube wall, the volume noted 
and the volumes of 'heavy solution' and NaCl/KBr (d =1.019 g/ml) solution added to the 
remaining infranatant were adjusted accordingly, using equation 2.1. The samples were 
centrifuged at 35,000 rpm for 21 hours 20 minutes (1.44 x 10  ^g.min) at 15 “C. The IDL 
fraction (d <1.019 g/ml) was removed in the top 1.2 ml.
LDL fraction (d <1.063 g/ml)
The density of the remaining infranatant in the tube was raised to 1.063 g/ml by adding 
1.13 ml of heavy solution (calculated from equation 2.1) and mixing. Tlie volume in the 
tube was restored to 6.5 ml by adding 0.07 ml of NaCl/KBr (d =1.063 g/ml) and mixing. 
The samples were centrifuged at 35,000 rpm for 24 hours 53 minutes (1.68 x 10® g.min) 
at 15 °C. The LDL fraction (d <1.063 g/ml) was removed in the top 1.2 ml.
Preservative was added to all fractions at 3 % of the final volume and the fractions were 
stored at - 20 “C until analysis.
The methods for preparation of lipoprotein fractions by SFUC in other rotors and from 
other volumes of plasma are outlined in the relevant chapters.
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2.3 MEASUREMENT OF PROTEIN IN LIPOPROTEIN FRACTIONS
2.3.1 Materials
Sodium carbonate, sodium hydroxide, sodium potassium tartrate and copper sulphate 
("Analar") grade were obtained from Fisons, Loughborough, Leics. Folin Ciocalteu 
reagent was obtained from BDH Laboratory Supplies, Merck Ltd., Lutterworth, Leics. 
Sodium dodecyl sulphate (SDS), bovine serum albumin (BSA) and human semm albumin 
(HSA) were from Sigma Chemical Co. Ltd., Poole, Dorset.
2.3.2 Procedure
The method used for analysing the protein content of lipoprotein fractions was a 
modification of the Lowry protein assay (Lowry et al, 1951). To prevent interference by 
lipid, SDS was added to all the samples.
Stock solutions
Solution A - 2 % Na2C0 3  in 0.1 M NaOH (w/v)
Solution B - 2 % NaK Tartrate (w/v)
Solution C - 1 % C11SO4 (w/v)
Solution D - Folin Ciocalteu reagent
Working reagents
Biuret reagent: 100 ml solution A, 1 ml solution B and 1 ml solution C were mixed with 
100 mg SDS.
Folin Ciocalteu reagent: 5 ml of the stock Folin Ciocalteu reagent was diluted with 5 ml 
of deionised water.
The working reagents were prepared fresh immediately before the assay.
A stock solution of HSA (1.0 mg/ml) was used to prepare a standard curve in the range 
0-75 |ig in a final volume of 400 \xl. Stock solutions of HSA at 0.15 mg/ml and 0.30 
mg/ml were used as quality controls (QCs) and 100 pi was used to give 15 pg and 30 pg 
of protein respectively in the final volume of 400 pi. The samples were diluted as 
appropriate to fall within the range of the standard curve and the final volume adjusted to 
400 pi. CM-enriched fractions were diluted 1:80, LDL fractions were diluted 1:40 and 
other lipoprotein fractions were used neat.
2 ml of Biuret reagent was added to 400 pi of standar d, QCs and samples. The tubes 
were vortexed and left at RT for 10 minutes. 200 pi of working Folin Ciocalteu was 
added, immediately vortexed and left at RT for 30 minutes. The optical density was read 
on a spectrophotometer at 750 nm witliin 2  hours.
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2.4. SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS AND 
IMMUNOBLOTTING 
2.4.1 Principle
Detailed infoimation on the principles of electrophoresis can be found in Hames (1990). 
In brief, the technique is based on the fact that a charged ion or group will migrate when 
placed in an electric field. Proteins carry a net charge at any pH other than their 
isoelectric point. Therefore the application of an electric field to a protein mixture in 
solution results in different proteins migrating at different rates towards one of the 
electrodes. The use of a porous gel also produces a molecular sieving effect so that, in 
the basic gel electrophoresis system, the separation of proteins is dependent on both 
charge density and size. Application of a gradient polyacrylamide gel provides an 
efficient mechanism for separating proteins over a wide molecular weight range. The 
pore size in the gel decreases as the proteins migrate away from the origin, therefore large 
proteins stop migrating close to the origin when the pore size becomes small enough to 
prevent their movement; the smaller proteins can migrate further from the origin. The 
presence of SDS in the system eliminates the effect of protein charge. SDS binds to 
proteins in a constant weight ratio (1.4 g of SDS per gram of polypeptide). If excess SDS 
is added, SDS-polypeptide complexes migrate in the polyacrylamide gels according to 
polypeptide size alone. The addition of SDS thus creates a denaturing buffer system. 
This denaturing system also contains a thiol reagent (to cleave disulphide bonds) and urea 
(to disrupt hydrogen bonds) with the net result that proteins dissociate into their 
individual polypeptide units.
After electrophoresis, proteins can either be visualised directly on the polyacrylamide gel 
by staining with Coomassie Blue, or they can be transferred by electroblotting to a 
support matrix such as a nitrocellulose membrane. Although the mechanism of protein 
binding to nitrocellulose is not fully understood it is believed to be non-covalent and 
probably involves hydrophobic interactions. Following electrotransfer, the membrane 
can be incubated with antibody solutions to allow detection of particular proteins. Non­
specific binding of antibody to the filter matrix is prevented by blocking vacant sites with 
a protein such as that contained in dried milk.
2.4.2 Materials
Ponceau Red, Tween 20, high molecular weight marker proteins, SDS, dithiothreitol, 
ammonium persulphate, tetramethylethylenediamine (TEMED), Tris (7-9), 
2-mercaptoethanol, Coomassie Blue R-250, biotinylated goat anti-rabbit immunoglobulin
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G (IgG) and extravidin-peroxidase conjugate were all from Sigma Chemical Co. Ltd., 
Poole, Dorset. Sodium chloride, disodium hydrogen phosphate (anhydrous), potassium 
dihydrogen phosphate, urea, glycine, sucrose, trichloroacetic acid, glycerol, methanol (all 
"Analar" grade) and bromophenol blue were obtained from BDH Laboratory Supplies, 
Merck Ltd., Lutterworth, Leics.
Butanol, potassium chloride, sodium hydroxide and hydrochloric acid (all analytical 
reagent grade) were from Fisons Scientific Equipment, Loughborough, Leics. Proto gel 
was supplied by National Diagnostics, Aylesbury, Bucks. and Marvel milk powder was 
from Tesco Stores Ltd., Ware, Herts. The nitrocellulose membrane (BA 85) was 
manufactured by Schleicher and Schuell and supplied by Anderman and Company Ltd., 
Kingston-upon-Thames, Surrey. The Saianwrap was manufactured by the Dow Chemical 
Company and supplied by Gene Research Insti'umentation Ltd., Dunmow, Essex.
Hoefer Scientific Instruments, Newcastle-under-Lyme, Staffs., supplied the 
electrophoresis equipment. The densitometric scanner was a dual wavelength flying spot 
CS-9001PC model manufactured by Shimadzu and supplied by V.A. Howe, Banbury, 
Oxon. Enhanced chemiluminescence (ECL) reagents and ECL film were supplied by 
Amersham International Pic., Little Chalfont, Bucks..
2.4.3 Stock solutions
3 M Tris buffer (pH 8.8)
36.3 g of Tris was weighed and dissolved in 48 ml of 1 M HCl. The pH was adjusted to
8 .8  with 12 M HCl if necessaiy and water was added to a final volume of 100 ml. This 
solution was stable for several weeks when stored at 4 °C.
0.5 M Tris buffer, (pH 6.8)
6.02 g of Tris was dissolved in approximately 40 ml of water. The pH was adjusted to
6 .8  by adding 1 M HCl (approximately 48 ml) and water was added to a final volume of 
100 ml. This solution was stable for several weeks when stored at 4 ^C.
Urea/SDS/dithiothreitol solution
19.2 g of urea, 12.3 mg of dithiothreitol and 0.08 g of SDS were dissolved in 25 ml of 
water and the final volume was made up to 40 ml. This was made up fresh each day.
1.5 % ammonium persulphate solution
0.15 g of ammonium persulphate were dissolved in 10 ml of water. This was made up 
fresh each day.
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Sample buffer (two-fold concentrated)
1.51 g of Tris was dissolved in 35 ml of water, 20 ml glycerol was added and the pH 
adjusted to pH 6.75 with 12 M HCl. Then 4 g of SDS, 10 ml of 2-mercaptoethanol and 
2  mg of bromophenol blue were added and diluted with water to a final volume of 1 0 0  
ml. This was stable at room temperature (RT) for 4 weeks.
Electrode buffer (pH 8.3)
71 g of glycine, 15.3 g of Tris and 5 g of SDS were dissolved in 5 L of water. This was 
made up fresh each day.
Transfer buffer (pH 8.3)
86.4 g of glycine, and 18.15 g of Tris were dissolved in 6  L of water. This was made up 
fresh each day.
PBS buffer (10-fold concentrated, pH 7.4)
80 g of sodium chloride, 11.5 g of disodium hydrogen phosphate, 2 g of potassium 
chloride and 2 g of potassium dihydrogen phosphate were dissolved in 1 L of distilled 
water. This solution was stable for two weeks when stored at RT.
PBS-Matyel Tween (PBSMT) buffer (pH 7.4)
25 g of Marvel milk powder was dissolved in 500 ml of water and 0.25 ml of Tween 20 
was added. This was made up fresh each day.
2.4.4 Procedure
Preparation o f SDS-polyacrylamide gel
Lineal' gradient (5-22 %) polyacrylamide gels were prepared following the method of 
Hames (1990) according to the original method of Laemmli (1970). For the analysis of 
apo B-48 and apo B-100 a 5 % (w/v) acrylamide resolving gel (16.36 ml) and a 22 % 
(w/v) acrylamide resolving gel (13.7 ml) were prepared as shown in Table 2.2.
The final concentrations of each component in the 5 % resolving gel were: 0.34 M Tris- 
HCl (pH 8 .8 ), 0.015 % (w/v) SDS, 0.0023 % (w/v) dithiothreitol, 3.53 % (w/v) urea and
0.032 % (w/v) ammonium persulphate. The final concentrations in the 22 % resolving 
gel were: 0.41 M Tris-HCl (pH 8 .8 ), 0.0022 % (w/v) SDS, 0.00034 % (w/v) 
dithiothreitol, 0.55 % (w/v) urea, 0.17 % (w/v) sucrose and 0,038 % (w/v) ammonium 
persulphate.
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Table 2.2 Gel mixtures for forming a 5 - 22 % gradient gel
Resolving gels 
5 % 22 %
Stacking gel
Sucrose — 2.25 g —
Tris buffer 1.85 ml 1.85 ml 3.75 ml
Protogel 2.50 ml 1 0 .0 0  ml 1.85 ml
Urea/SDS/
dithiothreitol
1.50 ml 0.15 ml 0.30 ml
1.5 % ammonium 
persulphate
0.35 ml 0.35 ml 1.15 ml
water 1 0 .1 0  ml 1.35 ml 7.50 ml
3 M Tris buffer, pH 8.8, was used for the resolving gels and 0.5 M Tris buffer, pH 6.8, was used for tlie 
stacking gel. Neat protogel is a mixture of 30 % (w/v) acrylamide and 0.8 % (w/v) N, N'-bis-methylene 
acrylamide.
Immediately before pouring the gel, 11.5 \xl of TEMED was added to both the 5 % and 
22 % gels to initiate polymerisation. The gel was poured with the aid of gradient forming 
apparatus following the manufacturer's (Hoefer Scientific Instruments, Newcastle-under- 
Lyme, Staffs.) instructions. Basically, the procedure was as follows: the 22 % solution 
was placed in the mixing chamber and the 5 % solution in the reservoir chamber. The 
free end of the tubing from the mixing chamber was placed between the glass plates of a 
gel mould. Stirring was started and the valve to the outlet port was opened. 
Simultaneously, the peristaltic pump was started and the valve between the two chambers 
opened, thus forming a concentration gradient of acrylamide from 5-22 % (top to 
bottom). The gel was then overlayered with water saturated butanol. Following 
polymerisation, the top of the gel was rinsed several times with distilled water.
A stacking gel (14.55 ml) was prepared as shown in Table 2.2. The final concentrations 
in the stacking gel were: 3.8 % (w/v) acrylamide, 0.13 M Tris-HCl (pH 6 .8 ), 0.0041 %
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(w/v) SDS, 0.00062 % (w/v) dithiothreitol, 1.0 % (w/v) urea, 0.1 % (w/v) ammonium 
persulphate. Immediately before pouring, 11.25 pi of TEMED was added to the stacking 
gel which was then poured on top of the resolving gel using a syringe bairel as a funnel. 
A fifteen-well sample comb was quickly inserted and the gel allowed to polymerise. 
Following polymerisation the sample comb was carefully removed and the resultant wells 
filled with electrode buffer.
Electrophoresis sample preparation
Usually, 50 pi of CM-enriched samples were mixed with 150 pi of sample buffer (two­
fold concentrated) in an Eppendoif tube and heated at 95 ®C for 2 mins to denature the 
proteins. The tubes were then centrifuged at 13,000 ipm for 2 min (2.1 x 1 0 ^ g.min) to 
separ ate insoluble material. Molecular weight markers were dissolved in sample buffer 
(two-fold concentrated) according to the supplier's (Sigma Chemical Co. Ltd.) 
instinctions, aliquotted and stored at -20 ®C. A lipoprotein sample containing a relatively 
high concentration of apo B-48 was used as a standard. Sample buffer was added to the 
standard sample at a ratio of 3:1 sample buffer : sample. This was thoroughly mixed, 
aliquotted and stored at -20 °C. Before each electrophoresis run molecular weight 
markers and standard were defrosted and treated as for samples described above. After 
allowing samples to cool to RT, 10 pi of molecular weight markers were loaded into the 
first lane with the aid of gel loading tips, 40 pi of standard were loaded into the second 
lane and 50 pi of each sample loaded into the following 13 lanes. Variations of the 
amounts of other samples loaded and standards used are given in the appropriate 
Chapters.
Electrophoresis
The upper electrode chamber was attached to the gel cassette and the lower chamber was 
filled with 3.5 L of electrode buffer. The plate assembly was placed in the lower chamber 
and the upper chamber was filled with electrode buffer. The lid of the upper chamber 
was fitted and the water cooling system switched on. Electrophoresis was carried out at 
30 mA (60 mA if two gels run) until the bromophenol blue marker reached the resolving 
gel after which the cuixent was raised to 60 mA (120 mA if two gels run). When the dye 
reached the bottom of the resolving gel (after about 3 hours) the power was switched off. 
The gel was then removed from the apparatus and either stained for protein or 
electrotransferred for immunodetection.
Protein staining of aciylamide gel
The gel was immersed in stain containing 10 % (w/v) trichloroacetic acid, 40 % (v/v) 
methanol and 0.1 % (w/v) Coomassie Blue R-250 and shaken gently for 30 mins. It was
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then diffusion-destained with several changes of 1 0  % (w/v) trichloroacetic acid over 16 
hours.
Electrotransfer
This is based on the method first described by Towbin et al. (1979). The gel was 
equilibrated in transfer buffer for 30 min. Some transfer buffer was poured into the 
bottom of a tray and into it was placed one half of the cassette, two pieces of sponge and 
two pieces of filter paper (Whatman chromatography paper 3mm). The gel was carefully 
placed onto the filter paper and any air bubbles were smoothed out. A piece of 
nitrocellulose membrane was cut to size and carefully placed onto the gel, smoothing out 
air bubbles and adding more buffer if necessary. Two further pieces of filter paper and 
two pieces of sponge were placed on top and the other half of the cassette was used to 
clamp the whole sandwich together. The tank was filled with transfer buffer and the 
cassette placed at the back of the tank with the gel towai'ds the cathode. The tank was 
topped up with transfer buffer and the water cooling system was switched on. The lid 
was attached and electrotransfer carried out for 17 hours at a constant voltage of 50 V.
Immimostaining of the nitrocellulose
The transfer cassette was dismantled and the nitrocellulose membrane was placed in a 
plastic tray with the protein side uppermost. The membrane was immersed in Ponceau 
Red stain for 1 min and then the excess stain was washed off with distilled water. The 
appearance of protein bands was noted before the membrane was placed inside a 
hybridisation tube. Incubation steps were carried out by adding solutions to the tube and 
rotating on a roller mixer. The Ponceau stain was removed and unoccupied sites on the 
membrane were blocked simultaneously, by incubation with 2 x 20 ml of PBSMT for 
1 hour with one change after 30 min. The membrane was then incubated sequentially 
with 15 ml (diluted in PBS) of: 1) primary antibody, 2) secondary antibody and 3) an 
extravidin peroxidase conjugate (Fig. 2.1) at the following dilutions:
1. 15 ml of rabbit anti-apo B-48 (1:1000)
2. 15 ml of biotinylated goat anti-rabbit immunoglobulin G (IgG) (1:1000)
3. 15 ml of extravidin-peroxidase conjugate (1:1000)
Each of the three incubations was for 1 hour and separated by 6  x 5 min washes with 
PBSMT. Following addition of the extravidin peroxidase conjugate, the membrane was 
washed four times with PBSMT and twice with PBS. The membrane was then removed 
from the tube and immersed in PBS in a tray.
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Figure 2.1. Schematic representation of immunoblotting method.
53
Enhanced chemiluminescence detection
This was carried out according to the manufacturer's instructions (Amersham 
International Pic.) in a dark room. 5 ml of each of the two enhanced chemiluminescence 
(ECL) reagents were mixed. The PBS was poured off and the ECL reagent was pipetted 
evenly over the surface of the membrane. After precisely 60 seconds excess reagent was 
poured off and the membrane was placed on a piece of Saranwrap film. The Saranwrap 
film was folded around the membrane to form a watertight seal and placed in a 
photographic film cassette. A piece of pre-flashed ECL film was exposed to the 
membrane and then developed using an automatic developing machine.
Densitometric scanning
This was performed using a dual wavelength flying spot scanner with the parameters 
shown in Appendix I. The wavelength used for both the ECL blots and Coomassie Blue 
protein stain gels was 550 nm. The lanes were scanned in zig-zag mode and integrated 
manually.
The reproducibility of the immunoblotting method was determined by another 
investigator. The mean inter-assay CV was 22.3 % (n=4). The mean intra-assay CV was
28.3 % (n=4).
An example of the protein bands obtained from a postprandial profile of CM-enriched 
fractions by Coomassie blue staining of a polyacrylamide gel and immunoblotting with 
the antisera for apo B-48 is shown in Figure 2.2.
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Figure 2.2. A) a protein stain and B) an immunoblot, visualised for apo B-48 by ECL, of 
postprandial CM-enriched samples after a 40 g fat meal. Lane 1 is MWM, lane 2 is the apo B-48 
containing-standard, lanes 3 and 4 are fasting samples, lane 5 is a sample taken 30 minutes after 
the meal and lanes 6  to 13 are samples taken at hourly intervals after the meal. Approximate 
positions of two molecular weight markers are indicated on the immunoblot as a guide.
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2.4.5 Expression of results
At the time of these experiments there was no method for quantitating the absolute level 
of apo B-48 found on the blot and no standard curve was run on the gel because of the 
minimal space for samples. The apo B-48 levels were therefore measured in a semi- 
quantitative way. In Chapters 3 and 6  it was necessary to compaie the results of different 
blots and therefore an internal standard was run on each gel. The band intensity (peak 
area measured in arbitrary units) of apo B-48 in each sample was expressed as a 
percentage of the band intensity of the internal standard, to allow for daily variation in the 
method. This allowed a direct compaiison of relative levels of apo B-48 postprandially in 
different subjects measured on different gels. In Chapter 4, where direct comparison of 
apo B-48 levels between gels was not necessary, the level of apo B-48 in different 
samples run on the same gel was expressed in terms of the band intensity (peak aiea 
measured in ai'bitraiy units).
2.4.6. Validation of a new apo B-48 standard
After 70 % of the samples of the exercise study in Chapter 3 had been run the apo B-48 
standard ran out and had to be replaced. A postprandial blood sample was taken 2.5 
hours after consuming an 80 g fat meal from the same volunteer as for the original 
standard. A VLDL/CM fraction (d <1.006 g/ml) was prepared from the plasma by SFUC 
as described in Section 2.2.3 and used as the new standard.
In order to establish the difference in band intensity between the two standards, four 
samples of each of the two different standards were run on the same gel. The band 
intensities were measured after immunoblotting as described above. The mean band 
intensity of the original standard was 81 (aibitrary units) and the mean band intensity of 
the new standard was 164 (arbitrary units). In order to allow a direct comparison between 
apo B-48 levels in samples measured on gels with the new and old standard in Chapter 3, 
a factor was devised according to equation 2 .2 :
Equation 2.2 Factor = mean band intensitv of new standard
mean band intensity of original standard
164 = 2.02 
81
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The band intensities of all samples expressed as a percentage of the new standard were 
therefore multiplied by the factor (2 .0 2 ) in order to allow a direct compaiison with the 
samples expressed as a percentage of the original standar d.
2.4.7. Immunostaining of nitrocellulose without enhancement of the signal
After analysis of samples in Chapter 3, the immunoblotting method was altered to allow 
for a change in the primary anti apo B-48 antisera to the same as that used in the ELISA 
described in Section 2.5 (i.e. antisera from rabbit 2009 taken 13 days after the first boost). 
This antisera had a much higher titre and avidity than the initial antisera used by Peel et 
a l (1993) and therefore a much more dilute solution of primary antisera was required. 
The higher avidity also meant that amplification of the signal through the avidin-biotin 
system (extravidin peroxidase) was not required, therefore the secondary antibody was 
changed to a horseradish peroxidase (HRP)-labelled donkey anti-rabbit IgG and the 
extravidin peroxidase was not used. These alterations also had the added advantage of 
decreasing the number of steps during the procedure and increasing the length of 
exposure time of the nitrocellulose to the film. Both these factors should improve the 
reproducibility of the method.
2.4.8 Validation of immunoblotting with new antisera
The linearity of the method with the new antisera was checked by setting up a standard 
curve of a CM-enriched fraction containing a high concentration of apo B-48. The 
samples were run in duplicate on the gel and the results are shown in Figure 2.3. The 
response was found to be linear over a protein loading range of 7.5 - 75.0 pg when using 
the rabbit anti-apo B-48 at a dilution of 1:10,000 and the HRP-labelled donkey anti-rabbit 
IgG at a dilution of 1:2000. The range of protein loaded in each well in the CM-enriched 
samples was 51 to 125 pg, but the majority of the CM-enriched samples fell within the 
lower end of this range (51 to 82 pg protein). The range of protein loaded in each well in 
the infranatant samples was 385 to 515 pg.
The intra-assay and inter-assay coefficients of variation (CV) were determined using CM- 
enriched fractions of a medium and a high apo B-48 content. The intra-assay CVs were 
found to be 22.5 % and 25.2 % respectively (n=9) and the inter-assay CVs were 31.2 % 
and 32.6 % respectively (n=4); these were similar to those found for the original method 
(Peel et al., 1993).
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Figure 2.3. Relationship between apo B-48 band intensity after immunoblotting and the 
amount of protein loaded on the gel. The standard curve was set up by dilution of a CM- 
enriched fraction from a postprandial sample and then the sample buffer was added to 
each standard. 50 pi of the standard mixed with sample buffer were loaded in each lane. 
The protein concentration in the CM-enriched fraction was measured by a modification of 
the method of Lowry et a l (1951) (Section 2.3).
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2.5 APO B-48 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
2.5.1 Principle
There are various ELISA formats, using antibodies or antigens conjugated to enzymes, 
which result in products which can be measured by spectrophotometry. The ELISA 
developed to measure apo B-48 is a competitive system. The peptide used to raise the 
anti-apo B-48 antisera is conjugated to a large cairier protein (thyroglobulin) and bound 
to the ELISA plate. The sample is incubated with the anti-apo B-48 antisera in a separate 
tube; the specific antibodies will bind to any apo B-48 present in the sample. The mixture 
is then added to the plate, incubated, then washed. Unbound antibodies bind to the 
peptide on the plate; the remaining antibodies bound to the apo B-48 aie washed off. A 
secondary enzyme-labelled anti-IgG antibody is added, incubated and washed. A 
substrate is then added which is converted to a coloured product by the enzyme. The 
amount of colour produced is inversely proportional to the amount of apo B-48 present in 
the sample. The principles of this procedure are represented schematically in Figure 2.4.
2.5.2 Materials
Gelatin (biochemical grade), sodium carbonate, sodium hydrogen carbonate, citric acid, 
disodium hydrogen phosphate (anhydrous), potassium dihydrogen phosphate and 
hydrogen peroxide (all "Analar" grade) were from BDH Laboratoiy Supplies, Merck Ltd., 
Lutterworth, Leics. Potassium chloride and sodium chloride (both analytical reagent 
grade) and hydrochloric acid were obtained from Fisons Scientific Equipment, 
Loughborough, Leics. Tween 20, HSA, 3, 3', 5, 5'-tetraniethylbenzidine (TMB), 
dimethyl formamide (DMF) and porcine thyroglobulin were from Sigma Chemical Co. 
Ltd., Poole, Dorset. The HRP-labelled donkey anti-rabbit IgG was obtained from 
Guildhay, Guildford, SuiTey. The Maxisoip micro titre plates were from Nunc, Roskilde, 
Denmark.
Human thoracic duct lymph, obtained from a patient undergoing thoracic surgery, was 
kindly supplied by Dr. J. Wright at the Royal Surrey County Hospital, Guildford and was 
used as the standard for the ELISA. Two different lymph samples were used for the 
analysis of apo B-48 in different chapters (lymph E and H). The quantitation of the 
absolute amounts of apo B-48 and apo B-100 in the lymph samples was carried out by Dr 
Frederik Kai’pe at the Karolinska Institute, Sweden using their published method (Kaipe 
and Hamsten, 1994). The values found were 19.2 p.g/ml of apo B-48 and 42.9 pg/ml of 
apo B-100 in lymph E and 12.3 |Xg/ml of apo B-48 and 37.0 P-g/ml apo B-100 in 
lymph H.
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Figure 2.4. Schematic representation of the competitive ELISA procedure for measuring 
apo B-48.
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2.5.3 Stock solutions
Coating bujfer-0.1 M bicarbonate/carbonate bujfer (pH 9.6)
3.18 g of sodium carbonate and 5.88 g of sodium hydrogen carbonate were dissolved in 
1 L of water and adjusted to pH 9.6. This was stored at 4 °C.
PBS bujfer (10-fold concentrated, pH 7.4)
160 g of sodium chloride, 58 g of disodium hydrogen phosphate, 4 g of potassium 
chloride and 4 g of potassium dihydrogen phosphate were dissolved in 1 L of distilled 
water. This solution was stable for two weeks when stored at RT.
Wash bujfer-PBS-gelatin Tween
100 ml of PBS (xlO) was added to 900 ml water. 1 g of gelatin was added to 100 ml of 
this PBS, dissolved with heating and mixed with the remaining PBS. 0.5 ml of Tween 20 
was added and mixed. This was prepared fresh each day.
Standard diluent-HSA
HSA, at a concentration of 35 mg of HSA per ml of PBS, was prepared fresh each day. 
Substrate bujfer-citrate-phosphate bujfer (pH 5.3)
2.61 g citric acid and 3.55 g disodium hydrogen phosphate (anhydrous) were dissolved in 
500 ml of water. This was stored at 4 °C.
TMB stock solution
20 mg of TMB was dissolved in 1 ml of DMF. This was stored at 4 °C.
TMB substrate
100 pi of TMB substrate stock and 16 pi of H2O2 were added to 20 ml of substrate 
(citrate-phosphate) buffer. This was made up within 10 minutes of use.
Stop reagent
1 M HCl was made up by adding 50 ml of concentrated HCl to 450 ml of distilled water. 
Coating conjugate-heptapeptide-SPDP-thyroglobulin
A  heptapeptide consisting of the caitoxy terminal 6  amino acids (2147-2152) of apo B-48 
bound to an amino terminal cysteine residue, was custom synthesised by the National 
Institute of Medical Research (Mill Hill, London). The terminal isoleucine carboxy 
group was negatively charged to produce a peptide with the sequence: 
H3N+-Cys-Leu-Gln-Thr-Tyr-Met-Ile-C0 0 “.
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In order to produce the coating conjugate, the heptapeptide was conjugated to 
thyroglobulin using SPDP as a conjugating agent as detailed previously (A.S. Peel 1993, 
thesis. University of Surrey). The conjugate was stored at -20 °C and diluted in 0.1 M 
bicarbonate/carbonate coating buffer at a dilution of 1 :8 ,0 0 0  before use.
Lymph standard curve
Aliquots of lymph E or H were stored at -20 “C, defrosted and double diluted in standard 
diluent (35 mg/ml HSA in PBS) to produce a 9 point standard curve (1:1 to 1:256).
Apo B-48 antisera (taken from, rabbit 2009 after 1 boost +13 days)
The stock antisera was stored at 4 °C and diluted in PBSGT at a dilution of 1:125,000 
before use.
Secondary antibody (HRP-labelled donkey anti-rabbit IgG)
The stock antisera was stored at 4 “C and diluted in PBSGT at a dilution of 1:40,000 
before use.
Quality controls (QCs)
Pooled plasma samples were used as QCs which contained either low (fasting), medium 
(postprandial normal) or high (postprandial hyperlipidaemic) concentrations of apo B-48.
2.5.4 Procedure
The inner 60 wells of a NUNC maxisorp micro titre plate were coated with 100 pi per 
well of diluted coating conjugate (1:8,000). The plate was incubated in a humid chamber 
at 4 °C overnight.
The following day, a 9 point lymph standard curwe was prepared by double dilution using 
standard diluent (35 mg/ml HSA in PBS). A zero standard containing HSA only was also 
prepared. The standard curve, zero, QCs and samples were pre-incubated with an equal 
volume of anti-apo B-48 antiserum (1:125,000) at room temperature for 1 hour. The 
coating conjugate was emptied out and the wells of the plate were washed three times 
with PBSGT. The plates, containing 250 pi per well of PBSGT to block vacant sites, 
were incubated at 37 ”C for 1 hour.
After the pre-incubation, 100 pi of the samples, standards and QCs were added to the 
plate in duplicate wells and incubated for 2 hours. The plates were then washed three
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times with PBSGT and 100 p.1 of the secondary antibody (HRP-labelled donkey anti­
rabbit IgG) at a dilution of 1:40,000 added to each well. The plates were incubated for a 
further two hours, washed three times with PBSGT and 100 |il of TMB substrate added to 
each well. The substrate was incubated on the plate for approximately 30 minutes. The 
reaction was then stopped by the addition of 50 |ml of 1 M HCl and the absorbance of each 
well was read at 450 nm on an automated ELISA plate spectrophotometer (Labsystems, 
Basingstoke, Hants). A standard curve was plotted from which the amount of apo B-48 
in the QCs and samples was determined. Figure 2,5 shows a typical standard curve 
produced from the 9 point lymph E standard curve.
2.5.5 Validation experiments for the apo B-48 ELISA
Details of the sensitivity, recovery, and cross-reactivity of the method are given in 
Chapter 4. The coefficients of variation for different plasma QCs are given in the 
relevant chapters (Sections 4.3.9 and 5.2.6).
£c0
81I
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Figure 2.5. A typical 9-point standaid curve produced by double dilution of a lymph E 
standard.
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2.6 AUTOMATED ANALYSES ON THE COBAS MIRA PLUS
Analysis of TAG, cholesterol, NEFA, glucose, paracetamol and apo B were carried out 
using an automated analyser- the COBAS Mira plus (Roche Diagnostics Ltd., Welwyn 
Garden City, Herts). TAG, glucose, paracetamol, cholesterol and NEFA were measured 
by sequential enzymatic analysis and apo B was measured by immunoturbidometry. All 
analytes were measured in fasting and postprandial plasma samples. In addition, TAG 
measurements were made in the CM-enriched fraction and infranatant fractions obtained 
by ulti'acentrifugation of plasma during the postprandial studies.
For each analyte, all the samples from one subject were measured in the same run. 
External QC samples with assigned values were measured at regular intervals within each 
run to ensure identical assay conditions for each run.
2.6.1 Analysis of triacylglycerol (TAG)
The working reagent and calibrator were supplied in kit form from Roche Diagnostics 
Ltd., Welwyn Garden City, Herts. The QC was suppHed by Nycomed, Birmingham.
Working reagent: Unimate 5 TRIG reagent kit
Calibrator: Lipid control semm
Quality control: Seronorm lipid
Principle
The analysis is an enzymatic colorimetric method based on the following reactions:
triacylglycerol -------------------------------------- ► glycerol + fatty acids
glycerol + ATP -------------------------------------- ► glycerol-3-P + ADP
glycerol-3-P + 0%-------------------------------------- ^  dihydroxyacetone phosphate + H2O2
H2O2 + 4-chlorophenol 4- 4-aminophenazone quinoneimine derivative
The first step is catalysed by LPL, the second by glycerol kinase, the third by glycerol 
phosphate oxidase and the fourth by peroxidase. The red-coloured quinoneimine 
derivative absorbs at 500 nm. The intensity of the colour formed is proportional to the 
TAG concentration.
The assigned value for Seronorm lipid QC was 2.2 mmol/1. The mean intra-assay CV for 
this QC was 2.4 % ± 1.5 (n=ll) and the inter-assay CV was 2.6 % (n=ll). The linearity 
limit of the assay was 8 mmol/1; any samples with concentration greater than this were 
diluted with saline.
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2.6.2 Analysis of total cholesterol
The working reagent and calibrator were supplied in kit form from Roche Diagnostics 
Ltd., Welwyn Garden City, Herts. The QC was supplied by Nycomed, Birmingham.
Working reagent: Unimate 5 CHOL reagent kit
Calibrator: Lipid control serum
Quality control: Serononn lipid
Principle
The analysis is an enzymatic colorimetric method based on the following reactions:
cholesterol ester + H2O ------------------------------------------ ^  cholesterol + fatty acids
cholesterol + O2  ► cholest-4-en-3-one + H2O2
H2O2 + 4-chlorophenol + 4-aminophenazone  ► quinoneimine derivative
The first step is catalysed by cholesterol esterase, the second by cholesterol oxidase and 
the third by peroxidase. The red-coloured quinoneimine derivative absorbs at 500 nm. 
The intensity of the colour formed is proportional to the cholesterol concentration.
The assigned value for Seronorm lipid QC was 7.8 mmol/1. The mean intra-assay CV 
was 1.15 % ± 0.36 (n=4) and the inter-assay CV was 1.23 % (n=5). The linearity limit of 
the assay was 18 mmol/1.
2.6.3 Analysis of HDL-cholesterol
The reagents, QC and calibrator were supplied by Roche Diagnostics Ltd., Welwyn 
Garden City, Herts.
Precipitation reagent: HDL reagent 
Working reagent: Unimate 5 CHOL reagent kit
Calibrator: Control serum N
Quality control: Lipid control senim
Principle
The samples were pre-treated to remove apo B-containing lipoproteins by precipitation 
using HDL reagent which contained phosphotungstic acid and magnesium chloride. 
After centrifugation the HDL remain in the supernatant and the VLDL and LDL are
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pelleted. The HDL-cholesterol level in the clear supernatant can be assayed using the 
same cholesterol reagent kit as for total cholesterol.
The standard for this assay must be diluted with saline to allow for dilution of the HDL- 
cholesterol due to the precipitation reagent. The QCs are treated in the same way as the 
samples. The assigned HDL-cholesterol value for lipid control serum was 2.24 mmol/1. 
The mean intra-assay CV was 1.93 % ± 1.06 (n=3) and the inter-assay CV was 2.04 % 
(n=4).
2.6.4 Analysis of LDL-cholesterol 
Principle
After measurement of total and HDL-cholesterol, the LDL-cholesterol level can be 
determined from the Friedewald formula (Friedewald et ai, 1972) in the following 
equation:
Equation 2.3
LDL-cholesterol = total cholesterol - ( HDL-cholesterol + total TAG 1
2.2
The formula relies on the assumption that, when the level of TAG in plasma is below 4.5 
mmol/1, the level of VLDL-cholesterol bears a constant relationship to the level of TAG 
in the plasma. This assumption is not valid if the TAG concentration in the plasma is 
greater than 4.5 mmol/1 and therefore cannot be used for some postprandial plasma 
samples. For the purposes of this thesis HDL- and LDL-cholesterol levels were only 
measured in fasting samples.
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2.6.5 Analysis of non-esterified fatty acids (NEFA)
The working reagent, QC and calibrator were supplied in kit manufactured by Wako and 
supplied by Alpha Laboratories, Eastleigh, Hants.
Working reagent: Wako NEFA C test kit
Calibrator: NEFA C standard
Quality control: NEFA C kit
Principle
The analysis is an enzymatic colorimetric method based on the following reactions:
NEFA + ATP + CoA ------------------------------------------ ► acyl Co A + AMP + PPi
acyl CoA + O2  2,3-trans-enoyl-CoA + H2O2
H2O2 + 3-methyl-N-ethyl-(B-hydroxyethyl)-aniline + 4-amino-antipyrene
------------------------------------------ ► purple coloured adduct
The first step is catalysed by Acyl CoA synthetase in the presence of magnesium ions, the 
second by acyl CoA oxidase and the third by peroxidase. The purple-coloured adduct
absorbs at 550 nm. The intensity of the colour formed is proportional to the NEFA
concentration.
The assigned value for the NEFA C-kit QC was 0.50 mmol/1. The mean intra-assay CV 
was 4.3 % ± 1.7 (n=ll) and the inter-assay CVwas 8.9 % (n=ll).
Validation of the NEFA assay
Blood samples for NEFA analysis should be collected into EDTA tubes as heparin may 
increase the activity of LPL and thus more NEFA could be formed in the blood tube. For 
this research, blood samples for all COBAS analyses were collected into lithium heparin 
tubes. Validation of the NEFA assay for plasma samples collected in EDTA or heparin 
tubes was carried out by another worker in the laboratory. There was found to be no 
significant difference between the NEFA levels measured from the same sample collected 
into the two different tubes.
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2.6.6 Analysis of paracetamol
The working reagent and calibrator were supplied in kit form from Cambridge Life 
Sciences pic, Cambridge Science Park, Cambridge.
Working reagent: Acetaminaphen assay kit (lyophihsed enzyme, enzyme diluent,
colour reagent A and colour reagent B) 
Calibrator: aqueous paracetamol standard
Quality controls: postprandial plasma sample and paracetamol standard
Principle
The analysis is an enzymatic colorimetric method based on an enzyme specific for the 
amide bond of acylated aromatic amines (aryl-acyl-amide aminohydrolase). The enzyme 
cleaves the paracetamol molecule to produce acetate and p-aminophenol. The p- 
aminophenol reacts with o-cresol in the presence of ammonia and copper ions to produce 
a blue indophenol dye colour. The intensity of colour is measured at 615 nm and is 
proportional to the concentration of paracetamol.
The assay was set up for the COBAS Mira by another investigator as outlined by the 
manufacturer (Cambridge Life Sciences). The standard curve dilutions were produced 
automatically by the machine. The assigned value for the paracetamol standard was 2.0 
mmol/1. The value for the postprandial plasma sample was 0.14 mmol/1. The mean intra­
assay CVs for the postprandial plasma sample was 1.4 % ±1.9 (n=10). The inter-assay 
CVs were 0.9 % and 4.4 % for the paracetamol standard and the postprandial plasma 
sample respectively (n=1 0 ).
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2.6.7 Analysis of Apolipoprotein B
The working reagent, QC and calibrator were supplied from Roche Diagnostics Ltd., 
Welwyn Gaiden City, Herts.
Working reagent: Unimate 3 apo B test kit (apo B antisera)
Calibrator: apolipoproteins T standard
Quality control: apolipoproteins T control
Principle
Human apo B forms a precipitate with a specific antiserum. The level of precipitate is 
determined turbidimetrically at 340 nm. The antigen-antibody complex results in a 
decrease in transmitted light which is proportional to the concentration of the particles in 
suspension. Serial dilutions of the calibrator were performed automatically on the 
COBAS Mira plus and a standard curve produced. The samples and QCs were 
automatically diluted by the auto analyser and the apo B values determined from the 
standard curve.
The assigned value for the apo B control was 1.10 g/L (range 0.93-1.27 g/L). Intra-assay 
and inter-assay CVs for this QC were 1.0 % (n=5) and 5.2 % (n=5) respectively.
Standard curve for samples containing low concentrations of apo B.
All lipoprotein samples except the LDL fraction had very low concentrations of apo B 
(less than 0.25 g/L). The apo B standard curve on the COBAS Mira was set up to 
measure apo B concentrations over a range of 0.24 -3.83 g/L, tlierefore the machine had 
to be reprogrammed to measure lower apo B concentrations. The programme was set up 
to use a dilution factor of 4 instead of the normal 21. This enabled a standar d curve to be 
produced over a range of concentrations of 0.05 - 0.75 g/L. At the same time the samples 
were diluted less than usual so they would fall within this range. Because of the dilution 
factor lipaemic samples could not be accurately measured as the analysis was based on a 
turbidimetric assay. The apo B control was diluted by two with 0.9 % NaCl and used as a 
QC for the assay. The intra-assay CV was 3.8 % and the inter-assay CV was 4.3 % at a 
concentration of 0.53 g/L (n=5).
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2.7. RETINYL ESTER ANALYSIS 
Principle
RE are used to follow the metabolism of intestinally-derived lipoproteins. A known 
amount of retinol (usually in the form of RP) is taken orally and metabolised in a similar 
fashion to CE. Thus, RE become incorporated into the core of CM and are believed to 
remain in the particle throughout their metabolism until the CMR is cleared by the liver. 
Since RE are not re-secreted by the liver, measurement of plasma levels of RE acts as a 
marker of CM. See Section 1 .5 .1.2 for more details. RP is the princip alRE found in 
plasma after the intake of retinol.
2.7.1 Analysis of retinyl palmitate
The main method used to separate and analyse RE is high performance liquid 
chromatography (HPLC). The method published by de Ruyter and de Leenheer in 1978 
described the resolution of a mixture of compounds into four RE peaks using a reverse 
phase column. Each RE moved at a different rate through a stationary phase under the 
influence of a mobile phase. Separation of the RE was based on chain length and 
unsaturation of the fatty acid but retinyl oleate and RP co-eluted in the same peak. In 
order to separate the two esters a modification of the method was published (de Ruyter 
and de Leenheer, 1979) which used silver ions in the mobile phase. Addition of silver 
decreased the retention time of RE with a single unsaturated bond, due to interaction 
between tlie silver ions and the double bond, and therefore the retinyl oleate was eluted 
before the RP.
Procedure
The method used to measure RP is based on the reverse phase HPLC procedure of de 
Ruyter and de Leenheer (1978; 1979) with modifications by Ah-Sing in our laboratory. 
The analysis was carried out by a co-worker and was only sensitive enough to measure 
RP in the CM-enriched fraction. In brief, the process involves chloroform extraction of 
RP from the CM, drying and reconstitution of the solid extract in chloroform and 
methanol before injection into the column. Retinyl acetate (RA) was used as an internal 
standard in order to improve precision and compensate for possible losses during the 
extraction procedure. The area under the RP and RA peaks was calculated and peak area 
ratios determined. The concentration of RP was determined from a standard curve 
measured in pg/ml.
70
All samples from one subject were analysed in a single run to minimise effects of inter­
assay variation; a standard curve was set up for each run and a RP standard was run as a 
quality control in each run. The mean intra-assay CV was 4.2 % ± 0.02 (n=5). The inter­
assay CVs for 4 standards were 13.5 % (0.17 |ig/ml), 10.7 % (0.34 p.g/ml), 10.6 % (1.37 
|ig/ml) and 9.1 % (4.80 jig/ml).
2.7.2 Analysis of retinyl ester
There are various disadvantages with using the reverse phase HPLC method for 
measuring RP. The use of silver nitrate in the column is both expensive and haimful to 
the equipment (shortening of column life due to silver deposits), the extraction procedure 
is very extensive and the run time for each sample is very long (80 minutes). A normal 
phase HPLC method was described by Ruotolo et al. (1992) which enabled all RE in 
plasma to be co-eluted in one peak. This method had the advantage of shorter run times 
(10 minutes) and simpler sample processing. Three peaks are observed using this 
method: RA, RE and retinol.
Materials
RP and RA (both all-trans configuration and crystalline purity) were obtained from the 
Sigma Chemical Company, St Louis, USA. Hexane and 1-chlorobutane (both HPLC 
grade) were obtained from Sigma-Aldrich, Dorset. Methanol, acetonitrile (both HPLC 
grade) and acetic acid (Analar) were obtained from Fisons Scientific Equipment, 
Loughborough, Leics.
Instrumentation and Instrument settings 
Pump: Severn Analytical Model SA 6480
(Severn Analytical, UK)
Autosampler: Gynotek GINA model 160 precision autosampler
(Severn Analytical, UK); Injection volume: 50 |il 
Column: Hichrom Spherisorb S5W (5 mm, 25 cm x 4.6 mm ID)
(Hichrom, UK); Flow rate: 1 ml/min 
Detector: RAPISCAN SA 6508 multiple wavelength UV/VIS
(Severn Analytical, UK); Detection: UV 330 nm 
Integrator: Model 160 Serial Chromatography Signal interface
(Autochrom Incorporated, UK)
Computer software: Apex software model 625-1 (integration)
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Preparation of mobile phase buffer
The mobile phase buffer (MPB) was prepared fresh each day by mixing hexane, 1- 
chlorobutane and acetonitrile in the ratio 82:13:5 v/v/v respectively. The MPB was 
sonicated under vacuum to expel dissolved air and 1 0  pi glacial acetic acid added.
Standard solutions
Stock solutions of RP and RA (0.5 mg/ml) were prepared in MPB and stored protected 
from light at 4 °C for 2 weeks. Standard solutions of RP and RA were made up from the 
stock solutions each day in MPB. For plasma and CM-enriched fractions the 
concentration of RP was 25 pg/ml and RA was 5 pg/ml. For the infranatant samples the 
concentrations of the standards were 12.5 pg/ml for RP and 2.5 pg/ml for RA.
Standard curve prepai'ation
The final concentrations of RP in the standards for the CM-enriched fractions and plasma 
were 1.25, 2.50, 5.00 and 10.00 pg/ml. The final concentrations of RP in the standards 
for the infranatant fractions were 0.63, 1.25, 2.50 and 5.00 pg/ml. The different standard 
curves were used in order to achieve a similar range of concentrations as those found in 
the different samples.
Extraction procedure
The extraction procedure is described in Ruotolo et al. (1992). Briefly, 100 pi of sample 
(300 p i for infranatant) was placed in a glass tube. 400 pi of saline (200 pi for 
infranatant), 500 pi of methanol, 450 pi of MPB and 50 pi of RA (2.50 or 1.25 p g/ml) 
were added and a push-on lid fitted. The tubes were vortex mixed for a few seconds and 
placed on a rotary wheel for 10 minutes. The tubes were than centrifuged at 1000 rpm for 
10 minutes (2000 g.min) in a Beckman J6  centrifuge (Beckman, UK). 200 pi of the clear 
upper phase was pipetted into an autosampler vial.
For each run, fasting plasma, CM-enriched or infranatant fraction samples spiked with 
different volumes of the standard RP solution were used to produce a standard curve 
which was analysed together with the samples. Three RP QCs (2.5 pg/ml for plasma and 
CM-enriched fractions, and 1.25 pg/ml for infranatant fractions) were also placed 
between the sets of samples in each run to monitor the efficiency of extraction and the 
variation of the assay.
Sampling and analysis
50 pi of extracted sample was injected into the column. The mean (SD) retention times 
for each of the components in the sample were: RE 2.55 (0.08) minutes, RA 3.47 (0.09) 
minutes, retinol 8.62 (0.05) minutes. A typical chromatogram showing the RE, RA and
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retinol peaks produced after a single injection is shown in Figure 2.6. A data handling 
software package (Apex chromatography) was used to integrate the chromatograms and 
to determine the peak areas. The RE/RA peak aiea ratios were computed using Quattro 
Pro and the RE levels obtained using the response factor determined from the slope of the 
standard curve.
The calculation is as follows: since the amount of the internal standard (RA) was always 
the same for each sample and standard in the run (2.5 pg/ml for plasma and CM-enriched 
and 1.25 pg/ml for infranatant), the ratio of the RP concentration to the RA concentration 
and the ratio of the RP peak area to the RA peak area allow the calculation of a response 
factor for each of the RP standards as shown in equation 2.4:
Equation 2.4
Response factor (RF) = RA peak area x RP concentration
RP peak area RA concentration
The mean RF for the 4 standards can be used to calculate the concentration of RE in the 
samples from the peak areas of RE and RA in each sample according to equation 2.5:
Equation 2.5
Concentration RE (pg/ml ) = RF (mean) x RA concentration x RE peak area
RA peak area
Validation experiments
The linearity of the method and the percentage recovery of RP from spiked plasma, CM- 
enriched and infranatant fractions following the extraction procedure were determined by 
another investigator. The linearity of 5 standards was found to be good with an r value of 
0.99 (± 0.004 n=10). The mean percentage recovery of RP over the RP standard 
concentration range was 96.9 % (± 3.43).
Intra-assay CVs were determined by preparation of several standards of the same 
concentration (1.25 pg/ml and 2.5 pg/ml) for each run. The mean intra-assay CVs for the 
two standards were 8.1 % (± 4.9) at 1.25 pg/ml (n=ll) and 3.8 % (±1.9) at 2.5 pg/ml 
(n=22). The inter-assay CVs for the two standards were 11.1 % at 1.25 pg/ml (n=ll) and 
7.7 % at 2.5 pg/ml (n=22).
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Figure 2.6 Example of a typical HPLC chromatogram for the determination of RE in 
plasma, CM-enriched and infranatant samples. The major retinyl esters co-elute in the 
first peak (RE), the RA internal standard in the second peak and the retinol in the third 
peak.
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2.8. ANALYSIS OF LIPOPROTEIN LIPASE ACTIVITY 
Principle
The analysis of LPL activity was carried out by two other collaborating investigators for 
the different studies, according to the method originally described by Nilsson-Ehle & 
Schotz (1976) and modified by Knapper et a l (1995). The method uses the detection of 
^H-labelled free fatty acids from a ^H-labelled triolein substrate emulsion as an index of 
the rate of fatty acid hydrolysis by LPL.
Procedure
Briefly, the procedure involved incubating 5 and 15 minute post-heparin plasma with an 
emulsion of triolein (supplied by Amersham International Pic., Little Chalfont, 
Bucks.), cold triolein, phosphatidyl-choline and glycerol, which had previously been 
incubated with heat-inactivated serum (as a source of apo C-II) and either 0.2 M NaCl or 
4 M NaCl. After a 30 minute incubation at 37 °C (pH 8) the reaction was stopped by 
adding an organic-phase fatty acid extraction mixture and the amount of radioactive 
oleate liberated was measured in the upper organic phase. The results were expressed in 
units of enzyme activity (U) where one unit represents 1 pmol oleate released per minute 
at 37 °C. The enzyme activity is expressed per ml of plasma (U/ml). Samples of milk 
were used as quality controls. The intra-assay CVs were 5.6 % at 270 mU (n=6) and
4.9 % at 70 mU (n=6). The inter-ass ay CV was 8.7 % at 270 mU (n=6).
2.9. ANALYSIS OF INSULIN 
Principle
Insulin was measured by two other collaborating investigators in the two studies 
according to an RIA method originally described by Albano et a l (1972) with 
modifications by Flatt and Bailey (1981). The method is a double antibody RIA 
technique, involving the incubation of plasma samples with antisera to insulin and a fixed 
amount of radiolabelled insulin. Competition between the radiolabelled and unlabelled 
insulin results in variations in the level of antibody-radiolabelled antigen which are 
proportional to the level of insulin in the plasma. The unbound radiolabelled insulin is 
removed after adding an antiserum to guinea pig IgG which binds to the primary antibody 
and causes the precipitation of the antibody-antigen complexes in the presence of 
polyethylene glycol (PEG). The radioactivity in the precipitate is measured.
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Procedure
Briefly: plasma samples were mixed with insulin antisera and assay diluent and left at 
4 for 24 hours. On the second day, I-Insulin (ICN Biomedicals) and a secondary 
antibody to guinea pig IgG were added and incubated for 24 hours. On the third day, 
normal guinea pig serum and PEG were added and incubated for 2 hours. The tubes were 
centrifuged, the supernatant removed and the level of radioactivity in the pellet counted 
on a gamma radiation counter (Wallac 1260 Multigamma II, Wallac Oy, Finland). 
Insulin concentrations were expressed as pmol/1. A QC was run in each assay. The intra­
assay CV was 9.03 % at 35 pmol/1 (n=8 ). The inter-assay CV was 10.7 % at 35 pmol/1 
(n=1 0 ).
2.10. ANALYSIS OF GLUCOSE-DEPENDENT INSULINOTROPIC  
POLYPEPTIDE
Glucose-dependent insulinotropic polypeptide (GIP) levels were measured by another 
collaborating investigator by a double-antibody RIA technique as described by Morgan et 
al (1978). The principle for RIA is described in Section 2.9.
Procedure
The method is similar to that described for insulin in Section 2.9 except that the GIP was 
purified and radiolabelled with I during the assay. GIP concentrations were expressed 
in pmol/1. A QC was run in each assay and the inter-assay CV was 8.0 % at 360 pmol/1 
(n=1 0 ).
Variations to methods described in this chapter and additional methods used during 
method development are outlined in the relevant chapters.
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CHAPTER THREE THE EFFECTS OF EXERCISE ON POSTPRANDIAL LIPIDS AND LIPOPROTEINS
3.1 INTRODUCTION
EXERCISE AND POSTABSORPTIVE LIPOPROTEINS
Epidemiological evidence has shown that physical activity is associated with a reduction 
of the risk of CAD (Ekelund et a l, 1988), as more active people appear to suffer fewer of 
the clinical manifestations of CAD than sedentary people (Haskell, 1986). The 
mechanism by which this protective action occurs is not entirely clear, but may involve 
positive effects on lipoprotein metabolism. There is a vast amount of literature detailing 
studies which have attempted to establish the nature of this effect. The majority of these 
have investigated the changes in fasting lipoprotein concentrations brought about by 
exercise. Several reviews have been published detailing the results of many of these 
studies (Haskell, 1986; Goldberg and Elliot, 1987; Pronk, 1993, Taylor and Ward, 1993; 
Berg et al, 1994; Cox, 1994). Although the studies have not produced entirely consistent 
results, in general the findings from cross-sectional studies showed that active subjects 
had lower fasting plasma-TAG, LDL-cholesterol and total cholesterol levels (Wood et al, 
1977) than sedentary subjects, and longitudinal studies showed that increasing exercise 
levels resulted in lower LDL-cholesterol and an increase in HDL-cholesterol levels 
(Peltonen e? fl/., 1981).
EXERCISE AND POSTPRANDIAL LIPAEMIA
Despite the potential importance of postprandial lipoproteins in the pathogenesis of CHD 
(Zilversmit, 1979), very few studies have investigated the effects of exercise on this 
aspect of lipoprotein metabolism. It has been suggested that improving fat tolerance 
could be a way of reducing atherogenesis, either by reducing the time of exposure of the 
arterial wall to potentially atherogenic remnant particles, or through beneficial increases 
in HDL levels secondary to an initial decrease in postprandial lipaemia (Section 1.4.2.3). 
Consequently studies of exercise and postprandial lipaemia should provide valuable 
information on these processes.
The chronic effects of exercise have been investigated in several cross-sectional studies 
which have compared the responses of trained and untrained individuals to a meal. A 
study by Ericsson et a l (1982) showed that young, trained subjects had lower plasma- 
TAG, VLDL-TAG and LDL-TAG levels and an increased clearance rate of an 
intravenously administered bolus of Intralipid compared with a group of matched 
sedentary controls. Similar studies by Merrill et a l (1988) and Hartung et a l (1993) also 
showed that untrained individuals had a poorer fat tolerance after a high fat meal than
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athletes. It was concluded from these studies that habitual endurance exercise results in a 
lower postprandial lipaemia after a high fat meal.
To gain more information on the effects of exercise on postprandial TAG and lipoprotein 
metabolism, CM and CMR fractions were isolated from plasma. Cohen et al. (1989) 
investigated the differences in response to medium and very high fat meals between 
trained endurance athletes and untrained sedentary men. All the men were matched for 
fasting TAG concentrations, as a positive correlation between fasting TAG levels and the 
magnitude of postprandial lipaemia has frequently been documented (Patsch et ai, 1992). 
This ensured that any differences in response were not due to differences in fasting TAG 
level but due to the independent effects of exercise on postprandial TAG cleaiance. 
Three different tests (described in Section 1.5.1) were carried out to investigate the 
mechanisms underlying the differences in postprandial TAG metabolism in active and 
inactive subjects. An oral fat tolerance test showed that the active group had a lower 
lipaemic response to different fat loads than the inactive group. An intravenous fat 
tolerance test showed that the active group had faster rate of TAG clearance than the 
inactive group when the effects of absorption and variation in the composition and size of 
the lipoproteins between the groups were eliminated. Thirdly, a duodenal perfusion 
study, first described by Grundy and Mok (1976) showed that the CM-TAG half-life was 
3 minutes in the active group and 4 minutes in the inactive group.
Cohen et a l (1991) found no relationship between HDL-cholesterol, HDL2-cholesterol 
and postprandial lipaemia, measured by RP concentrations, in 52 normolipidaemic 
endurance-trained men. The men were split into groups according to high or low fasting 
HDL2 levels but no differences in postprandial lipaemia were seen between them, 
although the authors noted that all the athletes had relatively high HDL2 levels compared 
with sedentary men so that even the "low" HDL2 levels were quite high. No LPL activity 
measurements were carried out which prevented comparison with work by Sady et al 
(1984) who showed that there was no significant difference between the post-heparin 
LPL activities in mnners with high or low HDL2. These results suggest that the different 
HDL levels seen in athletes are not entirely due to increased CM-TAG hydrolysis as 
hypothesised by Miesenbock and Patsch (1992).
An important question raised by these findings is whether athletes with low HDL2 levels 
are at a higher risk for CAD and whether this is associated with decreased CM hydrolysis 
or CMR clearance. A recent study looked at tlie differences between older athletes with 
silent myocardial infarction (SMI) and age-matched, healthy control athletes (Katzel et 
al, 1994). The athletes with SMI had lower HDL-cholesterol levels, but there was no 
difference in fasting TAG and LDL-cholesterol between the two groups. The
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postprandial AUC for insulin, plasma-TAG, VLDL-TAG and CM-TAG were all elevated 
in the SMI athletes. In the fasting state HL activity was found to be higher in the SMI 
group, but the adipose tissue-LPL activity levels were similar in both groups. However 
the expected increase in adipose tissue-LPL activity in response to feeding, which was 
seen in the controls, did not occur in the SMI group. Increased HL activity will increase 
catabolism of HDL2 , whilst low LPL activity will reduce the production of HDL2 from 
HDL3 which normally occurs through transfer of TGRL surface remnants during lipolysis 
(Eisenberg, 1984). In contrast to the results by Cohen et al. (1991), tliese findings support 
the proposal that the beneficial effects of exercise on HDL levels are modulated through 
changes in TGRL metabolism. Whether these metabolic differences are a result of, or a 
cause of the SMI in this group is difficult to determine.
The beneficial effects of exercise training were demonstrated initially through work by 
Patsch et a l (1983). In a longitudinal study of two people, increased exercise caused a 
marked rise in fasting HDL2 levels and a decreased TAG response to a fat-containing 
meal. This suggested a negative correlation between HDL2 levels and TAG response to a 
meal and indicated the favourable effect of exercise on TAG metabolism. However the 
two subjects were different sexes and were not controlled for various factors including 
calorie intake and output, body fat, alcohol consumption, medications and smoking. 
These factors are all known to affect lipoprotein metabolism (Merrill et al, 1988) and 
thus further studies were needed to confirm these interesting but preliminary 
observations.
Further, more detailed investigation of the effects of training sedentary individuals was 
carried out by Weintraub et a l (1989). Six nonnolipidaemic sedentary young men were 
studied before and after seven weeks on an exercise programme of two or three 30- 
minute jogging sessions per week. After the exercise period the fasting TAG, VLDL, 
LDL and total cholesterol levels, and postprandial CM and CMR levels were significantly 
reduced. The LPL activity had increased and HL activity decreased. Postprandial 
lipoprotein levels were measured using the oral vitamin A fat loading test which allows 
CM and CMR to be specifically monitored using RP as a marker as described in Section
1.5.1.2. After seven weeks of training, the RP in the CM fraction was 37% lower than 
during the stabilisation phase and the RP in the CMR fraction was 28% lower although 
this decrease was not significant. The CM-RP AUC was found to be inversely 
proportional to LPL activity and directly proportional to the fasting TAG level. Although 
there was a trend before training for CM-RP AUC to be inversely proportional to HDL, 
no correlation was shown between HDL and CM-RP levels after the exercise period, this 
was unexpected in light of previous results in the study by Patsch et a l  (1983). 
Weintraub et a l (1989) suggested that a change in CM clearance may have been detected
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before changes in HDL levels occur thus supporting the theory that high HDL levels 
observed in active individuals may be a secondary phenomenon to the decreased 
residence time of CM particles (Miesenbock and Patsch, 1992). Alternatively any 
changes in HDL in response to exercise training may partly reflect changes in body 
composition (Wood et al, 1988) which may not have started to occur after only 7 weeks. 
The study by Weintraub et al. (1989) ensured that body weight remained stable, although 
no body fat measurements were made. Losing body fat tends to accompany long-term 
exercising and is therefore very difficult to control.
In studies by Podl et a l (1994) and Aldred et al (1995), contrasting results were obtained 
when the effects of training on postprandial lipaemia in women in different age groups 
were investigated. In the former study, young adult female distance runners were 
compared with age-matched, sedentary controls. The fractional clearance rate of an 
intravenous fat load was faster in the active group. The trained group also had lower 
fasting TAG and higher HDL-cholesterol and LPL activity. Conversely in the latter 
study, when sedentary middle-aged women were trained by brisk walking over a period 
of 12 weeks, there was no change in the fasting HDL-cholesterol levels and no effect on 
postprandial peak TAG levels or AUC for the postprandial TAG response when 
compared with their sedentary response. This constant HDL-cholesterol level was in 
contrast to previous findings in middle-aged women by the same laboratory (Hardman et 
a l, 1989), although other studies have also found no effect of exercise on HDL- 
cholesterol (Davis et al, 1992). The active group in the study by Podl et a l (1994) had a 
lower body weight and significantly lower percentage body fat than the control group, 
both of which have been shown to be independently associated with increased HDL- 
cholesterol levels (Wood et al, 1988) and may in part explain the different results 
between the two studies. Aldred et al. (1995) found a decrease in the postprandial insulin 
AUC after the training period. This suggests an improvement in insulin sensitivity which 
might have been expected to decrease the postprandial TAG response, however this was 
not observed.
Mankowitz et a l (1992) investigated whether an interruption in normal exercise 
programmes would produce undesirable changes in postprandial lipoprotein metabolism. 
Postprandial lipoprotein metabolism was assessed in CM and CMR fractions by the 
vitamin A fat loading test in athletes in their trained state and after 14-22 days detraining. 
After detraining, LPL activity and HDL-cholesterol levels decreased significantly in 
fasting plasma. The RP-AUC increased for both the CM and CMR fractions although 
this was only significant in the CM fraction. No change in body weight or fat loss 
occurred over this short detraining period which suggests that exercise was the main 
factor responsible for the changes.
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The results of this detraining study were in accordance with those of Weintraub et al. 
(1989) showing a major effect of exercise on CM and a less marked effect on CMR. The 
accompanying decrease in LPL activity on detraining support the theory that exercise has 
a favourable effect on lipoprotein metabolism at least partly through increasing TGRL 
hydrolysis by LPL. A higher LPL activity has been demonstrated in trained athletes 
compared with sedentary individuals (Nikkila eta l, 1978.). Other studies have shown an 
increase in the activity of LCAT (Mamiemi et al, 1982) and a decrease in CETP (Foger 
et a l, 1994) and HL activity (Mendoza et a l, 1991). Despite these findings, the 
mechanisms by which exercise cause a decrease in postprandial lipaemia have not been 
fully elucidated. More studies on the effects of exercise on the regulatory enzymes and 
proteins involved in postprandial lipoprotein metabolism, including LCAT, CETP, LPL 
and HL may provide a greater insight into the protective effects of exercise.
One problem with investigating the effects of chronic exercise is the potentially 
confounding acute effects of the most recent previous exercise session prior to the 
experimental sampling period. The postprandial studies outlined above were all 
conducted at varying times after the previous exercise session and all attempted to justify 
this aspect of the study design. Cohen et a l (1989) showed that postprandial lipaemia 
was slightly but not significantly reduced by acute exercise of one hour 1 2  hours before 
the test meal and they concluded there were no acute effects of exercise 1 2  hours after the 
last bout of exercise. Annuzi et a l (1987), however, suggested that the acute effects of 
exercise depended on the intensity and duration of the exercise. They showed a decrease 
in postprandial lipaemia the day after exercising for 3 hours at 50 % V0 2 max, but not the 
day after exercising for 1.5 hours at the same intensity. Aldred et a l (1994) found that 
both fasting TAG and postprandial lipaemia were lower 15 hours after exercising at 31 % 
V0 2 max for 2 hours compar ed with resting. Results showing the acute effects of exercise 
on LPL activity and postabsorptive lipoprotein levels have also been conflicting. Some 
studies have suggested that the acute effects of exercise may last for longer than 2 0  hours 
(Kantor et al, 1984) whereas other studies show no effect on lipoprotein levels the day 
after exercise (Davis et a l, 1992). A study by Lithell et a l (1984) showed a sustained 
increase in LPL activity 3-5 days after very prolonged, very high intensity exercise. In 
general it appears that both the intensity and duration of an exercise session may be the 
most important factors in determining its acute effects.
In summary, the postprandial studies which have been undertaken to date have studied a 
limited range of lipoprotein parameters in relation to a wide variety of exercise situations. 
In many cases the subjects have not been matched closely and various parameters which 
are known to affect postprandial lipaemia (e.g. smoking, body composition and alcohol
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consumption) have not been controlled. Also, many studies have used very high fat test 
meals consisting only of double cream which could be criticised as this is clearly not 
testing a physiological situation.
Although the effects of exercise on postprandial plasma-TAG and CM-TAG levels has 
been fairly extensively documented, the effects on CM and CMR particle levels are less 
clear. Vitamin A fat-loading studies have suggested that CM metabolism may be 
increased in active people. However as the reliability of this method has been questioned 
recently due to studies which have shown the presence of RE in LDL particles several 
hours after a meal Krasinski et a l (1990a) and a discrepancy between the time-course of 
the RP response compared with the CM-TAG and apo B-48 responses (Demacker et al, 
1992), investigations of CM metabolism using apo B-48 as a marker may provide more 
reliable information on these processes.
Although some studies have been carried out on younger men, most have investigated the 
difference between endurance trained athletes and sedentaiy peers, often in older subjects. 
These are levels of exercise that average individuals would find difficult to attain, so that 
the applicability of these findings to public health are limited. Guidelines for a healthy 
lifestyle have advocated doing three 30-minute sessions of aerobic activity each week 
which is much lower than the exercise programmes described in many of the studies 
above.
Aims of the study
The aim of the present study was to investigate the effect of a moderate, habitual exercise 
level on the postprandial lipaemic response to a mixed meal in young, healthy men in a 
cross-sectional study. This was achieved by comparing the responses of two groups; one 
group who undertook no regular physical activity and one group who habitually exercised 
three times a week. In addition the effects of varying meal fat content in the two groups 
was assessed. The study aimed to control for any confounding variables by matching all 
subjects for body composition, age, habitual diet and fasting plasma-TAG.
To provide a detailed view of the processes involved in the lipaemic response to a meal 
various parameters were measured. The TAG levels in both plasma and CM-enriched 
fractions were measured. CM and CMR metabolism was studied more closely using 
measurement of both RP and apo B-48 levels in the CM-enriched fraction. The 
postprandial responses of these two specific markers of CM particles were compared. 
NEFA levels in plasma and LPL activity in post-heparin plasma were also measured in 
order to provide information on possible mechanisms.
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3.2. METHODS
3.2.1 Subject recruitment
Eighteen non-obese, healthy, male subjects were recruited through advertisements placed 
across the university and divided into two groups according to their self-reported habitual 
exercise levels. The active group consisted of subjects who participated in some form of 
aerobic exercise for at least 30 minutes three times a week, the subjects in the inactive 
group took no regular exercise. Four of these subjects subsequently had to be omitted 
from the study due to poor compliance to the protocol i.e. eating and drinking within the 
12 hour period prior to the test meal. Exclusion criteria for this study were:
- Body mass index (BMI) lower than 19 or greater than 26 kg/m^
- History of liver or intestinal disorders or alcoholism
- Fasting TAG greater than 1.5 mmol/1
- Habitual alcohol consumption greater than 30 units per week
- Habitual fat intake lower than 30% or higher than 45% total energy intake
- Smoking
- Taking dietaiy supplements
- Following a reducing diet
- Apo E phenotype E4/E4 or E2/E2
The two groups were matched as far as possible for age, BMI and habitual dietary fat 
intake assessed from a three-day food diary (including one weekend day) completed 
during the week before the first study day and analysed using Compeat, a commercial, 
computerised database of McCance and Widdowson food tables (Holland et al, 1991). 
The subjects height and weight were measured to determine BMI. Body fat was 
measured using Kabi Vitrium callipers and was carried out by one individual to minimise 
inter-individual variation. Skinfold thickness was measured at the triceps, biceps, 
subscapular and suprailiac sites and used to detemine percentage body fat according to 
the equation of Durnin and Womersley (1974). Ethical consent for the study was 
obtained from the University of SuiTey Research Ethics Committee. The subjects gave 
informed written consent to participate. The subject characteristics are shown in the 
results in Table 3.3.1.
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3.2.2 Test meal
Each subject received one of three test meals on each occasion. The test meals were 
designed to reflect normal variations in meal fat content and to highlight differences 
between the metabolic capacities of the two groups. The fat contents represented 
different types of meal. The low fat meal contained 20 g of fat which approximates the 
fat content of a typical breakfast of cereal and toast. The medium fat meal contained 40 g 
of fat, reflecting a typical lunch-time or evening meal. The high fat meal contained 80 g 
of fat, which represents a very large load of fat, although one which may be consumed in 
a single sitting and was designed to stress the system. The test meals differed only by 
their fat and energy contents. The basis of these meals was breakfast cereal and milk, 
cheese sandwiches and orange juice. The different fat contents were achieved by varying 
the amount of margarine, using different types of milk or cream and using cheese of 
varying fat content. This kept the physical size of the meal and the protein and 
carbohydrate content constant whilst changing the fat and energy content of each meal. 
100 mg of RP in an oil-based form (170,000 lU) was taken orally by mixing with the 
orange juice. The nutrient and energy content of the three meals was determined by 
collaborators in the study and are shown in Tables 3.2.1 to 3.2.3.
3.2.3 Study day protocol
On three separate occasions the subjects were asked to come into the clinical 
investigation unit at the University of Surrey at 8 am after a 12 hour overnight fast. 
Subjects had been asked to refrain from taking any exercise or drinking any alcohol the 
day before the study day and to standaidise their evening meal the night before each of 
the three study days.
On arrival at the unit, an indwelling cannula was inserted into the forearm under local 
anaesthetic and two fasting blood samples taken over the following 10 minutes. Each 
subject received the three different test meals in a randomly assigned order on each 
separate occasion. The subjects were asked not to eat or take any exercise during the 8 
hour study period. Decaffeinated, milk- and sugar-free drinks and water could be 
consumed freely throughout the day and the subjects continued with their normal, 
sedentary, daily activities.
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Table 3.2.1 Composition of low fat test meal
FOOD Weight
(g)
Energy
(kj)
Fat Protein Carbohydrate
(g)_____
Frosties 50 794 0.3 3 25
Orange juice 250 378 0.3 0.3 2 2
White bread 180 1642 2.5 14 84
Skimmed milk 2 0 0 277 0 .2 7 1 0
Half-fat cheese 65 714 1 0 2 0 Tr
Flora margarine 1 0 311 8 Tr Tr
TOTAL 4116 20 45 141
Table 3.2.2 Composition of the medium fat test meal
FOOD Weight Energy Fat Protein Carbohydrate
(g) (kJ) (g) (g) (g)
Frosties 50 794 0.3 3 25
Orange juice 250 378 0.3 0.3 2 2
White bread 180 1642 2.5 14 84
Semi-skim milk 2 0 0 387 3.0 7 10
Full fat cheese 75 1298 26 26 Tr
Flora margarine 10 311 8 Tr Tr
TOTAL 4809 40 44 141
Table 3.2.3 Composition of the high fat test meal
FOOD Weight Energy Fat Protein Carbohydrate
(g) (kJ) (g) (g) (g)
Frosties 50 794 0.3 3 25
Orange juice 250 378 0.3 0.3 2 2
White bread 180 1642 2.5 14 84
Full fat milk 150 416 6 7 7
Full fat cheese 75 1298 26 26 Tr
Flora margarine 2 0 622 16 Tr Tr
Double cream 65 1361 31 1 2
TOTAL 6510 82 43 140
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3.2.4 Blood sampling
Blood samples (16 ml) were taken at 30 minutes and 1 hour after the start of the meal and 
then every hour for 8 hours. After the 8 hour sample had been taken each subject was 
given an injection of hepaiin (7500 units) at a site distant from the cannula and post- 
hepaiin blood samples of 5 ml were taken 5 and 15 minutes after the injection.
3.2.5 Preparation of plasma samples
The 16 ml blood samples were divided into duplicate 10 ml hepaiinised blood tubes. The 
5 ml post-heparin samples were collected into single 5 ml hepaiinised blood tubes. The 
tubes were centrifuged at room temperature at 7000 g.min (3000 rpm for 10 minutes) 
within 20 minutes of being collected. For each time-point plasma was isolated, aliquotted 
into 0.5 ml samples for analysis of various parameters and frozen at -20  ^C until analysis.
3.2.6 Preparation of chylomicron-enriched fraction
Plasma from each time-point was also used to prepare a CM-enriched fraction by 
ultracentrifugation as detailed in Section 2.2.2.1.
A "preservative cocktail" (Section 2.1.2) was added at a volume of 5% of the total sample 
volume to the samples for apo B-48 analysis to prevent proteolysis. All tubes were 
frozen at -20 until analysis. Samples for RP analysis were protected from light by 
wrapping them in foil.
The infranatant remaining after removing the CM-enriched fraction was stored for later 
analysis of the non-CM fraction. The volume of the infranatant was made up to 7 ml by 
adding the appropriate volume of NaCl. The infranatant was then aliquotted, preservative 
added to the sample for apo B-48 analysis and stored at - 20 ®C until analysis.
3.2.7 Analysis of samples 
Analysis of TAG
TAG levels in both plasma and CM-enriched samples were determined by automated, 
enzymatic spectrophotometric analysis performed on the COBAS Mira Plus using the 
Unimate 5 TRIG kit (Roche Products Ltd, UK) as described in Section 2.6.1.
86
Analysis of NEFA
NEFA levels in plasma samples were determined by automated, enzymatic 
spectrophotometric analysis performed on the COBAS Mira Plus using the NEFA C kit 
(Wako Chemical GmbH, Germany) as described in Section 2.6.5.
Analysis of apolipoprotein B-48
The apo B-48 in the CM-enriched fraction was measured by denaturing, gradient SDS- 
PAGE followed by immunoblotting with an antibody to apo B-48 as described in Section 
2.4. 50 |il of the CM-enriched samples mixed with sample buffer was loaded in each of 
the wells. This corresponded to between 51 to 125 pg of protein.
Analysis of retinyl palmitate
This analysis was canied out by another investigator using the method of De Ruyter and 
De Leenheer (1979) as described in Section 2.7.1. RP in the CM-enriched fraction 
samples was measured using reverse-phase HPLC following chloroform extraction of the 
CM-eniiched fraction.
Measurement of lipoprotein lipase activity
LPL activity in the post-hepaiin plasma samples was measured by another investigator as 
described in Section 2.8 using a stable radioactive substrate emulsion of 
^H-trioleolylglycerol.
Analysis of GIF and Insulin
The analysis of insulin and GIP were caiTied out by other investigators as described in 
Section 2.9 and 2.10 respectively using the double antibody RIA technique.
3.2.8 Analysis of results
The data is presented as time response curves for each variable with values at each time- 
point plotted as mean with standard error of the mean (SEM). The postprandial lipaemic 
response was assessed by statistical analysis of the total area under the 480 minute time 
response curve (AUC) for each parameter. The AUC data is presented in the results and 
shown diagramatically as histograms for analytes in the CM-enriched fraction. The 
incremental AUC (lAUC) was also calculated for the plasma-TAG and CM-TAG results 
(i.e. the AUC from the fasting level). As both groups had very similar fasting TAG levels 
the pattern of results were similar to those obtained from the total AUC and therefore the 
lAUC are not presented in this chapter. The mean data for all parameters is presented in 
Appendix in.
87
Statistical analysis was performed using the Instat package on the Apple Macintosh 
computer. Statistical analyses were carried out on two different aspects in this study. 
The difference between the active and inactive groups for each meal was determined 
using an unpaired student's t test. The difference between the responses within each 
group to the meals of different fat contents was determined using one-way analysis of 
variance (ANOVA). If the ANOVA was found to be significant (P<0.05) the difference 
was identified using the post-hoc Tukey test. Normality of the data was determined using 
the Kolmogorov-Smimov goodness of fit test. If the data was not normally distributed it 
was log-transformed to allow parametric statistical analysis to be carried out. If this did 
not normalise the data non-parametric statistical analysis was used. All the RP results 
and the apo B-48 results after the high fat meal were log transformed. Non-parametric 
statistical analysis was used for the plasma-TAG results after the high fat meal. For 
unifoimity of presentation, however, all data are shown as mean and SD in the Tables.
Differences in the pattern of responses after the three meals within the groups, and 
differences between the pattern of responses between the 3 maikers of CM particles were 
analysed by repeated measures ANOVA. This was carried out using the Data Desk 
package on the Apple Macintosh computer.
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3.3 RESULTS
3.3.1 SUBJECT CHARACTERISTICS
Table 3.3.1 shows the physical and dietary characteristics of the subjects in the active and 
inactive groups. Table 3.3.2 shows the fasting plasma-TAG levels of the subjects for 
each of the test meal days. No significant differences were seen between the groups for 
any of these characteristics.
Analysis of the subject's self-reported activity levels showed that all of the subjects 
allocated to the inactive group took no regular exercise other than walking across the 
university campus and around the town. There was a range of exercise levels in the 
active group as most of the subjects were members of university sports clubs and trained 
according to their abilities at the sport. The activity levels of the subjects in the active 
group ranged from three 40 minute sessions a week at the fitness club (aerobic activities 
and weight training) to four 45 minute sessions a week at the fitness club plus additional 
rowing or football for 1 -2  hours per week.
89
Table 3.3.1. Subject characteristics: age, anthropometric measurements and habitual
Characteristic Active group 
Mean (SD) n=7
Inactive group 
Mean (SD) n=7
Age (years) 20.9 (2.4) 21.7 (2.8)
Body mass index (kg/m^) 23.2 (1.9) 20.6 (2.7)
% body fat 18.0 (2.5) 17.2 (3.0)
Energy intake (MJ) 10.15(2.52) 10.09 (2.76)
Fat intake (g) 1 0 0  (2 2 ) 100 (33)
P:S ratio 0.77 (0.36) 0.44 (0.26)
Protein (g) 88 (27) 6 8  (18)
Carbohydrate (g) 291(72) 294 (90)
% energy as fat 37 (5) 38(5)
Table 3.3.2. Fasting plasma-tiiacylglycerol concentrations (mmol/1) of all the subjects
each test meal occasion.
Active group Inactive group
subject low medium high subject low medium high
fat meal fat meal fat meal fat meal fat meal fat meal
( 2 0  g) (40 g) (80 g) (20 g) (40 g) (80 g)
1 0.71 0.87 0.69 5 0.71 0.49 0.52
2  0.80 0.62 0.84 6 0.76 0.90 0.92
4 0.74 1.03 0.76 9 0.77 0.83 0 .6 6
7 1.22 1.05 1.33 10 0.96 0.95 0.89
8 0.81 0.78 0.70 11 0.78 1.08 1.39
14 0.69 0.56 0.45 12 0.98 0.85 0.87
15 1.00 0.94 0.76 13 1 .1 2 1 .0 2 1.18
mean 0.85 0.84 0.79 mean 0.87 0.87 0.92
SD 0.19 0.19 0.27 SD 0.15 0.19 0.29
Values are means of 2 fasting samples for each subject on each occasion. No significant differences were 
seen between the 2 groups before any meal.
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The results from this study are described under three different Sections;
3.3.2) the effects of exercise,
3.3.3) the effect of meal fat content on responses in the CM-enriched fraction and NEFA
3.3.4) a comparison of markers for CM par ticles
3.3.2. EFFECTS OF EXERCISE
3.3.2.1 Plasma-TAG
Figure 3.3.1 shows the effects of exercise on plasma-TAG responses to meals of varying 
fat content. The response curve after the low and medium fat meals for the active 
subjects has no clear peak, compared with the inactive group where the peak occurs at 
240 minutes after the low fat meal and at 180 minutes after the medium fat meal. The 
peak occurs at 180 minutes after the high fat meal in the inactive group and at 1 2 0  
minutes in the active group.
The 8 hour plasma-TAG AUC were lower in the active subjects compared with the 
inactive after each of the meals (Table 3.3.3). This difference was statistically significant 
after the medium fat meal (P<0.05) and the high fat meal (P<0.01). The peak plasma- 
TAG concentrations were statistically significantly lower in the active subjects compared 
with the inactive in response to all three meals ( f  <0.05) (Table 3.3.4). The fasting 
plasma-TAG levels were veiy similar* in the two groups as shown in Table 3.3.2.
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Figure 3.3.1. The effects of exercise on plasma-triacylglycerol responses to three different meals containing a) 20 g, b) 40 g and c) 80 g of fat, consumed in random order on three separate occasions following a 12 hr overnight fast. Values represent means with SEM of 7 subjects in each group. The active group are represented by (O) and the inactive group by (■).
The area under the curve (AUC) was statistically significantly different between the groups for the 40 g fat meal (E<0.05) and the 80 g fat meal (P<0.01) meal.
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Table 3.3,3. Total AUC (8 hour) for plasma-triacylglycerol, CM-triacylglycerol, CM- 
apolipoprotein B-48 and CM-retinyl palmitate for the active and inactive groups after 
each meal.
TOTAL AUC (8 hour)
low fat (20 g) medium fat (40 g) high fat (80 g)
Active
(n=7)
Inactive
(n=7)
Active
(n=7)
Inactive
(n=7)
Active
(n=7)
Inactive
(n=7)
Plasma-TAG mean 456 546 461 603* 526 676**(mmol/l.min) SD 82 80 101 114 85 34
CM-TAG mean 115 208* 163 281* 237 330*(mmol/l.min) SD 13 69 64 106 64 69
CM-apo B-48 mean 7602 11725 7969 18977 7903 23046*(% standard.min) SD 7635 8170 3474 13862 3559 15195
CM-RP mean 143 436** 284 618** 413 847**
(|Lig/ml.min) SD 45 343 82 184 114 297
Significant differences between the active and inactive groups for each meal are shown by ** P<0.01, 
*T<0.05
Table 3.3.4. Peak values for plasma-triacylglycerol, CM-triacylglycerol, CM- 
apolipoprotein B-48 and CM-retinyl palmitate for the active and inactive groups after 
each meal.
Peak value
low fat (20 g) medium fat (40 g) high fat (80 g)
Active
(n=7)
Inactive
(n=7)
Active
(n=7)
Inactive
(n=7)
Active
(n=7)
Inactive
(n=7)
Plasma-TAG mean 1.04 1.51* 1.09 1.47* 1.52 1.92*(mmol/1) SD 0.24 0.38 0.33 0.47 0.25 0.31
CM-TAG mean 0.32 0.76** 0.46 0.71* 0.82 1.03*(mmol/1) SD 0.10 0.31 0.24 0.38 0.18 0.26
CM-apo B-48 mean 34 72 40 69 36 77(% standard) SD 52 47 26 24 22 69
CM-RP mean 0.81 1.71* 1.17 2.07** 1.47 2.81*
(Mg/ml) SD 0.24 0.65 0.36 0.55 0.52 0.79
Significant differences between the active and inactive groups for each meal are shown by ** P<0.01, 
*P<0.05
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3.3.22 CM-TAG
Figure 3.3.2 shows the effects of exercise on the CM-TAG responses to each meal. The 
CM-TAG responses showed a similar pattern to the plasma-TAG responses for both 
groups after each meal. The 8 hour AUC for the active subjects was significantly lower 
than that for the inactive subjects for all meals (P<0.05) (Table 3.3.3). The fasting CM- 
TAG values were similar in the inactive and the active groups (0.17 mmol/1 v. 0.13 
mmol/1 respectively and these values were 20% of the fasting plasma-TAG values (0.89 
mmol/1 V. 0.83 mmol/1 respectively) (Appendix III). The peak CM-TAG values for both 
groups after all meals were approximately 50% (range 43 % - 54 %) of the plasma-TAG 
value except the peak CM-TAG level of the active group after the low fat meal which 
was 31 % of the plasma-TAG level (Table 3.3.4).
After the low and medium fat meals there was a 2- to 3-fold increase in the CM-TAG 
level from fasting to peak in the active group, and a 5-fold increase in the inactive group 
(Figure 3.3.2). After the high fat meal there was a 6 -fold increase from fasting in both 
groups. The active group had significantly lower peak CM-TAG levels than the inactive 
group after the 20 g fat load ( f  <0.01) and after the 40 g and 80 g fat meals ( f  <0.05) 
(Table 3.3.4). The levels of CM-TAG had returned to baseline 8  hours after the low fat 
meal in both the groups. The levels were still elevated after the medium and high meals 
for both groups, however the values for the active subjects reached a lower level.
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Figure 3.3.2 The effects of exercise on chylomicron-triacylglycerol responses to three different meals containing a) 20 g, b) 40 g and c) 80 g of fat. Values represent means 
with SEM of 7 subjects in each group. The active group are represented by (O) and the inactive group by (■).
There was a statistically significant difference between the AUC for the two groups after the 20 g, 40 g and 80g fat meals (P<0.05 in each case)
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3.3.2.3 CM-apo B-48
Figure 3.3.3 shows the apo B-48 time-response curves for the active and inactive groups 
after each of the three meals. A comparison of the time to peak between the active and 
inactive subjects from Figure 3.3.3 shows that the peak occuixed at 240 minutes after the 
low fat meal for both groups, at 240 and 180 minutes respectively after the medium fat 
meal and at 60 and 120 minutes respectively after the high fat meal. After the low fat 
meal the levels fell back down to baseline in both groups. The levels remained elevated 
above baseline 8  hours after the 40g and 80g fat meals in both groups, however they were 
higher in the inactive subjects.
After the medium and high fat meals there appeared to be a small second peak between 
the 6  and 7 hour timepoint in the inactive subjects. In the active group the apo B-48 
levels fell back down to baseline levels after 6-7 hours and then appeared to rise again 
slightly after both the medium and high fat meals.
The 8 hour AUC (Table 3.3.3) was lower in the active group compared with the inactive 
group after all three meals, but this was only significant after the 80g fat load (P<0.05). 
The apo B-48 peak levels were between 1.7 and 2.2 times higher in the inactive compared 
with active subjects after all three meals, although this did not reach significance for any 
meal (Table 3.3.4).
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Figure 3.3.3. The effects of exercise on chylomicron-apolipoprotein B-48 responses to 
three different meals containing a) 20 g, b) 40 g and c) 80 g of fat. Values represent 
means with SEM of 7 subjects in each group. The active group are represented by (O) 
and the inactive group by (■).
The AUC was statistically significantly different between the two groups for the 80g fat 
meal (P<0.05).
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3.3.2.4 CM-retinyl palmitate
Figure 3.3.4 shows the effects of exercise on CM-RP responses to each of the meals. 
After all three fat loads the peak occurred at the 6  hour time-point for both groups except 
the high fat meal for the active subjects where the peak level occurred at 5 hours. In all 
cases no RP was present in the CM-enriched fraction until the sample taken 2 hours after 
the meal and the levels did not return to baseline after 8 hours in either of the groups.
The 8 hour AUC was significantly lower in the active group after all the meals (P<0.01 in 
each case) (Table 3.3.3). The CM-RP peak levels were lower in the active than inactive 
subjects in response to the low (P<0.05) medium (P<0.01) and high fat meals (P<0.05) 
(Table 3.3.4).
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Figure 3.3.4. The effects of exercise on chylomicron retinyl palmitate responses to three different meals containing a) 20 g b) 40 g and c) 80 g of fat. Values represent means with 
SEM of 7 subjects in each group. The active group are represented by (o) and the inactive group by (■).
The AUC was statistically significantly different between the two groups for all the meals (P<0.01).
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3.3.2.S Plasma-NEFA
The plasma-NEFA time-response curves are shown in Figure 3.3.5. After the low and 
medium fat meals the patterns exhibited the classical inverted-bell response with values 
decreasing rapidly after intake and reaching their lowest levels between 1 2 0  and 180 
minutes. In the active subjects the NEFA levels continued to remain low until 300 
minutes after the low and medium fat meals, whereas they started to rise after 1 2 0  
minutes in the inactive subjects after both the low and medium fat meals. The response to 
the high fat meal was different from that after the other meals in both groups, with levels 
beginning to rise after 60 minutes and fluctuating over the following 420 minutes. 
Repeated measures analysis of variance did not identify any differences between the 
pattern of responses between the two groups for any of the meals.
Both the total AUC (0 to 480 minutes) and the AUC for the responses between 30 and 
360 minutes were calculated (Table 3.3.5). There were no statistically significant 
differences between the two groups for the total 8 hour AUC or the 30-360 minute AUC 
after any of the meals.
Table 3.3.5. Total (0-480 min) and 30-360 minute AUC for NEFA responses to each 
meal in the active and inactive groups. Values are mean (SD) for 7 subjects in each
group.___________________________________________________________________
________ NEFA AUC (mmol/l.min) ___________
Active group (n=7) Inactive group (n=7)
0-480 min 30-360 min 0-480 min 30-360 min
low fat mean 154 64* 149 75**
(20 g) SD 56 29 64 43
medium fat mean 155 70* 168 93*
(40 g) SD 95 43 58 37
high fat mean 111 103 195 131
(80 g) SD 72 51 5(5 55
* indicates significant difference compared to the 80 g fat meal within a group (P<0.05) 
** indicates significant difference compared to tire 80 g fat meal within a group (P<0.01)
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Figure 3.3.5. The effects of exercise on plasma-non-esterified fatty acid responses to three different meals containing a) 20 g b) 40 g and c) 80 g of fat. Values represent means with SEM of 7 subjects in each group. The active group are represented by (o) and the inactive group by (■).
There were no statistically significant differences between the total AUC for the two groups after any of the meals
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3.3.2.6 Post-heparin plasma LPL activity
Figure 3.3.6 shows the LPL activities measured in samples taken 5 and 15 minutes after 
an injection of heparin at the end of the postprandial period for 5 subjects in each group. 
The analysis was carried out by another investigator and has not been completed for the 
whole group. Both the 5 and 15 minute post-heparin LPL activities were greater in the 
active than the inactive group after all three meals, however this was only statistically 
significantly different for the 15 minute values after the high fat meal (P<0.05) (Table 
3.3.6).
Table 3.3.6. Post-heparin LPL activity (5 and 15 minutes) in the active and inactive 
groups following each meal. Values are mean (SD) for 5 subjects in each group.
LPL ACTIVITY (mU/ml)
Active group (n=5) Inactive group (n=5)
5 min 15 min 5 min 15 min
low fat Mean 76 171 39 146
(20 g) SD 40 69 9 60
medium fat Mean 105 217 54 191
(40 g) SD 31 78 17 76
high fat Mean 187 374* 93 177
(80 g) SD 76 148 25 37
Significant differences between the active and inactive groups for each meal are shown by * (P<0.05).
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Figure 3.3.6. The effects of exercise on LPL activity after meals of varying fat content, 
low (20g), medium (40g) and high (80g). Each bar shows the level of LPL activity 
measured by the amount of radioactive oleate released per minute after each meal and 
represent means with SEM of 5 subjects in each group. The active group are represented 
by H, and the inactive group by □ . Graph a) shows LPL activity 5 minutes after an 
injection of hepaiin and b) shows LPL activity 15 minutes after the injection.
There was a statistically significant difference between the active and inactive groups for 
the 15 minute post-hepaiin LPL activity after the high fat meal (P<0.05).
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3.3.2.7 Insulin and GIP
The AUC for the insulin and GIP results after each meal are shown in Table 3.3.7 for 5 
subjects in each group. The analysis was carried out by another investigator and has not 
been completed for the whole group.
The insulin AUC was higher in the inactive group after all three meals, although this 
difference was not statistically significant. There was also no significant effect of meal 
fat content on the insulin response in either group.
There was no significant difference in the AUC for GIP between the active and inactive 
groups after any of the meals. In both groups the AUC for GIP was higher after the high 
fat meal than after the low and medium fat meals, however this difference was not 
significant.
Table 3.3.7. Total AUC (8  hour) for insulin and GIP for the active and inactive subjects 
after each meal.
TOTAL AUC (8 hour)
low fat (20 g) medium fat (40 g) high fat (80 g)
Active
(n=5)
Inactive
(n=5)
Active
(n=5)
Inactive
(n=5)
Active
(n=5)
Inactive
(n=5)
Insulin mean 59115 78090 81443 101595 75818 85328
(pmol/l.min) SD 12705 52875 11123 22540 31762
GIP mean 129 129 134 127 152 191
(nmol/l.min) SD 75 56 69 54 89 165
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3.3.3. THE EFFECT OF MEAL FAT CONTENT
3.3.3.1 CM-TAG
The effects of meal fat content on the CM-TAG time-response curves for the inactive 
group are shown in Figure 3.3.7a and for the active group in Figure 3.3.8a. In the 
inactive group the levels fell back to baseline after the low fat meal, but remained 
elevated after the medium and high fat meal. In the active group the levels had fallen 
back almost to baseline after each meal. The time to peak after the high fat meal was 
earlier than after the low and medium fat meals in botli groups. Repeated measures 
analysis of variance showed that the postprandial pattern of CM-TAG was significantly 
different between the low and high fat meals in the active group (P<0.05) but not in the 
inactive group.
The peak levels after each meal are shown in Table 3.3,4. The peak level in response to 
the low and medium fat meals were similar within both groups (0.32 and 0.46 mmol/1 
after the low and medium fat meals respectively for the active group, and 0,76 and 0,71 
mmol/1 after the low and medium fat meals respectively for the inactive group). The peak 
CM-TAG levels after the high fat meal were 0.82 mmol/1 and 1.03 mmol/1 in the active 
and inactive groups respectively, this was 2.5 to 1.8-fold higher than after the low and 
medium fat meals respectively in the active group and 1.4-fold higher than after the low 
and medium fat meals in the inactive group.
The AUC values for the CM-TAG responses to each meal (Figure 3.3.9a) showed an 
increase in AUC with increasing fat content for both groups. The AUC was significantly 
different between the low and high fat meals (P<0.01) and the medium and high fat meals 
in the active group (P<0.05), and between the low and high fat meals (P<0.05) in the 
inactive group.
3 3.3.2 CM-apo B-48
The effects of meal fat content on the CM-apo B-48 profiles for the active group are 
shown in Figure 3.3,7b and for the inactive group in Figure 3,3,8b. In both groups the 
peak apo B-48 level was similar after the low, medium and high fat meals (34%, 40% and 
36% of standard respectively for the active group; 72%, 69% and 77% of standard 
respectively for the inactive group). The time to peak was eaiiier after the high fat meal 
than the low and medium fat meals in both groups, however repeated measures analysis 
of variance showed that there was no significant difference between the pattern of the
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time-response curves after each of the meals in either of the groups. In the inactive group 
the apo B-48 levels fell back to baseline after the low fat meal, but remained elevated 
after the medium and high fat meals. In the active group the levels almost fell back to 
baseline after each meal.
The AUC values for the CM-apo B-48 responses to each meal (Figure 3.3.9b) showed an 
increase in AUC with increasing fat content for the inactive group. The AUC was 
significantly different between the low and high fat meals in the inactive group (P<0.05). 
The AUC in the active group remained the same for the different fat contents.
3 3.3.3 CM-retinyl palmitate
The effects of meal fat content on the CM-RP profiles for the inactive group are shown in 
Figure 3.3.7c and for the active group in Figure 3.3.8c. There was a dose-response 
increase in both the 8 hour AUC (Figure 3.3.9c) and in the peak level of CM-RP (Table
3.3.4) with increasing fat content in both groups. In the active group there was a 
significant difference between the AUC after each of the meals (P<0.01 between the low 
and high fat meals, and P<0.05 between the low and medium and the medium and high 
fat meals). In the inactive group there was a significant difference between the low and 
high fat meals (P<0.01) and the low and medium fat meals (P<0.05). There was no 
difference in the time to peak between any of the meals for either of the groups.
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Figure 3.3.7. Time response-curves for a) CM-triacylglycerol, b) CM-apo B-48 and c) CM-retinyl palmitate for the inactive group. Values represent means with SEM of 7 
subjects after each meal. The 20 g fat meal is shown by (A), the 40 g fat meal by ( • )  and 
the 80 g fat meal by (□),
Significant differences between the AUC for the meals are shown in Figure 3.3.9
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Figure 3.3.8. Time response-curves for a) CM-triacylglycerol, b) CM-apo B-48 and c) CM-retinyl palmitate for the active group. Values represent means with SEM of 7 
subjects after each meal. The 20 g fat meal is shown by (A), the 40 g fat meal by ( • )  and 
the 80 g fat meal by (□)
Significant differences between the AUC for the meals are shown in Figure 3.3.9
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Figure 3.3.9. Total AUC for a) CM-TAG, b) CM-apo B-48 and c) CM-retinyl palmitate
in the active and inactive subjects after the 20 g (■). 40 g (□ ) and 80 g (# ) fat meals. The AUC is the mean with error bars indicating SEM for 7 subjects in each group.
* indicates significant difference compared to the 80 g fat meal within a group (P<0.05).
** indicates significant difference compared to the 80 g fat meal within a group (P<0.01). 
t  indicates significant difference compared to the 40 g fat meal within a group (P<0.05).
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3.3.3 4 Plasma-NEFA
Figure 3.3.10 shows the effect of meal fat content on the NEFA responses in the inactive 
and the active groups. The NEFA levels remained suppressed between 60 minutes and 
300 minutes after the low and medium fat meals in both groups. After the high fat meal 
the NEFA levels began to rise at 120 minutes in both groups and fluctuated over the next 
360 minutes. There was no significant difference between the patterns of response with 
increasing fat content in either of the groups as measured by repeated measures analysis 
of variance.
Figure 3.3.11 shows the total (0-480 minute) AUC and the 30-360 minute AUC for 
plasma-NEFA after the three meals. There were no differences between the total AUC 
after any of the meals in the active or inactive groups. The 30-360 minute AUC was 
significantly greater after the high fat meal compared with the low fat meal and after the 
high fat meal compared with the medium fat meal in the active group ( f  <0.05 in both 
cases). In the inactive group there was a significant difference between the 30-360 
minute AUC after the low and high fat meals (P<0.01) and between the 30-360 minute 
AUC after the medium and high fat meals (P<0.05).
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Figure 3.3.10. Time response-curves for the NEFA responses in a) the active group and
b) the inactive group. Values represent means with SEM of 7 subjects after each meal. 
The 20 g fat meal is shown by (A), the 40 g fat meal by ( • )  and the 80 g fat meal by (□) 
Significant differences between the AUC after each of the meals are shown in Figure 
3.3.11.
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Figure 3.3.11. Total (0-480 minute) AUC and 30-360 minute AUC for NEFA responses 
in the a) active group and b) inactive group after the 2 0  g (I). 40 g (□ ) and 80 g (0 )  fat 
meals. Values are mean (SEM) for 7 subjects in each group.
* indicates significant difference compared to the 80 g fat meal within a group (P<0.05) 
** indicates significant difference compared to the 80 g fat meal within a group (P<0 .0 1 )
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3.3.4. COMPARISON OF MARKERS FOR CM PARTICLES
Figures 3.3.7 and 3.3.8 show the time response profiles in the active and inactive groups 
for the three markers of CM metabolism a) CM-TAG, b) CM-apo B-48 and c) CM-RP. 
In both groups the apo B-48 and TAG showed very similar patterns for all three meals. 
In comparison with the CM-RP responses there were 3 main differences;
a) The time to peak RP was 360 minutes for each meal (except after the high fat meal in 
the active group which was 300 minutes). This was between 2  to 4 hours later than the 
apo B-48 and CM-TAG peaks depending on the meal fat content. Repeated measures 
analysis of variance showed that the postprandial profile of CM-RP was significantly 
different to that of CM-TAG and apo B-48 for each meal.
b) The RP was not detectable in the CM-enriched fraction until 2 hours after the meal, 
whereas the TAG and apo B-48 levels had begun to rise 30 minutes after the meal.
c) The RP levels remained elevated well above baseline levels 8 hours after each of the 
meals in both groups, whereas the CM-TAG and apo B-48 returned to baseline levels in 
both groups after the low fat meal. The apo B-48 and TAG levels are close to baseline 
levels after the medium and high fat meals in the active group and above baseline in the 
inactive group.
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3.4 DISCUSSION
The main aim of this study was to investigate the difference in lipid metabolism between 
young men who habitually exercise 3 times a week compaied with men of the same age 
and body mass index who did no regular exercise. The study shows that the postprandial 
lipaemic response to meals of varying fat content is lower in people who exercise 
regularly. Various aspects of the lipaemic response were studied in order to present a 
detailed picture of the metabolic changes and possible mechanisms underlying these 
differences. A difference was observed in both the peak levels and the AUC of plasma- 
TAG, CM-TAG, CM-apo B-48 and CM-RP responses of the active subjects compared 
with the inactive subjects. These paiameters were taken as measurements of the degree 
of postprandial lipaemia. A difference was also seen in the levels of LPL activity 
between the groups, with the active group having a higher LPL activity than the inactive 
group after each meal. These results indicate the importance of exercise as a preventative 
measure for CAD even at a relatively young age.
The second aim of the study was to investigate the effects of meal fat content on 
postprandial lipaemia. In both groups there was an increase in the plasma-TAG, CM- 
TAG and CM-RP levels with increasing fat content, as measured by peak levels and total 
AUC. However the increase in the TAG response was not directly proportional to the 
increase in fat intake between the meals in either group. A difference was obseiwed in the 
postprandial responses of apo B-48 to the meals between the two groups. Although the 
apo B-48 responses in the inactive group increased with the increasing fat content, there 
was no increase in the apo B-48 response to increasing fat loads in the active group as 
measured by both peak apo B-48 level and AUC. Measurement of apo B-48 is a novel 
contribution to the study of the effects of exercise and meal fat content on postprandial 
lipaemia. These apo B-48 results are interesting and warrant further investigation.
After each meal the active group had a lower plasma-TAG and CM-TAG response 
indicating that they clear any given meal faster than the inactive subjects. These findings 
were consistent with several other studies. Haitung et al (1993) and Merrill et a i (1988) 
showed that endurance-trained subjects had a faster clearance of TAG than sedentary 
individuals. Weintraub et a l (1989) showed that training previously sedentary men 
decreased their postprandial CM-TAG levels and Mankowitz et al (1992) showed that 
detraining active men caused an increase in their postprandial CM-TAG levels. There are 
four main features during the metabolism of dietary fat; absorption into the enterocyte, 
synthesis and secretion of CM particles, hydrolysis of CM-TAG by LPL and uptake of 
resultant CMR by the liver. Time-response cuiwes and AUC reflect all four processes and
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it is difficult to judge from them which aspect is being affected. The CM-enriched 
fraction is assumed to contain particles of Sf >400 (Lindgren et a l, 1972), therefore 
measurements of parameters in this fraction are unlikely to show effects on CMR 
metabolism. CMR particles (Sf <400) are mainly found in the infranatant fraction which 
has not yet been analysed.
The CM-enriched fraction contains TAG of both exogenous and endogenous origin due 
to the large range of paiticle sizes in both the VLDL and CM species. Apo B-48 and RP 
responses therefore provide direct information on CM metabolism as they are both 
specific markers of intestinal lipoproteins. The apo B-48 levels increased 30 minutes 
after the test meal in both groups and for the first 1-2 hours the apo B-48 levels of both 
groups follow similar patterns, although in the active group the apo B-48 levels are 
slightly lower during this time. This suggests that there is veiy little difference in the rate 
of synthesis and secretion of the CM particles between the two groups in response to meal 
ingestion. This is to be expected as it has been suggested that there is a supply of ready- 
synthesised apo B-48 in the enterocyte which prepares the enterocyte for the next intake 
of fat (Murthy et a l, 1992). In this study we could not specifically measure levels of apo 
B-48 in the enterocyte which may have shown a difference between the two groups.
The main difference between the two groups in terms of apo B-48 metabolism is seen 1-2 
hours after the meal when the apo B-48 in the inactive group starts to rise sharply 
whereas the active group shows either a plateau (low and medium fat meals) or a decline 
(high fat meal). If there is only one apo B-48 molecule per CM as suggested by Elovson 
et a l (1988) the level of apo B-48 in the active group indicates that there are fewer 
potentially atherogenic particles present during the postprandial period in these subjects. 
However, these apo B-48 results are measured in the CM-enriched fraction and do not 
strictly indicate CMR metabolism. The ability to measure levels of apo B-48 in the 
infranatant fraction would be of importance since it is particles in this density range 
which have been implicated in atherogenesis.
It has been shown that the uptake of CMR is dose-dependent and saturated by fat intakes 
of 70-100 g (Berr, 1992). Using RP as a mai'ker of CM and CMR, other studies have 
shown that there is a lower AUC for CMR in the active subjects compared to inactive but 
that the difference is not statistically significant (Weintraub et al, 1989; Mankowitz et 
a l, 1992). However these studies were both using over 70 g of fat in the test meal and 
would therefore be saturating the CMR uptake system. In the present study the test meals 
containing 20 g and 40 g of fat would not theoretically saturate the CMR uptake system 
according to this theory (Berr, 1992), and differences in CMR clearance between the two 
groups may be revealed using these fat load levels. Therefore apo B-48 levels measured
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in the infranatant fraction are of paiticular importance in interpreting the full extent of 
differences in lipoprotein metabolism between the active and inactive subjects. The RP 
results also show the same pattern as the apo B-48 and are lower in the active group after 
each meal. However in this study the RP results do not give as much information as apo 
B-48 levels as there is a clear lag phase before RP appears in the circulation compared 
with apo B-48. Possible consequences of this will be discussed later.
Part of the explanation for the lower TAG, apo B-48 and RP results in the active group is 
an increased clearance of CM-TAG by LPL. In this study the post-heparin LPL activity 
8 hours after the meal was higher in the active subjects after each meal although this was 
only significant after the 80 g fat meal. This has also been shown in other studies of the 
effects of exercise (Kantor et a l, 1987). Although postprandial LPL activity has not 
previously been measured in exercise studies, several other studies have shown that, in 
the fasting state, trained subjects have higher skeletal muscle LPL activity (Kiens and 
Lithell, 1989), adipose tissue LPL activity (Nikkila et a l, 1978) and total post-heparin 
LPL activity (Podl et a l, 1994; Haitung et al, 1993). A study by Farese et a l (1991) 
suggested that insulin is the important mediator of the tissue-specific regulation of LPL 
activity, increasing the adipose tissue LPL activity and decreasing the skeletal muscle 
LPL activity. Therefore immediately after the test meal and for a period of 3-4 hours 
after, the effect of muscle LPL is negligible in clearing CM-TAG due to its inhibition 
postprandially by the action of insulin. However the insulin levels had returned to 
baseline 4 hours after the meal (results not shown) and skeletal muscle LPL may play a 
prominent role in clearing dietary fat from the circulation in the late postprandial period 
for use in repleting its TAG stores. The higher levels of LPL activity in skeletal muscle 
in physically active subjects may therefore be an adaptive response to increase the 
potential of the body to hydrolyse TAG and to mobilise and oxidise fatty acids and 
therefore to efficiently utilise plasma TAG in both the fasting and postprandial state.
The plasma-TAG, CM-TAG and apo B-48 follow similar patterns during the early 
postprandial period, suggesting that the lipaemia caused by ingestion of a meal is caused 
mainly by intestinally-derived CM-TAG and secondarily by the release of TAG in 
VLDL. This is in accordance with the results of Cohn et a l (1993) who showed that 
82 % of the increase in plasma-TAG after a meal is due to TAG in apo B-48 containing 
lipoproteins and 18 % in apo B-lOO lipoproteins. Schneeman et a l (1993) also showed a 
postprandial rise in apo B-lOO containing lipoproteins with a 1.6 fold increase in apo 
B-lOO and a 3.5 fold increase in apo B-48. Despite the relative increases of the two 
species of apo B it was noted in both studies that apo B-lOO containing particles 
accounted for 80 % of the total increase in TGRL number which reflects the higher 
concentration of VLDL particles in the fasting state compaied to CM. The concentiation
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of TAG in CM and VLDL was found to be relatively similar between 2 to 6  hours after 
the meal. The increase in VLDL-TAG could be due to three possibilities; inhibition of 
the cleaiance of VLDL-TAG by CM, stimulation of secretion of apo B-lOO-containing 
particles from the intestine, or hepatic secretion of apo B-lOO-containing particles when 
the dietary lipid reaches the liver. Several researchers have proposed that the 
postprandial accumulation of VLDL is due to a competition with CM particles for LPL, 
the latter being preferentially hydrolysed (Brunzell eta l, 1973; Karpe and Hultin, 1995). 
Although some research has provided evidence for intestinal apo B-100 synthesis (Levy 
et al., 1990) this is still controversial and there is no data comparing relative levels of apo 
B 100 and apo B-48 in the intestine. Hepatic secretion of apo B-lOO containing particles 
is inhibited by insulin (Spai'ks and Sparks, 1994a). In this study insulin levels did not 
return to baseline levels until 4-5 hours after the meal and therefore the contribution of 
newly synthesised VLDL to the postprandial TAG levels would not be expected until the 
late postprandial period.
In this study it is difficult to determine the relative contribution of apo B-lOO containing 
particles to the postprandial TAG rise because apo B-lOO levels were not measured. An 
early study by Olefsky et al. (1976) showed a double TAG peak after a meal with the 
initial peak at 1-3 hours due to CM-TAG and the later peak at 4-7 hours due to VLDL- 
TAG. Conversely Cohn et al. (1989) showed that both postprandial peaks had high 
contents of both apo B-lOO and apo B-48 and proposed that the release of apo B-48 from 
the intestine was not constant. Our results show a similar pattern to the latter study with a 
tendency towards a second peak of apo B-48 in the late postprandial phase after the 
medium and high fat meals. This is in accordance with the proposed theory of Cohn et al. 
(1989) that secretion of apo B-48 containing lipoproteins is not constant throughout the 
postprandial period.
An interesting finding in this study is that both peak plasma-TAG and 8 hour AUC for 
plasma-TAG did not increase when the active subjects consumed 40 g of fat rather than 
20 g. In contrast, in the inactive group, although the peak levels are the same after the 
20 g and 40 g fat meals the 8 hour plasma-TAG AUC is higher after the 40 g fat. 
However this increase is not proportional to the increase in the amount of fat. These 
findings suggest that both groups have a mechanism which allows them to cope with an 
increased intake of fat, however in the inactive group this is not as effective and thus 
these inactive subjects already have a mild form of TAG intolerance. After the 80 g fat 
meal the peak and 8  hour AUC are higher than for the 40 g fat meal in both groups but 
again this is not in proportion to the increase in fat intake. This result is in accordance 
with a study by Chen et al. (1992) who showed that following a mixed meal containing 
100% more fat there was only a 10% increase in total plasma-TAG response in NIDDMs.
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However this is not in agreement with a study by Cohen et a l (1988) who showed a 
directly proportional increase in plasma-TAG response to meals containing 40 g, 80 g and 
120 g of fat in the form of double cream. The discrepancy between the present study and 
that of Cohen et a l (1988) may partly be due to the nature of the meals given in our study 
which consisted of mixed meals containing normal foods. These foods would probably 
be absorbed more slowly than the double cream and would stimulate a more effective 
insulin and GIF response and these factors may contribute to the apparently more 
effective clearance of increasing fat seen in our subjects as described below.
In the present study an explanation for the apparent increase in the rate of TAG clearance 
with increasing fat content is the increase in LPL activity noted in both groups after the 
meals containing more fat. This may be an adaptive mechanism to maintain homeostasis 
in the body. Insulin is known to stimulate LPL activity and the rise in adipose tissue LPL 
activity following a meal is well documented (Eckel, 1989), however in this study the 
carbohydrate intake was kept constant for each meal and the insulin peak and 8 hour 
AUC were not found to increase with increasing fat load, therefore the fat itself must 
somehow be influencing the LPL response. There was a trend for higher GIF secretion 
with increasing fat load which was to be expected as fat is a potent stimulator of GIF 
secretion (Morgan et al, 1992) and this may have an effect on LPL activity. The peaks 
for both apo B-48 and CM-TAG occur eai’lier after the high fat meal than for the two 
other meals which may also be due to an acute effect of the fat on LPL.
The CM-TAG results also showed no increase in peak levels after 40 g of fat compared to 
20 g in both groups, however the AUC is seen to rise in both groups, so the homeostasis 
mechanism enables the peak level of TAG to be maintained at a constant level but the 
TAG is in the circulation for longer after a meal containing 40 g of fat.
In contrast to the CM-TAG results there is no increase in either peak CM-apo B-48 or 
8 hour AUC CM-apo B-48 for any of the meals in the active group. There is a dose- 
response increase in the apo B-48 AUC in the inactive group. These contrasting results 
suggest a difference in the handling of dietary fat between the two groups. It is 
speculated that as the fat content of the meal increases, the enterocyte of the active 
subjects may continue to produce the same number of CM but each CM contains more 
TAG. Therefore the active group produces larger CM in response to a high fat meal 
compared with a low fat meal. This would appear to be a beneficial and appropriate 
adaptation as it is believed that laiger CM are better substrates for LPL (Karpe et a l, 
1993a) and may partly explain the attenuated CM-TAG response in the active group. The 
inactive subjects have an increase in both apo B-48 and CM-TAG levels suggesting that 
they continue to produce CM of the same size and therefore produce more CM particles
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to transport the extra fat. This has a second disadvantage as the CMR uptake system of 
the inactive group is more likely to be more saturated than that of the active group after 
the intake of medium and high fat meals as discussed earlier (Berr, 1992) since more 
CMR pai'ticles are being produced. Therefore these subjects may be more likely to have 
CMR remaining in the circulation for longer. This stresses the importance of the 
interaction between dietaiy fat content and lipid metabolism in sedentary individuals, an 
effect which may be exacerbated when meals of medium or high fat content are 
consumed at a single sitting.
The CM-RP peak and AUC in the both groups was seen to increase with increasing fat 
content of the meal even though the same amount of RP was given with each meal. This 
suggests that with a high fat meal proportionally more dietary cholesterol ester will be in 
the circulation than after a low-fat meal which may have implications for LDL and 
cholesterol metabolism. However this result was not in accordance with the study by 
Chen et a i (1992) who showed that after a low fat meal there was a higher level of RP in 
the circulation than after the high fat meal despite the plasma-TAG levels being lower 
after the low fat meal. The difference may in part be due to the subjects in the study of 
Chen et a l  (1992) being non-insulin dependent diabetics.
The three markers for CM paitides, CM-TAG, CM-RP and CM-apo B-48 do not show 
the same pattern in response to the three meals. The CM-TAG and CM-apo B-48 
responses to the lower fat loads show similar patterns, peaking at the same time point in 
both groups. The CM-RP peak occurs 2-4 hours later than the apo B-48 and TAG after 
all three meals. RP is not present until the sample taken 2 hours after the meal, whereas 
both CM-TAG and CM-apo B-48 begin to rise 30 minutes after the meal. This could be 
due to slower absorption of cholesterol ester compared with TAG from the lumen of the 
intestine. The oil-based form of retinyl palmitate administered in this study could have 
caused the delay in the absorption. Studies which have used aqueous preparations of RP 
have not usually found a delay in appeaiance of RP in the circulation (Wilson et a l 1983; 
Brown and Roberts, 1991; de Bruin et a l, 1993) whereas studies using an oil-based 
preparation have often found a delay in RP compared with TAG (Cohn et a l, 1989; 
Krasinski et a l, 1990b; Cohn et al, 1993). Another possible reason for the RP being 
delayed is that the initial CM are relatively TAG-rich and cholesterol-ester poor in order 
to bring the primaiy metabolic fuel to the tissues quickly (Krasinski et al, 1990). At later 
time-points the CM may therefore become increasingly cholesterol ester enriched and 
TAG poor. Further possible problems with RP as a marker for intestinally derived 
lipoproteins are that some studies have shown that there is transfer of RP from CM to 
endogenous lipoproteins during the late postprandial period (Demacker et al, 1992). 
However recent evidence from our group suggests that this RP may in fact be in very
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small CMR co-isolated with IDL and LDL (see Section 6 ). Although both apo B-48 and 
RP are markers for lipoproteins of intestinal origin, in this study they appear to be 
showing different responses to each meal which is in accordance with results from other 
groups (Krasinski et a i, 1990a). Only one apo-B-48 molecule is incorporated into each 
CM particle and is essential for CM assembly and release. However the number of RP 
molecules incorporated into each CM and the time at which this occurs has not been 
defined. Therefore apo B-48 appeal's to be a more specific mai'ker for CM metabolism.
Although the differences in the AUC for the plasma NEFA results aie not statistically 
significant between the active and inactive subjects, the different patterns of response 
between the two groups may be important. There is evidence that if NEFA 
concentrations build-up around the LPL it causes the release of the LPL from the 
endothelial wall onto the lipoprotein particle where it continues to hydrolyse TAG whilst 
in the circulation (Karpe et al, 1992) and act as a ligand for CMR binding to the receptor 
(Beisegel et a l, 1991). If the LPL were not rapidly replaced, this could reduce the rate of 
hydrolysis of CM produced at later timepoints, thus causing an accumulation of CM. 
Plasma-NEFA concentrations begin to rise more quickly in the inactive subjects in the 
mid-postprandial period and could thus cause the release of LPL. The lack of NEFA 
suppression after the high fat meal in both groups is important as it suggests that the LPL 
is hydrolysing the TAG at a faster rate than the adipocyte can take up the resultant NEFA. 
This leads to a build up of NEFA in the circulation which could then lead to the release of 
LPL as described earlier. This suggests another reason to avoid eating regular meals of 
high fat content.
The subjects were well-matched in both groups to ensure that the differences seen were 
due to the effects of exercise. No significant differences were found between the 
anthropometric measurements or the habitual dietaiy intakes between the two groups, 
although the mean P:S ratio was higher in the active group. The reliability of a 3 day 
non-weighed food diaiy is questionable as a measurement of habitual dietary intake and 
may not be sufficient to accurately compaie the day-to-day variations in habitual intake of 
fat and fatty acids (Livingstone, 1990). The effect that a small difference in P:S ratio may 
have on postprandial lipaemia is probably quite small unless there are major differences 
in the intake of n-3 PUFA. Studies by Weintraub et a l (1988) and Dem acker et a l  
(1991) suggested that the "so-called" chronic effects of n- 6  PUFA may be due to the 
acute effects of meals rich in n- 6  PUFA rather than a chronic effect of the background 
diet. As the subjects in the present study consumed identical test meals and the P:S 
content did not change significantly with the different fat contents in the test meals, this 
non-significant difference in the subjects habitual diet would probably not have had a
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marked effect and is unlikely to account for the marked differences in the postprandial 
TAG responses that were observed.
Fasting TAG levels have been shown to be positively correlated with the level of 
postprandial lipaemia (Nestel, 1964; Patsch et al, 1992; Potts et al, 1994). In studies of 
postabsorptive lipid levels, active subjects have been shown to have significantly lower 
fasting plasma-TAG levels (Haskell, 1986) and this has been proposed as a reason for the 
lower postprandial lipaemia observed in athletes compared with sedentary individuals 
(Cohen et al, 1989). In the present study this potential confounding factor was contioHed 
for as no difference was found between the fasting TAG levels of each group, despite the 
difference in habitual physical activity levels. Similar results were also obtained in a 
study by Cohen et a l (1989) who compared the lipaemic responses to a test meal of an 
inactive and active group. They found that, although the two groups had similar fasting 
TAG levels, the inactive group had significantly higher postprandial lipaemia. In the 
same study they found that the CM half-life was shorter and the fractional clearance rate 
of Intralipid was faster in the active group, thus suggesting that the lower postprandial 
lipaemia was due to a direct effect of exercise on the TAG removal system. Due to the 
competition between CM and VLDL for LPL (Brunzell et al, 1973), faster clearance of 
CM would be expected to cause a faster clearance of VLDL and thus a lower fasting 
TAG level in active people as shown in other studies. A possible reason for the similar 
fasting TAG in the subjects in the present study and in that of Cohen et al (1989) is the 
young age of the subjects in both these studies. Lower fasting TAG levels have often 
been seen in older athletes compared with sedentary individuals (Wood et a l, 1977). 
This difference may reflect the long-term benefits of exercise and reflect the overall 
higher TAG levels usually observed in older subjects compared with young subjects 
(Krasinski et al, 1990b). Despite the identical plasma-TAG and CM-TAG levels 
obseiwed in the present study a difference between the postprandial handling of each meal 
was observed between the two groups, showing the independent effects of exercise on 
postprandial lipid metabolism.
Because the aim of the present study was to evaluate the effects of differences in habitual 
exercise levels, it was also important to control for the well documented possible acute 
effects of exercise. Several studies have shown a reduction in serum-TAG levels the day 
after intense exercise (Kantor et al, 1984; Lithell et al, 1984; Foger et al, 1994). Kantor 
et a l (1987) showed an increase in LPL activity 1 day after 1-2 hours of exercise in both 
trained and untrained men. Annuzi et a l (1987) found an increased clearance of 
Intralipid 1 day after 3 hours of exercise but not after 1.5 hours of exercise. Aldred et al 
(1994) found that both fasting TAG and postprandial lipaemia were lower 15 hours after 
exercising at 31 % V0 2 max for 2 hours compared with resting. In view of these findings
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the subjects in the present study were not allowed to do any exercise the day before the 
study and therefore had not exercised for at least 36 hours before the test meal. This 
ensured that any effects seen could be attributed to the background exercise levels.
There are certain limitations in the interpretation of the results of this study. It would be 
easier to measure the relative contributions of intestinal and hepatic lipoproteins to 
postprandial lipaemia if both apo B-48 and apo B-lOO were measured, since the CM- 
enriched fraction has been shown to contain TAG in both CM and VLDL. At the time of 
this study the method available in our laboratory for measuring apo B-48 levels was an 
immunoblotting technique which, although novel and specific to apo B-48, was only 
semi-quantitative as indicated by the very large standard errors. Since the analysis of 
these samples, a specific ELISA for apo B-48 in the CM-enriched fraction has been 
developed in our laboratory and work is continuing to develop a specific ELISA for apo 
B-lOO containing lipoproteins.
The process by which any difference in CMR uptake occurs could not be defined by this 
study. Possible mechanisms by which the CMR uptake system could be altered include 
direct effects on the CMR receptor and alterations in the CM composition or size which 
change the recognition of binding sites by the receptor. Further infonnation about CMR 
metabolism could be gained through measurement of parameters in the infranatant 
fraction, however at the time of this study there were problems with the apo B-48 and RP 
assay in the infranatant fraction and thus these paiameters could not be measured.
No measurements of HDL or LDL-cholesterol were made. These values could have been 
very useful to provide information on the relationship between the level of postprandial 
lipaemia and HDL-cholesterol.
It has been suggested that individuals who choose to take up exercise may have lower 
fasting TAG concentrations beforehand (Williams et a l, 1982) and that lower 
postprandial lipaemia seen in habitual exercisers may be a consequence of self-selection 
rather than an adaptation to chronic exercise (Cohen et al, 1989). This theory suggests a 
genetic influence is involved and that people who choose to take up exercise may already 
have a preferable genetic make-up conferring protection on them without the need for 
exercise. Very few studies have so far been carried out on tlie difference in generic make­
up between active and inactive subjects but such studies could potentially provide 
important information relating to lipid metabolism. It is unclear whether the effects 
observed in this study are due to an increase in the lipid metabolism system due to 
exercise or a defect in the system due to lack of exercise, although most of the evidence 
points to the foiiner.
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In conclusion, epidemiological studies have shown that physical exercise reduces the risk 
of CHD. Part of this protective effect may be due to a reduction in the potentially 
atherogenic CMR particles induced by chronic exercise. This is the first study to show 
apo B-48 levels in a compaiative study of active and inactive subjects, and suggests that a 
reduction in the magnitude and duration of intestinal lipoproteins in the circulation occurs even 
at a young age and with quite a low level of habitual exercise
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CHAPTER FOUR VALIDATION OF A SPECIFIC ELISA FOR APO B-48
4.1 INTRODUCTION
The results from the exercise study in Chapter 3 showed that the apo B-48 responses in 
the CM-enriched fraction were very different between the two groups. It would have 
been very interesting to examine the apo B-48 patterns in the infranatant fraction since 
the small, potentially atherogenic CMR are found in this fraction. The immunoblotting 
method used in the study therefore has several disadvantages: It is only possible to 
measure apo B-48 in the CM-enriched fraction, the immunoblotting method is only semi- 
quantitative and the assay is long and complicated so that very few samples can be 
processed in one day. A specific, competitive ELISA method for quantitation of apo B- 
48 in the CM-enriched fraction had been developed mainly by a post-doctoral colleague. 
However the specificity of the assay had not been established and the use of the assay for 
plasma and infranatant fractions had not been validated.
Since the discovery of two major forms of apo B, apo B-48 and apo B-lOO (Kane et a l, 
1980), compaiatively little work on the measurement of apo B-48 has been carried out. 
Various methodological problems have hampered the investigation including the very 
large size and insolubility of the protein and the fact that its structure is identical to the N- 
terminal 48 % of apo B-100. In view of these difficulties the most commonly used 
method for the measurement of apo B-48 has been densitometric scanning of stained 
protein bands after separation of proteins using gel electrophoresis (Kane et a l, 1980; 
Zilversmit and Shea, 1989; Poapst et a l, 1987; Kai'pe and Hamsten, 1994). This has 
provided useful information but, as mentioned above, this method is not entirely suitable 
for analysing large numbers of samples such as from a postprandial study and the 
technique is susceptible to a high degree of intra- and inter-assay variation. Sample 
preparation is extensive, as the method requires the prior removal of the majority of 
plasma proteins other than apolipoproteins by ultracentrifugation, and the stained gels 
have very low sensitivity.
One approach used by two groups to increase the sensitivity of the method has involved 
transfer of the separated proteins to a nitrocellulose membrane following electrophoresis, 
and immunoblotting with a specific antiserum against apo B. This has enabled 
quantitation of apo B-48 and apo B-100 (Myserth et al, 1989; Cartwright and Higgins, 
1992). In the foimer study, even with the proposed added sensitivity, the apo B-48 band 
could not be detected or quantified any better than on a Coomassie-stained gel. In the 
second study the immunoblotting method was very long and complicated and required the 
use of 1251. The method would therefore not be suitable for large-scale analysis as in 
postprandial studies.
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Despite the problems with the stained SDS-PAGE procedure several studies have been 
described which have used this method to analyse apo B-48. These have involved 
investigation of normal subjects (Seishima et a l, 1988; Cohn et a l, 1989; Kiasinski et 
a l,  1990a; Cohn et a l, 1993; Curtin et a l, 1993; Schneeman et a l, 1993; Karpe and 
Hamsten, 1994; Kotite et a l, 1995), CAD patients (Simons et a l, 1987; Karpe et a l, 
1993a; Karpe et a l, 1993b; Karpe et a l, 1993c; Karpe et a l, 1994), diabetic patients 
(Nakai et a l, 1991; Curtin et a l, 1994) and effects of PUFA and SFA diets (Demacker et 
al, 1991). Various methods were used in the studies for quantifying apo B-48 including; 
expression of apo B-48 as a percentage of the fasting or peak level, expression of the 
level of apo B-48 in arbitrary units (peak areas), expression of apo B-48 by ratio to apo 
B-100, or by direct quantitation from an apo B-100 standard curve.
Although there aie many published immunoassay methods for analysis of total apo B 
(reviewed by Rosseneu et a l, 1983 and Labeur et a l, 1990), the quantitation of apo B-48 
by immunoassay had not been possible until the novel antisera to apo B-48 was raised by 
our group (Peel et a l, 1992). An assay for apo B-48 was required which would be very 
sensitive, due to the very low concentrations of apo B-48 in plasma, and allow 
measurement of large numbers of samples. Of the possible immunoassay formats, an 
ELISA method appeared to be the most practical choice. The other potential assay 
formats had various disadvantages. Electroimmunoassay and radial immunodiffusion are 
not suitable for large numbers of samples. Immunoturbidometry and 
immunonepholometry require the formation of an antigen-antibody lattice. Assuming 
that the antisera against apo B-48 is monospecific to the carboxy teiminal it would not be 
possible to form a lattice structure as formation of a lattice requires that the antibody and 
the antigen are bivalent. A draw-back with RIA is the use of expensive and potentially 
hazai'dous radioactive substances.
The possibility of cross-reactivity of the anti-apo B-48 antisera with HSA, ovalbumin and 
thyroglobulin and interference by intralipid in the ELISA assay had been ruled out during 
development of the assay. It was therefore necessary to investigate potential cross­
reactivity with apo B-100, as this protein is present in very high concentrations in both 
plasma and infranatant (between 100 to 1000 times more than apo B-48). Since the 
amino-terminal half of the apo B-IOO molecule is identical to the apo B-48 protein (as 
described in Section 1.6.2), it is important to ensure there is no cross-reactivity of the 
antisera to apo B-48 with the apo B-100 molecule.
Several methods for the isolation and purification of apo B-48 and apo B-100 had already 
been attempted by a previous post-graduate student in this laboratory (A.S. Peel, personal
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communication). These included chromatofocussing, affinity chromatography, elution of 
protein from gels and organic precipitation. None of these methods were found to be 
adequate for the separation and isolation of these apolipoproteins. The format of the 
ELISA involves measuring apo B-48 on intact lipoproteins and therefore the isolation of 
apo B-48 and apo B-100 from their lipoproteins was not felt to be a valid method to 
produce a standard with which to prove the specificity of the ELISA. In addition the 
published immunoblotting method demonstrates that the anti-apo B-48 antisera does not 
cross-react with the isolated apo B-100 molecule (Peel et a l, 1993).
In order to separate intact lipoproteins, two groups have employed affinity 
chromatography techniques using antibodies to LP-B (obtained from columns of 
Sepharose bound to LDL2) (McConathy et al., 1985) or monoclonal antibodies to apo 
B-100 (Cohn et al., 1993). Using these methods the authors have claimed to obtain pure 
apo B-100 containing fractions. Other investigators have attempted to isolate apo B-100 
on intact lipoproteins using ultracentrifugation (Kaipe and Hamsten, 1994; Kotite et a l, 
1995). Analysis of an LDL fraction, produced by either discontinuous density gradient 
ultracentrifugation (Sf 0-12) or by sequential flotation ultracentrifugation (density range 
1.025 - 1.055 g/ml), on a stained, Coomassie blue polyacrylamide gel showed it to 
contain apo B-100 only. There aie no pure, commercially-available apo B-100 and apo 
B-48 samples. Therefore in view of these findings it was proposed to use the methods of 
ultracentrifugation and immunoaffinity chromatography to isolate both apo B-48 
containing lipoproteins and apo B-100 containing lipoproteins in order to test the cross- 
reactivity within and specificity of the ELISA.
There were four techniques already established in our laboratory for measuring apo B; 
The specific immunoblotting technique for apo B-48 (Peel et a l, 1993), the non-specific 
analysis of Coomassie-stained gels as well as an immunoblotting technique specific for 
apo B, and an automated COB AS method used for the measurement of total apo B in 
plasma samples. It was intended to use these methods as a way of indirectly validating 
the specific ELISA for apo B-48 by compaiing postprandial profiles of CM-enriched, 
infranatant and plasma fractions with each of these methods.
In addition to cross-reactivity, other potential interferences in the assay from components 
of the plasma and infranatant fractions needed to be investigated. This included 
interference due to large concentrations of proteins and cross-reactivity of the HRP- 
labelled secondary antibody with components in the plasma or infranatant fractions.
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Aim of the study
The aim of this research therefore was to validate an existing ELISA for the measurement 
of apo B-48 by confiiming specificity to apo B-48 and analysing cross-reactivity with apo 
B-100 and interference of proteins in the assay. The validation checks were cairied out in 
a routine, logical manner with the results of each experiment leading to decisions on the 
next step to be taken. The methods, results and conclusions from each individual 
experiment are therefore presented sequentially in this chapter to enable the logical 
analysis of the problem to be described. The work in this chapter was carried out in 
collaboration with two other investigators.
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4.2 MATERIALS
Human thoracic duct lymph from a patient undergoing thoracic surgery was kindly 
supplied by Dr John Wright (Royal SuiTey County Hospital). Monoclonal antibodies to 
the C-terminal end of apo B-100 were gifts from L.K. Curtiss, Sciipps Research Institute, 
California (MB43 and MB47) and Sanofi, Montpelier, France (BL3). The solid phase 
matrices used for the affinity columns were 3000 Â porous amino-activated silica beads 
(Clifmar, University of Surrey, Guildford, UK) or Sepharose 4B (Pharmacia). The 
horseradish peroxidase-labelled donkey anti-rabbit IgG antiserum was also purchased 
from Clifmar, University of Surrey, Guildford, UK. A polyclonal sheep anti-apo B 
antiserum was obtained from Boehringer Mannheim, Lewes, Sussex, UK. The 
spectrophotometer was a Kontron Uvikon instrument, Zurich, Switzerland. Ultrafiltration 
of fractions was carried out using a 25 |L im  YMIOO membrane in a 10 ml Diaflo 
ultrafiltiation unit (Amicon Inc., Beverley, USA). The concentration of apo B in samples 
was measured using a Unimate 3 apo B kit on a COBAS Mira (Roche Products Ltd, 
Welwyn Garden City, UK). Materials for the apo B-48 immunoblot and apo B-48 ELISA 
are listed in Section 2.4 and 2.5 respectively. Materials for the ultracentrifugation of 
plasma are described in Section 2.2.
4.3 METHODS AND RESULTS
4.3.1 ISOLATION OF INTACT LIPOPROTEIN SAMPLES CONTAINING A 
SINGLE SPECIES OF APOLIPOPROTEIN B.
4.3.1.1 ISOLATION OF APO B-IOO-CONTAINING LIPOPROTEIN FRACTIONS 
BY ULTRACENTRIFUGATION.
Three approaches using different samples were used in an attempt to isolate a fraction of 
lipoproteins containing apo B-100 only:
Preparation of a lipoprotein fraction in the density range 1.006 - 1.063 g/ml 
Fasting blood was obtained from a 25 year old female volunteer. Ultracentrifugation 
spins were carried out using a Beckman ultracentrifuge according to the protocol 
described in Mackness and Durrington (1992), as outlined in Section 2.2.3, with the 
following alterations:
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i) A CM-enriched fraction was separated by overlayering 4 ml plasma with 4 ml NaCl 
(d= 1.006 g/ml) and spinning in a 60.2 Ti rotor at 40,000 rpm for 30 minutes 
(4.2 X 10  ^g.min). The top 1.5 ml was removed.
ii) A VLDL fraction was separated after 1.5 ml of NaCl (d=1.006 g/ml) was added to the 
infranatant and mixed and the tubes were spun at 30,000 rpm for 20 hours 
(1.68 X 10  ^g.min) at 15 “C. The top 1.5 ml was removed.
iii) An IDL/LDL fraction (d =1.006-1.063 g/ml) was separated after the addition of 
1.44 ml heavy solution of KBr/NaCl (d =1.33 g/ml) to raise the density of the plasma to 
1.063 g/ml and mixing the infranatant. The tubes were spun at 30,000 rpm for 22 hours 
(1.85 X 10  ^g.min). The top 1.5 ml was removed.
Preparation of a lipoprotein fraction in the density range 1.019 ~ 1.063 g/ml 
Fasting blood was obtained from a 32 year old male volunteer. Ultracentrifugation spins 
were carried out using a Beckman ultiacentrifuge according to the protocol described in 
Mackness and Durrington (1992) as outlined in Section 2.2.3, with the following 
alterations:
i) A CM-enriched fraction was separated by overlayering 12 ml plasma with 8 ml NaCl 
(d= 1.006 g/ml) and spinning in a 60.2 Ti rotor at 40,000 rpm for 30 minutes 
(4.2 X 10  ^g.min). The top 4 ml was removed.
ii) A IDL/VLDL fraction (d <1.019 g/ml) was separ ated after 0.33 ml of heavy solution 
(d =1.33 g/ml) was added to raise the density of the plasma to 1.019 g/ml, the volume of 
the infranatant was made up to 20 ml and mixed. The tubes were spun at 30,000 ipm for 
24 hours (2.01 x 10  ^g.min). The top 4 ml was removed.
iii) An LDL fraction (d =1.019-1.063 g/ml) was separated after adding 1.71 ml heavy 
solution to raise the density of the plasma to 1.063 g/ml, the volume of the infranatant 
was made up to 20 ml and mixed. The tubes were spun at 30,000 rpm for 22 hours 
(1.85 X 10  ^g.min). The top 4 ml was removed.
Preparation o f a lipoprotein fraction in the density range 1.050 -1.070 g/ml 
Fasting blood was obtained from a 28 year old male volunteer. Ultracentrifugation spins 
were carried out using a Beckman ultracentrifuge according to the protocol described in 
Mackness and Durrington (1992), as outlined in Section 2.2.3, with the following 
alterations:
i) A CM-enriched fraction (d <1.006 g/ml) was separated by overlayering 4 ml plasma 
with 2.5 ml NaCl (d=1.006 g/ml) and spinning in a 70.1 Ti rotor at 40,000 rpm for 
30 minutes (4.4 x 10  ^g.min). The top 1.5 ml was removed.
ii) A VLDL/IDL/LDL fraction (d =1.006-1.050 g/ml) was separated after 0.79 ml of 
heavy solution (d=1.33 g/ml) was added to raise the density of the plasma to 1.050 g/ml.
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the infranatant volume was made up to 6.5 ml and mixed. The tubes were spun at
40,000 rpm for 24 hours (2.1 x 10  ^g.min). The top 1.5 ml was removed,
iii) An LDL fraction (d =1.050-1.070 g/ml) was separated by adding 0.38 ml heavy 
solution until the density of the plasma was 1.070 g/ml, the volume of the infranatant was 
made up to 6.5 ml and mixed. The tubes were spun at 40,000 rpm for 20 hours 
(1.8 X 10  ^g.min). The top 1.5 ml was removed.
Analysis of the purity of the isolated lipoprotein fractions by an immunoblotting 
technique for total apo B
All the fractions isolated by ultracentrifugation were tested by the immunoblotting 
technique to check for the presence of apo B-48 and apo B-100. The protocol for 
immunoblotting was earned out as described in Section 2.4.4 with the following antisera 
modifications: After separation of the proteins by SDS-PAGE, electro transfer to a 
nitrocellulose sheet and blocking with PBSMT, the bands were immunoblotted with a 
polyclonal sheep antibody to apo B at a 1:1500 dilution. After the washing step the bands 
were incubated with a secondary antibody (HRP-labelled donkey anti-sheep IgG). The 
apo B bands were visualised by ECL as described in Section 2.4.4. A standard was 
included on each gel to identify the apo B-100 and apo B-48 bands.
Apo B species found in lipoprotein fi’actions
The immunoblotting results for each of the lipoprotein fractions isolated from the fasting 
plasma from the 32 yeai' old man are shown in Figure 4.3.1 as a typical example of the 
findings from each of the subjects. Apo B-48 was found in every lipoprotein fraction 
isolated by ultracentrifugation from all the subjects, including the infranatant remaining 
after removal of the LDL fraction. The nature of the antiserum to apo B made it 
impossible to quantitate relative amount of apo B-100 to apo B-48 from densitometric 
scanning of the ECL bands, as the background was too high.
The LDL fraction (d =1.019-1.063 g/ml) from the fasting plasma of the 32 year-old man 
appealed to have the least apo B-48 and the most apo B-100 (lane 4) and was used in the 
ELISA tests described later (Section 4.3.2)
130
5  6
Apo B-100
— Apo B-48
— Albumin
Figure 4.3.1. Protein bands obtained in lipoprotein fractions isolated from the fasting 
plasma from a 32 year old male volunteer after immunoblotting with an antisera to apo B 
and visualisation by ECL. Lane 1 indicates a standard sample of apo B-48, lane 2 is a 
CM-enriched fraction (d< 1.006 g/ml), lane 3 is a VLDL/IDL fraction (d =1.006-1.019 
g/ml), lane 4 is an LDL fraction (d =1.019-1.063 g/ml), lane 5 is the infranatant remaining 
after removal of the LDL and lane 6  is a pure apo B-100 containing lipoprotein fraction 
isolated by immunoaffinity chromatography (Section 4.3.1.2).
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4.3.1.2 ISOLATION OF INTACT APO B-lOO-CONTAINING LIPOPROTEINS BY 
IMMUNOAFFINITY CHROMATOGRAPHY
Principle
Specific antibodies aie bound to a support matrix and packed in a column. A mixture of 
molecules is put through the column and the specific antibody binds to its antigen. The 
other molecules pass through the column and can be collected. The binding between the 
antibody antigen is broken by the addition of a dissociating agent and the pure antigen 
can be collected as it runs through the column.
Wash buffer-PBS
8.0 g of sodium chloride, 1.15 g of disodium hydrogen phosphate, 0.2 g of potassium 
chloride and 0.2 g of potassium dihydrogen phosphate were dissolved in 1 L of distilled 
water. This was stable for several weeks at 4 °C.
Dissociating agent- 3 M Sodium thiocyanate (NaTCN)
87.8 g of NaTCN was dissolved in 250 ml distilled water. This was stable for several 
weeks at RT.
Dialysis buffer-0.02 M boric acid pH 8
6.18 g boric acid, 43.83 g NaCl and 1.46 g EDTA were dissolved in 5 L of distilled water 
and the pH adjusted to 8  using NaOH (concentrated). This was made up fresh before 
each use.
Elution of bound apo B-100 from anti apo B-100 columns (eluate)
The MB43 and MB47 monoclonal antibodies to the carboxyl terminal of apo B-100 were 
bound to Sepharose 4B by another investigator using the method described by the 
suppliers (Phaimacia), and packed in separate columns (referred to as Sepharose-MB43 
column and Sepharose-MB47 column). After using these individual columns 
unsuccessfully, the two columns were mixed to produce a larger column volume (referred 
to as Sepharose-MB43/47 column). The BL3 monoclonal antibody to the carboxyl 
terminal of apo B-100 was bound to Sepharose 4B in one column (referred to as 
Sepharose-BL3) and 3000 Â porous amino-activated silica beads in a second column 
(referred to as silica-BL3) by another investigator.
The protocol used for isolation of lipoproteins by elution from immunoaffinity columns 
was as follows: The column was washed with 5 column volumes of PBS. The sample 
(lymph, CM-enriched fraction, infranatant fraction or plasma as detailed in Table 4.3.1)
132
was loaded on the column, equilibrated at room temperature for 1 hour and 1 ml fractions 
were collected by washing with PBS. In order to elute the apo B-lOO-containing 
lipoproteins bound to the antibodies, 3 M sodium thiocyanate was added to the column, 
equilibrated at room temperature for 1 0  minutes and eluted with further volumes of 
sodium thiocyanate followed by PBS. Fractions of 1 ml were collected. The eluate 
fractions were immediately dialysed against three changes of 0.02 M boric acid buffer 
pH 8.0. Variations in the procedure were achieved by using different columns, different 
samples and different volumes of sample.
Apo B-100 in the wash fractions from an anti apo B-48 column
The antisera to apo B-48 was bound to Sepharose 4B by another investigator using the 
method described by the suppliers and then packed in a column. The protocol described 
above was used to separate apo B-100 from the apo B-48 which should remain bound to 
the column. The apo B-lOO-containing lipoproteins should come through in the first few 
fractions close to the void volume of the column. Variations in the procedure were 
achieved by using different columns, different samples and different volumes of sample.
Analysis of the purity of the fractions
Fractions containing protein were monitored by measuring the absorbance of each 
fraction at 280 nrn. The fractions containing protein were defined as samples with 
absorbance greater than 0.20 at 280 nm. In lipaemic lymph and CM-enriched fractions 
the absorbance was artificially high due to turbidity. The turbidity was assumed to be 
lipid associated with apo B-48 or apo B-100 and therefore turbid fractions were included 
in the above definition of fractions containing protein. Fractions containing protein were 
analysed for purity by SDS-PAGE followed by immunoblotting using a polyclonal sheep 
anti-apo B antiserum at a dilution of 1:1500 as described in Section 4.3.1.1.
Table 4.3.1 shows the samples and columns used to isolate apo B-100 and the purity of 
the fractions analysed by immunoblotting with an antiserum to apo B. In the Table, the 
fractions containing proteins which did not bind to the columns and were washed through 
with PBS are referred to as the wash and the number of the fraction used is indicated. 
The fractions collected which did bind to the columns and were eluted with sodium 
thiocyanate aie referred to as the eluate.
The eluates obtained after running the lymph through the Sepharose MB43/47 and the 
fasting CM-enriched fraction through both the Sepharose MB43/47 and silica-BL3 
columns were pooled with the wash fractions 5 and 6  from running the fasting CM-
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enriched fraction through the Sepharose-anti apo B-48 column. An example of the 
protein content of a pure-apo B-lOO containing lipoprotein fraction is shown in Figure
4.3.1 (lane 6 ). This pooled sample of appaiently pure apo B-lOO-containing lipoproteins 
was used in Section 4.3.2
4.3.1.3 ISOLATION OF APO B-48-CONTAINING LIPOPROTEINS BY 
IMMUNOAFFINITY CHROMATOGRAPHY
The columns described in Section 4.3.1.2 were also used to isolate apo B-48-containing 
lipoproteins using the same principles and procedures. It was expected to be able to 
isolate apo B-48 lipoproteins in the eluate from the Sepharose anti-apo B-48 column and 
in the first wash fractions from the columns containing monoclonal antibodies to apo B- 
100. For some samples the fractions collected after washing the sample through with 
PBS were pooled and put through the column a second and third time (referred to in 
Table 4.3.2 as x2 and x3). The purity of the fractions was measured by immunoblotting 
with an antiserum to apo B.
Table 4.3.2 shows the samples and columns used to isolate apo B-48 and the purity of the 
fractions analysed by immunoblotting with an antiserum to apo B. The wash fractions 1 
to 3 obtained after running a 500 |il lymph sample 3 times through the silica-BL3 column 
were pooled with wash fraction 5 obtained after running a 200 |xl lymph sample twice 
through the Sephai'ose-MB43/47 column. This pooled sample of apo B-48-containing 
lipoproteins was used in Section 4.3,2.
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Table 4.3.1 Columns and samples used for the isolation of apo B-lOO-containing 
lipoproteins and results obtained from analysing the purity of the fractions by 
immunoblotting.
COLUMN SAMPLE SAMPLE
VOLUME
FRACTION BANDS ON 
IMMUNOBLOT
Sepharose-MB43+MB47 lymph 2 0 0  pi eluate apo B-lOO and B-48
Sepharose-MB43+MB47 CM-enriched fraction (fasting) 1 0 0  pi, 
2 0 0  pi
eluate apo B-lOO and B-48
Sepharose-MB43/47 hyperlipidaemic postprandial plasma 2 0 0  pi eluate apo B-lOO, apo B-48, breakdown products
Sepharose-MB43/47 CM-enriched fraction (fasting) 250 pi eluate apo B-lOO only
Sepharose-MB43/47 lymph 300 pi eluate apo B-lOO only
Sepharose-BL3 lymph 500 pi eluate apo B-lOO and B-48
Sepharose-BL3 CM-enriched fraction (fasting) 500 pi eluate apo B-lOO and B-48
silica-BL3 lymph 500 pi eluate apo B-lOO and B-48
sllica-BL3 CM-enriched 
fraction (fasting) 500 pi
eluate apo B-lOO only
Sepharose- 
a-apo B-48
hyperlipidaemic postprandial plasma 500 pi 1 -6 apo B-lOO, apo B-48, breakdown products
Sepharose- 
a-apo B-48
noiinal 
fasting plasma 500 pi
1 -6 apo B-lOO and B-48
Sepharose- 
a-apo B-48
fasting infranatant after CM removed 500 pi 1 -6 apo B-lOO and B-48
Sepharose- 
a-apo B-48
CM-enriched 
fraction (fasting) 500 pi
1-4
5-6 apo B-lOO and B-48 apo B-lOO only
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Table 4.3.2 Columns and samples used for the isolation of apo B-48-containing 
lipoproteins and results obtained from analysing the purity of the fractions by 
immunoblotting.
COLUMN SAMPLE SAMPLE
VOLUME
FRACTION BANDS ON 
IMMUNOBLOT
Sepharose-MB43+MB47 lymph 2 0 0  |il 1-3 (x2) apo B-lOO and B-48
Sepharose-MB43+MB47 CM-enriched fraction (fasting) 1 0 0  [Û, 
2 0 0  III
1 apo B-lOO and B-48
Sepharose-MB43/47 hyperlipidaemic postprandial plasma 2 0 0 ^ 0 1 apo B-lOO, apo B-48, breakdown products
Sepharose-MB43/47 fasting CM-enriched fraction 250 pi 1 -2 apo B-48 and B-lOO
Sepharose-MB43/47 lymph 2 0 0  pi 5(x2) apo B-48 only
Sepharose-BL3 lymph 500 pi 1-4 (x3) apo B-lOO and B-48
silica-BL3 lymph 500 pi 1 -2 apo B-lOO and B-48
silica-BL3 lymph 500 pi 1-3 (x2) apo B-lOO and B-48
silica-BL3 lymph 500 pi 1-3 (x3) apo B-48 only
Sepharose- 
a-apo B-48
hyperlipidaemic 
postprandial plasma 500 pi eluate no bands
Sepharose- 
a-apo B-48
normal postprandial plasma 500 pi eluate apo B-lOO and B-48
Sepharose- 
a-apo B-48
fasting infranatant 
after CM removed 500 pi eluate apo B-lOO and B-48
Sepharose- 
a-apo B-48
fasting CM-emiched 
fraction 500 pi eluate apo B-lOO and B-48
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4.3.2 ANALYSIS OF PURIFIED LIPOPROTEIN SAMPLES
Concentration of purified lipoprotein ft’actions by ultrafiltration
The pure fractions of apo B-48 containing lipoproteins isolated by immunoaffinity 
chromatography were pooled to give a volume of 3 ml and concentrated using 
ultrafiltration. Briefly, a 25 pm YMIOO membrane was fitted in a 10 ml Diaflo 
ultrafiltration unit. The exclusion criteria for this membrane is MW 100,000. The sample 
was diluted to 10 ml, pipetted into the unit and nitrogen gas at a pressure of 5 bar was 
passed through the unit. The pooled apo B-48 sample was concentrated down to 1 ml 
under vacuum.
The pure fractions of apo B-lOO containing lipoproteins isolated by immunoaffinity 
chromatography were pooled to give a volume of 3 ml and concentrated in the same way 
as the apo B-48 sample to give a final volume of 1 ml.
Analysis of purified, isolated lipoprotein samples by COBAS for apo B
The concentrations of apo B in the pure, concentrated lipoprotein samples and in the LDL 
fraction from Section 4.3.1 were measured by automated, turbidimetric analysis using a 
Unimate 3 kit on a COBAS Mira. The procedure and principles of the assay are 
described in Section 2.6.7. The normal standard curve was used for the LDL fraction and 
the lower concentration standard curve was used for the pure lipoprotein fractions.
The concentration of apo B in both the pure apo B-48 and apo B-lOO containing 
lipoprotein samples was on the lower linearity limit of the standard curve for the assay. 
The concentration of apo B in the apo B-lOO sample was determined to be approximately 
50 |ig/ml. The concentration of apo B in the apo B-48 sample was determined to be less 
than 50 |ag/ml. However as this value was the lowest concentration on the standard curve 
an absolute concentration could not be assigned. The concentration of apo B in the LDL 
fraction was found to be 1 1 0 0  |ig/ml.
Analysis of isolated lipoprotein samples by ELISA for apo B-48
The concentrated, pure apo B-48 and apo B-lOO containing lipoprotein samples from 
Section 4.3.1.2 and 4.3.1.3 and the LDL fraction from Section 4.3.1.1 were analysed by 
the ELISA for apo B-48. A fasting CM-enriched fraction was also analysed, as it was 
found to have a similar, but slightly lower, concentration of apo B-48 as the LDL fraction 
when analysed using the immunoblotting technique for apo B-48 (Figure 4.3.4). The 
procedure for the ELISA for apo B-48 is described in Section 2.5. Standard curves of the
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pure apo B-48 and the pure apo B-lOO containing lipoprotein samples were run on the 
ELISA. A single sample of the LDL fraction and the fasted CM-enriched fraction were 
tested on the ELISA.
Results for the standard curve of the pure apo B-lOO containing lipoprotein sample are 
shown in Figure 4.3.2. The horizontal line produced with the increasing concentiation of 
apo B-lOO indicates that no cross-reaction was found when the apo B-lOO containing 
lipoprotein sample at an apo B concentration of 50 p.g/ml was run on the ELISA. This 
concentration of apo B 100 is approximately that found in a CM-enriched fraction (Karpe 
et ah, 1993).
The apo B-48 containing lipoprotein sample did not give a reading on the ELISA.
Both the LDL fraction and the CM-enriched fraction showed similar, small displacements 
in the ELISA assay, indicating a concentration of apo B-48 of 0.50 p-g/ml and 0.30 (ig/ml 
respectively.
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Figure 4.3.2. A typical standard cuiwe obtained using serial dilutions of a lymph sample 
as the standard, and the results obtained when a standard curve of a pure apo B-lOO 
containing lipoprotein sample was analysed on the ELISA.
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4.3.3 INDIRECT VALIDATION OF THE ELISA FOR APO B-48
4.3.3.1 INDIRECT VALIDATION OF THE APO B-48 ELISA BY COMPARISON 
WITH IMMUNOBLOTTING METHOD
The immunoblotting technique had been used to show the postprandial pattern of apo 
B-48 in CM-enriched fractions (Chapter 3). A comparison of the postprandial apo B-48 
patterns in the CM-enriched fractions obtained by the two methods was therefore earned 
out as a further validation test for the ELISA.
Postprandial samples
Twelve different postprandial profiles of CM-enriched fractions were analysed by the apo 
B-48 immunoblotting and ELISA methods as described in Section 2.4 and 2.5 
respectively. The same antiserum was used in both methods to allow comparison 
between the results. The postprandial blood samples were obtained from various 
volunteers over an 8 to 1 2  hour period after a test meal, with details as described below.
Subjects 1-to 4
These subjects were diabetic men aged 51 to 56 years. The subjects were given a fat- 
containing meal at 7 pm, after eating standardised meals throughout the day. Postprandial 
samples were taken every hour for 12 hours after the test meal. The meal consisted of 
normal foods (lasagne, salad and bread) and contained 4.7 MJ energy, 50 g fat, 38 g 
protein and 140 g carbohydrate.
Subjects 5-11
These subjects were healthy young men aged 19 to 23 years. The subjects were given a 
fat-containing meal after a 12 hour overnight fast. Postprandial samples were taken every 
hour for 8 hours. Three different meals were used containing varying amounts of fat. 
Subjects 5 and 6  consumed a low fat meal (20 g fat), subjects 7, 8 and 9 consumed a 
medium fat meal (40 g fat) and subjects 10 and 11 consumed a high fat meal (80 g fat). 
The meals consisted of normal foods (cereal, milk, bread and cheese). The low and high 
fat meals contained 44 g protein and 168 g carbohydrate, the medium fat meal contained 
24 g protein and 150 g carbohydrate.
Subject 12
This subject was a 57 year- old healthy man who consumed a mixed, fat-containing meal 
after a 12 hour overnight fast. Postprandial samples were taken every hour for 7 hours. 
The meal contained 6.4 MJ energy, 82 g fat, 44 g protein and 168 g carbohydrate.
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Preparation of CM-enriched fraction
Plasma was isolated from blood by centrifugation for 7000 g.min as described in Section
2,1. The CM-enriched fraction was isolated from the plasma by overlayering with NaCl 
(d=1.006 g/ml) and spinning for 5.0 x 10® g.min as described in Section 2.2.3. 
Preservative was added to each CM-enriched fraction at 5 % of the total volume. The 
samples were frozen at -20 “C until analysis.
Correlation between immunoblotting and ELISA methods
The values obtained for each timepoint by the two methods were correlated using 
Pearson's correlation. There was a total of 137 samples. The correlation values for the 
individual postprandial profiles are shown in Table 4.3.3. The values for all the profiles 
were positively correlated and the mean 'r' value was 0.74. Figure 4.3.3 shows the apo B- 
48 postprandial profiles obtained from subject 10 measured by both the methods. Figure
4.3.4 shows a typical apo B-48 postprandial profile obtained by immunoblotting..
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Figure 4.3.3. Postprandial apo B-48 profiles in subject 10 obtained by immunoblotting and ELISA.
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Table 4.3.3. Comparison of postprandial profiles of apo B-48 in CM-enriched fractions 
measured using immunoblotting and ELISA.
Subject Number of 
time points
Correlation 
Coefficient (r)
Significance (P)
1 13 0.76 0.003
2 13 0.70 0.008
3 13 0.61 0.025
4 13 0.52 0.070
5 7 0.78 0.038
6 9 0.73 0 .1 0 0
7 13 0.79 0 .0 0 1
8 12 0.75 0.005
9 12 0.80 0 .0 0 1
10 11 0.90 0 .0 0 0 2
11 11 0 .6 6 0 .0 0 2
12 9 0.84 0.005
Lane Number
1 2 3 4 5 6 7 8 9 10 11 12 13
Apo B-48
unknownprotein
Figure 4.3.4. A typical postprandial apo B-48 profile in subject 12 obtained by 
immunoblotting with a specific antisera to apo B-48 and visualisation by ECL. Lane 1 
indicates MWM, lane 2 a standard apo B-48 containing sample, lane 3 the fasting LDL 
fraction obtained in Section 4.3.1.1, lane 4 a fasting CM-enriched fraction and lanes 5 to 
13 apo B-48 in postprandial CM-enriched fractions taken 30 minutes after a meal and 
every hour for 8 hours.
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4.3.3.2 INDIRECT VALIDATION OF APO B-48 ELISA BY COMPARISON 
WITH STAINED GEL METHOD
It has been shown that the time-course of the postprandial changes in the level of apo 
B 100 in a TGRL fraction differs from that of apo B-48 (Cohn et oL, 1993). If there is no 
cross-reactivity with apo B-lOO in the ELISA assay for apo B-48, there should be no 
correlation between the apo B-lOO postprandial profile and the postprandial profile 
obtained by the ELISA. In Section 4.3.1 it was reported that the relative levels of apo 
B-48 and B-lOO could not be quantitated from an immunoblot using an antisera to apo B 
due to the very high background. Other groups measure apo B-48 and apo B-lOO in 
lipoprotein fractions by analysis of stained protein bands on a polyacrylamide gel (Karpe 
et a.L, 1994). In our group we have found it difficult to detect apo B-48 in CM-enriched 
fractions using Coomassie blue staining of polyacrylamide gels. The levels of apo B-48 
on a stained gel can more easily be quantified in a TGRL fraction (d <1.006 g/ml) as the 
long spin time used to produce this fraction (18 hours) i) concentrates the apo B-48 more 
than in the short preparation used to produce a CM-enriched fraction and ii) removes 
most of the plasma proteins other than the apolipoproteins from the TGRL fraction. The 
TGRL fraction contains VLDL, CM and some CMR. Assuming no cross-reactivity with 
apo B-lOO in the ELISA for apo B-48, there should be no coiielation between the pattern 
obtained from a postprandial profile of TGRL fractions using the apo B-48 ELISA with 
the patterns of apo B-lOO obtained from a stained gel. At the same time there should be a 
positive correlation between the pattern obtained using the apo B-48 ELISA with the apo 
B-48 profile from the stained gel. TGRL fractions were obtained from two, healthy male 
subjects in order to test this hypothesis.
Postprandial samples
Both subjects consumed a high fat meal after a 12 hour overnight fast. The meal 
consisted of normal foods and contained 6.4 MJ energy, 82 g fat, 44 g protein and 168 g 
cai'bohydrate. In the first subject (subject 13) blood samples were collected 30 minutes 
after the meal and then eveiy hour for 7 hours. In the second subject (subject 14) blood 
samples were collected 30 minutes after the meal, then every hour for 10 hours and a final 
sample 1 2  hours after the meal.
Preparation of TGRL fraction
Plasma was isolated from blood by centrifugation at 7000 g.min as described in Section
2.1. The TGRL fraction was isolated from the plasma by mixing with NaCl (d=1.006 
g/ml) and spinning for 1.1 x 10  ^ g.min (18 hours at 40,000 rpm) as described in Section 
2.2.3. The TGRL fraction was removed in 1.5 ml and preservative was added at 5 % of 
the total volume. The samples were used immediately for the SDS-PAGE and ELISA.
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These methods are described in Section 2.4 and 2.5 respectively. The values obtained at 
each time-point were compared using Pearson's conelation.
Correlation between the ELISA pattern and apo B-48 and B-lOO patterns
Subject 13
The apo B-48 results obtained by the ELISA and gel methods are shown in Figure 4.3.5 
The ELISA was significantly correlated with the apo B-48 pattern obtained from the 
stained gel (r =0.86; P =0.003).
The apo B-48 results obtained by ELISA and the apo B-lOO results from the gel are 
shown in Figure 4.3.6. There was no coiTelation between the apo B-lOO pattern obtained 
from the gel with the ELISA pattern (r =-0.43; P =0.25). There was also no coiTelation 
between the apo B-lOO and B-48 patterns obtained from the stained gel (r =0.31; P =0.42) 
(results not shown graphically).
Subject 14
The apo B-48 results obtained by the ELISA and gel methods for subject 14 are shown in 
Figure 4.3.7 The ELISA was positively correlated with the apo B-48 pattern obtained 
from the stained gel (r =0.56; P =0.06), this was not quite significant.
The apo B-48 results obtained by ELISA and the apo B-lOO results from the gel are 
shown in Figure 4.3.8. There was no coiTelation between the apo B-lOO pattern obtained 
from the gel with the ELISA pattern (r =-0.24; P =0.45). There was also no correlation 
between the apo B-lOO and B-48 patterns obtained from the stained gel (r =0.39; P =0.21) 
(results not shown graphically).
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Figure 4.3.5 Comparison of apo B-48 postprandial pattern measured by ELISA and gel 
for subject 13. The ELISA was significantly correlated with the apo B-48 pattern 
obtained from the stained gel (r -0.86; P =0.003)
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Figure 4.3.6 Comparison of the apo B-48 postprandial pattern measured by ELISA and 
apo B-100 pattern measured by stained gel for subject 13. There was no correlation 
between the apo B-100 pattern obtained from the gel with the ELISA pattern 
(r =-0.43; P =0.25)
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Figure 4.3.7 Comparison of apo B-48 postprandial pattern measured by ELISA and gel 
for subject 14. The ELISA was positively correlated with the apo B-48 pattern obtained 
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B-100 pattern measured by gel for subject 14. There was no correlation between the apo 
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4.3.4 VALIDATION OF THE APO B-48 ELISA FOR PLASMA AND 
INFRANATANT SAMPLES
4.3.4.1 COMPARISON OF THE ELISA AND IMMUNOBLOTTING 
TECHNIQUE FOR INFRANATANT FRACTIONS
The level of apo B-48 in corresponding infranatant and CM-enriched fractions were 
compared by mnning both samples on the apo B-48 immunoblotting and ELISA methods 
according to the protocols described previously (Section 2.4 and 2.5).
Subjects and sample preparation
Seven subjects were given one of three different meals as described in Section 4.3.3. 
Subject 15 ate the low fat meal, subjects 16 to 18 ate the medium fat meal and subjects 19 
to 2 1  ate the high fat meal.
The CM-enriched fraction was prepared using a short spin as described previously 
(Section 4.3.3.1). The infranatant fraction was the diluted plasma remaining after the 
CM-enriched fraction had been removed. Fasting and postprandial CM-enriched and 
infranatant fractions were run on the apo B-48 immunoblot and ELISA as described 
previously.
An immunoblot showing the apo B-48 bands obtained for subject 17 in four CM-enriched 
fractions and the corresponding four infranatant fractions is shown in Figure 4.3.9. The 
apo B-48 values obtained for these fractions on the immunoblot and the ELISA are 
shown in Table 4.3.4 after collection for dilution and concentration.
There was a clear discrepancy between the results for the immunoblot and the ELISA. 
When measured by the ELISA, the infranatant apo B-48 concentrations were between 
eight and twenty-three times higher than the apo B-48 levels in the CM-enriched fraction. 
Conversely when measured by the immunoblotting technique, the infranatant apo B-48 
levels were only slightly lower than the apo B-48 levels in the CM-enriched fraction, witii 
the 480 minute infranatant value being higher than the CM-enriched fraction. This 
pattern was found to be the case in every set of infranatant and CM-enriched fractions 
measured.
There were also several much stronger bands visualised in the lower region of the blot 
(Figure 4.3.9) in the infranatant compared with the same region of the blot for the CM- 
enriched fractions, especially just below the albumin region (approximately 50-60 kDa). 
Both these discrepancies were investigated further in the following sections.
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Table 4.3.4. Level of apo B-48 in CM-enriched and infranatant fractions measured by 
immunoblotting and ELISA for subject 17.
Immunoblot apo B-48 
(% of internal standard)
ELISA apo B-48 
(^g/ml)
time after meal CM-enriched Infranatant CM-enriched Infranatant
(minutes) fraction fraction fraction fraction
0 9 6 0.16 3.75
120 24 18 0.39 5.82
360 23 13 0.42 3.42
480 6 24 0.28 3.50
1 2 3 4  5 6 7 8 9  10
0
é
Apo B-48 
unknown 1
unknown 2 
unknown 3
Figure 4.3.9. Apo B-48 bands in fasting and postprandial CM-enriched and infranatant 
fractions visualised by ECL after immunoblotting using an antisera specific to apo B-48. 
Lane 1 indicates MWM, lane 2 is a standard containg apo B-48, lane 3 is the fasting CM- 
enriched fraction (0 minutes), lanes 4, 5, and 6  are the 120, 360 and 480 minute CM- 
enriched fractions respectively, lane 7 is the fasting infranatant fraction, lanes 8 , 9, and 10 
are the 120, 360 and 480 minute infranatant fractions respectively.
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Investigation of the cross-reactivity in the immunoblot with lower molecular weight 
proteins
i) Spiking CMft'actions with albumin
It appeared from the immunoblot of infranatant fractions (Figure 4.3.9) that there was 
some cross-reactivity with proteins in the albumin region (approximately 50 kDa). This 
was investigated by diluting three different CM-enriched samples from subject 16 (0, 240 
and 480 minutes) with an equal volume of HSA (20 mg/ml in PBS) before loading on the 
gel and comparing with the same three CM-enriched fractions diluted with an equal 
volume of PBS only. The proteins were immunoblotted with the antisera to apo B-48 
followed by HRP-labelled donkey anti-rabbit IgG. The results of the immunoblotting are 
shown in Figure 4.3.10.
The results in Figure 4.3.10 show that a protein slightly smaller than albumin which 
migrated in a similai' region to albumin is cross-reacting with one of the antisera on the 
immunoblot. The proposed moleculai* weight of this protein is approximately 50 kDa. 
This protein is present in the unspiked CM fraction but is quite diffuse. The addition of 
the albumin concentrates the protein, making it appeal" a sh onger band.
Addition of the albumin to a CM-enriched fraction also maikedly reduced the intensity of 
the apo B-48 band. This could be because there is an excess of protein in the sample 
loaded on the gel compared with the amount of SDS in the sample buffer. Thus there was 
a large amount of non-linear protein at the interface of the resolving gel which was 
prevented from entering the gel. These results suggest that it is not possible to compaie 
the apo B-48 levels in the infranatant and plasma obtained from the immunoblot and 
ELISA, as the excess of protein in these samples prevents reliable results being obtained 
from the immunoblot.
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1 2 3 4 5  6 7  8 9  10 11
II
Apo B-48
Unknownprotein
Figure 4,3.10. Apo B-48 bands in three CM-enriched fractions diluted with either PBS 
or HSA. Lane 1 indicates MWM, lane 2 is a standard containing apo B-48, lanes 3 and 4, 
6  and 7, and 9 and 10 are duplicate samples of the fasting, 240 and 420 minute CM- 
enriched fractions respectively from subject 16 diluted with an equal volume of PBS. 
Lanes 5, 8 and 11 are the fasting, 240 and 420 minute CM-enriched fractions respectively 
from subject 16 diluted with an equal volume of HSA (20 mg/ml).
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ii) Effect of immunohlotting without antiserum to apo B-48
The level of cross-reactivity or non-specific binding with other smaller proteins in the 
immunoblot is a concern since the same antibodies used for the immunoblotting method 
are used in the ELISA method. To investigate which of the antibodies were binding to 
the proteins the nitrocellulose was incubated without the primary antibody. The presence 
of bands when using the secondary antibody alone suggests non-specific binding or cross­
reactivity of the secondary antibody.
Several CM-enriched and infranatant samples from Section 4.3.4.1 were run on a gel as 
described in Section 2.4 and immunoblotted with the secondary antibody (donkey anti­
rabbit IgG conjugated to HRP) only. The results for the experiment are shown in Figure 
4.3.11. All the bands that are visible on an immunoblot incubated as normal with the 
primary antiserum to apo B-48 and the secondaiy HRP-labelled antiserum (Figure 4.3.9) 
were present on the immunoblot incubated only with the secondary antibody, except the 
apo B-48. There were more bands revealed in the infranatant fractions than the CM- 
enriched fraction.
A further experiment to test the cross-reactivity of the antiserum to apo B-48 was earned 
out using the antiserum to apo B-48 directly conjugated to an HRP label to remove the 
need for a secondary antibody to IgG. A lymph sample, a CM-enriched fraction and an 
infranatant fraction were run in duplicate on different halves of the same gel. After the 
electrophoresis was finished the gel was cut in half. One half was immunoblotted with 
the specific antisera to apo B-48 directly conjugated to a HRP label and the other half was 
immunoblotted with the secondaiy antibody conjugated to HRP. The results after using 
the HRP-labelled apo B-48 antisemm are shown in Figure 4.3.12. and show that no bands 
aie seen except the apo B-48.
These results suggest that it was the secondaiy antibody that was involved in binding to 
the proteins other than apo B-48. This is a potential disadvantage in the ELISA system as 
the entire plasma sample is placed in each well without separation of the plasma proteins 
from the apo B-48. This could produce artificially high apo B-48 results in the plasma 
and infranatant if these proteins were able to bind to the ELISA plate and were recognised 
by the secondary antibody.
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1 2 3 4 5
unknown 1 
i unknown 2
unknown 3 
unknown 4
Figure 4.3.11 Bands visualised in CM-enriched and infranatant fractions after 
immunoblotting with the secondary antibody (HRP-labelled donkey anti-rabbit IgG) only. 
Lanes 1 to 3 are postprandial CM-enriched fractions, lanes 4 and 5 are serial dilutions of 
the CM-enriched fraction in lane 3, lanes 6  to 8 are infranatant fractions.
Apo B-48 unknown 1
unknown 2
unknown 3 unknown 4
Figure 4.3.12 Bands visualised in lymph, CM-enriched and infranatant fractions. Lanes 
1 to 6  were immunoblotted with HRP-labelled rabbit anti-apo B-48 (the primary 
antibody) only. Lanes 7 to 12 were the same samples immunoblotted with the HRP- 
labelled donkey anti-rabbit IgG (the secondary antibody) only. Lanes 1 and 7 are a 
lymph sample, lanes 2 and 8 are the lymph sample diluted with PBS, lanes 3 and 9 are a 
postprandial CM-enriched fraction, lanes 4 and 10 are the CM-enriched fraction diluted 
with PBS, lanes 5 and 11 are the CM-enriched sample diluted with HSA (20 mg/ml), 
lanes 6  and 12  are a postprandial infranatant sample.
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Hi) Further investigation o f  intetference in the ELISA fo r  apo B-48
Several experiments were conducted to further investigate the possibility that there may 
be interference from plasma proteins in the ELISA assay for apo B-48 and to attempt to 
minimise the effect. The results from these experiments were inconclusive and will only 
be briefly described.
The binding of the secondary HRP-labelled donkey anti-rabbit IgG antiserum on the 
ELISA plate was investigated by leaving out the anti apo B-48 antiserum in the ELISA 
assay for apo B-48. Standard curves of various plasma and infranatant samples were set 
up by double dilution. The neat and diluted samples were incubated for 1 hour with HSA 
instead of the anti-apo B-48, and then treated as normal as described in Section 2.5. For 
some samples it was found that a decrease in colour occurred with a decrease in protein 
concentration, suggesting that some of the proteins in the sample were binding to the 
plate and the secondary antibody was binding to the proteins. As the protein 
concentration decreased by subsequent dilution of the sample, less proteins bound to the 
plate and therefore produced less colour. However these results were not produced 
consistently witli every sample or on eveiy day.
In order to prevent any potential non-specific binding, several methods were investigated.
a) Plasma was added to the secondary antibody at a volume of 5 % of the total. This was 
found to remove the binding to proteins other than apo B-48 on the immunoblot. 
However, when the secondary antibody containing plasma was added to the ELISA plate 
it did not markedly affect the apo B-48 concentrations given in plasma and infranatant but 
it was found to lower the lymph standard curve.
b) Variations in the blocking materials were investigated. Casein, gelatin and BSA at 
different concentrations were used, however none of the combinations appealed to be 
more effective than the 0.05 M PBSGT already used.
c) The results in Figure 4.3.12 showed that there was no non-specific binding with any 
proteins when using the antibody to apo B-48 conjugated directly with HRP. However 
the antisera had to be affinity purified before it could be conjugated to the HRP and this 
diluted the antiserum to a large extent. Experiments using this HRP-conjugated 
antiserum to apo B-48 in the ELISA were unsuccessful as the standard curve was very 
shallow due to the dilution.
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In conclusion, more work needs to be carried out on the possibility that there may be 
interference from plasma proteins in the ELISA assay for apo B-48. Further experiments 
with the HRP-labelled antisemm to apo B-48 may be useful.
4.3.4.2 CONCENTRATION OF THE APO B-48 IN THE INFRANATANT 
FRACTION BY ULTRACENTRIFUGATION
The level of apo B-48 in the infranatant gives an indication of the concentration of CMR 
in the plasma. The discrepancy between the infranatant results on the immunoblot and in 
the ELISA appeared to be due to the excess of proteins preventing the accurate 
measurement of the apo B-48 on the immunoblot (Table 4.3.4 and Figure 4.3.9). In order 
to measure the level of apo B-48 in the infranatant on the immunoblot the plasma proteins 
other than apolipoproteins need to be removed. This can be achieved by 
ultracentrifugation as most plasma proteins sediment, whereas apolipoproteins float by 
virtue of their association with lipid. It has been generally accepted that most of the CMR 
are in the density range 1.006 to 1.019 g/ml (Weintraub et a l, 1987b; Havel, 1994). 
Therefore ultracentrifugation of a plasma sample at a density greater than 1.019 g/ml 
should concentrate all the CMR and remove all the excess plasma proteins. In order to 
ensure all CMR were obtained, a density of 1.065 g/ml was chosen to float lipoproteins of 
density less than 1.065 g/ml (CM, CMR, VLDL, IDL, LDL). The method used was a 
modification of SFUC described in Section 2.2.3.
Preparation of a concentrated CMR fraction
i) Single time-point
Five subjects were given a high fat meal containing 80 g of fat. A postprandial blood 
sample was taken 3 hours after the meal. Plasma was isolated by centrifugation at 7000 
g.min. A CM-enriched fraction (A) was isolated from 4 ml plasma as described in 
Section 4.3.5 in 2 separate tubes for each sample. After removal of the 1.5 ml fraction in 
the first tube the infranatant was mixed and frozen as usual and refened to as the "nonnal 
infranatant" (B). The infranatant in the second tube was mixed and 1.44 ml heavy 
solution (d =1.27 g/ml) added to make up the density of the solution to 1.065 g/ml. After 
ultracentrifugation at 2.1 x 10  ^ g.min (40,000 rpm for 24 hours) the concentrated CMR 
fraction (C) contained in the top 1.5 ml was removed. The infranatant remaining after 
this spin, referred to as the final infranatant (D), was also retained for analysis. The four 
fractions would be expected to contain different combinations of lipoproteins. The CM- 
enriched fraction (A) contains CM and large VLDL, the normal infranatant (B) contains 
all CMR, VLDL, IDL, LDL and HDL, the CMR fraction (C) contains all CMR, VLDL,
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IDL and LDL, the final infranatant (D) contains HDL and some small, dense LDL. The 
four fractions were analysed by immunoblotting for apo B-48 and by ELISA.
The apo B-48 levels detected by immunoblotting in each of the four fractions at the 3 
hour time-point for subject 23 are shown in Figure 4.3.13a. The calculated apo B-48 
results from the ELISA for these fractions, corrected for dilution or concentration, are 
shown in Table 4.3.5.
ii) Postprandial time-course
A fasting blood sample was taken from a single subject (subject 27) who was then given 
an 80 g fat meal. Postprandial blood samples were taken every hour for 4 hours and then 
eveiy two hours until 8 hours after. The fractions A to D were produced as for the single 
time-point samples described above.
The apo B-48 levels detected by immunoblotting in the CM-enriched fraction, normal 
infranatant and concenhated CMR fraction (fractions A to C) in the postprandial samples 
are shown in Figure 4.3.13b.The apo B-48 levels measured by the ELISA for these CM- 
enriched, normal infranatant and concentrated CMR fractions, corrected for dilution or 
concentration, are shown in Table 4.3.6. The postprandial final infranatant samples were 
not analysed.
The results from both these experiments show that there was more apo B-48 in the 
infranatant than in the CM-enriched fractions (A) as measured in both the normal 
infranatant (B) and the concentrated CMR fraction (C) by ELISA. The results also 
showed that the apo B-48 level in the concentrated CMR fraction (C) measured by the 
immunoblotting technique was higher than in the normal infranatant (B), indicating that 
the albumin and excess proteins in the normal infranatant affect the running of this 
fraction on the gel.
An unexpected finding was that the concentration of apo B-48 in the normal infranatant 
(B) was 2-fold higher than in the CMR fraction (C) as measured by the ELISA. There are 
several possible reasons for this discrepancy. The simplest explanation is that a large 
proportion of the CMR was found in the density range greater than 1.063 g/ml, i.e. in the 
HDL size range. This is a very novel and unexpected finding as CMR aie believed to be 
in the density range less than 1.019 g/ml (Havel, 1994). However the apo B-48 
concentration in the final infranatant (D) after concentrating the CMR was higher than the 
normal infranatant (B). This is not possible as the sum of the apo B-48 levels in fractions 
C plus D should equal the apo B-48 level in fraction B. These results suggest that there
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Table 4.3.5. Apo B-48 concentration, measured by the ELISA, in the CM-enriched 
fraction, normal infranatant, concentrated CMR fraction and the final remaining 
infranatant of the 3 hour time-point for 5 subjects (see Section 4.3.4.2for details of 
preparation).______________________________________________________________
Subject
Apo B-48 (pg/ml) measured by ELISA
CM-enriched Normal CMR Final
fraction (A) infranatant (B) fraction (C) infranatant (D)
22 0.23 2.46 1 .2 0 3.53
23 0.44 2 .1 1 0.83 3.20
24 0.35 2.36 0.94 5.41
25 0.75 5.75 0.92 8.42
26 0.50 6.61 0 .8 8 6.05
Apo B-48
unknown
protein
Figure 4.3.13a. Apo B-48 bands in each of the fractions taken 3 hours after an 80 g fat 
meal from subject 23. Lane 1 indicates MWM, lane 2 is a standard containing apo B-48, 
lanes 3, 5 and 7 are triplicate samples of the CM-enriched fraction (A), lane 4 is normal 
infranatant (B), lane 6  is CMR fraction (C) and lane 8 is the final infranatant (D) (see 
Section 4.34.2for details of preparation).
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Table 4.3.6. Apo B-48 concentration measured by the ELISA in the CM-enriched 
fraction, nonnal infranatant and concentrated CMR fraction in postprandial samples taken
time after meal
Apo B-48 (pg/ml) measured by ELISA
CM-enriched 
fraction (A)
Normal infranatant 
fraction (B)
CMR 
fraction (C)
0 0.23 2.54 1 .2 0
60 0.38 5.28 0.84
120 0.38 5.18 0.87
180 0.43 5.12 0.83
240 0.24 4.94 1.03
360 0 .2 0 4.41 0.97
480 0 .2 2 5.64 1.69
18 19 20 21
Apo B-48 
unknown 1
unknown 2
unknown 3
Figure 4.3.13b. Apo B-48 bands in fasting and postprandial CM-enriched, CMR and 
normal infranatant fractions from subject 27. Lane 1 is MWM; lanes 2 to 8 are CM- 
enriched fractions (A) 0, 60, 120, 180, 240, 360 and 480 minutes respectively; lanes 9 to
15 are CMR fractions (C) 0, 60, 120, 180, 240, 360 and 480 minutes respectively; lanes
16 to 21 are normal infranatant fractions (B) 0, 60, 120, 180, 240 and 360 minutes 
respectively (see Section 4.3.4.2for details of preparation).
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must be some background interference in the measurement of the infranatant fraction by 
the ELISA which causes an aitificially high apo B-48 concentration in fractions with high 
protein concentrations. This could either be through cross-reactivity with apo B-100 or 
interference by other plasma proteins. When the final infranatant (D) was run on an SDS- 
PAGE system (results not shown) it was shown to have a low concentration of apo B-100 
(similar to that in a CM-enriched fraction). This suggests that the discrepancy is due to 
plasma proteins rather than cross-reactivity with apo B-100.
4.3.4.3 INDIRECT VALIDATION OF THE APO B-48 ELISA BY COMPARISON 
WITH COBAS METHOD
The level of apo B-100 is usually between 100 and 1000 times greater than the level of 
apo B-48. It has been shown that there is an increase in apo B-100 in the TGRL 
postprandially (Cohn et a l, 1993; Schneeman et a l, 1993; Karpe et a l, 1993a), but the 
absolute increase in apo B-100 after a meal is negligible since most of the apo B-100 is 
found in LDL particles whose concentration does not significantly change postprandially. 
If there was significant cross-reactivity with apo B-100 in the ELISA it would be 
expected that there would be no postprandial increase shown by this method. To test this 
hypothesis several postprandial plasma and infranatant profiles were analysed on the 
ELISA and compared with the total apo B concentrations obtained by 
immunoturbidimetric analysis.
Subjects
The plasma and infranatant samples from four of the subjects used in Section 4.3.4 
(subjects 15, 16, 19 and 20) were used to test the correlation. The fasting and 
postprandial samples were run on the apo B-48 ELISA as described previously and the 
apo B concentration in the samples was measured on the COBAS Mira using the apo B 
kit as described previously (Section 4.3.2). The postprandial patterns were compared 
using Pearson's correlation.
Table 4.3.7 shows the coiielation between the apo B and apo B-48 postprandial patterns 
in the plasma and infranatant of 4 subjects. There was no correlation between the two 
pai ameters in any of the subjects for either of the fractions
A comparison of the postprandial pattern of total apo B and apo B-48 seen in the 
infranatant samples of one of the subjects are shown in Figure 4.3.14. There was a 50 % 
increase in apo B-48 at the 360 minute time-point compared with fasting. The maximum 
increase from fasting of total apo B was 3 % which occurred at 360 minutes.
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Table 4.3.7 Correlation coefficient (r value) and significance (P value) for comparisons 
of apo B-48 and apo B postprandial patterns in plasma and infranatant of 4 subjects 
(n= number of time-points compared).
Subject
PLASMA INFRANATANT
r value P value r value P value
15 (n=8) -0.26 0.62 -0.23 0 .6 6
19 (n=6) 0.52 0.29 0.03 0.93
20 (n=8) 0.06 0.91 -0.41 0.42
21 (n=6) -0.44 0.26 0.05 0.90
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Figure 4.3.14. Comparison of the postprandial patterns of apo B-48 measured by ELISA 
and total apo B measured by COBAS in the infranatant fractions from subject 15.
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4.3.5 VALIDATION TESTS ON THE APO B-48 ELISA FOR THE 
MEASUREMENT OF PLASMA AND INFRANATANT
Reproducibility
The intra-assay and inter-assay reproducibility of the ELISA were measured by another 
investigator using 3 plasma samples containing low, medium and high concentrations of 
apo B-48 (4.09 pg/ml, 13.00 pg/ml and 16.10 |0.g/ml respectively). The results are shown 
in Table 4.3.8 (Lovegrove et al, 1996)
Parallelism
Sample linearity was measured by serial dilution of infranatant or plasma samples and 
compar ing the corrected values against the lymph standard curve.
In general the infranatant and plasma fractions ran par allel to the standard. An example is 
shown in Figure 4.3.15.
Recovery
The recovery of a known amount of apo B-48 from a spiked sample was carried out by 
another investigator. There was a wide variation in the recoveries depending on the 
combination of fractions mixed. The mean recovery of samples spiked with apo B-48 
from CM-enriched fractions was 102 % ± 10 % (Lovegrove et a l, 1996). The mean 
recovery of apo B-48 obtained from mixing infranatant and plasma fractions was 89.9 % 
± 40.8 % (n=7). The mean recovery of apo B-48 obtained from mixing infranatant or 
plasma samples with lipoprotein fractions (VLDL or LDL) was 92.6 % ± 33.4 % (n=7). 
The mean recovery of apo B-48 obtained from mixing lipoprotein fractions (VLDL and 
IDL) was 77.1 % ± 19.4 % (n=7).
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Table 4.3.8 Intra-assay and inter-assay coefficients of variation (CV) of the apo B-48 
ELISA for three plasma quality control samples.
Quality
control
Mean apo B-48
(|Lig/ml) ±SD (n=6)
Intra-assay
CV
Mean apo B-48 
(lag/ml) ±SD (n=6)
Inter-assay
CV
Low 4.09 ±0.19 4.5 % 3.95 ±0.36 9.0%
Medium 13.00 ±0.50 3.8% 12.97 ±0.97 7.5%
High 16.10 ±0.52 3.2% 16.12 ±1.50 9.3 %
Mean CV 3.8 % 8.6 %
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Figure 4.3.15. Parallelism of an infranatant sample. The sample was serially diluted, the 
concentration of apo B-48 in each dilution was measured and plotted alongside the 
standard curve for lymph.
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4.4 DISCUSSION
The main aim of this work was to ensure the specificity of the ELISA for apo B-48 and 
evaluate the level of cross-reactivity with apo B-lOO in CM-enriched, infranatant and 
plasma samples. The investigation proved the ELISA to be a specific, sensitive and 
relatively easy method to use for the accurate quantitation of apo B-48 in CM-enriched 
fractions. A pure apo B-lOO lipoprotein sample was prepared using immunoaffinity 
chromatography. This showed no cross-reaction in the apo B-48 ELISA. Several tests 
were carried out to investigate the use of the ELISA for plasma and infranatant which 
contain a relatively high concentration of apo B-lOO and other plasma proteins. Although 
the tests indicated that there was no cross-reactivity with these samples this could not be 
proved conclusively.
The published immunoblotting method (Peel et al., 1993) shows that there is no cross­
reactivity of the antisera with apo B-lOO in a denatured, linear form. This indicates that 
the antisera reacts with the negatively char ged carboxyl group on the amino acid ile-2152 
in apo B-48. On the apo B-lOO molecule the carboxyl group on ile-2152 is bound in a 
peptide bond. The sequence of amino acids in the carboxy-terminal of apo B-lOO is 
different from the heptapeptide used to raise the apo B-48 antisemm and therefore there is 
no cross-reactivity in the immunoblot system. The ELISA is designed to measure the apo 
B-48 in an intact lipoprotein. It was therefore necessary to ensure that the conformation of 
the apo B-lOO when in the lipoprotein did not increase its interaction with the antisera. In 
order to do this a pure sample of apo B-IOO-containing lipoproteins was required.
A pure apo B-lOO lipoprotein sample was isolated using an adaptation of the affinity 
chromatography method described by McConathy et at. (1985) and Cohn et a l, (1993). 
Cohn et at., 1993 reported isolating pure apo B-lOO from TGRL. In the present study 
there were various difficulties in isolating the apo B-lOO despite using monoclonal 
antibodies to apo B-100. Initially hyperlipidaemic plasma was used to try to isolate apo 
B-lOO using the BL3 and MB43/47 columns as it contained a very high concentration of 
apo B-100. However there were many breakdown products of apo B-100 identified with 
the apo B antiserum in this sample and therefore it was preferable to use samples from 
healthy subjects. The BL3 and MB43/47 columns did not adequately separate apo B-48 
from apo B-100 in most of the samples used. This was probably because the capacity of 
the column was small and therefore not all the apo B-100 in a sample could bind to the 
column and was washed through. Also apo B-48 was often found in the eluates from 
these columns. This could have been due to non-specific binding of lipid in apo B-48 
containing lipoproteins to the solid matrix as described by McConathy etal. (1985).
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The method of McConathy et al. (1985) suggests using a desalting (PDIO) column to 
remove the sodium thiocyanate from the eluted lipoprotein fraction, however when this 
method was used for the eluate obtained from the Sepharose-anti apo B-48 column it was 
found to dilute the sample and no protein bands were seen on the immunoblot. This was 
possibly because the lipoproteins remained in the PDIO column (although this had not 
been previously reported) or because the sample was too dilute. Attempts to concentrate 
the sample with polyethylene glycol were not successful and therefore it was decided to 
use dialysis to remove the sodium thiocyanate. The pure apo B-100 obtained from the 
Sephai'ose anti apo B-48 did not contain sodium thiocyanate and the pooled pure apo B- 
100 lipoproteins did not cross-react in the ELISA.
The concentration of apo B-100 in the pure sample was approximately 50 |Lig/ml. This is 
the concentration of apo B-100 usually found in a VLDLi or a CM-enriched fraction 
(Karpe and Hamsten, 1994) and therefore suggests that the postprandial patterns seen in 
CM-enriched samples detected by ELISA are due to changes in the level of apo B-48. 
Attempts to concentrate the sample further were not successful, therefore the effects of 
high concentrations of apo B-100 (above 500 p.g/ml) as found in plasma and infranatant 
could not be tested.
Karpe and Hamsten (1994) and more recently Kotite et al. (1995) described isolation of a 
pure, concentrated apo B-lOO-containing lipoprotein fraction by ultracentrifugation. In 
both cases the purity of the fraction was assessed by SDS-PAGE and densitometry of 
stained protein bands. The sensitivity of the gel system for apo B-48 is low 
(concentrations of apo B-48 less than 0.2 p-g/ml cannot be detected). In the work 
described here, using the same principles of ultracentrifugation, the LDL fraction was 
found to contain a low concentration of apo B-48 as detected by specific antibodies to 
both apo B and apo B-48. Even an LDL fraction in the density range 1.05 to 1.07 g/ml 
contained some apo B-48. This finding was unexpected in view of other work showing 
the presence of apo B-48 only in the Sf >12 flotation range (Karpe et al., 1994) which 
corresponds to a density range greater than 1.019 g/ml. This finding prompted an 
additional study on the size distribution of CMR which is presented in Chapter 6.
When run on the ELISA, the LDL fraction registered a slightly higher concentration of 
apo B-48 than that found in a fasted CM-enriched fraction. Analysis by immunoblotting 
for apo B-48 showed a similar level of apo B-48 in these two fractions. The level of total 
apo B in the LDL fraction was 1100 |ig/ml, whereas the level of apo B in a CM-enriched 
fraction was less than 50 |ig/ml. These results indicate that there is no appreciable cross­
reactivity with apo B-100 in the ELISA even at very high concentrations.
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Isolation of a pure apo B-48 fraction was difficult. The pure sample obtained could not 
be concentrated by ultracentrifugation, ultrafiltration or PEG and therefore could not be 
used to test the specificity of the ELISA. The column containing the antiserum to apo 
B-48 did not appear to be efficient in binding apo B-48. Most of the apo B-48 was 
washed straight through the column and very little, if any, was found in the eluted 
fraction. This was thought to be because the solid phase matrix used in this column was 
Sepharose 4B. The CM particles may be too large to pass into the pores where the 
majority of the antibodies are bound despite the range of separation of proteins with 
molecular weight up to 20 million Da. Further work using the antiserum to apo B-48 
bound to silica or Sepharose 2B may prove more efficient in retaining and separating apo 
B-48. 3000 Â porous amino-activated silica beads were found to be the most effective 
matrix for isolation of apo B-100. A further problem with the Sepharose anti apo B-48 
column was that apo B-100 was found in the eluate. This could be because the apo B-100 
was binding to the antibody to apo B-48 or may have been due to non-specific adsoiption 
to the matrix due to the lipid content of the lipoprotein as described by McConathy et al. 
(1985).
The nature of the antiserum to apo B-48 requires that the negatively charged carboxyl 
terminal of the apo B-48 on ile-2152 is accessible on the lipoprotein surface for 
interaction to occur. Because of the difficulties in isolating large volumes of pure apo 
B-48-containing lipoproteins, a lymph sample was used as a standard for the ELISA. The 
apo B concentrations of this sample were measured by another group using the published 
SDS-PAGE method (Karpe and Hamsten, 1994). The lymph contains a very high 
concentration of apo B-48 (19.1 p.g/ml) but also contains 42.0 pg/ml apo B-100. 
However due to the validation tests using pure apo B-100 this level of apo B-100 was 
believed not to interfere with the specific detection of apo B-48 in the lymph.
Indirect validation of the ELISA by comparison of postprandial profiles with the 
immunoblotting method provided good correlations between the two methods. Further 
comparison of the postprandial patterns from the ELISA with the postprandial pattern of 
apo B-100 from a stained gel in two subjects showed no correlation between these 
measures. These results were taken as further evidence that the ELISA is specific to apo 
B-48 and does not cross-react with low concentrations of apo B-100 (less than 50 pg/ml). 
Other groups have not reported a decrease in apo B-100 after a meal (Cohn et al., 1988; 
Schneeman etal., 1993), however these groups only measured samples every three hours. 
In the present study a decrease in apo B-100 was observed during the early postprandial 
phase which highlights the importance of regular sampling to give a full picture on 
metabolic processes. A specific ELISA for apo B-100 may have enabled more rigorous
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validation of the specificity of the anti apo B-48 antisera. This assay is in the process of 
being developed in this group.
Validation of the ELISA for infranatant and plasma was more difficult since it was shown 
that the immunoblotting method did not give accurate levels of apo B-48 in these samples 
due to their high protein content. Various tests were carried out to investigate the 
accuracy of the apo B-48 measures obtained for infranatant and plasma. Concentration of 
the CMR remaining in the infranatant after removal of the CM-enriched fraction showed 
that there was more apo B-48 in the infranatant than in the CM-enriched fraction. This 
suggests that the concentration of CMR is higher than CM even postprandially, 
supporting the evidence that CM aie rapidly metabolised by LPL to form CMR (Grundy 
and Mok, 1976).
The concentrated CMR also showed a similar postprandial pattern to the normal 
infranatant on the apo B-48 ELISA suggesting that changing levels of apo B-48 were 
being measured. However the concentration of apo B-48 measured by the ELISA in the 
normal infranatant was 2 to 3 fold higher than in the concentrated CMR fraction, and the 
concentration of apo B-48 in the infranatant remaining after removing the CMR 
(d <1.063 g/ml) was higher than in the normal infranatant. This was an unusual result for 
which there were several possible explanations. The first suggestion is that there was 
more apo B-48 in the density range greater than 1.063 g/ml than in the density range less 
than 1.063 g/ml. This is contrary to all current concepts in lipoprotein metabolism and 
does not seem feasible. It is possible that some CMR of density less than 1.063 g/ml did 
not float up during ultracentrifugation, however again this would seem to be contrary to 
current beliefs. The presence of apo B-48 in the infranatant remaining after concentiation 
of the CMR could not be verified by immunoblotting due to the high protein content of 
this sample.
A further explanation for these results is that there is interference in the assay by some 
component in the ELISA and infranatant fraction. The most likely candidate for this are 
the immunoglobulins. The immunoblot of infranatant fractions clearly shows cross­
reactivity or non-specific binding to a range of proteins of lower molecular weight than 
apo B-48. This was attributed to interactions of the secondaiy enzyme-labelled antibody 
rather then the specific antibody to apo B-48. The molecular weight of the larger proteins 
was postulated to be 100 kDa and the smaller was 50 kDa. This could suggest that these 
proteins are sub-units of immunoglobulins. If this were correct and these plasma 
immunoglobulins bound to the thyroglobulin molecule on the ELISA plate, artificially 
high values for apo B-48 would be obtained. This would give a constant background 
level, as the concentration of IgG would not be expected to significantly change
164
postprandially. However this may produce problems in interpreting apo B-48 data from 
different subject groups if there is a high inter-individual variation in IgG levels. The 
blocking step was carefully optimised during development of the ELISA and therefore 
should prevent non-specific binding to the ELISA plate or coating material. Clearly these 
results ar e anomalous and requke further investigation.
In conclusion a reproducible, specific ELISA for the accurate quantitation of apo B-48 in 
CM-enriched fractions has been developed. The antisera has been shown to be specific to 
apo B-48 and the postprandial patterns measured in the infranatant have been shown to 
reflect changes in apo B-48 levels in this fraction. However the absolute concentrations 
of apo B-48 given by this method have not been conclusively proved to be correct. The 
use of the ELISA for measurement of apo B-48 in all fractions in postprandial studies will 
provide important information on effects of various factors on dietary-derived 
lipoproteins.
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CHAPTER FIVE THE EFFECTS OF MEAL FREQUENCY ON POSTPRANDIAL LIPAEMIA
5.1 INTRODUCTION
The traditional pattern of eating two or three large meals a day with no snacks in between 
has been called a "gorging" diet. Laboratory animals tend to eat their food in small 
portions frequently spaced throughout the day, a "nibbling" diet. In recent years a great 
deal of investigation has centred around the reduction of lipid and especially cholesterol 
levels in the blood by changing eating habits. The major focus of dietary change has been 
concerned with the amount and type of fat, carbohydrate and fibre in the diet. However 
relatively little attention has been paid to the effects of frequency of meals on lipid levels. 
It has been suggested that the metabolic consequences of a given diet may depend, in 
part, on the frequency at which the meals are eaten (Fabry and Tepperman, 1970). 
Therefore investigation of the effects of meal frequency on lipid metabolism is potentially 
of clinical importance.
Initial evidence from studies in rats showed that animals trained to eat their food in one 
short daily period (gorgers) were more efficient in converting food energy to body energy 
than rats fed ad libitum (nibblers) i.e. the meal-eating animals tended to gain more body 
fat than the nibbling animals (Cohn and Joseph, 1959), and corresponding changes in 
intermediary metabolism were observed (Cohn and Joseph, 1960). In support of the latter 
observation. Le veille (1970) showed a higher fatty acid synthetic capacity in adipose 
tissue of meal-fed rats compared with nibbling rats, with increased activities of malic 
enzyme, acetyl CoA carboxylase and fatty acid synthetase enzymes. These increases in 
lipogenic capacity were referred to as "adaptive hyperlipogenesis" (Fabry and 
Tepperman, 1970). This increased capacity for fat synthesis in gorging animals was later 
confirmed by de Bont et a l  (1975). These workers showed that body fat and food 
conversion efficiency (measured by adipose tissue lipogenesis) were higher in meal-fed 
rats than in ad libitum fed rats. In addition, they showed that this adaptation occurred 
quickly when animals were changed from ad libitum feeding to meal-feeding, but reversal 
occurred slowly when changing from meal-feeding to ad libitum feeding.
Epidemiological studies in humans during the 1960s indicated that an infrequent meal 
pattern was associated with a tendency towards obesity and hypercholesterolaemia (Fabry 
et a l, 1964) and CHD (Fabiy et a l, 1968). A short-term clinical study of 5 subjects at 
this time showed that eating 1 0  meals a day compared with 1 meal a day resulted 
consistently in lower plasma TAG, total cholesterol and phospholipid levels (Gwinup et. 
al, 1963). Further studies on the influence of meal frequency on metabolism in the 
1960s did not produce entirely consistent results with those of Gwinup et a l (1963). A 
study of 51 male university students by Jagannathan e ta l  (1964) found no significant
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differences between fasting lipid levels measured after 8 days on a nibbling or a meal- 
eating diet. The volunteers in this study consumed a liquid formula diet throughout the 
trial rather than self-selected foods. Likewise, in a study conducted in a metabolic ward, 
Swindells et al. (1968) also showed no significant differences between the effects of 
gorging (2 meals a day) and nibbling (9 meals each day) in 6  female subjects. Irwin and 
Freely (1967) observed that the mean TAG and cholesterol levels in a group of 15 women 
increased after both a nibbling and gorging routine compared to during their normal diets, 
but the effect was varied in all subjects.
Following these early clinical studies, the effects of altering the frequency of meal intake 
on metabolic processes in humans was not widely investigated untü the late 1980s. It had 
been shown in NIDDM subjects that slow release of nutrients into the circulation (caused 
by high dietary fibre or alpha-glucosidase inhibitors) reduced the potentially adverse 
postprandial fluctuations of glucose and insulin (Creuzfeldt, 1983). In view of the 
potential importance of any dietary manipulation which may reduce serum lipid 
concentrations, the effects of altering meal frequency as a method to alter the rate of 
influx of nutrients into the circulation has been studied in diabetic patients and in other 
groups.
Various studies have been set up to investigate the effects of altering meal frequency on 
lipid and carbohydrate metabolism in the fasting state and postprandial periods 
throughout the day. Most of the studies have investigated the effects of alterations in 
meal frequency by measuring parameters over a day whilst the subjects are eating either a 
nibbling or gorging-type diet. These studies have involved either acute effects on a single 
day of measurement (Wolever, 1990; Jenkins et al., 1990; Jenkins et ai, 1992; Bertelsen 
et al., 1993) or chronic effects after habituation to different meal frequency patterns over 
a period of time i.e. intervention studies (Terpstra et al., 1978; Van Gent et al., 1979; 
Jenkins e ta l, 1989; Wilhelmine e ta l, 1991; Wilhelmine e ta l,  1993; Jones e ta l,  1993; 
Jones et a l, 1995). The effects of chronic alterations in meal frequency have been 
investigated by measuring fasting lipid, glucose and hormone levels after periods on 
different diets.
A study by McGrath and Gibney (1994) showed the effects of changing subjects' habitual 
frequency of meal consumption to the opposite pattern. The subjects were asked to 
continue eating their normal foods during the whole study. The results showed that the 
subjects who swapped from a 'snacking' to a 'meal-eating' pattern significantly increased 
their percentage of energy from fat (especially SFA) and protein and significantly 
reduced their alcohol intake. These changes accounted for the differences in cholesterol 
levels noted in this group. The subjects who changed from meal-eating to snacking did
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not change their diets and had a significantly lower total cholesterol level and higher 
HDL-cholesterol/LDL-cholesterol ratio after changing to a snacking diet. This study 
highlights the importance of maintaining a constant nutrient and energy intake when 
investigating effects of meal frequency.
In accordance with the results of McGrath and Gibney (1994), other studies have also 
shown a reduction of fasting total cholesterol and LDL-cholesterol after habituation to a 
nibbling diet compared with a gorging diet (Jenkins et a l, 1989: Arnold et a l, 1993). A 
large study in California showed that a higher meal frequency was associated with a 
lower cholesterol concentration even though the frequent eaters ate more calories, total fat 
and saturated fat (Edelstein e ta l, 1992).
Although significant effects on fasting levels of TAG after a nibbling diet have rarely 
been found, several studies have shown that the daily meal-related fluctuations in levels 
of TAG (Terpstra et a i, 1978; Van Gent et al., 1979; Jenkins et al., 1989; Jenkins et al.,
1992) and glucose (Jenkins et al., 1989), found when eating three large meals, are 
reduced by eating the same amount of food in several small meals a day. Wolever (1990) 
showed that continuous sipping over 12 hours compared with eating 3 meals reduced the 
meal-related fluctuations of insulin, glucose and TAG. The study also showed that NEFA 
remained suppressed for longer during sipping. Suppression of NEFA throughout the day 
whilst nibbhng was also observed in two studies of NIDDM patients (Jenkins et al., 1990; 
Bertelsen et a l, 1993). The authors suggested that high NEFA levels increase 
hyperglycaemia by reducing insulin-mediated glucose uptake by the muscle and 
increasing hepatic glucose output. For these reasons a controlled nibbling regimen in 
NIDDM patients would appear* to be beneficial.
In a study of healthy, middle-aged men Jenkins et al. (1989) showed that 2 weeks on a 
nibbling diet consisting of 17 meals a day resulted in a significantly lower 12 hour insulin 
response on the last day of the intervention period compared with eating 3 meals a day. 
The daily, periodic meal-related fluctuations of glucose were also reduced. The 
C-peptide levels were lower on the nibbling diet suggesting that insulin secretion had 
been reduced. The authors suggested that the lower insulin levels may have resulted in 
decreased hepatic cholesterol synthesis (through decreased stimulation of HMG-CoA 
reductase) and could thus be the cause of the lower cholesterol levels in nibblers. Lower 
serum insulin and C-peptide concentrations during the day were also observed in patients 
with NIDDM in two similar studies (Jenkins et a l, 1992; Bertelsen et a l, 1993). In 
addition to lower insulin concentrations observed during a nibbling diet, a study by Jones 
et a l  (1993) also found that GIF levels were lower throughout the day on the nibbling 
diet. These workers confirmed that cholesterogenesis is reduced during the nibbling diet
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by monitoring the incorporation of deuterium into cholesterol, thus substantiating the 
theory that honnonally-related mechanisms secondary to an altered pattern of food intake 
are important in regulating cholesterol synthesis.
In contrast to the studies described above, two studies by the same laboratory found that, 
compared with eating 3 meals each day, increasing meal frequency to 9 meals each day 
for a period of 2 weeks had no effect on the daily insulin or TAG levels in normal 
subjects (Arnold et. a l, 1993) or in hypercholesterolemic subjects (Arnold et al., 1994). 
In the study of hypercholesterolemic subjects they also found no change in the fasting 
total cholesterol and LDL-cholesterol levels after a period of nibbling. The authors 
suggested several possible reasons for the difference between the normal and 
hypercholesterolaemic subjects, including that the hypercholesterolaemic subjects may 
not have adhered to the changes in meal frequency. A second possibility was that, as the 
normocholesterolaemic and hypercholesterolaemic subjects had significantly different 
fasting insulin levels, there may have been a difference in the mechanism, proposed by 
Jenkins et al. (1989), whereby insulin and cholesterol metabolism are related through the 
effect of insulin on cholesterol synthesis. The hypercholesterolaemic subjects also had a 
significantly higher percentage of their total energy from fat than the 
normocholesterolaemic subjects (34 % compared to 30 %) and a correspondingly lower 
percentage of total energy from carbohydrate (49 % compared with 54 %). It has been 
suggested that the composition of the background diet may influence the metabolic 
response to an altered pattern of food intake (Fabry and Braun, 1976) and therefore the 
differences in diet between the two groups in the studies of Arnold et al. may be of 
significance.
Some studies have investigated possible mechanisms for the changes in metabolic 
processes caused by altered meal frequency. An early study in obese subjects by Bray et 
al. (1972) showed that lipogenesis rates were higher in gorgers than nibblers. This 
indicated that either the energy output of meal-eaters decreased or the efficiency of food 
utilisation is higher in meal-eaters. Some studies in rats showed similar results (De Bont 
et a l, 1975; Bazotte et a l, 1989; Wheeler et a l, 1990), whereas another study in rats 
could not find any differences in food efficiency due to changes in meal frequency (Hill 
et al, 1988). In a more recent study on energy metabolism in moderately obese humans, 
no significant differences were seen in rates of weight loss, or relative levels of fat mass 
loss or fat-free mass loss on different patterns of meal frequency (Wilhelmine et a l,
1993). In addition, Jones et al. (1995) found no effect of meal frequency on lipogenesis 
in humans.. Conversely a study by Leblanc et a l (1993) showed that a greater lipid 
mobilisation occurred with eating four small meals at 40 minute intervals compared with 
1 large meal. This was attributed to repeated stimulation of the sympathetic nervous
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system. The authors suggested that there may be a potentially undesirable increase in fat 
storage in people who eat few meals a day.
The effects of meal frequency on the metabolic response to a single meal has most 
frequently been studied in relation to glucose tolerance, with most studies showing 
reduced glucose tolerance in gorgers. Two studies have described TAG responses to a 
single meal. Wadwha et a l (1973) showed higher plasma TAG levels after a glucose 
load in gorgers compared to nibblers, but Arnold et a l  (1994) found no differences 
between the postprandial TAG responses to a high fat meal in hypercholesterolaemic 
subjects after periods on nibbling or gorging diets. A small study of the effects of meal 
frequency on the responses to a single, physiological test meal showed lower fasting and 
postprandial glucose and insulin levels after the nibbling diet, but lipid levels were only 
measured in the fasting state (Peters et a l, 1979). It has been suggested that postprandial 
plasma-TAG levels may provide a better measure of diurnal TAG transport than a single 
fasting TAG measure and may thus be a more significant indicator of CAD risk (Patsch, 
1992). A decrease in postprandial TAG responses to a high fat meal caused by alterations 
in meal frequency could therefore be of significance. Since the TGRL produced after a 
meal have been directly implicated in the formation of atherosclerotic plaques 
(Zilversmit, 1979), it is important to determine whether there are changes in the lipaemic 
response to a single meal after a period on both a nibbling and gorging diet.
Studies to date suggest that the early epidemiological obseiwations of an increased risk of 
CHD when eating fewer meals a day may in part be explained by the higher fasting total 
cholesterol and TAG levels; presumably caused by higher levels of insulin. The effects 
of meal frequency on various processes in lipid metabolism may also indicate that an 
adaptive response is occuiiing in tissues involved in these processes due to differences in 
the length of time that the gastrointestinal tract would be full or empty. A high fat meal 
provides a challenge to the lipid metabolic systems and thus should enable investigation 
of the theory that adaptive changes in these processes occur with alterations in meal 
frequency.
Problems with the interpretation of some previous studies have been encountered due to 
the differing study designs. Many studies have used small numbers of subjects where 
large differences are needed before significant differences can be seen. Several 
investigators have fed non-physiological foods to their subjects such as liquid formula 
diet, or changed the normal diet of the subjects to a metabolic diet consisting of normal 
foods. Both these measures may cause metabolic changes in addition to those caused by 
altering meal frequency. Some studies have shown variations in plasma lipid levels due 
to changes in nutrient and energy intakes and therefore it is important to ensure that there
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aie no differences between types of foods consumed during the experimental periods. A 
further criticism is that the differences in meal frequency patterns used in some studies 
have been too small to produce different results. However it is also important to have a 
practical level of meals as opposed to the 17 snacks a day, continuous sipping or 24 hour 
snacks used in some studies. It has been suggested that a minimum of 9 meals per day 
are needed to elicit metabolic alterations. Other studies may not have observed any 
effects of meal frequency because the subjects were not habituated to the diet for a long 
enough period. Gwinup et a i (1963) and Jenkins et al. (1989) noted a change in lipid 
levels after 1 2  days on a nibbling or gorging diet, therefore this appears to be the 
minimum time needed for adaptive changes to occur.
Aims of the study
In view of the results of several previous studies that showed that 24 hour TAG levels are 
lower and less fluctuating on a diet of higher meal frequency, the aim of the present study 
was to investigate any changes in lipid metabolism which may occur in response to 
altered meal frequency. In order to do this the effects of meal frequency on postprandial 
lipid metabolism were measured. Subjects were required to follow two separate 2  week 
periods of dietaiy inteiwention on both a nibbling diet and a gorging diet. Their metabolic 
responses to a single meal were assessed immediately after each period. The study was 
conducted in a free-living situation with subjects consuming their noimal diets.
Apo B-48 and RE, markers of CM particles, were used to examine changes in dietary 
lipoprotein clearance. LPL activity and NEFA levels were measured to investigate 
processes occurring in the adipose tissue. Fasting lipid levels were measured to allow 
comparison with the results of other studies.
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5.2 METHODS
5.2.1 Subject recruitment
Eleven healthy, non-obese female subjects 'were recruited from undergraduate and 
postgraduate students on the nutrition and biochemistry courses at the University of 
Surrey. The subjects all satisfied the following criteria:
- BMI greater than 19 kg/m^ but less than 29 kg/m^
- Alcohol intake less than 14 units per week
- Not taking any fish oil, evening primrose oil or dietary supplements
- Non-smokers
- No history of liver or intestinal disorders
- Not taking any prescribed medication known to affect lipoprotein metabohsm
The average age of the subjects was 22 years (range 21 to 24 years), Subject 
characteristics are shown in Table 5.3.1a (dietary intake) and 5.3.2b (weight and BMI). 
Height and weight were measured to detemiine BMI. Ethical consent was obtained from 
the South West Surrey Health Authority Local Research Ethics Committee and from the 
University of Surrey Research Ethics Committee. The subjects all gave informed written 
consent to participate in the study.
5.2.2 Dietary intervention periods
The subjects were allocated into one of two groups and randomly assigned to follow 
either a "nibbling" or a "gorging" diet for a two week period (diet A). At the end of this 
diet period the subjects returned to their normal dietary pattern for three weeks. The 
subjects then followed the other intervention diet (diet B) for a further two week period. 
A postprandial study was cairied out the day before star ting diet A, at the end of diet A 
and at the end of diet B. The intervention study design is outlined in Figure 5.2.1.
Figure 5.2.1. Intervention study design
Week 0 1 2 3 4 5 6 7
 ►- ^  ^diet normal diet diet A normal diet diet B
postprandial study 1 2
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During the nibbling period, the meals were split into 12 approximately equally-sized 
portions to be consumed every hour from around 8 am to 7 pm. During the gorging 
period, the same meals were split into two large portions to be eaten at approximately 1 2  
noon and 7.30 pm. Gorgers were permitted drinks between meals including tea and 
coffee with milk. Alcoholic drinks were permitted providing the same type and quantity 
were consumed at the same time during each diet period. Seven of the subjects started on 
the gorging diet first (diet A) and four on the nibbling diet.
The aim of this investigation was to explore the effects of alterations in meal frequency 
and therefore it was important to keep the diet composition identical during the two 
intervention periods and similar to the subjects' habitual diets. Although there were no 
restrictions on the subjects food choices, food tables listing energy contents of individual 
foods and suggested meal plans were devised by an undergraduate investigator in this 
study. These were given to the subjects with a set of scales in order to help them to 
divide up their meals and stick to the same foods and calorie intakes on both diets. These 
meal plans were devised in collaboration with the subjects in order to ensure they were 
consistent with each subject's normal food habits. An example of a suggested meal plan 
for both diet periods is shown in Figure 5.2.2. The average energy requirement for a 22 
year old woman is 1950 calories each day. The subjects were asked to eat their normal 
level of calories in order to maintain a constant body weight throughout the study period. 
BMI were calculated at the beginning of the study and at the end of each diet period.
The compliance to the diets and the acceptability of each regimen were assessed by 
interviewing the subjects on the study day after each diet period and by the completion of 
a questionnaire which used a linear analogue scale to quantitate the degree of compliance 
to the diet periods. An example of the questionnaire is shown in Appendix II. Twenty- 
four hour recall diet diaries were completed on each study day to assess standardisation of 
the subjects dietary intake the day before the study and as a measure of the nutrient 
composition of the diets during the intervention periods. Weights of foods eaten were 
recorded using standard household measures. The nutrient composition of the diets was 
calculated using COMPEAT, a nutrient analysis programme based on McCance and 
Widdowson food tables (Holland et al, 1991). The design of the questionnaire and 
analysis of the 24 hour recall diaries were carried out by undergraduate investigators on 
this project.
173
Figure 5.2.2 Example of a suggested days meal plan for the nibbling and gorging 
periods.
Gorging diet:
noon meal
ham and tomato sandwiches 
(3 slices of bread) 
crisps
apple, 1 satsuma 
small chocolate bar
7 pm meal
chilli and rice 
yoghurt 
orange juice 
2  small chocolate bars 
1 banana, 1 satsuma
Nibbling diet:
8 am ham sandwich (1/2 slice
bread), orange juice
9 am as above
1 0  am yoghurt
11 am 1/2 bag of crisps, 1 satsuma
1 2  am 1/2 bag of crisps, apple
1 pm ham sandwich (1  slice bread)
2  pm chocolate bar, 1/2 banana
3 pm ham sandwich (1 slice bread)
4 pm chocolate bar, 1/2 banana
5 pm 1/2 portion of chilli and rice
6  pm 1/2 portion of chilli and rice
7 pm small chocolate bar*, satsuma
Total energy intake 1835 calories Energy from fat 37 %
5.2.3 Test meal
Each subject received a standard test meal on each study day. The test meal was designed 
to highlight any differences between the metabolic capacities after the intervention 
periods without being too large for the nibblers who were accustomed to small meals. 
The test meal was therefore of a small size yet energy dense and contained mixed 
foodstuffs with a high fat content. The test meal consisted of a cheese sandwich, orange 
juice and a chocolate milkshake made with cream. 150 mg of retinyl palmitate was 
included in the orange juice as a marker for CM, and 1500 mg of soluble paracetamol was 
taken with the meal to be used as a measure of gastric emptying. The nutritional content 
of the test meal is shown in Table 5.2.1.
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Table 5.2.1 Macronutrient and energy composition of the study day test meal.
Food Quantity Energy Fat Protein Carbohydrate
(g or ml) (MJ) (g) (g) (g)
White bread 70 0.63 0.9 5.4 35
Orange juice 200 0.30 - 1 .0 18
Whole milk 130 0.35 5.1 4.2 6
Double cream 120 2 .2 2 57.6 2 .0 4
Cheddar* cheese 30 0.51 10.4 7.7 -
Margarine 10 0.30 8 .2 - -
Chocolate powder* 10 0.17 0.5 - 9.5
Total 4.48 82.7 20.3 72.5
5.2.4. Study day protocol
Subjects attended the Clinical Investigation Unit at the Royal Surrey County Hospital for 
a study day on three separate occasions. The first occasion was before starting on diet A 
to determine baseline postprandial responses to a fixed high fat meal. The second study 
day was immediately after 13 days on diet A and the final study day was immediately 
after 13 days on diet B. The study day protocol is outlined in Figure 5.2.3.
On arrival at the unit after a 12 hour overnight fast, a cannula was inserted into the 
subject's forearm vein under local anaesthetic. Two fasting blood samples were taken at 
rest during the next 10 minutes. The subjects were then given the test meal containing
82.7 g of fat which they were asked to consume within 20 minutes. The subjects rested 
quietly in the investigation unit during the 8 hour study period. Decaffeinated, milk- and 
sugar-free drinks and water could be consumed freely throughout the day.
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Figure 5.2.3. Study day protocol
T e s t  m e a l  
carbohydrate 7 3  g 
prote in  2 0  g 
f a t  83  g
energy  4 . 4 8  MJ IV HEPARIN
M  S n  m n DD 1 SO D  nnnnpinarptamnl'l  7 5 0 0  Unl tS
o v e r n i g h t  
1 2  h r  f a s t
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P LA S M A
F r a c t i o n s  f o r  a n a l y s i s  u l t r a c e n t l f u g a t l o n/  \
C M- E N R IC H E D  IN F R A N A T A N T
\  X
F r a c t i o n s  f o r  a n a l y s i s
5.2.5. Blood sampling
Two 18 ml blood samples were taken 10 minutes apait during the fasting period and at 30 
minutes and one hour after the meal was started. Further 18 ml samples were then taken 
eveiy hour for 8 hours after the meal. At the end of this period 7500 units of heparin was 
injected at a site distant from the cannula. Blood samples (5 ml) were taken 5 and 15 
minutes after the injection.
The blood was collected into heparinised tubes and centrifuged for 7000 g.min (3000 rpm 
for 10 minutes) within 20 minutes of being collected. At each time-point plasma was 
aliquotted into separate tubes for analysis of various paiameters. In addition 3.5 ml of 
each fasting and postprandial plasma sample was used to prepare a CM-enriched fraction 
and an infranatant fraction by ultracentrifugation as described in Section 2.2.2.2. A 
preservative cocktail (Section 2.1) was added at a volume of 5 % of total to samples for
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apo B-48 analysis. Samples for RE analysis were wrapped in foil before freezing. All 
samples were frozen at -20 “C until analysis.
5.2.6. Analysis of samples 
Analysis of TAG
Measurement of the concentration of TAG in the plasma, infranatant and CM-enriched 
fractions was cairied out using an automated, enzymatic, spectrophotometric technique 
on the COB AS Mira Plus as described in Section 2.6.1.
Analysis of NEFA
Measurement of the concentration of NEFA in the plasma fraction was carried out by an 
automated, enzymatic, spectrophotometric technique using the COBAS Mira Plus as 
described in Section 2.6.5.
Analysis of cholesterol
Concentrations of total-cholesterol and HDL-cholesterol in fasting plasma samples were 
analysed using an automated, enzymatic, spectiophotometric technique performed on the 
COBAS Mira Plus as described in Section 2.6.2 and 2.6.3 respectively. The 
concentration of LDL-cholesterol was determined using Friedewald's formula 
(Friedewald et al., 1972) as described in Section 2.6.4.
Analysis of Paracetamol
Paracetamol was given to the subjects in order to measure the rate of absorption of the 
meal, as paracetamol is not normally present in the circulation. The rate of appearance of 
paracetamol in the plasma gives an indication of the rate of entry of the components of 
the meal into the plasma. Any differences in the rate of appearance of paracetamol after 
the three diet periods would indicate a difference in gastric emptying or absorption into 
the enterocyte. The levels of paracetamol in the plasma samples were measured by an 
automated spectrophotometric technique using the COBAS Mira plus as described in 
Section 2.6.6.
Analysis of retinyl esters
Concentrations of RE in the plasma, infranatant and CM-enriched fractions were 
measured by noimal phase HPLC as described in Section 2.7.
177
Analysis of apolipoprotein B-48
A competitive ELISA was used for the measurement of apo B-48 in plasma, infranatant 
and CM-enriched samples as described in Section 2.5. Two plasma QCs were analysed 
in each run to check the reproducibility of the method. The intra- and inter-assay CVs 
respectively were 6.3 % and 14.3 % at a concentration of 3.40 p.g/ml and 7.3 % and 18.1 
% at a concentration of 2.96 pg/ml. The postprandial samples after the nibbling and 
gorging diets were run on the same plate for each subject to minimise variation.
Analysis of lipoprotein lipase activity
LPL activity in the 5 and 15 minute post-hepaiin plasma samples was measured using the 
radioactive substrate emulsion technique described in Section 2.8. This analysis was 
carried out by another investigator. The results are expressed in units of enzyme activity 
(U/ml) where one unit represents 1 |imol oleate released per minute at 37 “C expressed 
per ml of plasma.
Analysis of insulin
Insulin levels in the plasma samples were measured using the double-antibody RIA 
technique described in Section 2.9. This analysis was canied out by another investigator.
5.2.7. Analysis of results
The data is shown as time-response curves for each variable with responses after each 
diet period shown on the same graph. Values at each time-point are plotted as mean with 
standaid error of the mean (SEM) for 11 subjects. Graphs for the 3 markers of CM 
particles (TAG, apo B-48 and RE) are shown on the same page for each fraction (plasma, 
CM-enriched or infranatant) in order to allow the graphs to be displayed with y-axes at 
the optimal values. Thus the apo B-48 responses in the CM-enriched fraction, and the 
TAG and RE responses in the infranatant fraction have different y-axis scales compared 
with the same parameter in the other fractions. The mean data for all the parameters 
measured are shown in Appendix IV.
The postprandial response was determined by analysis of the area under the 480 minute 
time-response cuiwe and by the time to peak. Incremental AUC were also determined and 
resulted in the same general trends as for the AUC. Therefore I AUC data is only 
presented for the NEFA responses where the fasting levels were significantly different 
after each diet. Statistical significance tests were carried out using the Instat package for 
the Apple Macintosh computerHomogeneityof the data was tested using Bartlett's test for 
homogeneity. If the data was not normally distributed it was log-transformed to allow 
parametric statistical analysis to be carried out. Non-parametric analysis was used for all
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the time to peak data. Differences between the times to peak and the AUC responses 
after the three diet periods were determined by paired, one-way analysis of variance. If 
the ANOVA result was significant at the level P<0.05 a Tukey post-test was carried out 
to identify the difference. Differences between the responses after the diet periods were 
classed as significant at the P<0.05 level. Repeated measures analysis of variance was 
carried out using the Data Desk package for the Apple Macintosh computer to identify 
differences in patterns of response between the postprandial time-courses after the diet 
periods.
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5.3 RESULTS
5.3.1 ANALYSIS OF QUESTIONNAIRES
Results of the analysis of the questionnaire described in Appendix II showed that 
compliance to the dietary intervention was highest whilst on the gorging diet. Analysis of 
the answers to question 8 , using the linear" analogue scale, showed that the average self- 
reported compliance to the gorging diet was 90 % ± 10 and to the nibbling diet was 78 % 
± 10. This was significantly different (P <0.01) between the diets. Analysis of question 
10 showed that 5 out of 11 subjects had one snack on at least one day during the gorging 
diet. Of these, 2 subjects snacked on one day, 2 subjects snacked on 2 days and 1 sirbject 
snacked on 3 days. The snack was generally taken in the morning before the first meal. 
Analysis of question 11 showed that 6  of the 11 subjects ate less than 12 meals a day on 
one or more days during the nibbling diet. Of these, 1 subject missed meals on 1 day, and 
5 subjects missed meals on 3 days. The least number of meals eaten during the nibbling 
period was 5. This was on one day by one subject. The other 5 subjects missed between 
one and four meals on 3 days. The average compliance to the intervention period was 
higher after diet A (the first diet) compared with diet B (8 8  % ± 11 versus 80 % ± 12) 
regardless of the meal frequency during that period.
5.3.2 SUBJECT CHARACTERISTICS
Table 5.3.1a shows the BMI and the dietary intakes of the 11 subjects on each of the diet 
periods. There was a statistically significant difference between the fat intakes (measured 
in g) the day before the normal and gorging diets (P<0.05). There were no significant 
differences between the amounts of protein and caibohydrate, the percentage of total 
energy derived from fat, protein and carbohydrate or the total energy intake on any of the 
diets. The mean BMI of the 11 subjects did not change significantly throughout the 
study.
Table 5.3.1b shows the individual weights and BMI of the 11 subjects at the end of each 
diet period. Six of the eleven subjects had weight fluctuations of 1 kg or less during the 
inteiwention periods. Of the other subjects, most of the changes in body weight occuned 
during the nibbling diet.
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Table 5.3.1a. Subject chai’acteristics: comparison of anthropometric measurements and 
dietary macronutrient and energy intake on the last day of each diet period. Values are means (SD) for 11 subjects after each diet period.
CHARACTERISTIC NORMAL NIBBLING GORGING
DIET DIET DIET
Mean (SD) Mean {SD) Mean {SD)
Body mass index (kg/m^) 23.6 (2 .S) 23.4 (2.4) 23.7 (2,7)
Energy Intake (MJ) 7.94 (LOI) 8.64 {1.67) 8.89 {1.03)
Fat intake (g) 6 6  {16) 79 (22) 81* (2 0 )
Protein Intake (g) 67 (22) 76 (22) 74 (79)
Carbohydrate intake (g) 265 {44) 276 {53) 279 (23)
% Energy as fat 31,8 {6A) 34.4 (5.7) 36.1 (5.3)
% Energy as protein 13.7 (2.5) 15.0 (3.5) 13.9 (2.9)
% Energy as carbohydrate 54.0 (7.3) 50.7 (5.5) 49.8 (4.3)
* significant compared witli normal diet P <0.05
Table 5.3.1b Weight and BMI of each subject at the end of each diet period.
subject NORMAL DIET NIBBLING DIET GORGING DIET
WEIGHT BMI WEIGHT BMI WEIGHT BMI
(kg) (kg/m^) (kg) (kgW ) (kg) (kg/m^)1 6 8 .2 26.1 65.0 24.9 68.7 26.32 59.8 2 0 .6 60.1 20.7 59.7 20.53 59.8 2 2 .8 59.0 22.5 60.0 22.94 65.9 24.2 66.4 24.4 65.7 24.15 64.4 2 0 .8 62.6 2 0 .2 64.4 2 0 .86 65.3 27.2 64.1 26.7 65.7 27.37 65.7 2 1 .0 66.4 2 1 .2 67.1 21.48 65.5 25.1 66.7 25.7 65.1 24.99 69.0 28.4 6 6 .0 27.1 68.4 28.110 65.5 21.4 67.4 2 2 .0 65.7 21.511 56.0 21.5 58.1 22.4 58.3 22.4
mean(SD) 64.1(3.9) 23.6(2.8) 63.8(3.3) 23.4(2.4)
64.4(3.5) 23.7(2.7)
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5.3.3 THE EFFECTS OF MEAL FREQUENCY ON RESPONSES IN THE 
PLASMA 
5.3.3.1 Triacylglycerol responses
The plasma-TAG responses to a high fat meal after periods on a normal, nibbling and 
gorging diet aie shown in Figure 5.3.1 a. The TAG levels rose to a peak at 180 to 240 
minutes and fell back down to baseline fasting level at the end of the 8  hour study. There 
were no significant differences between the times to peak plasma-TAG after any of the 
diet periods (Table 5.3.2).
The calculated AUC for these responses are shown in Table 5.3.5 and the peak levels in 
Table 5.3.8. There were no statistically significant differences between the AUC or the 
peak levels after any of the diet periods.
5.3.3.2 Apo B-48 responses
The plasma-apo B-48 responses to a high fat meal after periods on a normal, nibbhng and 
gorging diet are shown in Figure 5.3.1 b. The levels rose to a peak at 180 minutes after 
the normal diet period, at 300 minutes after the nibbling diet period and remained at a 
plateau between 120 to 240 minutes after the gorging period. The levels had fallen back 
down to baseline levels at the end of the 8 hours after the normal and nibbling diets but 
remained elevated after the gorging diet. There were no significant differences between 
the times to peak plasma-apo B-48 after any of the diet periods (Table 5.3.3). Repeated 
measures analysis of variance showed there were no significant differences between the 
postprandial patterns of response after the diet periods.
The calculated AUC for these responses are shown in Table 5.3.6 and the peak levels in 
Table 5.3.9. There were no statistically significant differences between the AUC or the 
peak levels after any of the diet periods.
5.3.3.3 Retinyl ester responses
The plasma-RE responses to a high fat meal after periods on a normal, nibbling and 
gorging diet are shown in Figure 5.3.1 c. The levels rose to a peak at 360 minutes after 
each diet period and had not fallen back down to baseline levels at the end of the 8  hour 
study. There were no significant differences between the time to peak plasma-RE after 
each diet period (Table 5.3.4).
The calculated AUC for these responses are shown in Table 5.3.7 and the peak levels in 
Table 5.3.10. There were no significant differences between the AUC or the peak levels 
after any of the diet periods, although the highest AUC was seen after the gorging diet.
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Figure 5.3.1 The effects of meal frequency on the a) TAG, b) apo B-48 and c) retinyl 
ester responses to a high fat meal in the plasma. Values represent means with SEM of 11 
subjects in each group. Responses after the normal diet period are shown by (— □— ), the 
nibbling diet period by (- - A- -) and the gorging diet period by (•••••••).
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Table 5.3.2. Time to peak TAG in plasma, chylomicron-enriched and infranatantfractions in response to a standard high fat meal after periods on a nibbling, gorging and
normal diet. Values are mean (SD) for 11 subjects in minutes.
NORMAL
DIET
NIBBLING
DIET
GORGING
DIET
Plasma-TAG mean 2 0 2 196 196
(min) (SD) 55 61 39
CM-TAG mean 185 218 180
(min) (SD) 68 49 54
Infranatant-TA G mean 240 150* 191
(min) (SD) 81 82 65
* significant compared witli normal diet P <0.05
Table 5.3.3. Time to peak apo B-48 in plasma, chylomicron-enriched and infranatant fractions in response to a standard high fat meal after periods on a nibbling, gorging and 
normal diet. Values are mean {SD) for 11 subjects in minutes._______________________
NORMAL NIBBLING GORGING
DIET DIET DIET
Plasma-apo B-48 mean 205 237 2 0 2
(min) (SD) 96 95 67
CM-apo B-48 mean 196 272 267
(min) (SD) 114 86 78
Infranatant-apo B-48 mean 229 185 180
(min) (SD) 141 114 116
Table 5.3.4. Time to peak retinyl ester in plasma, chylomicron-enriched and infranatant fractions in response to a standard high fat meal after periods on a nibbling, gorging and 
normal diet. Values are mean {SD) for 11 subjects in minutes._______________________
NORMAL
DIET
NIBBLING
DIET
GORGING
DIET
Plasma-RE mean 387 404 420
(min) (SD) 68 85 47
CM-RE mean 393 355 382
(min) (SD) 49 115 55
Infranatant-RE mean 404 425 404
(min) (SD) 71 42 61
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Table 5.3.5. Area under the curve (8 hour) for TAG responses in plasma, chylomicron-enriched and infranatant fractions to a standard meal after periods on normal, nibblingand gorging diets. Values are mean (SD) for 11 subjects after each diet.
NORMAL NIBBLING GORGING
DIET DIET DIET
Plasma-TAG mean 752 788 835
(mmol/lmin) (SD) 266 284 250
CM-TAG mean 369 393 397
(mmol/l.min) (SD) 171 275 204
Infranatant-TAG mean 409 490* 452
(mmol/l.min) (SD) 79 116 119
* significant compared witli normal diet P <0.01
Table 5.3.6. Area under the curve (8  hour) for the apo B-48 responses in plasma, CM enriched and infranatant fractions to a standard meal after periods on normal, nibbling and gorging diets. Values aie mean (SD) for 11 subjects after each diet.
NORMAL NIBBLING GORGING
DIET DIET DIET
Plasma-apo B-48 mean 2187 2323 2415
(p-g/ml.min) (SD) 529 570 499
CM-apo B-48 mean 309 286 296
(pg/ml.min) (SD) 110 123 85
Infranatant-apo B-48 mean 2216 2344 2129
(pg/ml.min) (SD) 476 459 568
Table 5.3.7. Area under the curve (8  hour) for the retinyl ester responses in plasma, CM- 
enriched and infranatant fractions to a standard meal after periods on normal, nibbling 
and gorging diets. Values are mean (SD) for 11 subjects after each diet.
NORMAL NIBBLING GORGING
DIET DIET DIET
Plasma-RE mean 537 651 745
(pg/ml.min) (SD) 322 427 681
CM-RE mean 700 623 808
(pg/ml.min) (SD) 511 772 830
Infranatant-RE mean 105 125 144*
(p-g/ml.min) (SD) 57 53 63
* significant compared witli normal diet P <0.05
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Table 5.3.8. Peak TAG levels in plasma, chylomicron-enriched and infranatant fractionsin response to a standard meal after periods on normal, nibbling and gorging diets.
Values aie mean (SD) for 11 subjects after each diet.
NORMAL
DIET
NIBBLING
DIET
GORGING
DIET
Plasma-TAG mean 2 .1 2 2.32 2.52
(mmol/1.) (SD) 0.96 0.96 1.11
CM-TAG mean 1.33 1.41 1.44
(mmol/1.) (SD) 0.92 0.38 0.45
Infranatant-TAG mean 1.03 1.24 1 .1 1
(mmol/1.) (SD) 0.36 0.38 0.45
Table 5.3.9. Peak apo B-48 levels in plasma, CM-enriched and infranatant fractions in 
response to a standaid meal after periods on normal, nibbling and gorging diets. Values
NORMAL NIBBLING GORGING
DIET DIET DIET
Plasma-apo B-48 mean 5.18 5.95 5.91
(|ig/ml) (SD) 2.01 1.78 1.98
CM-apo B-48 mean 0.80 0.95 1 .0 1
(l-tg/ml) (SD) 0.41 0.70 0.56
Infranatant-apo B-48 mean 5.18 5.34 5.49
(|ig/ml) (SD) 1.31 1.35 1.40
Table 5.3.10. Peak retinyl ester in plasma, CM-enriched and infranatant fractions in 
response to a standard meal after periods on normal, nibbling and gorging diets. Values 
aie mean (SD) for 11 subjects after each diet. ____________  ______
NORMAL
DIET
NIBBLING
DIET
GORGING
DIET
Plasma-RE mean 2.17 3.29 3.12
(p.g/ml) (SD) 1.47 3.80 2.61
CM-RE mean 2.98 3.57 3.11
(pg/ml) (SD) 2.91 4.68 4.68
Infranatant-RE mean 0.51 0.72 0.57
(|ig/ml) (SD) 0.25 0.40 0.44
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5.3.4 EFFECTS OF MEAL FREQUENCY ON RESPONSES IN THE CM-
ENRICHED FRACTION
5.3.4.1 Triacylglycerol responses
The CM-TAG responses to a high fat meal after periods on a normal, nibbling and 
gorging diet are shown in Figure 5.3.2 a. The CM-TAG levels rose to a peak at 180 to 
240 minutes and fell back down to fasting level at the end of the 8 hour study. The times 
to peak CM-TAG after the different diet periods aie shown in Table 5.3.2. There were no 
significant differences between the times to peak after any of the diet periods. The 
calculated AUG for these responses are shown in Table 5.3.5 and the peak levels in Table
5.3.8. There were no significant differences between the AUC or the peak levels after 
any of the diet periods.
5.3.4.2 Apo B-48 responses
The CM-apo B-48 responses to a high fat meal after periods on a normal, nibbling and 
gorging diet are shown in Figure 5.3.2 b. After the normal diet period the CM-apo B-48 
response exhibited a double-peak pattern. The peak levels at 120 minutes and 300 
minutes were the same (0.80 fig/ml) There was also a double-peak pattern after the 
gorging diet with a small initial peak at 120 minutes followed by a larger peak at 240 
minutes. After the nibbling diet there was no early peak but a plateau occurred between 
240 to 300 minutes. Levels fell back down to baseline level at the end of the 8  hour study 
after the normal and gorging diets but appeared to be showing a tendency towards a 
second late peak after the nibbling diet. There were no significant differences between 
the times to peak CM-apo B-48 after any of the diet periods (Table 5.3.3) and repeated 
measures ANOVA showed there were no statistically significant differences between the 
patterns of response after each diet period.
The calculated AUC for these responses aie shown in Table 5.3.6 and the peak levels in 
Table 5.3.9. There were no significant differences between the AUC of the peak levels 
after any of the diet periods.
5.3 4.3 Retinyl ester responses
The CM-RE responses to a high fat meal after periods on a normal, nibblmg and gorging 
diet are shown in Figure 5.3.2 c. The levels rose to a peak at 360 minutes after each diet 
period and had not fallen back down to baseline levels at the end of the 8 hour study. 
There were no significant differences between the time to peak CM-RE after the different 
diet periods (Table 5.3.4). The calculated AUC for these responses are shown in Table
5.3.7 and the peak levels in Table 5.3.10. There were no significant differences between 
the AUC or the peak levels after the three diets.
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Figure 5.3.2 The effects of meal frequency on the a) TAG, b) apo B-48 and c) retinyl 
ester responses to a high fat meal in the CM-enriched fraction. Values represent means 
with SEM of 11 subjects in each group. Responses after the normal diet period are shown 
by (—□—), the nibbling diet period by (- - A- -) and the gorging diet period by (•••#■■•).
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5.3.5 THE EFFECTS OF MEAL FREQUENCY ON RESPONSES IN THE
INFRANATANT FRACTION
5.3.5.1 Triacylglycerol responses
The infranatant-TAG responses to a high fat meal after periods on a normal, nibbling and 
gorging diet are shown in Figure 5.3.3 a. The infranatant-TAG responses showed an 
initial peak at 180 minutes and a second peak at 300 minutes after the nibbling diet. The 
levels rose to a single peak at 180 minutes after the gorging diet and 240 minutes after the 
normal diet. The levels returned to baseline at the end of the 8 hour study. The times to 
peak infranatant-TAG after the different diet periods are shown in Table 5.3.2. The time 
to peak infranatant-TAG after the nibbling period was significantly shorter than after the 
normal diet period (P <0.05), however repeated measures analysis of variance showed 
that there was no statistically significant differences in the pattern of responses over the 
postprandial time-course between the diet periods.
The peak levels are shown in Table 5.3.8. There were no significant differences between 
the peak levels of TAG after any of the diet periods. The calculated AUC for these 
responses are shown in Table 5.3.5. The infranatant-TAG AUC after the nibbling period 
was significantly higher than the AUC after the normal diet period (P <0.05).
5.3.5.2 Apo B-48 responses
The infranatant-apo B-48 responses to a high fat meal after periods on a normal, nibbling 
and gorging diet are shown in Figure 5.3.3 b. After all three diet periods the apo B-48 
responses in the infranatant showed an early sharp rise in the first 30 minutes. After the 
gorging diet this was followed by a continued rise to a peak at 180 minutes followed by a 
sharp drop and then a plateau from 240 minutes to 480 minutes. After the nibbling diet 
the infranatant-apo B-48 patterns showed a similar pattern to the infranatant-TAG with an 
initial peak between 120 to 180 minutes and a second peak at 300 minutes. After the 
normal diet the apo B-48 levels decreased slowly after 30 minutes to a trough at 240 
minutes followed by a late peak at 360 minutes. The levels remained slightly elevated 
above baseline level at the end of the 8  hour study after all three diet periods. There were 
no significant differences in the time to peak infranatant-apo B-48 after the different diet 
periods (Table 5.3.3) and repeated measures ANOVA showed that the differences in the 
patterns of responses observed between the diet periods were not statistically significant.
The calculated AUC for these infranatant-apo B-48 responses are shown in Table 5.3.6 
and the peak levels in Table 5.3.9. There were no statistically significant differences 
between the peak levels of apo B-48 in the infranatant fraction or the AUC after any of 
the diet periods.
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5.3 5.3 Retinyl ester responses
The infranatant-RE responses to a high fat meal after periods on a normal, nibbling and 
gorging diet are shown in Figure 5.3.4 c. The levels rose to a peak at 360 minutes after 
the nibbling diet period, at 420 minutes after the gorging diet period and at 480 minutes 
after the normal diet period. The RE levels had not fallen back down to baseline levels at 
the end of the 8  hour study. The time to peak infranatant-RE after the different diet 
periods are shown in Table 5.3.4. There were no significant differences between the diet 
periods.
The peak levels of RE in the infranatant fraction are shown in Table 5.3.10. There were 
no significant differences between the diets. The calculated AUC for these infranatant- 
RE responses are shown in Table 5.3.7. The AUC was significantly higher after the 
gorging diet compared with the normal diet (P<0.05).
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Figure 5.3.3 The effects of meal frequency on the a) TAG, b) apo B-48 and c) retinyl 
ester responses to a high fat meal in the infranatant fraction. Values represent means with 
SEM of 11 subjects in each group. Responses after the normal diet period are shown by
(—□—), the nibbling diet period by (- -A- -) and the gorging diet period by (••••-•)•
The AUC for tlie TAG responses was statistically significantly higher after the nibbling diet compared to 
the normal diet (P <0.01) The AUC for tlie RE responses was statistically significantly higher after tlie 
gorging diet compared to tlie normal diet (P <0.05).
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5.3.6 THE EFFECTS OF MEAL FREQUENCY ON FASTING LIPID LEVELS
5.3.6.1 Fasting TAG levels
The fasting TAG levels in the three fractions after each of the diet periods are shown in 
Table 5.3.11. There were no statistically significant differences between the diets in any 
of the fractions.
5.3.6.Z Fasting cholesterol levels
The fasting levels of total cholesterol, HDL-cholesterol and LDL-cholesterol in plasma 
after each of the diet periods are shown in Table 5.3.12. There were no statistically 
significant differences between the diets for any of the measures of cholesterol.
5.3.7 THE EFFECTS OF MEAL FREQUENCY ON PLASMA-NEFA 
RESPONSES
The fasting plasma-NEFA levels after each of the diet periods are shown in Table 5.3.13. 
The fasting NEFA levels were statistically significantly lower after the nibbling and the 
gorging periods compared with the normal diet period (P<0.05).
Figure 5.3.4 shows the effects of a period on a nibbling, gorging or normal diet period on 
plasma-NEFA responses to a high fat meal. After all three diet periods the NEFA levels 
decreased to a similar level 60 minutes after the meal and then began to increase back to 
preprandial levels. Following the normal diet the NEFA levels returned to baseline level 
360 minutes after the test meal. After the gorging diet the NEFA levels rose slightly 
higher than fasting levels 300 minutes after the meal but had returned almost to fasting 
levels at the end of the study. After the nibbling diet period the NEFA levels rose above 
fasting levels 240 minutes after the meal and did not return to baseline at the end of the 
study.
The total (0-480 minute) 30-240 minute, 240-480 minute and incremental AUC for the 
plasma-NEFA responses are shown in Table 5.3.13. There were no significant 
differences between the total-AUC after each diet period (Figure 5.3.5). The AUC from 
30-240 minutes after the nibbling and gorging periods, and the AUC from 240 to 480 
minutes after the gorging diet were significantly lower than after the normal diet {P 
<0.05). The incremental-AUC was significantly higher after the nibbling diet compaied 
to the normal diet (P <0.05) (Figure 5.3.5).
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Table 5.3.11. Fasting levels of TAG in plasma, chylomicron-enriched and infranatantfractions after periods on normal, nibbling and gorging diets. Values are mean (SD) for
11 subjects after each diet.
n = ll NORMAL
DIET
NIBBLING
DIET
GORGING
DIET
plasma-TAG mean 1.07 1 .1 0 1.09
(mmol/1) (SD) 0.37 0.37 0.25
CM-TAG mean 0.23 0.25 0.25
(mmol/1) (SD) 0.10 0.11 0.15
Infranatant-TAG mean 0.84 0.95 0.92
(mmol/1) (SD) 0.16 0.25 0.26
Table 5.3.12 Fasting plasma concentrations of total cholesterol, HDL-cholesterol and LDL-cholesterol after periods on normal, nibbling and gorging diets. Values are mean (SD) for 11 subjects after each diet._____________________________________________
n = ll NORMAL
DIET
NIBBLING
DIET
GORGING
DIET
Total cholesterol mean 4.63 4.50 4.75
(mmol/1) (SD) 0.79 0.72 0.77
HDL-cholesterol mean 1.62 1.60 1.73
(mmol/1) (SD) 0.40 0.36 0.48
LDL-cholesterol mean 2.53 2.40 2.52
(mmol/1) (SD) 0.86 0.73 0.80
Table 5.3.13. Fasting plasma-NEFA levels and area under the curve (total, 30-240 min, 
240-480 min and incremental) for plasma-NEFA responses to a standard meal after 
periods on normal, nibbling and gorging diets. Values are mean (SD) for 11 subjects.
n = ll NORMAL NIBBLING GORGING
DIET DIET DIET
Fasting NEFA mean 0.763 0.475* 0.524*
(mmol/1) (SD) 0.275 0.193 0.218
Total AUC NEFA mean 308 270 258
(mmol/l.min) (SD) 66 42 68
30-240 min AUC NEFA mean 99 78* 84*
(mmol/l.min) (SD) 28 2 2 29
240-480 min AUC NEFA mean 191 179 160*
(mmol/l.min) (SD) 44 35 44
Incremental AUC NEFA mean -58 6 42*
(mmol/l.min) (SD) 135 115 116
* significant compared witli normal diet (P <0.05)
193
2LU
0.8  -
0.6  -
0 . 4 -
0 . 2 -
0.0
- 6 0  0 60 120 180 240  300 360  420  480
time (minutes)
Figure 5.3.4 The effects of meal frequency on plasma-NEFA responses to a standard 
high fat meal. Values are mean {SEM) for 11 subjects after each diet. Responses after 
the normal diet period are shown by (— □— ), the nibbling diet period by (- - A- -) and the 
gorging diet period by (•••#•••).
400-1
300
2 0 0 -
Ü 100-
LU
- 100 -
Incremental
AUC
Figure 5.3.5 Total (0-480 min) AUC and incremental (0-480 min) AUC for plasma- 
NEFA responses to a standard meal after periods on normal, nibbling and gorging diets. 
Values are mean (SEM) for 11 subjects after each diet. Responses after the normal diet 
are shown by (I ), after the nibbling diet by (□ ) and after the gorging diet by (13 )
* indicates incremental-AUC significantly higher than after the normal diet (P <0.05)
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5.3.7 THE EFFECTS OF MEAL FREQUENCY ON LPL ACTIVITY
Table 5.3.14 and Figure 5.3.6 show the 5 and 15 minute post-heparin LPL activity levels 
in the plasma after periods on each of the diets. The 5 and 15 minute LPL activities were 
higher after the nibbling and gorging diets compared with the normal diet but this was 
only statistically significant for the 5 minute post-heparin LPL activity level after the 
nibbling diet compared with the normal diet (P <0.05 j. Samples were not available for 2 
subjects after the normal diet period.
Table 5.3.14 5 and 15 minute post-heparin LPL activity
NORMAL 
DIET (n=9)
NIBBLING 
DIET (n=ll)
GORGING 
DIET (n=ll)
5 min post-heparin mean 54.2 1 0 2 .0 * 79.2
LPL-activity (mU/ml) (SD) 20.4 55.8 44.5
15 min post-heparin mean 104.0 137.1 116.3
LPL-activity (mU/ml) (SD) 38 36.5 70.7
significant compared with normal diet (P<0.05)
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Figure 5.3.6. LPL activity levels 5 and 15 minutes after an injection of heparin 8 hours
after a standard high fat meal. Values are mean (SEM) for 11 subjects after the nibbling
and gorging diets and 9 subjects after the normal diet. Responses after the normal diet are
shown by ( ■  ), after the nibbling diet by (□ ) and after the gorging diet by (13 )
* indicates LPL activity significantly higher than after the normal diet (P <0.05)
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5.3.8 EFFECTS OF MEAL FREQUENCY ON POSTPRANDIAL PLASMA
PARACETAMOL LEVELS
Figure 5.3.7 shows the levels of plasma-paracetamol after a standard high fat meal at the 
end of the periods on the normal, nibbling and gorging diets in 1 0  subjects (one of the 
subjects could not take paracetamol). Table 5.3.15 shows the AUC and the time to peak 
for these responses. There were no differences between these measures after any of the 
diet periods.
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Figure 5.3.7 Effects of meal frequency on levels of plasma-par acetamol after a standard high fat meal. Values are mean {SEM) for 10 subjects after each diet. Responses after
the normal diet period are shown by (—□—), the nibbling diet period by (- - A- -) and the 
gorging diet period by
Table 5.3.15 Total area under the curve and time to peak for paracetamol responses to a 
standard meal after periods on a normal, nibbling and gorging diet. Values are mean {SD) 
of 1 0  subjects.
n= 1 0 NORMAL
DIET
NIBBLING
DIET
GORGING
DIET
Total AUC paracetamol mean 39 40 39
(mmol/l.min) (SD) 6 7 6
Time to peak par acetamol mean 144 1 2 0 147
(min) (SD) 51 28 70
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5,3.9 EFFECTS OF MEAL FREQUENCY ON POSTPRANDIAL PLASMA 
INSULIN LEVELS
Figure 5.3.8 shows the levels of plasma-insulin after a standard high fat meal at the end of 
the periods on the normal, nibbling and gorging diets in 11 subjects. Table 5.3.16 shows 
the AUC and the time to peak for these responses. There were no differences between 
these measures after any of the diet periods.
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Figure 5,3.8. Effects of meal frequency on levels of plasma-insulin after a standard high fat meal. Values are mean {SEM) for 11 subjects after each diet. Responses after the
normal diet period are shown by (— □— ), the nibbling diet period by (- -A- -) and the 
gorging diet period by (••••••■).
Table 5.3.16. Total area under the curve and time to peak for insulin responses To a standard meal after periods on a normal, nibbling and gorging diet. Values are mean {SD) 
of 11 subjects.
n = ll NORMAL
DIET
NIBBLING
DIET
GORGING
DIET
Total AUC insulin mean 92096 92836 93869
(mmol/l.min) (SD) 31156 25385 29588
Time to peak insulin mean 6 8 93 109
(min) (SD) 36 70 52
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5.4 DISCUSSION
The aim of this study was to investigate if any adaptive changes occur in the postprandial 
metabolism of a fat-containing meal in response to alterations in meal frequency, which 
may provide an explanation for the potentially beneficial effects of a nibbling diet 
observed by other workers. There were no clear-cut results from this study, however 
there was a general trend for differences in the infranatant fraction to occur after the 
different diet periods. The infranatant contains the potentially atherogenic CMR and 
therefore any changes in this fraction are important. In summaiy the results of this study 
showed:
- The compliance of the subjects to both the dietary intervention periods was greater 
than 15%.
- There were no significant differences between the levels of TAG, apo B-48, total, 
HDL- or LDL-cholesterol in the fasting state after any of the diet periods
- Fasting NEFA levels were significantly lower after both the gorging and nibbling diets 
compared with the normal diet period (P <0.05).
- Postprandial TAG levels over time (total AUC) in the infranatant fraction were 
significantly higher after the nibbling diet compared with the normal diet (P <0.05).
- The time to peak infranatant-TAG was significantly shorter after the nibbling diet 
compared with the nonnal diet (P <0.05).
- Postprandial RE levels over time (total AUC) in the infranatant fraction were 
significantly higher after the gorging diet compared with the normal diet (P <0.05).
- Postprandial apo B-48 levels over time (total AUC) in the infranatant fraction were 
higher after the nibbling diet compared with the normal diet but this difference was not 
quite significant (P <0.08).
- The incremental AUC for NEFA responses was significantly higher after the nibbling 
diet compared with the normal diet (P <0.05).
- The 5 minute post-heparin LPL activity was significantly higher after the nibbling diet 
compared with the normal diet (P <0.05).
Several studies conducted since 1988 have shown that a high meal frequency (nibbling) is 
associated with a lower level of fasting total cholesterol and LDL-cholesterol (Jenkins et 
a l,  1989; Arnold et a l, 1993; McGrath and Gibney, 1994) compared with a low meal 
frequency. An early study also showed that a nibbling diet is associated with a lower 
level of fasting plasma-TAG (Gwinup et a l, 1963). In the present study we did not 
observe any significant effects on these fasting parameters, although the total cholesterol 
was lowest after the nibbling diet and highest after the gorging diet (4.50 mmol/1 versus 
4.75 mmol/1). LDL-cholesterol was also lowest after the nibbling diet, however the HDL
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cholesterol was highest after the gorging diet. A possible reason for not seeing any 
significant differences in the levels may be due to the nature of the subject group. 
Premenopausal, young females generally have low levels of cholesterol (Barrett-Connor, 
1994) and therefore potentially beneficial effects on these parameters may not be seen in 
such a group.
The effects of oestrogens on lipid metabolism may be important on studies in women. 
The effects of oral contraceptives on lipid metabolism depend on their formulation. The 
oestrogenic contraceptives used by 4 of the 11 subjects in this study are associated with 
higher levels of both fasting HDL-cholesterol and TAG (reviewed by Bemben, 1993). 
The use of these oral contraceptives may therefore have obscured any potentially 
beneficial changes in the lipid profile induced by alterations in meal frequency in these 
subjects which may have affected the results of the group as a whole. It has been 
suggested that studies of lipid metabolism in women should be carried out during the 
same phase in the menstmal cycle to minimise the effects of oestrogen (Taylor and Ward, 
1993). However this was an impractical improvement in the design of the present study.
The lack of significant effects on cholesterol levels in the present study may also be 
related to differences in insulin. Changes in LDL-cholesterol in response to meal 
frequency are believed to be mediated through insulin (Jenkins et al., 1989). No 
differences were seen in the fasting levels of insulin or postprandial insulin response to a 
meal after periods on the nibbling and gorging diets in the present study. These findings 
are consistent with the failure to observe differences in the cholesterol response.
It was also possible that the subjects may have had different responses to the two 
intervention periods depending on their habitual meal frequency. Analysis of the answers 
to question 1 showed that none of the subjects were true gorgers as no-one ate less then 
three times a day, and none of the subjects ate more than 6  times a day. There was veiy 
little range of meal frequencies in this subject group and it seemed impossible to separate 
them into habitual nibblers or gorgers on the basis of their self-reported habitual normal 
eating patterns. Thus both the nibbling and the gorging routines were unusual situations 
for the entire group.
It was important for this small-scale pilot study to have conscientious, informed 
volunteers who were personally known to the investigators as it was believed this would 
lead to increased compliance during the intervention periods. The subjects of this study 
were therefore all young, healthy female subjects. As described above, the disadvantages 
of choosing this population is the well-documented efficient lipid handling systems in 
young women. If a population of post-menopausal woman or a population of older men
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had been selected there may have been more clear-cut metabolic effects, however the 
levels of compliance would potentially have been much lower.
The self-reported levels of compliance to the inteiwention periods were considered to be 
high (gorging 90 %; nibbling 78 %) considering the anti-social nature of the study design. 
The average number of meals eaten each day was 11.7 ± 0.5 on the nibbling and 2.1 ± 0.1 
on the gorging diets. Only two subjects reported higher compliance on the nibbling diet. 
It is interesting to note that the compliance to the first diet period was higher than to the 
second ( 8 8  % versus 80 %). The subjects were randomly allocated to either nibbling or 
gorging for their first diet period, however 7 out of 11 subjects were gorging in the first 
diet period which may explain the differences in compliance. It is possible that the 
subjects were more conscientious on the first diet period regardless of the meal frequency 
and began to get fed up with the intervention during the second diet period. Subjects 
reported that the most difficult times during the diets were in the morning for the gorging 
diet and at work or at weekends during the nibbling diet. Several of the subjects who 
missed meals during the nibbling period did so due to not being able to leave laboratory 
work in the middle of an experiment. The other main reason was due to social pressures 
at the weekend. Despite these problems all the subjects ate 12 meals a day on at least 10 
of the 13 days. This study was designed so that the number of meals eaten each day 
during the two intervention periods would provide an extreme between the diets so that 
any effects of meal frequency would be magnified. The results from the questionnaire 
suggest that even if there were beneficial effects of a high meal frequency it would be 
difficult for the general public to maintain such a high number of meals each day.
Investigators have examined the acute effects of meal frequency by looking at the levels 
of lipid, glucose and insulin over a 24 hour period whilst either nibbling or gorging. 
Studies by Jaganathan et a l (1964), Terpstra et a l  (1978), Van Gent et al. (1979) and 
Jenkins et al. (1989) showed that the total level of TAG over a 24 hour period was lower 
whilst subjects were eating several times a day compared with three times a day. 
Wolever (1990), Jenkins etal. (1992) and Jones etal. (1993) also showed that the daily 
fluctuations of insulin and glucose did not occur whilst subjects were nibbling. In view 
of these effects it was considered important to investigate if there were any adaptive 
changes occuiiing in the enterocyte or in the circulation as measured by RE and apo B-48 
levels which may explain these findings. In order to do this a study design was chosen 
whereby an intervention period on either a nibbling or gorging diet was followed by a 
challenge to the lipid metabolism system in the form of a high fat test meal. Subsequent 
measurement of the postprandial levels of various parameters for an 8  hour period after 
this challenge were designed to highlight any differences in lipid handling caused by the 
previous period of meal frequency.
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There were several potential confounding variables in this study which it was important 
to standardise. McGrath and Gibney (1994) showed that subjects changed their dietary 
intakes when they changed their diet from snacking to meal-eating routine. Changes 
were significant in the levels of fats and protein as well as the type of fatty acids and 
alcohol intake between the two patterns of eating. The authors believed these differences 
in nutrient composition accounted for the changes in cholesterol observed in the study 
after changing to a meal-eating regimeirather than the change in meal frequency. In order 
to prevent any confounding variables in the present study the subjects were requested to 
eat their normal foods during the intervention periods. Compliance to this request was 
assessed by both the questionnaire and the 24 hour recall diaries. Analysis of the 24 hour 
diaries showed that there were no significant effects on the intake of any of the 
macronutrients or on the energy intakes at the end of the intervention periods. A more 
accurate picture of dietary intakes may have been obtained if the subjects had been asked 
to complete three-day diet diaries during each of the two intervention periods and during 
the normal diet. However the use of three-day diet diaries has been criticised 
(Livingstone, 1990) and therefore the application of the questionnaire was believed to be 
another useful method for assessing differences in dietary intake. Although there was no 
specific question to determine changes in food intake alone, subjects were asked to 
include their compliance to both the number of meals each day and to the consistency of 
their diets within their answer to question 10 of the questionnaire. They were also asked 
in questions 14 to 16 whether they ate the same amount of food on all diets. Although 
some subjects felt they had eaten a bit more on one or other of the diets they admitted that 
this could have been because it was unusual to eat so many meals (nibbling) or so much 
food in one meal (gorging). It would have been preferable to have had separate questions 
to investigate all possible variables in food intake. Analysis of the 24 hour food diaries 
during the normal diet revealed that the percentage of calories from fat was very low in 
this group compared to the UK average (30 % in the subject group compared to 40 % in 
the UK) and this did not significantly change during the diet periods. This was probably 
due to the nature of the group as the subjects were all nutrition-conscious and may have 
been another factor which prevented many differences being observed in fasting and 
postprandial responses between the diets
Although the beneficial effects of increased meal frequency have been demonstrated in 
reference to reduced insulin and glucose concentrations, in acute situations these effects 
are due to a decrease in the rate of absorption of the carbohydrate by spreading the 
nutrient load over several meals. The main aim of this study was to investigate any long­
term adaptive changes within the enterocyte or circulation which could be measured by a 
high fat test-meal challenge. A potential problem with the design of this study was that
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the test meal would be unusually large for the nibblers and therefore there may have been 
differences in gastric emptying and absorption of the test meal in the nibblers which 
would mask any other changes. Many studies have used double cream for the test meal 
challenge as described by Patsch et al. (1983), however this is not a physiological 
situation and it would seem more desirable to use a more physiological, mixed meal in 
postprandial studies. In view of these points the test meal was designed as a small, mixed 
meal with a very high fat content to prevent discrepancies between gastric emptying. In 
order to investigate the rate of absorption of the test meal 1500 mg of soluble paracetamol 
was included in the meal. Both the levels and rate of appearance of paracetamol in the 
plasma were taken as markers for gastric emptying and absorption. There were no 
significant differences in either the pattern of plasma paracetamol (Figure 5.3.7) or the 
AUC and time to peak (Table 5.3.12) and therefore any differences in the parameters 
were taken to be caused by adaptive changes invoked by the meal frequency pattern.
The main aims of this study were to look at adaptive changes in the metabolism of lipids 
and lipoproteins and especially CM and CMR. The most interesting postprandial results 
from this respect were the changes which occurred in the infranatant fraction. Although 
these changes were small, some were significant and it is possible to speculate on 
mechanisms which may be involved in the differences. The cumulative levels of TAG in 
the infranatant fraction in the 8 hours after the meal were significantly higher after the 
period on the nibbling diet compared with the normal diet (490 mmol/l.min versus 405 
mmol/l.min). The time to peak TAG after the period on the nibbling diet was also 
significantly shorter than after the normal diet (150 minutes versus 240 minutes) and 
there appears to be a double peak pattern, although no difference was identified between 
the patterns by repeated measures ANOVA, The cumulative levels of apo B-48 in the 
infranatant fraction in the 8 hours after the meal and the time to peak apo B-48 were also 
higher after the period on the nibbling diet compared with the normal diet (2344 
|ig/ml.min versus 2216 pg/ml.min and 185 minutes versus 229 minutes) although this did 
not reach significance in either case. There also appears to be a double peak pattern in 
the infranatant-apo B-48 responses after the nibbling diet. These results could suggest 
that there is a difference in enterocyte processing in the subjects accustomed to a nibbling 
pattern of eating. The higher levels of apo B-48 and TAG in the infranatant fraction at 
eaiiier time-points could indicate direct release of smaller CM from the enterocyte after 
the nibbling diet. However the results in this study cannot conclude very much about 
site-specific events as AUC are measures of the cumulative effect of metabolic processes 
in the enterocyte, circulation, adipose tissue and liver. Any or all of these processes may 
be affected by changes in meal frequency and therefore it would be necessary to test this 
hypothesis by examining lipoprotein particle size or changes in apo B-48 production rates
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in the enterocyte. Investigation of the levels of apo B-lOO postprandially may also 
provide more information on the possible effects of meal frequency speculated on here.
An alternative hypothesis to explain the differences between the responses after the 
nibbling diet compared with the normal diet are that these higher levels of apo B-48 and 
TAG in the infranatant could indicate increased rate of formation of CMR due to faster 
clearance of CM-TAG by LPL, as indicated by the 5 minute post-heparin LPL activity 
which was shown to be significantly higher after the nibbling diet compared with the 
normal diet. If either of these hypotheses were correct it would be expected that the 
levels of RE in the infranatant were also higher after the nibbling diet. Although the 
infranatant-RE AUC was higher after the nibbling diet compared with the normal diet 
(125 |ig/ml.min versus 105 |ig/ml.min) this difference was not significant. Also the 
highest infranatant-RE AUC was observed after the gorging diet (144 p.g/ml.min). This 
result was unexpected in view of the other results in the infranatant, however the use of 
RE as a marker for CM has been questioned (Krasinski et al., 1990). One of the reasons 
is due to the uncertainty of the number of RE molecules and the rate of their 
incorporation into the CM at different time-points after a meal. The AUC for RE is 
higher in each of the fractions after the gorging period compared with both the nibbling 
and the normal diet period, despite no differences in the apo B-48 AUC. This suggests 
that a larger number of RE molecules are being incorporated into each CM pai ticle after 
the gorging period than after the normal or nibbling diets. This would agree with the 
hypothesis that a gorging pattern of eating is associated with a more efficient lipid 
assimilation and storage system (Fabry et al., 1970). Studies in the rat (De Bont et al., 
1975) and in humans (Bray et al., 1972; Wilhelmine et al, 1991) have provided evidence 
for adaptive hyperlipogenesis in the adipose tissue after habituation to a gorging pattern 
in order to efficiently utilise the infrequent energy sources. In the present study the 
enterocyte may have adapted to incorporate more CE into the CM particles due to the 
long periods of time when the gastrointestinal tract is empty, however again this can only 
be speculated upon until further work is caiiied out to investigate direct effects of meal 
frequency on the enterocyte.
Following on this assumption it would be expected that there would also be an increase in 
incorporation of TAG into CM after the periods on the gorging diet. Although the TAG 
AUC was higher in all the fractions after the gorging diet compared with the normal diet, 
this was not significant in any case. However the postprandial AUC is a measure of TAG 
input and clearance and it is impossible to distinguish between these two processes from 
this measurement. Therefore it is possible that if the systemic clearance system, i.e. LPL 
activity, was working below maximum capacity, then any increases in TAG would not be 
reflected in the AUC as this higher concentration of TAG would be cleared at the same
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rate as a lower concentration of TAG. The LPL activity levels after a period of gorging 
were higher than after the normal diet (non-significant) which may have accommodated 
any increases in TAG.
The reason for the higher LPL activity after the nibbling diet is unclear but may be due to 
constant activation of LPL due to the regularity of the meals. This is a beneficial 
adaptation as high levels of LPL activity have been correlated with the decreased risk of 
CAD associated with exercise (Weintraub et a l, 1989) and n-3 PUPA intake (Herzberg, 
1991).
The higher LPL activity levels in the nibblers may explain the reason for the overshoot of 
NEFA levels in the mid to late postprandial phase. A high LPL activity produces a large 
amount of NEFA. It is possible that the subsequent uptake mechanism of NEFA into the 
adipose tissue after the nibbling diet was not sufficient to cope with the increase in NEFA 
concentrations as the subjects were not accustomed to a single, large fat load and 
therefore there was a concomitant increase in plasma-NEFA. This is potentially a 
disadvantage as high local NEFA levels have been suggested to cause the release of LPL 
from the capillary wall (Karpe et a i, 1993), thus preventing hydrolysis of TAG from CM 
released in the late postprandial phase. The higher level of LPL activity observed in the 
nibbling group 8 hours after the meal may suggest that this problem could be overcome, 
possibly by constant release of LPL. In studies of acute effects of meal frequency, 
plasma-NEFA levels are suppressed for longer during the day whilst nibbling compaied 
with gorging (Bertelsen et al., 1993). The effect on postprandial NEFA noted in the 
present study may therefore not reflect the everyday situation whilst eating frequently.
The significantly lower levels of fasting NEFA after the intervention diet periods 
compared with the normal diet were unexpected. Peters et al. (1979) showed lower 
fasting levels of NEFA after a period on a gorging compared to a nibbling diet. It is 
possible that the higher levels of NEFA on the first study day were due to nerwousness of 
the subjects as none of the subjects had been involved in trials before and were not used 
to the cannulation procedure. Another possibility is that the subjects were over- 
conscientious on the first study day and fasted for longer than 12 hours. A long period of 
fasting results in release of NEFA from adipose tissue for use in TAG synthesis by the 
liver (Frayn, 1992). Consumption of alcohol the day before the first study day may also 
have caused a high NEFA level. The written information given to each subject requested 
that they refrained from drinking alcohol the day before the study day and none of the 
subjects reported drinking alcohol on the previous day. The levels of NEFA were 
consistently higher in every subject on the baseline study day (Appendix III) and these 
levels are higher than fasting NEFA levels reported in other studies. Therefore an effect
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of the diet, a long fast or nervousness of the subjects are the more probable reasons for 
the high fasting NEFA levels on the first study day.
One point to note is that the levels of TAG, apo B-48 and RE in the infranatant and CM- 
enriched fraction do not add up to the level in the plasma fraction. This is especially 
evident in the RE responses where the CM-RE AUC are as high as the plasma-RE AUC 
despite the contribution of the infranatant-RE. This could be because the CM-enriched 
fraction is a concentrated fraction in which the levels of RE are very high. In order to 
determine the CM-RE levels in the total plasma the concentration of CM-RE obtained 
during the assay must be divided by the volume of the CM-enriched fraction obtained 
after ultracentrifugation of a certain volume of plasma. If there was a small discrepancy 
in the volume of CM from the assumed volume this would make a large difference in the 
overall calculated concentration of CM-RE. The same reasoning may explain why the 
infranatant-apo B-48 levels are similar to the plasma-apo B-48 levels. The infranatant 
fraction is diluted and a calculation must be done in order to obtain the infranatant-apo B- 
48 levels in the total plasma. A further potential cause of the lower RE levels in the 
plasma compared with the CM is the very high concentration of proteins in the plasma 
compared with the CM-enriched fraction. These proteins may interfere with the 
extraction of RE from the plasma and thus give a slightly lower RE value. As the level of 
protein in all plasma samples is comparable, this would be a systematic error in every 
plasma sample and therefore should not affect comparisons between the groups.
In conclusion the results of this study suggest that increasing meal frequency has small 
but significant effects on lipid metabolism in young female subjects. The study was 
designed to investigate metabolic adaptations after habituation to eating many, small, 
frequent meals or two large infrequent meals each day. The TAG, apo B-48 and RE 
responses in the infranatant revealed differences between the nibbling and normal 
routines which, it is speculated, may be due to adaptations in enterocyte processing of 
dietary TAG. Variations in NEFA responses'and LPL activity may reflect differences in 
the metabolic processes in the adipose tissue caused by altered meal frequency. The 
results of this study using apo B-48 as a marker for dietary-derived lipoproteins are novel 
and need to be verified. A similar, well-controlled study in a free-living situation in older 
subjects coupled with direct investigations of the processes in the enterocyte and adipose 
tissue may provide more information on these effects.
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CHAPTER SIX INVESTIGATION OF THE DISTRIBUTION OF CHYLOMICRON REMNANTS IN PLASMA
6.1 INTRODUCTION
In 1979 Zilversmit put forward the theory that atherogenesis is a postprandial 
phenomenon. He proposed that CMR may be able to infiltrate the arterial wall and thus 
be directly atherogenic. The evidence for this theory was initially proposed from work in 
animals. Further in vitro investigations provided evidence for a direct link between 
postprandial lipoproteins and atherosclerosis in humans. Floren and coworkers (1981) 
showed that, in vitro, CMR can gain access to human arterial SMC if endothelial injury 
has occurred. Chung and Segrest (1990) showed that TGRL remnants can cause both 
foam cell formation, via lipid-loading in macrophages, and cell death in the endothelial 
cells. More recently there has been doubt cast over the direct involvement of CMR in the 
atherogenic process. The lipoproteins that infiltrate the arterial wall most readily are in 
the LDL (d =1.019 to 1.063 g/ml) size range (Brown and Goldstein, 1983), whereas it is 
widely assumed that all CMR are isolated at a density less than 1.019 g/ml (Weintraub et 
a i, 1987; Gianturco and Bradley, 1991; Havel, 1994), i.e. the size and density range of 
IDL and VLDL particles. Furthermore, it has recently been proposed that CMR cannot 
be directly atherogenic as they are removed from the circulation before gaining a size 
small enough to infiltrate the arterial wall (Karpe and Harnsten, 1995). It has thus been 
suggested that CMR are more likely to be indirectly involved in the risk of CAD through 
their interactions with other lipoproteins, especially HDL (Section 1.4.2.3).
Some work has been carried out to investigate the metabolism of apo B-48 containing 
lipoproteins in the Sf 12-400 size range (i.e. CMR). This has mainly been achieved 
through the application of the SDS-PAGE method described in Section 1.8 and 
subfractionation of lipoprotein species by ultracentrifugation. Using these techniques, 
Karpe and co-workers found that the increase in apo B-48 in the postprandial state 
occuiTed predominantly in the Sf 60-400 lipoprotein range, and to a lesser extent in the Sf 
20-60 range (Karpe and Hamsten, 1994). Using Coomassie-stained polyacrylamide gels, 
apo B-48 in the Sf >400 and Sf 12-20 fractions was below the detection limit (less than 
0.2 pg/ml) and an LDL fraction was not isolated as apo B-48 containing lipoproteins 
were not believed to reach this size.
During the development of the ELISA method for measuring apo B-48 (Chapter 4), the 
difficulty of producing a pure apo B-lOO sample by ultracentrifugation was highlighted. 
Despite attempts to produce a 'narrow-cut' LDL fraction (density range 1.050 to 1.075 
g/ml), apo B-48 was still found in this small, dense lipoprotein fraction (Section 4.3.1.1). 
This was an interesting finding as all previous work had suggested that CMR were not 
present in this small size range (Weintraub et a l, 1987; Gianturco and Bradley, 1991;
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Kai'pe and Hamsten, 1995). In light of these results the size and density distribution of 
CMR needed to be reassessed. In Section 4.3.1.1, a fixed angle rotor was used to separate 
lipoprotein fractions using a sequential flotation technique whereby lipoproteins float or 
sediment in a fixed density solution. Other studies have separated apo B containing 
lipoprotein fractions by ultracentrifugation using a discontinuous density gradient in a 
swing out rotor (Kaipe et al., 1994). In this method, lipoproteins of different densities 
float through a gradient at different rates. These two ultracentrifugation techniques are 
quite different and this difference seemed a possible reason for the discrepancy between 
the results of our group and those of other groups who had reported isolating a pure apo 
B-lOO fraction (Karpe and Hamsten, 1994; Kotite et al., 1995). However it is also 
possible that the SDS-PAGE used by these groups to investigate the apolipoprotein 
content of the lipoprotein fractions was not sensitive enough to detect the presence of apo 
B-48 in the supposedly pure apo B-lOO containing LDL fractions. The investigation 
described in Section 4.3.1.1 had the advantage of utilising a very sensitive 
immunoblotting technique which could detect apo B-48 at concentrations much lower 
than 0.2 |ig/ml which was the detection limit for SDS-PAGE (Karpe et al., 1994b).
A further reason for interest in the apo B-48 distribution in lipoprotein fractions is related 
to the use of RE as a marker for CM particles. Over recent years there has been criticism 
of the RE method for following the metabolism of CM and CMR due to the presence of 
RP in LDL and HDL fractions at late time-points after a meal (Krasinski et al., 1990a; 
Demacker et at., 1992; Cohn et al., 1993). This was presumed to be RE associated with 
apo B-lOO containing lipoproteins due to exchange of TAG and CE between TGRL and 
CE-enriched lipoproteins by CETP. The results in Section 4.3.1.1 showing the presence 
of apo B-48 in the LDL fraction suggested that the RE found in small dense lipoprotein 
fractions may be associated with very small dense CMR. This possibility needs to be 
confirmed and the level of transfer of RE molecules to endogenous lipoproteins 
quantified.
Aims of the study
The aim of this study therefore was to investigate the size and density distribution of 
CMR particles in postabsorptive and postprandial plasma. This was achieved by using 
two different ultracentrifugation techniques, density gradient ultracentrifugation and 
sequential flotation ultracentrifugation, to isolate the lipoprotein fractions. A comparison 
of the results from the two ultracentrifugation methods could then be made in an attempt 
to explain the discrepancy between the results in Chapter 4 showing the presence of apo 
B-48 in the LDL fraction with other published results in which pure apo B-lOO containing 
LDL fraction have been obtained. In order to provide as much information as possible
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both RE and apo B-48, the markers for CM and CMR, were analysed. Analysis of the 
chemical composition of each lipoprotein fraction was also carried out to compare with 
other published results to ensure that the ultracentrifugation methods produced the 
expected separations. Due to the very long and complicated nature of these 
ultracentrifuge methods only a small number of subjects were analysed. This study was 
therefore set up to provide preliminary evidence for the presence of CMR in small, dense 
lipoprotein fractions on which further, more detailed studies could be based.
6.2 METHODS
6.2.1 Study design
Five subjects (4 male, 1 female) were studied after a 12 hour overnight fast. The subjects 
characteristics ar-e shown in Table 6.3.1. A fasting blood sample was taken and the 
subjects were given a high fat (80 g) meal as detailed in Table 3.2.3. The meal was 
consumed within 20 minutes. Four of the subjects took RP with the meal. Blood samples 
were taken 4 hours and 8 hours (4 subjects only) after the meal. All blood samples were 
collected into EDTA tubes.
Plasma was isolated from each blood sample by centrifugation at 7000 g.min as described 
in Section 2.1. Immediately after separation, preservative was added to the plasma at 5 % 
of the total volume. The plasma was kept at 4 “C until ultracentrifugation so that the 
three time-points from each person were put in the same rotor.
6.2.2 Ultracentrifugation methods
6.2.2.1 Cumulative discontinuous density gradient ultracentrifugation (DGUC)
The method described below was modified from a published technique for separating apo 
B-containing lipoproteins (Gaw et al, 1992) to allow for lipaemic postprandial samples 
and a lower speed rotor. The modified times required for each spin were calculated by 
another investigator from the cumulative co^ t for each of the stages in the gradient (i.e. the 
centrifugal effect), o h  is the relationship between the rate of rotation measured in 
radians per second (cû) and the time. Each step of the gradient has an o h  value which is 
calculated from the relationship between the flotation rate of the lipoprotein in the 
interval, the standard density, the standard viscosity, the hydrated density of the 
lipoprotein, the viscosity of the solvent in the intei-val and the density of the solvent in the
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interval. This gave a required centiifugal effect measured by co^ t rather than by g.min and 
therefore only spin times and rotor speeds are quoted.
Materials
NaCl, NaBr and KBr were obtained from Fisons, Loughborough, Leics. Ultracleai' SW40 
ultracentrifuge tubes (part no. 344060) were obtained from Beckman RIIC Ltd., High 
Wycombe, Bucks. The ultracentrifuge was a Beckman L-8  model and the rotor was a 
Beckman SW40.
Density solutions
Solutions of varying density were made up and the density tested using a digital density- 
meter at 23 “C as described in Section 2.2.3. Initial stock solutions were NaCl (d =1.006 
g/ml), as described in Section 2.2.2.1, and NaBr/NaCl (d =1.182 g/ml) made up from 
24.98 g NaBr and 100 ml NaCl (d =1.006 g/ml). The intermediate density solutions were 
made up using different volumes of these two stock solutions, shown in Table 6.2.1, 
determined from Equation 2.1, where V i=  volume of NaCl (d =1.006 g/ml), V2 = 
volume of NaCl/NaBr ( d =1.182 g/ml), D = density of NaCl/NaBr required, Di = 1.006 
g/ml (density of NaCl), D2 = 1.182 g/ml (density of NaCl/NaBr)
Table 6.2.1. Volumes of stock solutions required to produce solutions of various 
densities.
Density required 
(g/ml)
Volume of NaBr/NaCl 
d=1.182 g/ml (ml)
Volume of NaCl 
d =1.006 g/ml (ml)
1.059 43.1 1 0 0
1.064 49,2 1 0 0
1.072 60.0 1 0 0
1.079 70.9 1 0 0
1.086 83.3 1 0 0
1.099 1 1 2 .0 1 0 0
The density of 2 ml of plasma from each time-point was increased to 1.118 g/ml by 
addition of 0.344 g solid KBr and rolling until dissolved. A Beckman ultraclear SW40 
rotor tube was clamped at 30 " to the horizontal and 0.5 ml of NaCl/NaBr (d =1.182 g/ml) 
was pipetted into the bottom to act as a cushion to minimise the effects of the curvature of 
the tube. The 2.0 ml of plasma followed by the six-step salt gradient were overlayered on 
the cushion as indicated in Figure 6.2.1 using a peristaltic pump at a flow rate of 1
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ml/minute. Each tube was placed in a SW40 Ti swing-out rotor bucket and spun under 
the following conditions:
VLDLi + CM(Sf>60)
The tubes were centrifuged at 30,000 rpm for 2 hours 44 minutes at 23 “C to float the 
VLDLi fraction to the top of the gradient. The spin was decelerated without braking. 
The VLDLi was removed in the top 1.0 ml using a glass pasteur pipette and measured in 
a 1.0 ml volumetric flask. If the VLDLi fraction was very lipaemic in the postprandial 
samples, 2.0 ml were removed to ensure no lipid remained stuck to the tube walls. The 
volume of gradient removed was replaced by carefully overlayering with the same 
volume of NaCl/NaBr (d =1.059 g/ml), i.e. 1 or 2 ml, on the top of the gradient, ensuring 
that the gradient was not disturbed.
VLDL2 (Sf 20-60)
The tubes were centrifuged at 18,500 ipm for 15 hours 41 minutes at 23 °C to float the 
VLDLz fraction to the top of the gradient. The VLDL2 fraction was removed in 0.5 ml. 
The volume of solution was not replaced at this stage.
IDL (Sf 12-20)
The tubes were centrifuged at 30,000 ipm for 4 hours 25 minutes at 23 “C to float the IDL 
fraction to the top of the gradient. The IDL fraction was removed in 0.5 ml. The volume 
of solution was not replaced at this stage.
LDL (Sf 0-12)
The tubes were centrifuged at 30,000 ipm for 22 hours 28 minutes at 23 °C to float the 
LDL fraction to the top of the gradient. The LDL fraction was removed in 1.0 ml.
Preservative was added to all fractions at 3 % of the final volume and the fractions were 
stored at - 20 “C until analysis.
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Figure 6.2.1. Discontinuous NaCl/NaBr-gradient used for the subfractionation of apo B 
containing lipoprotein fractions.
6 2.2.2 Sequential flotation ultracentrifugation (SFUC)
Lipoprotein fractions were isolated using a fixed angle rotor according to the method 
described in Section 2.2.3, which was modified from a published technique by Mackness 
and Durrington (1992) to allow for lipaemic postprandial samples.
Density solutions
Two density solutions of d = 1.019 g/ml and d = 1.063 g/ml were made up according to 
the equation 2.1 using the initial stock NaCl solution (d =1.006 g/ml) and a stock 'heavy 
solution' of KBr/NaCl (d = 1.27 g/ml).
Lipoprotein fractions
A VLDL + CM fraction (d <1.006 g/ml), IDL fraction (d <1.019 g/ml) and LDL fraction 
(d <1.063 g/ml) were isolated from each plasma sample as described in Section 2.2.4.
Preservative was added to all fractions at 3 % of the final volume and the fractions were 
stored at - 20 °C until analysis.
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6.2.3 Analysis of fractions 
COBAS analysis
All the fractions from each time-point were analysed for TAG, total cholesterol and apo B 
according to the methods described in Section 2.6.1, 2.6.2 and 2.6.7 respectively.
Retinyl ester analysis
The RE concentration in all the fractions isolated from the 4 and 8  hour time-point 
samples was measured using normal phase HPLC as detailed in Section 2.7.2. RE was 
measured in only 4 of the subjects.
Apo B-48 analysis by immunoblot
The presence of apo B-48 in the fractions was determined by the immunoblotting 
technique described in Section 2.4 using HRP-labelled anti-rabbit IgG as secondary 
antibody. The ranges of protein loaded in each well for the fractions were: 3.7 - 5.9 qg 
(VLDL and IDL fractions); 40 - 63 p,g (LDL fractions). An example of the levels of apo 
B-48 obtained in each lipoprotein fraction at one time-point from two of the subjects is 
shown in Figure 6.3.2.
Apo B-48 analysis by ELISA
The concentrations of apo B-48 in each fraction were detemiined by the specific ELISA 
method described in Section 2.5.
6.2.4 Presentation of results
The pattern of results for each of the subjects were similar therefore, for clarity, the 
results are presented showing the mean values for 5 subjects for the 0 and 4 hour time- 
points and 4 subjects for the 8 hour time-point (except the RE results where the mean of 4 
subjects is shown for each time-point). Figures 6.3.3 to 6.3.5 show the data for the 
markers of CM particles graphically. The SD are not shown on the graphs but are 
indicated in the Tables. Due to the low number of subjects and the differences between 
their characteristics no statistical analyses were carried out on the data for the CM 
markers. Statistical analysis was used only for the TAG data to investigate whether the 
lipoprotein fractions isolated by the 2  methods were of comparable particle composition. 
In order to compare the VLDL fractions from the two methods the levels of each 
component in the VLDLi and VLDL2 isolated by DGUC were added together to give the 
level in the total VLDL (Sf >20) and allow comparison with the d <1.006 g/ml fraction.
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6.3 RESULTS
6.3.1 SUBJECT CHARACTERISTICS
The characteristics of the five subjects are shown in Table 6.3.1. The age range was large 
in the group. Subject 5 was a volunteer with NIDDM, his fasting TAG fell within the 
normal range and his postprandial TAG response was in the same range as the other 
subjects (Figure 6.3.1). The total cholesterol level of subject 5 was high which caused the 
mean total cholesterol for the whole group to be on the borderline of the normal and 
moderately elevated concentration (defined as 5.2 mmol/1) (Table 6.3.3).
Table 6.3.1 Characteristics of the subjects
Subject Age Sex Body Mass 
Index
Fasting TAG 
(mmol/1)
NIDDM?
1 32 M 24.7 1.36 No
2 25 M 2 1 .0 0.74 No
3 57 M 26.9 1.60 No
4 24 F 22.7 1.25 No
5 56 M 24.8 1.04 Yes
iEÎ
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Figure 6.3.1. Postprandial plasma-TAG responses to a high (80 g) fat meal in each of the 
five subjects. A, subject 1: a, subject 2: x, subject 3: o, subject 4: ■, subject 5.
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Western Blot Analysis of Apo B-48 in Lipoprotein Fractions
Apo B-48
unknownprotein
B
Western Blot Analysis of Apo B-48 in Lipoprotein Fractions
Apo B-48
unknownprotein
Figure 6.3.2. Examples of apo B-48 bands measured by the immunoblotting technique in 
the lipoprotein fractions. A) shows the apo B-48 bands in each lipoprotein fraction 
isolated by DGUC (cumulative) and SFUC (sequential) at the 4 hour time-point from 
subject 3. B) shows the apo B-48 bands in each lipoprotein fraction isolated by DGUC 
(cumulative) and SFUC (sequential) at the 8 hour time-point from subject 5.
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6.3.2 POSTPRANDIAL PATTERNS OF THE MARKERS FOR CM PARTICLES
6.3.2.1 APOLIPOPROTEIN B-48 (IMMUNOBLOTTING)
Figure 6.3.3 shows the mean apo B-48 patterns of the 5 subjects in the lipoprotein 
fractions isolated from 0, 4 and 8 hour plasma by the two different methods of 
ultracentrifugation (DGUC and SFUC). Apo B-48 was detected in the LDL fraction 
isolated by both SFUC and DGUC in the fasting and postprandial states.
There was a difference in the distribution of apo B-48 in the corresponding fractions 
isolated by the two different methods (Table 6.3.2). There was between 4 and 5 times 
more apo B-48 in the IDL fraction (d <1.019 g/ml) isolated by SFUC than in the IDL 
fraction (Sf 12-20) isolated by DGUC at each time-point. There was also between 3 and 
4 times more apo B-48 in the LDL fraction (d <1.063 g/ml) isolated by SFUC than in the 
LDL fraction (Sf 0-12) isolated by DGUC at each time-point. The level of apo B-48 in 
the VLDL fractions (d <1.006 g/ml and Sf >20) isolated by the 2 methods was similai*. 
The approximate total percentage of apo B-48 in the fractions isolated by DGUC was 5 % 
in the LDL, 7-22 % in the IDL and 72-89 % in the VLDL. The approximate total 
percentage of apo B-48 in the fractions isolated by SFUC was 8-14 % in the LDL, 38-41 
% in the IDL and 37-55 % in the VLDL.
There was also a difference in distribution in the lipoprotein fractions over time. Using 
DGUC the majority of the apo B-48 was found in the VLDL2 size range (Sf 20-60) in the 
fasting state, postprandially using this method there was a large increase in apo B-48 in 
the VLDLi and CM fraction (Sf >60). No large changes were seen in the apo B-48 levels 
in die other fractions isolated by DGUC in response to the meal.
Using SFUC the majority of the apo B-48 was found in the IDL (d <1.019 g/ml) fraction 
in the fasting state. Postprandially there was an increase in the apo B-48 level in the 
VLDL (d<1.006 g/ml) fraction using this method.
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Figure 6.3.3. Apo B-48 levels (expressed as a percentage of the ODsso of a standard) 
measured by immunoblotting in lipoprotein fractions isolated by A) density gradient 
ultracentrifugation and B) sequential flotation ultracentrifugation. Apo B-48 levels in 
each fraction isolated from the 0  hour plasma are represented by D, in each fraction 
isolated from the 4 hour plasma by 0 ,  and in each fraction isolated from the 8 hour 
plasma by I.
For the 0 and 4 hour time-points each bar shows the mean apo B-48 level for 5 subjects, 
and for the 8 hour time point each bar shows the mean for 4 subjects.
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6.3.2.2 APOLIPOPROTEIN B-48 (ELISA)
Figure 6.3.4 shows the apo B-48 patterns in the lipoprotein fractions isolated from 0, 4 
and 8  hour plasma by the two different methods of ultracentrifugation (DGUC and 
SFUC) measured by ELISA. There was a difference in the apo B-48 concentrations in 
the corresponding fractions isolated by the two different methods (Table 6.3.2). There 
was between 4 and 5 times more apo B-48 in the VLDL (Sf >20) fractions isolated by 
DGUC than in the VLDL (d <1.006 g/ml) isolated by SFUC. The levels of apo B-48 in 
the IDL and LDL fractions were similar when isolated by both methods. The 
approximate total percentage of apo B-48 in the fractions isolated by DGUC was 
19-33 % in the LDL, 9-19 % in the IDL and 49-72 % in the VLDL. The approximate 
total percentage of apo B-48 in the fractions isolated by SFUC was 37-52 % in the LDL, 
27 % in the IDL and 21-35 % in the VLDL.
Using DGUC the majority of apo B-48 was found in the LDL fraction in the fasting state. 
Postprandially the increase in apo B-48 levels occurred in the VLDLi plus CM fraction 
(Sf >60). No large changes were noted in the apo B-48 levels postprandially in the other 
fractions.
Using SFUC the majority of the apo B-48 was found in the LDL fraction in the fasting 
state. Postprandially there were increases in the apo B-48 levels in the VLDL plus CM 
fraction (d <1.006 g/ml) but the majority of the apo B-48 was found in the LDL fraction 
at all time-points after SFUC.
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Figure 6.3.4. Apo B-48 concentration measured by ELISA in lipoprotein fractions 
isolated by A) density gradient ultracentrifugation and B) sequential flotation 
ultracentrifugation. Apo B-48 levels (pg/ml) in each fraction isolated from the 0 hour 
plasma are represented by □ , from the 4 hour plasma by and from the 8 hour plasma 
by I.
For the 0 and 4 hour time-points each bar shows the mean apo B-48 level for 5 subjects, 
and for the 8 hour time point each bar shows the mean for 4 subjects.
218
6.3.2.3 RETINYL ESTER
Figure 6.3.5 shows the RE patterns in the lipoprotein fractions isolated from the 4 and 8 
hour plasma by two different methods of ultracentrifugation (DGUC and SFUC) The RE 
concentrations were similar in the fractions isolated by the two different methods. Most 
of the RE was found in the VLDL plus CM fraction using both methods. The higher RE 
concentration occurred at the 8 hour time-point in all the fractions isolated by both 
methods. RE was found in the LDL fractions at 4 and 8 hours postprandially. The levels 
of RE found in each fraction at the 4 and 8 hour time-points are shown in Table 6.3.2.
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Figure 6.3.5. Retinyl ester concentrations in lipoprotein fractions isolated by A) density 
gradient ultracentrifugation and B) sequential flotation ultracentrifugation. RE levels in 
each fraction isolated from the 0  hour plasma are represented by □ , in each fraction 
isolated from the 4 hour plasma by and in each fraction isolated from the 8 hour 
plasma by M.
For all the time-points each bar shows the mean RE concentration fpr 4 subjects.
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Table 6.3.2. Concentrations of retinyl ester and apo B-48 (measured by immunoblotting 
and ELISA) in the lipoprotein fractions isolated by DGUC and SFUC. Values are mean 
± SD for 5 subjects (0 and 4 hour) and 4 subjects (8  hour).
Parameter
DGUC SFUC
0 hour 4 hour 8 hour 0 hour 4 hour 8 hour
Sf>60 d <1.006
Apo B-48 4.0 24.4 1 0 .2 13.4 2 2 .1 17.7
(% std) 3.3 11.9 6.7 10.5 15.1 12.3
Apo B-48 0.67 1.92 1 .0 0 0.23 0.45 0.33
(fig/ml) 0.14 0.81 0.43 0.08 0.18 0.04
RE - 2.39 3.61 - 2.44 4.73
(qg/ml) 3.77 1.35 3.75 2.34
Sf 20-60
Apo B-48 7.1 8.4 7.2
(% std) 4.0 6.2 4.6
Apo B-48 0.38 0.42 0.33
(|Lig/ml) 0.11 0.09 0.11
RE - 0 .1 1 0.48
( i^g/ml) 0.14 0.66
Sf 12-20 d <1.019
Apo B-48 3.4 2.5 2 .6 17.8 15.3 14.1
(% std) 2.1 2.9 2.7 3.6 14.2 5.1
Apo B-48 0.40 0.29 0.32 0.29 0.36 0.33
(|ig/ml) 0.11 0.13 0.12 0.06 0.03 0.05
RE - 0.06 0 .2 0 - 0.16 0.60
(|ig/ml) 0.05 0.04 0.17 0.47
SfO-12 d <1.063
Apo B-48 0.9 1 .6 1 .0 5.1 3.1 3.5
(% std) 0.9 1.2 0.7 3.7 2.4 0.6
Apo B-48 0.70 0.62 0.61 0.56 0.47 0.56
(|ig/ml) 0.22 0.16 0.20 0.06 0.15 0.12
RE - 0.37 0.73 - 0.32 0.72
(|Lig/ml) 0.14 0.35 0.16 0.42
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6.3.3 ANALYSIS OF LIPOPROTEIN FRACTION COMPOSITION
Table 6.3.3 shows the TAG, cholesterol and apo B concentrations in each of the fractions 
isolated by DGUC and SFUC. There was a difference in the distribution of TAG in the 
corresponding fractions isolated by the two different methods. There was between 3 and 
5 times more TAG in the IDL fraction (d <1.019 g/ml) isolated by SFUC than in the IDL 
fraction (Sf 12-20) isolated by DGUC at each time-point. There was a statistically 
significant difference between the level of TAG in the IDL fraction (d <1.019 g/ml) 
isolated by SFUC and the IDL fraction (Sf >12) isolated by DGUC at the 0 hour and 8 
hour time-points {P <0.05 in both cases). The level of TAG in the VLDL fractions (d 
<1.006 g/ml and Sf >20) and in the LDL fraction (d <1.063 g/ml and Sf 0-12) isolated by 
the two methods was similai* and not significantly different.
The approximate total percentage of TAG in the fractions isolated by DGUC was 11-24 
% in the LDL, 4-12 % in the IDL and 66-85 % in the VLDL. The approximate total 
percentage of TAG in the fractions isolated by SFUC was 11-23 % in the LDL, 18-29 % 
in the IDL and 48-68 % in the VLDL.
There was an increase in the TAG concentration postprandially in the VLDL plus CM 
fraction after both methods. No large changes in the TAG concentration occurred in the 
other fractions, although in the IDL fraction (Sf 12-20) the TAG concentration decreased 
slightly postprandially, whilst in the IDL (d<1.019 g/ml) the TAG concentration 
increased slightly 4 hours after the meal then decreased below fasting level 8 hours after 
the meal.
There was a small increase in cholesterol in the VLDL plus CM fractions and a decrease 
in the cholesterol level in the LDL fractions 4 hours after the meal after both methods. 
No changes in the cholesterol concentrations in the other fractions occurred. A similar 
pattern was observed for the apo B concentrations.
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Table 6.3.3. Concentrations of TAG, total cholesterol and apo B in the lipoprotein
fractions isolated by DGUC and SFUC. Values are mean ± SD for 5 subjects (0 and 4
hour) and 4 subjects (8 hour).
Parameter
DGUC SFUC
Ohour 4 hour 8 hour 0 hour 4 hour 8 hour
Sf>60 d <1.006
TAG 0.40 1.19 0.66 0.44 1.14 0.73
(mmol/I) 0.21 0.61 0.56 0.29 0.70 0.58
Cholesterol 0.07 0.12 0.05 0.20 0.26 0.18
(mmol/1) 0.05 0.09 0.06 0.10 0.10 0.11
Apo B 0.01 0.04 0.03 0.05 0.11 0.05
(g/1) 0.01 0.03 0.02 0.03 0.03 0.03
Sf 20-60
TAG 0.15 0.16 0.12
(mmol/1) 0.06 0.03 0.06
Cholesterol 0.09 0.09 0.10
(mmol/1) 0.03 0.04 0.07
Apo B 0.03 0.03 0.03
(g/1) 0.00 0.01 0.02
Sf 12-20 d <1.019
TAG 0.10 0.06 0.05 0.27 0.34 0.21
(mmol/1) 0.04 0.03 0.09 0.14 0.29 0.06
Cholesterol 0.24 0.20 0.24 0.20 0.19 0.18
(mmol/1) 0.13 0.07 0.11 0.07 0.10 0.09
Apo B 0.06 0.05 0.06 0.05 0.05 0.04
(g/1) 0.03 0.02 0.03 0.03 0.03 0.03
SfO-12 d <1.063
TAG 0.20 0.17 0.20 0.21 0.19 0.22
(mmol/1) 0.05 0.06 0.06 0.04 0.04 0.06
Cholesterol 2.46 2.39 2.47 2.74 2.54 2.74
(mmol/1) 0.79 0.85 0.98 0.91 0.86 0.99
Apo B 0.70 0.62 0.68 0.72 0.70 0.71
(g/1) 0.12 0.16 0.22 0.18 0.16 0.10
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6.3.4 COMPARISON WITH PLASMA CONCENTRATIONS
Table 6,3.4 shows the concentration of TAG, apo B, cholesterol, ELISA-apo B-48 and 
RE in the plasma before ultracentrifugation (apo B-48 level in plasma could not be 
measured by immunoblotting due to the high total protein content). Table 6.3.5 shows 
the percentage recovery of each of these analytes in the fractions isolated by the two 
methods compared to the plasma level. The recovery was higher for each analyte after 
SFUC compared with DGUC. The recovery was less than 100 % for all analytes except 
the RE for which the recovery was 137 % and 144 % after DGUC and SFUC 
respectively.
Table 6.3.4 Fasting and postprandial levels of TAG, apo B, cholesterol, apo B-48 and retinyl ester in the plasma. Values are means (5D) for 5 subjects (0 and 4 hour) or 4 
subjects (8 hour) except RE results where all values are means (SU) for 4 subjects.
0 hour 4 hour 8 hour
TAG (mmol/1) 1.20 2.21 1.45
0.32 0.66 0.59
CHOLESTEROL (mmol/1) 5.22 5.15 5.12
1.38 1.25 1.42
APO B (g/1) 1.09 1.08 1.09
0.34 0.29 0.31
APO B-48 (|ig/ml) 5.77 6.49 6.32
1.20 1.06 0.60
RETINYL ESTER (|ig/ml) - 1.88 4.29
2.64 3.20
Table 6.3.5 Percentage recoveries of TAG, apo B, apo B-48, cholesterol and retinyl ester 
after ultracentrifugation compared with total plasma. Values are means of the 0, 4 and 8 hour recoveries (except RE results where values are means of 4 and 8 hour recoveries).
% recovery from total plasma concentration 
DGUC SFUC
TAG 71 % 77%
CHOLESTEROL 55% 59%
APOB 71 % 76%
APO B-48 44% 2 0 %
RETINYL ESTER 136% 144%
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6.4 DISCUSSION
The discrepancies between the different methods for measuring CM and CMR particles 
made the data difficult to interpret fully. No clear conclusions can be made about the 
metabolism of CMR as it is not clear which, if any, of the methods provides full and 
reliable data. The apo B-48 and RE results presented in this chapter were therefore taken 
as preliminary, qualitative evidence to indicate the presence of CMR in fractions rather 
than absolute concentrations. The main conclusion that can be drawn from the data 
presented in this chapter is that CMR are present in the small, dense size range i.e. the 
IDL and LDL lipoprotein fractions isolated by both forms of ultracentrifugation in both 
postabsorptive and postprandial plasma. The most conclusive evidence for this is derived 
from the immunoblotting method for detecting apo B-48 after ultracentrifugation. This is 
a novel finding as the majority of literature quote the size range of CMR within the 
VLDL and IDL size range (Weintraub et aL, 1987; Gianturco and Bradley, 1991; Karpe 
and Hamsten, 1995) and is potentially of pathological significance in CAD.
Although the immunoblotting method provides definitive evidence for the presence of 
apo B-48 in the LDL fractions, it is not clear from this data whether CMR ate in fact 
small and dense, or if the presence of apo B-48 in the LDL fractions is an artefact due to 
contamination through lipid of CM or large VLDL sticking to the wall of the 
ultracentrifuge tube. There are three lines of evidence that suggest that the presence of 
apo B-48 in the LDL fractions was not an artefact. Firstly great care was taken to ensure 
that no lipid was left in the tube when aspirating the VLDL and CM fractions and if 
necessary more than the required volume was removed and calculations adjusted. Also 
an additional experiment was carried out whereby the majority of the lipid was removed 
by the normal CM preparation (Section 2.2,2) in a different tube prior to 
ultracentrifugation. The results of analysis of these lipoprotein fractions also indicated 
the presence of apo B-48 in the LDL fractions (results not shown). Thirdly all of the 
subjects were normolipidaemic and apo B-48 was found in the LDL fractions of all the 
postabsorptive LDL fractions even when no lipaemia was evident in the VLDL plus CM 
fraction.
The data from both the ELISA and immunoblotting procedures show a significant 
proportion of the apo B-48 in the IDL and LDL fractions even in the fasting state, 
suggesting that CMR do become small, dense particles. The percentage of apo B-48 
found in the fasted state in the LDL plus IDL fractions after DGUC was 52 % and after 
SFUC was 79 % as measured by ELISA. The percentage of total apo B-48 found in the
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fasted state in the LDL plus IDL fraction after DGUC was 28 % and after SFUC was 
64 % as measured by die immunoblotting technique.
The availability of a specific antisera to apo B-48 and a sensitive technique for 
demonstrating the presence of apo B-48 enabled this investigation to show the presence 
of low concentrations of apo B-48 in the small, dense lipoprotein fractions. Even if the 
presence of apo B-48 in these fractions were an artefact the results from this study 
suggest that apo B-48 is co-isolated with supposedly pure apo B-lOO containing 
lipoproteins and care should be taken when interpreting data from fractions isolated by 
ultracentrifugation. It may be possible to remove the apo B-48 from the LDL fraction by 
a second ultracentrifugation spin of this fraction at the same density. Kotite et ai, (1995) 
reported isolation of pure apo B-lOO after this 'washing' of the LDL fraction by re­
centrifugation. This pure apo B-lOO fraction of high concentration could then be 
ultimately used for checking of the cross-reactivity of the specific antisera in the ELISA 
(Section 4.3.4). However the aim of the present investigation was not to produce a pure 
apo B-lOO fraction.
The results from the two types of apo B-48 analysis suggest that there was a difference 
between the composition of correlating lipoprotein fractions isolated by the two different 
methods of ultracentrifugation. There appeared to be a much larger proportion of apo 
B-48 in the IDL and LDL fractions isolated by SFUC than in the IDL and LDL fractions 
isolated by DGUC. This difference between the two methods of ultracentrifugation was 
also indicated by the TAG results which showed that there was significantly more TAG 
in the IDL fraction isolated by SFUC than in the IDL fraction isolated by DGUC. No 
significant differences were noted between the TAG levels in the two VLDL fractions 
(d <1.006 g/ml and Sf >20) or in the LDL fractions (1.063 g/ml and Sf 0-12), nor between 
the cholesterol and apo B concentrations in any of the fractions. The difference between 
the two methods of ultracentrifugation is not totally unexpected due to differences in the 
criteria used for separation in the two methods. It is well known that duplicate 
separations cannot merely be achieved by using identical number of total gravity minutes 
in different types of fixed angle rotors (Schumacker and Puppione, 1986). Rotor speed, 
tube angle, the viscosity of the solution and the temperature of spin can all affect the 
separation because the redistribution of the salt during the spin varies with these factors. 
Similarly the DGUC method potentially produces a more sensitive separation of the 
lipoprotein fractions by utilising their rates of migration in a discontinuous density 
gradient. The gradient can be adjusted to allow even more separation of the sub-classes 
within each lipoprotein class. The use of a single density in SFUC to float each particle 
type is not as sensitive. Density ranges are used as a convenient description of the 
lipoprotein classes, however the heterogeneity of all lipoprotein fractions is clear
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(Lindgren et ai., 1972) and adequate separation into these density ranges may not be 
achievable. Small, dense VLDL (Sf 20-60) may not float at a density of 1.006 g/ml and 
may therefore contaminate the IDL fraction, likewise not all IDL may float at a density of 
1.019 g/ml and therefore they may contaminate the LDL fraction. This was tested in a 
separate experiment by another investigator in which the three lipoprotein classes were 
initially separated by SFUC to produce a VLDL, an IDL and an LDL fraction. Each of 
these SFUC fractions were than ultracentrifuged sepaiately using the DGUC method to 
produce a VLDLi, a VLDL2, an IDL and an LDL fraction from each fraction. Analysis 
of the apo B-48 content of these fractions by immunoblotting showed that each 
supposedly pure fraction isolated by SFUC was contaminated with both smaller and 
larger lipoproteins which migrated at different rates in the DGUC system.
The analysis of the chemical composition of each lipoprotein fraction also indicates a 
difference between the two methods, with a higher percentage recovery of TAG, 
cholesterol and apo B being achieved after SFUC. It is not suiprising that the percentage 
recovery was less than 100 % for TAG and cholesterol as other studies have shown that 
approximately 10 % of total TAG and approximately 25 % of cholesterol is found in the 
HDL fraction (Karpe et aL, 1993a). Measurements in an HDL fraction were not made in 
the present study but, if the above assumptions are made, the percentage recovery after 
DGUC is 80 % and the percentage recovery after SFUC is 85 %. These values are 
comparable with other studies (Mackness and Durrington, 1992). The percentage 
recovery of total apo B was unexpectedly low (71 % and 76 %), as these 
ultracentrifugation methods were designed to isolate all the apo B-containing 
lipoproteins. This could be an effect of the automated analysis used for the measurement 
of apo B in the fractions. The principle of the analysis is an immunoturbidimetric 
reaction which is set up to measure the relatively high concentrations of apo B in plasma 
and LDL fractions. The assay conditions had to be altered to measure the very low 
concentrations of apo B in the TGRL fractions and there may have been errors due to the 
lack of sensitivity of the method at this level. The assay was also difficult to use for 
lipaemic samples as this affected the final measurement of turbidity. The very low 
recovery of apo B-48 compared to plasma was probably due, in part, to the problems witli 
measuring apo B-48 in plasma by ELISA described in Chapter 4 i.e. potential interference 
of plasma proteins in the assay.
The results of this study also highlight differences between the methods used for- 
measuring the presence of apo B-48; the specific quantitative ELISA and the semi- 
quantitative immunoblotting technique. There were two main differences between the 
apo B-48 methods. The first discrepancy was the very high concentration of apo B-48 
measured by ELISA in the LDL fractions after both DGUC and SFUC. Figure 6.3.4
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showed that there was apparently more apo B-48 in the LDL fractions than in the VLDL 
and IDL fractions isolated by SFUC. The second discrepancy was the large difference 
between the concentration of apo B-48 measured by ELISA in the VLDL plus CM 
fractions isolated by SFUC compared to DGUC which was not seen using the 
immunoblotting technique. There are several possible reasons for these results which 
need to be investigated experimentally before the full conclusions from this investigation 
can be drawn.
Firstly the difference in the relative concentrations of apo B-48 in the LDL fractions 
measured by the two methods need to be addressed. The data in Section 4.3.4 showed 
that the specific antisera to apo B-48 did not cross-react with apo B-lOO at a 
concentration of 50 p.g/ml, a concentration similar to that found in a VLDL fraction. 
However it was not possible to isolate a pure apo B-lOO sample of a very high apo B-lOO 
concentration similar to that found in an LDL or plasma sample for reasons described in 
Section 4.3 and above. The possibility that there is some cross-reactivity of the specific 
antisera with apo B-lOO if present in very high concentrations (i.e. greater than 
3000 pg/ml as in the concentrated LDL fractions) has therefore not been completely mled 
out. The high concentration of apo B-48 in the LDL fractions measured by ELISA may 
therefore be a reflection of the very high apo B-lOO concentration in these fractions, i.e. 
cross-reactivity of the antisera with apo B-lOO, rather than an absolute apo B-48 
concentration. However there is some evidence to suggest that the levels of apo B-48 
measured by ELISA in the LDL fraction were not false. The indirect validation of the 
ELISA method shown in Section 4.3.9 suggested that there was probably very little cross­
reactivity of the antisera with apo B-100. Also, the pattern of apo B-48 results measured 
by ELISA in the DGUC fractions in the present study showed a strong comparison with 
the RE results (Figures 6.3.4 and 6.3.5 respectively), with the level of RE and apo B-48 in 
the LDL fractions being higher than in the VLDL% and IDL fractions. A possible reason 
why these findings were not confirmed by the immunoblotting method for apo B-48 may 
be due to a methodological problem relating to the LDL fraction. It was noted that a 
precipitate was formed when the LDL fraction was added to the sample buffer prior to 
loading on the gel and that this was not dissolved after heating. This precipitation has not 
been reported by any other investigators (Karpe and Hamsten, 1994; Kotite et aL, 1995) 
although these workers delipidated and diluted the protein in their samples before loading 
on the gel to ensure the protein concentration fell within the linear range of the method. 
It was felt that dilution of the LDL to prevent precipitation would dilute out the apo B-48 
which was already present at very low concentrations. For the purposes of this 
investigation the immunoblotting technique was used as visual method to show the 
presence of apo B-48 in these fractions rather than an absolute amount. In light of both 
the RE and apo B-48 ELISA results it would seem possible that the precipitate in the
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LDL fraction may have prevented some apo B-48 present in the solution from entering 
the gel. If this was the case it would mean that a large proportion (over 25 %) of the apo 
B-48 is present in the very small, dense LDL-size lipoprotein fractions.
The second inconsistency between the two methods was the difference in the apo B-48 
levels measured in the large lipoprotein fractions. Using the immunoblotting method the 
results in the corresponding VLDL lipoprotein fractions were similar after both 
ultracentrifugation methods. Using the ELISA method between 30 % and 60 % of the 
apo B-48 was found in the VLDL plus CM fraction (Sf >60) isolated by DGUC (between 
49 % and 72 % of the total apo B-48 was found in the total VLDL fractions Sf >20), 
whereas after SFUC only between 20 % and 35 % of the apo B-48 was found in the 
VLDL plus CM fraction (d<1.006 g/ml) and the majority of the apo B-48 was found in 
the LDL (d <1.063 g/ml) fraction at each time-point. These results were consistent for 
each subject and have subsequently been confirmed by another investigator. The TAG, 
cholesterol and apo B results were similar in the VLDL fractions isolated by the two 
different ultracentrifugation procedures which suggest that the composition of the 
particles isolated by the two methods were similar. The results therefore suggest that 
there is a difference in the reactivity of the particles in corresponding fractions isolated by 
different ultracentrifugation procedures in the ELISA method. The main difference 
between the VLDL plus CM (Sf>60) isolated by DGUC and the VLDL plus CM 
(d <1.006 g/ml) isolated by SFUC was the length of spinning time. The Sf >60 fraction 
was isolated in 2 hours 25 minutes by DGUC, whereas the d <1.006 g/ml was isolated in 
18 hours by SFUC. A possible explanation for the discrepancy was that a prolonged 
ultracentrifugation time causes the antibody recognition site of the apo B-48 (the charged 
carboxyl terminus) to be masked so that an artificially low level of apo B-48 is measured. 
However if this were the case this would have implications for the other lipoprotein 
fractions all of which had been in the ultracentrifuge for very long periods of time and 
would suggest that the apo B-48 level measured in these fractions was also questionable. 
The other difference between the two fractions is that SFUC uses a mixture of KBr and 
NaCl to produce the required density, whereas DGUC uses a mixture of NaBr and NaCl. 
This difference in solute would not be expected to have any effect on the reactivity of apo 
B-48 with the antibody. This difference between the apo B-48 levels in the VLDL 
fractions is therefore difficult to explain. A potential method to overcome any adverse 
effects of ultracentrifugation would be to separate different sized lipoproteins by a gentler 
method such as gel filtration chromatography (Mai'z et aL, 1993) and then measure the 
apo B-48 levels in each of the fractions collected.
It is not clear from these results whether the reactivity of the antibody with lipoproteins of 
different sizes is the same. There may be an effect of lipid masking or changes in protein
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conformation on the antibody binding which may affect the results of both the gel and 
immunoblotting system as well as the ELISA. Poapst et al. (1987) noted that the relative 
chromogenicity of both apo B-100 and apo B-48 on a polyacrylamide gel decreased with 
decreasing particle size (increasing density). The authors suggested two possible 
interpretations for this observation: Differences in chromo genicity may reflect
i) differences in organisation of the apo B molecule on the lipoprotein in vivo and
ii) differences in the level of delipidation of different size paiticles by the SDS system. 
Immunological evidence suggests that significant changes in the physical organisation of 
the apo B molecule occurs as a consequence of lipoprotein catabolism. Heterogeneity of 
the immunoreactivity of intact lipoproteins of the VLDL/IDL/LDL cascade with 
monoclonal anti-LDL antibodies has been documented (Tikkanen et ah, 1983; Curtiss 
and Edgington, 1982; Teng et ah, 1985). Differences in epitope expression indicate 
differences in the conformation of apo B on the lipoprotein as it decreases in size. This 
was shown by a number of techniques in both delipidated apo B as well as native 
lipoproteins on a gel and also after immunoblotting delipidated apo B.
Poapst et al. (1987) suggested that there appears to be some analogy between the 
differences of interaction of apo B from different lipoprotein fractions with dye in a gel 
and the interactions of different size native lipoproteins with antibodies. It has been 
shown that apo B is not denatured to random secondary structures even under condition 
of maximal SDS binding as in the sample buffer and apo B has been shown to have 
significant ordered structure when separated on an SDS-gel (Steele and Reynolds, 1979, 
cited in Poapst et ah, 1987). This may affect the binding of antibodies in the 
immunoblotting system for apo B-48 and in the ELISA system. However, even though 
the conformation of the apo B-48 molecule may change with decreasing size of the CMR 
it is possible that this would not affect the antibody binding site of the apo B-48, because 
the charged nature of the carboxy terminal should ensure that the antibody binding 
sequence is always available on the surface of the lipoprotein. More experiments to 
detennine the accessibility of the apo B-48 antibody binding site on CMR of vaiying size 
and lipid content are necessary before absolute concentrations of CMR particles in the 
lipoprotein fractions can be made. A simple experiment would be to incorporate a lipase 
into a CM-enriched fraction and monitor the apo B-48 content of the delipidated 
lipoproteins. The apo B-48 content would remain the same but the delipidation would 
presumably produce a conformational change of the apo B-48 similar to that found in 
vivo during lipolysis by LPL.
Approximately 12 % of the RE in the lipoprotein fractions was found in the LDL fraction 
4 and 8 hours after the meal. This is in agreement with other studies (Krasinski et ah, 
1990a; Demacker et ah, 1992), however most other studies suggest that contamination of
230
the small lipoprotein fractions with RE does not occur until the late time-points (9 hours 
or more). The presence of RE in the LDL fraction 4 hours after the meal may be due to 
various reasons, including: contamination of the LDL fraction with large, lipaemic 
particles, transfer of RE from CM to endogenous lipoproteins, delipidation of the CMR to 
form a very small, dense particle or direct entry of very small CM from the enterocyte. 
The results from the analysis of apo B-48 suggest that the RE found in the LDL fraction 
indicated, at least in par t, the presence of CMR in this fraction. Unfortunately the relative 
contributions of RE in the LDL fractions from intestinally-derived lipoproteins, or from 
endogenous lipoproteins through transfer from CMR could not be determined due to the 
problems with the apo B-48 methods. Also, because the relative numbers of RE and apo 
B-48 on different size lipoproteins is not clear*, the possibility of contamination by large 
lipaemic lipoproteins could not be determined.
Some work has been carried out by other laboratories to investigate the metabolism of 
apo B-48 and the involvement of CMR in CAD. In a series of clinical trials a conelation 
was observed between the level of apo B-48 in the Sf 20-60 lipoprotein size range and 
small, dense LDL, the latter being a determinant of the rate of progression of CAD, 
(Karpe et aL, 1993b). Karpe et al. (1993a) also showed that the metabolism of CMR is 
severely defective in hypertriglyceridaemic CAD patients compared with 
normolipidaemic controls. Hypertriglyceridaemic CAD patients had no increase in apo 
B-48 in the Sf 20-60 fraction. This was taken as a sign of reduced conversion of large 
CMR to small CMR. Using the same study group a conelation was shown between the 
progress of CAD over a 5-year period with the apo B-48 levels in the Sf 20-60 lipoprotein 
fraction (i.e. the number of intestinal particles in the small TGRL fraction) (Kaipe et al., 
1994). From these results Kaipe and Hamsten (1995) have suggested that CMR interfere 
with the metabolism of cholesterol-enriched lipoproteins which results in a potentially 
atherogenic situation and are not directly atherogenic particles.
In conclusion this study has provided preliminary evidence for the presence of small, 
dense CMR in both the fasting and postprandial plasma of normolipidaemic individuals. 
This was shown through the availability of a highly specific antisera to apo B-48, which 
may explain why other groups have not reported the presence of CMR in the small, dense 
size ranges. As expected from the results in Chapter 4, the two different methods of 
ultracentrifugation produced slightly different results suggesting that the composition of 
lipoprotein particles in fractions isolated by sequential flotation in a fixed angle rotor are 
not comparable to fractions isolated using a discontinuous density gradient in a swing out 
rotor.
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The pathological significance of small, dense CMR is unclear. The work in this Chapter 
was only sufficient to indicate the presence of CMR. The metabolic implications of this 
finding were beyond the scope of the work at this time. It is, however, possible to 
speculate on the significance of this finding. Small, dense CMR may directly infiltrate 
the arterial endothelium, leading to lipid deposition and contributing to the progression of 
atherosclerosis. Alternatively CMR of a size and density similar to LDL particles may 
interfere with the metabolism of these endogenous lipoproteins and thus indirectly 
contribute to CAD. Further work is needed to determine the metabolic origin of these 
remnant particles, to determine their metabolic interactions with other atherogenic 
lipoproteins and to characterise their distribution in health and disease.
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CHAPTER SEVEN GENERAL DISCUSSION
7. GENERAL DISCUSSION
Cardiovascular disease has become one of the major causes of death in Western 
countries. The role of LDL and HDL in the process of atherogenesis is now well 
established, but the role of plasma-TAG, especially in the postprandial state, has been 
largely overlooked until more recent yeai'S. The possible involvement of postprandial 
lipoproteins in the pathogenesis of atherosclerosis was first postulated in a paper by 
Zilversmit in 1979. In this theory Zilversmit proposed that CMR could be directly 
atherogenic and infiltrate the arterial endothelium in a similar manner to LDL. In 
response to this paper, interest grew in postprandial lipaemia, its role in CAD and 
investigation into factors which may affect the level of lipaemia after a meal. During 
these investigations a further theory was postulated for the role of postprandial 
lipoproteins in CAD. Patscli and his group (1992) proposed that CMR were not 
atherogenic particles within themselves, but their interactions with other endogenous 
lipoproteins created an atherogenic state. In this theory a long residence time of CMR in 
the circulation could lead to TAG-enrichment of HDL, increasing its metabolism and 
uptake and thus reducing the level of this so-called "anti-atherogenic" particle.
It has frequently been shown that physical exercise is linked to a lower risk of CAD. 
Studies in the postabsorptive state have shown lower levels of LDL-cholesterol and 
higher levels of HDL-cholesterol in more active subjects. Some studies have investigated 
the effect of exercise on postprandial lipaemia, but most of these have looked at plasma- 
TAG levels. To provide more information on the effects of exercise on postprandial 
lipoprotein metabolism, a CM-enriched fraction was isolated which contained most of the 
large CM and some large VLDL particles. The level of TAG measured in this CM- 
enriched fraction would therefore be a measure of TAG of both hepatic and dietary 
origin. The one discriminating feature between lipoproteins of hepatic and dietary origin 
is the form of apo B on these particles. Apo B-48 is uniquely found on lipoproteins 
carrying dietary lipids. The availability, in our group, of a specific antisera to apo B-48 
allows the metabolism of exogenous lipid to be followed. The majority of studies on 
postprandial lipaemia had used RP as a marker of CM and CMR. In order to gain a fuller 
picture of CM metabolism, both apo B-48 and RP were used in the studies on 
postprandial lipaemia in this thesis. At the time of the study on exercise in Chapter 3, the 
analysis of apo B-48 was carried out following protein separation by SDS-PAGE, using a 
specific immunoblotting method developed in our laboratory (Peel et a l, 1993). There 
were various disadvantages with this method. These included that i) the procedure was 
long and complicated, ii) the assay CVs were high, iii) most plasma proteins had to be 
removed before the samples could be run on the gel and so only CM-enriched or
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lipoproteins isolated by ultracentrifugation could be analysed, iv) it was not possible to 
process many samples in one day and v) no standard curve could be run on the gel so that 
the results were only semi-quantitative. However despite these difficulties, the method 
allowed more extensive measurements of apo B-48 than had previously been achieved by 
other groups.
In Chapter 3 the aim of the study was to investigate the effects of habitual exercise on the 
lipaemic response to a test meal. The main aim of this study was to look at the effects of 
a relatively low level of exercise (approximately 3 sessions a week) which would be 
achievable by the majority of the general public. The results of this study showed that the 
active subjects had lower responses to a test meal in all parameters measured when 
compared with the inactive group. In response to meals containing 20 g, 40 g and 80 g of 
fat, the active subjects had lower CM-apo B-48-AUC than the inactive group by 35 %, 
58 % and 66 % respectively, lower CM-TAG-AUC by 45 %, 42 % and 28 % respectively 
and lower CM-RP-AUC by 67 %, 54 % and 49 % respectively. The subjects were 
matched in all characteristics except for their habitual exercise levels in order to eliminate 
any confounding factors in the study. This study showed that, even at a young age 
(18-24 years), the importance of exercise as a protective mechanism against CAD is 
apparent.
It has been suggested that there may be a genetic factor involved in the effect of exercise 
obseiwed in cross-sectional comparisons between active and inactive individuals such as 
in the present study i.e. the "HDL-cholesterol and triglyceride concentrations observed in 
cross-sectional studies may partially reflect the tendency of people with this initial lipid 
pattern to take up running and other endurance activities" (Williams et al, 1982). It 
would have been interesting to train the inactive subjects in the present study to the 
government guidelines of 3 sessions of 30 minutes a week to see if this had any effect on 
the postprandial lipaemic responses. This may help to establish whether individuals who 
are active chose to do so because they have a protective genetic makeup in the first place, 
or if exercise has an independent beneficial effect on lipid levels.
The second aim of the study in Chapter 3 was to investigate the effects of varying meal 
fat content on postprandial lipaemia. As the two groups obviously had different 
responses when compared with each other, the effects of meal fat content was 
investigated in the two groups separately. There was an increase in the AUC for all the 
parameters with increasing fat content (20 g, 40 g and 80 g) in the inactive group, and in 
the TAG and RP AUC for the active group, however the increase was not directly 
proportional to the increase in fat in either group. This suggests that the mechanisms 
involved in postprandial lipid metabolism can be increased to maintain lipid homeostasis.
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This possibility was supported by the increase in LPL activity with increasing fat load. 
The most intriguing findings from this aspect of the study were the apo B-48 AUC 
results. In the inactive group the apo B-48 AUC increased with increasing fat load, but in 
the active group the apo B-48 AUC remained constant after each meal, despite the 4-fold 
increase in fat content of the meal. This result suggested that the active group dealt with 
an increase in fat entry into the enterocyte by increasing the size of the CM to be secreted. 
On the other hand the inactive subjects appeared to deal with an increase in fat entry into 
the enterocyte by increasing the number of CM to be secreted and maintaining the same 
size of CM. If this were the case this appears to be a beneficial adaptation in the active 
group as larger TGRL are preferentially hydrolysed by LPL (Karpe et a l, 1993a). 
However the calculation of AUC is a measure of a number of steps in postprandial 
lipaemia including rate of fat absorption, secretion of CM, LPL hydrolysis and CMR 
uptake. The LPL activity results indicate that the active subjects had a higher rate of 
hydrolysis of CM-TAG, although it is not clear whether this increase is sufficient to 
explain the constant apo B-48 AUC with increasing fat load. Clearly the question as to 
whether there is an increase in size and/or number of CM with increasing fat load is 
important to answer. Early studies with the light microscope after meals of different 
composition indicated that there was an increase in CM number after a fat meal (Gage 
and Fish, 1929). More recent studies of infused lipid emulsion in the rat indicated that 
the number of CM released from the intestine remains constant during fasting or active 
lipid uptake and transport (Hayashi et a i, 1990), i.e. the size of the CM particles increase 
in response to lipid absorption. The use of the apo B-48 antisera should allow the 
questions relating to CM synthesis and secretion to be investigated more fully.
In order to investigate CMR metabolism more fully it would be useful to study apo B-48 
levels in the d >1.006 g/ml fraction i.e. in the infranatant remaining after the removal of 
the CM-enriched fraction. The results of the exercise study were interesting but 
interpretation of the apo B-48 results was limited by the lack of measurements in the 
infranatant fraction and plasma. The limitations of the immunoblotting method for this 
aspect of postprandial studies is obvious. The immunoblotting method was the first 
convenient method for semi-quantitative analysis of apo B-48 in our laboratory. In order 
to measure a greater number of samples, more rapidly and accurately and in all fractions 
of plasma it was important to develop a more specific immunoassay. An ELISA assay 
for the specific analysis of apo B-48 in CM-enriched fractions had been developed by a 
post-doctoral colleague. However the specificity of the assay for apo B-48 and its 
application for plasma and infranatant samples had not been fully determined. The aim of 
the research in Chapter 4 was to validate the specificity of the existing ELISA assay for 
apo B-48 on intact lipoproteins and to examine its use for plasma and infranatant samples
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by investigating cross-reactivity with apo B-lOO and interference of other plasma 
proteins.
Although it was clear from the immunoblotting method that the antisera did not cross- 
react with the denatured apo B-lOO, it was not clear whether this would also be the case if 
native apo B-lOO was present on the intact lipoprotein particles. The apo B-48 antisera 
was raised to a short sequence of amino-acids at the negatively-charged C-terminal end of 
apo B-48 and the corresponding sequence is in a hydrophobic region in apo B-lOO, which 
should be buried in the lipoprotein paiticle and therefore inaccessible to the antibodies. 
However there was a high level of scepticism from other groups concerning the 
possibility of raising an antisera to apo B-48 which did not cross-react with apo B-100. 
Therefore this assumption of a lack of cross-reactivity with apo B-100 in the ELISA 
assay had to be proved. This was especially important for the application of the ELISA 
for plasma and infranatant samples where apo B-100 was present at a concentration 
between 100-1000 times greater than that of the apo B-48.
The first aim of the research in Chapter 4 was to produce a pure, concentiated sample of 
apo B-100. Two methods were used to achieve this aim, ultracentrifugation and 
immunoaffinity chromatography, as both had been used successfully by other groups to 
isolate apo B-100 containing lipoproteins. Neither of these methods were particularly 
successful in our hands. It was impossible to produce a pure apo B-100 containing 
sample using sequential flotation ultracentrifugation, even when a very narrow density 
range of 1.050 - 1.070 g/ml was used. This was unexpected in light of other research 
(Kai'pe and Hamsten, 1994; Kotite et al., 1995), but may be explained by the fact that 
these groups investigated the presence of apo B-48 in lipoprotein fractions by using 
Coomassie-stained SDS-PAGE. This method is not very sensitive and levels of apo B-48 
lower than 0.2 jig/ml could not be detected. The availability of an antisera to apo B-48 
allowed the presence of apo B-48 to be seen in the LDL fractions isolated by 
ultracentrifugation in Chapter 4. This finding in itself led to a separate investigation into 
the size and density distribution of apo B48 containing lipoproteins in plasma described 
in Chapter 6. Although a pure sample of apo B-lOO-containing particles was isolated 
successfully by immunoaffinity chromatography (as demonstrated by immunoblotting), 
the concentration of apo B-100 was relatively low (50 qg/ml) and attempts to concentrate 
the sample were unsuccessful. This pure sample of apo B-100 was used to show that 
there was no cross-reactivity in the ELISA with apo B-100 at a concentration of 
50 qg/ml, the level of apo B-100 found in a normal CM-enriched sample, however the 
level of apo B-100 in plasma is between 450 to 1500 qg/ml so that this sample was not 
adequate for assessing the potential cross-reactivity of the antisera with apo B-100 
present at these higher concentrations. Because of this, alternative methods were used to
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provide evidence that there was no cross-reactivity with apo B-100 in plasma and 
infranatant samples. Analysis of apo B-100 and apo B-48 patterns obtained from a 
Coomassie-blue stained gel showed that there was no correlation between the 
postprandial apo B-100 pattern and the pattern obtained from the ELISA, whilst there was 
a significant, positive correlation between the apo B-48 pattern and the ELISA pattern. 
There was also no correlation between the total apo B pattern measured by COBAS and 
the pattern from the ELISA. In order to produce a pure, concentrated apo B-100- 
containing lipoprotein sample the most convenient method appears to be 
ultracentrifugation because immunoaffinity chromatography requires too much dilution 
of the sample. If the presence of apo B-48 in the LDL fraction were due to contamination 
from large, lipaemic lipoproteins sticking to the tube walls, experimentation to produce 
an LDL fraction (d= 1.050-1.070 g/ml) as described in Chapter 4 and then 
re-ultracentrifugation of the LDL fraction at a density of 1.050 g/ml to float the large 
lipoproteins may produce an uncontaminated apo B-100 sample. Alternatively, if apo 
B-48 containing particles are present in the LDL fraction, as indicated by the results in 
Chapters 4 and 6, it may prove very difficult to isolate a pure, concentrated apo B-100 
containing lipoprotein sample by ultracentrifugation.
During the validation of the ELISA, it was noted that the apo B-48 levels in the 
infranatant measured by ELISA were up to 25 times higher than the apo B-48 measured 
in the postprandial CM-enriched fractions. This was an interesting finding as work by 
others had shown that there was less than 10 times the amount of apo B-48 in the "CMR" 
fractions (Sf <400) compared with the "CM" fractions. At the same time it was noticed 
that there was some reactivity with proteins smaller than apo B-48 on the immunoblot. 
This additional reactivity was attributed to non-specific binding from the secondary 
antibody. It seemed possible that the results obtained by ELISA for the plasma and 
infranatant samples may be artificially high due to interference with other plasma proteins 
which are not present in the CM-enriched fraction to such a great extent. Despite 
numerous, extensive tests on the ELISA to investigate the interference of other plasma 
proteins in the ELISA, varied and inconclusive results were obtained. More work needs 
to be done to investigate potential interference with other plasma proteins in the ELISA 
for apo B-48. The most promising result obtained during the validation tests were with 
the antisera to apo B-48 conjugated directly to HRP, eliminating the need for a secondary 
antibody to IgG. Using this affinity-purified antisera there was no binding to any protein 
other than apo B-48 on the immunoblot. Unfortunately the process of affinity purifying 
the antisera caused a laige dilution factor and the antisera did not produce an adequate 
standard curve when used on the ELISA. However further work to concentrate this 
antisera to apo B-48 conjugated directly to HRP may prove beneficial.
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It was believed that, if there was any interference in the ELISA from plasma proteins, this 
was likely to produce a relatively constant background level and any changes in apo B-48 
levels would be seen overlaid on the background. Therefore for the study on the effects 
of meal frequency on postprandial lipaemia, maikers for CM paiticles were measured in 
all fractions. The study in Chapter 5 was designed to highlight changes in lipid 
metabolism in response to meal frequency by using a high fat test meal challenge. 
Differences in the AUC and time to peak for the various parameters after the meal would 
indicate alterations in the lipid metabolic capacity caused by altered meal frequency. 
Fasting lipid levels (total cholesterol, HDL- and LDL-cholesterol, fasting TAG and 
fasting insulin) were measured to provide a comparison between the present study and 
previous studies. In contrast to other published studies, no significant differences were 
seen between these parameters after any of the meals. There aie several limitations to the 
study which may have prevented similar effects to other studies (Jenkins et a l, 1989) 
being seen. The use of young women may not be appropriate in a study of this kind, as it 
is well documented that women have a lower lipaemic response to a meal than men, and 
younger subjects also have a lower lipaemic response to a meal than older subjects. 
Women also have higher HDL-cholesterol, lower LDL-cholesterol and lower insulin 
concentrations than men. Therefore any potential benefits of the meal frequency on lipid 
metabolism, as seen in other studies of middle-aged men, may not occur in an already 
high capacity system. The length of the intervention periods may also have been too 
short (2 weeks) to produce adaptations. However this is unlikely as previous studies 
showed changes in fasting lipid paiameters after a 2 week intervention period (Gwinup et 
al., 1963; Jenkins et al, 1989). There were, however, some interesting significant results 
in this study, from which it was felt possible to speculate on possible alterations in 
processes involved in lipid metabolism produced by changes in meal frequency. There 
was a significantly higher NEFA-AUC in the later postprandial period (240-480 minutes) 
after the nibbling diet compared to the normal diet and there was also a significantly 
higher LPL activity after the nibbling diet compared to the noiinal diet. The higher LPL 
activity could have caused an increase in the rate of hydrolysis of CM-TAG resulting in 
an increase in the level of NEFA which may not be taken up by the adipose tissue and 
thus builds up in the circulation. There were also some significant differences in the 
infranatant fraction from which it was speculated that there may be alterations in 
enterocyte processing of dietary lipids into CM so that the enterocyte produces more, 
smaller CM in response to a high fat meal which may be released directly into the size 
range in the infranatant fraction. However, as with the exercise study results, it is 
difficult to make conclusions about site-specific events from a measurement (AUC) 
resulting from several metabolic stages.
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Studies of subjects on the last day of an intervention period of nibbling or gorging have 
shown lower TAG and insulin AUC during the day on a nibbling diet compaied with a 
gorging diet of the same amount of calories. It would be interesting to look at apo B-48 
levels throughout the day on a nibbling or gorging diet to see whether reductions in apo 
B-48 levels throughout the day occur. This may be of clinical significance as lower apo 
B-48 levels in the circulation would mean a reduction in the time of exposure of the 
arterial wall to potentially atherogenic CMR particles. It would be interesting to repeat 
the study using post-menopausal women or middle-aged men as subjects, to investigate 
the effects of meal frequency on lipid metabolism. It would also to be interesting to look 
more closely at site-specific events occurring in the adipose tissue or enterocyte.
Both the postprandial studies in this thesis have indicated that changes may be occurring 
in the enterocyte which would be interesting to investigate further. More specific 
investigation of the processes occurring in the enterocyte (possibly by cell culture 
studies), or in the adipose tissue (possibly by adipose tissue perfusion) may provide more 
information on the effects of altered meal frequency. The availability of the antisera to 
apo B-48 should allow more specific analysis of processes in the enterocyte. Also, 
measurements of apo B-100 levels would prove useful to build up a fuller picture of 
effects of various factors on metabolic processes.
Although the results in Chapter 6 were difficult to interpret, the clear conclusion from this 
study was that apo B-48 containing lipoproteins are co-isolated with small, dense apo B- 
100 containing lipoproteins. Whether this is due to CMR being small and dense or 
whether these results were artefacts from lipaemic lipoproteins is unclear, however the 
results in normolipidaemic postabsorptive plasma indicate that some CMR do attain a 
size and density similar to LDL particles. This could be further investigated by 
subfractionation of plasma from an individual after a 48 or 72 hour fast. The presence of 
apo B-48 in the LDL fraction of plasma after an extended fast would validate the results 
of the study in Chapter 6 and discount the possibility of contamination from larger, 
lipaemic lipoproteins.
The presence of CMR in the small, dense size ranges has implications for the "Zilversmit 
hypothesis" proposing a direct role of CMR in atherogenesis. This would also indicate 
the importance of factors such as exercise, meal frequency and diet in lowering the 
circulating level of postprandial lipoproteins. There are other possible implications for 
CAD, for example if small, dense CMR were to interfere with the metabolism of 
endogenous lipoproteins, LDL and HDL, through interactions with other components of 
lipid metabolism such as CETP and HL. The metabolic inter-relationships of CMR with
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other lipoproteins and proteins involved in lipoprotein metabolism need to be studied to 
provide a more detailed view of the importance of postprandial lipaemia in CAD.
In Chapter 6, the discrepancy between the results from the ELISA and immunoblotting 
methods for measurement of apo B-48 highlighted other aspects which need to be studied 
in order to further validate the ELISA method. Effects of lipoprotein size and lipid 
content on reactivity in the ELISA need to be assessed, as it is possible that the reactivity 
of the antibody to the apo B-48 may be affected by changes in lipoprotein composition 
during its metabolism.
The presence of apo B-48 in LDL fractions indicates that RE found in these fractions by 
other groups (Demacker et al., 1992) may not be entirely due to transfer by CETP as 
originally believed. The studies in this thesis outlined the differences between RP and 
apo B-48 as markers for CM particles. The time to peak for RE and RP was 2 to 4 hours 
later than for apo B-48 and TAG. This is probably at least paitly due to the type of RP 
used in the studies (an oil-based preparation). A comparison with other studies showed 
that groups using the oil-based preparations of RP always showed a discrepancy between 
the RP and TAG results, whereas those who used an aqueous preparation showed a good 
agreement between the responses. Despite the differences in RE and apo B-48, both have 
proved useful as markers of CM particles in postprandial studies.
The availability of the specific antisera to apo B-48 could enable several of the 
assumptions involved in studies of CM metabohsm to be verified, such as: do CMR enter 
the arterial endothelium?; Is there only one apo B-48 molecule per CM?; do the numbers 
or size of CM increase on feeding a high fat meal? The development of the specific 
ELISA for apo B-48 would also enable the full extent of the effect of exercise on 
postprandial lipoprotein metabolism to be determined. Apo B-48 levels in the plasma and 
infranatant fractions i.e. "the CMR fraction" from this study need to be analysed to 
investigate changes in CMR metabolism.
The main aims of this research were to develop and use a specific immunoassay for apo 
B-48. The existing immunoblotting method was used successfully for CM-enriched 
fractions to show that active subjects have a lower apo B-48 response to a test meal than 
inactive subjects. A more accurate ELISA assay was validated for the CM-enriched 
fraction and used in a postprandial study to investigate the effects of meal frequency. The 
ELISA was also used to show changes in apo B-48 patterns in the plasma and infranatant 
after changes in meal frequency but there is still some doubt as to whether the results 
produced by the ELISA in these fractions correspond to the actual amounts of apo B-48 
present. Finally the question as to the size and density of CMR was addressed. From the
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results it is assumed that a proportion of CMR are present in the small, dense size range, 
however more work is needed to quantify this and to investigate the implications of this 
finding.
In conclusion, the results from this research have provided important information on 
effects of physical and dietaiy factors on the metabolism of dietary-derived lipoproteins. 
The true significance of these effects will be clearer when the contribution of CM and 
CMR to atherogenesis has been conclusively determined. Possibly the most significant 
result from this work in this respect is the finding of apo B-48-containing particles at high 
densities. More extensive measurements of important paiameters in the postprandial state 
and continuation of the subfractionation of plasma aie needed to further this research. 
The availability of the specific antisera to apo B-48 used throughout this research should 
enable many of the questions concerning CMR metabolism to be answered.
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APPENDICES
APPENDIX I: PARAMETER SETTINGS ON THE DENSITOMETRIC SCANNER
PARAMETER REPORT - Shimadzu CS-9001PC
Meth Name 
Operator
: PPB48.2 
: Gail
Date: 4/3/95
Photo Mode : Transmission Scan Type Zig Zag
Scan Mode Normal
Lineai'izer : Off ZZ Width 9
Lamp Mode : Visible BC Smooth 8
Y resolution : 0 .2 0 Zero Mode Off
Wavelength Settings
Wave Mode : Single
Wave : 1 Y Position : 0.0 ram Sample Wvlen ; 550.0 nm
Peak Detection Paiameters
Y Posn 
5.0
Sens Drift Line
100.000 0.500
Min Width
2.000
Min Area 
1000.000
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APPENDIX II - QUESTIONNAIRE TO ASSESS COMPLIANCE OF SUBJECTS 
DURING THE DIETARY INTERVENTION PERIODS AND FEASIBILITY OF THE 
NIBBLING AND GORGING DIETS - See Chapter 5.
1) Please indicate your normal eating pattern
Breakfast, lunch, evening meal
Breakfast, mid-morning snack, lunch, mid-afternoon snack, evening meal, supper
2  meals per day
Snacks throughout the day
Other (please specify)
2) Which meal pattern in the study did you find it easier to follow?
3) Why was this?
4) On the nibbling diet was the quantity of food
Too much 
Too little 
O.K.
5) On the nibbling diet was the quantity of food
Too much 
Too little 
O.K.
6 ) Were die suggested meal plans useful?
7) Any comments on meal plans?
8 ) How convenient did you find each diet
very inconvenient very convenient
9) How hungry were you on each diet
very hungry not at all hungry
10) How compliant do you feel you were with each diet
not at all completely
11) Was there a particular time on each diet when compliance was more difficult? Why 
do you think that was?
12) On the gorging diet did you snack
Not at all 
Once a week
265
Three times a week 
At weekends 
Other (please specify)
13) On the nibbling diet did you stick to twelve meals a day
Everyday 
Five times a week 
Three times a week 
Not at all
Other (please specify)
14) On the nibbling diet do you think you ate more compared to your normal diet?
15) Do you think you ate more on the nibbling diet compared with the gorging diet?
16) On the gorging diet do you think you ate more compared to your normal diet?
17) How many hours exercise do you normally do in a week?
Of what nature is this exercise?
How does this compare to your activity level whilst on each diet?
18) How many units of alcohol did you consume in a week while on each diet? 
When during the week was this alcohol consumed?
Was this amount typical of one week?
19) Do you take any vitamin and mineral supplements?
20) Are you currently using oral contraceptives?
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APPENDIX III: MEAN DATA FOR ACTIVE AND INACTIVE GROUPS IN
EXERCISE STUDY - CHAPTER THREE.
Table 1. Mean (SD) triacylglycerol levels (mmol/1) measured in plasma in active and 
inactive subjects with 7 subjects in each group.
Time Lom Fat ____Medii im fat Higi1 fat
(min) Active Inactive Active Inactive Active Inactive
-10 0.87 0.20 0.88 0.14 0.85 0.19 0.89 0.18 0.82 0.29 0.87 0.22
0 0.80 0.17 0.82 0.14 0.79 0.22 0.85 0.20 0.75 0.25 0.94 0.42
30 0 .8 8  0.20 0.84 0.15 0.83 0.19 1.01 0.35 0.82 0.28 0.87 0.24
60 0.98 0.18 0.96 0.14 0.93 0.23 1.13 0.37 1.04 0.28 1.30 0.47
120 0.99 0.27 1.05 0.25 1.04 0.30 1.23 0.35 1.52 0.25 1.60 0.23
180 1.02 0.23 1.39 0.31 1.09 0.33 1.47 0.47 1.21 0.41 1.92 0.31
240 1.04 0.24 1.51 0.38 1.08 0.35 1.44 0.41 1.18 0.32 1.62 0.16
300 0.99 0.19 1.34 0.31 1 .0 2  0.22 1.35 0.34 1.09 0.25 1.28 0.24
360 0.94 0.19 1.04 0.20 0 .8 8  0.21 1.22 0.39 1 .0 0  0.20 1.36 0.36
420 0.84 0.12 0.92 0.12 0.83 0.11 1.24 0.38 0.91 0.09 1.22 0.31
480 0.80 0.14 0.99 0.42 0.87 0.36 1.07 0.39 0.93 0.23 1.24 0.40
Table 2. Mean {SD) 
in active and inactive
triacylglycerol levels (mmol/1) measured in CM-enriched fractions 
subjects with 7 subjects in each group.
Time
(min)
Low Fat Medium fat High fat
Active Inactive Active Inactive Active Inactive
-10 0.13 0.09 0.16 0.14 0.11 0.09 0.15 0.12 ' 0.16 0.15 0.20 0.19
0 0.14 0.11 0.15 0.13 0.12 0.09 0.16 0.12 0.11 0.07 0.16 0.10
30 0 .2 1  0.16 0 .2 2  0.10 0.25 0.15 0.38 0.34 0.18 0.11 0.30 0.16
60 0.26 0.12 0.31 0.12 0.33 0.11 0.41 0.28 0.43 0.18 0.45 0.22
120 0.24 0.08 0.38 0.22 0.38 0.19 0.62 0.32 0.82 0.18 0.87 0.19
180 0.32 0.10 0.68 0.24 0.43 0.25 0.71 0.38 0.65 0.33 1.03 0.26
240 0.28 0.07 0.76 0.31 0.46 0.24 0.70 0.30 0.53 0.31 0.97 0.23
300 0.26 0.06 0.60 0.38 0.37 0.21 0.62 0.36 0.54 0.38 0.64 0.19
360 0.22 0.07 0.32 0.15 0.28 0.10 0.63 0.48 0.41 0.09 0.55 0.41
420 0.19 0.08 0.27 0.12 0.26 0.09 0.63 0.35 0.40 0.14 0.61 0.32
480  ^ 0.15 0.08 0.19 0.06 0.29 0.31 0.47 0.40 0.36 0.18 0.60 0.36
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Table 3 Mean {SD) levels of apolipoprotein B-48 (% of standard) in the CM-enriched
fraction in active and inactive subiects, 7 subjects in each groun
Time
(min)
Low Fat Medium fat High fat
Active Inactive Active Inactive Active Inactive
-10 0.3 0.3 1.8 4.6 0 ,8  0.8 3.6 6.3 0.6 1.5 3.0 6.7
0 0.3 0.5 0.5 0.7 1.4 2.8 2.3 5.3 0.4 0.6 1 .1  1.2
30 3.0 3.0 0.7 0.9 4.3 2.9 16.6 25.9 4.8 6.4 24.2 49.0
60 9.2 12.0 4.5 6.6 19.1 11.5 25.1 40.4 35.8 22.3 54.4 68.0
120 16,6 14.4 13.5 16.7 16.7 12.3 24.0 24.9 28.6 26.0 77.2 69.5
180 31.8 36.3 38.7 39.5 19.5 19.7 69.4 62.3 21.9 24.6 76.3 74.7
240 34.1 52.3 72.1 47.0 40.4 25.6 55.2 48.4 13.4 17.6 68.2 65.4
300 13.8 14.8 43.5 49.3 19.3 17.0 38.4 52.2 19.1 27.3 30.3 28.3
360 16.3 23.9 17.8 35.1 7.5 11.1 47.9 78.6 5.8 4.8 23.9 32.0
420 3.3 3.8 4.2 4.6 5.6 7.1 41.9 79.2 7.0 6.3 41.0 45.2
480 4.9 6.7 3.3 6.2 14.1 22.9 22.5 28.4 13.4 21.1 27.7 36.6
Table 4. Mean {SD) levels of retinyl palmitate (|JLg/ral) measured in the CM-enriched
fraction in the active and inactive g^roups with 7 subjects in eac  ^group.
Time _______ Low Fat _____ Medium fat High fat
(min) Active Inactive Active Inactive Active Inactive
-10 0 0 0 0 0 0
0 0 0 0 0 0 0
30 0 0 0 0 0 0
60 0 0.03 0.07 0.03 0.08 0 0.11 0.07 0
120 0.13 0.09 0.46 0.36 0.43 0.16 0.53 0.17 0.75 0.19 0.71 0.18
180 0.19 0.11 1.36 1.18 0.55 0.21 1.70 0.52 1.17 0.35 2.40 1.15
240 0.33 0.17 1.38 1.32 0.81 0.22 1.78 0.93 1.40 0.32 2.78 1.25
300 0.56 0.22 1.27 1.03 0.70 0.22 1.72 0.40 1.47 0.52 2 .6 6  1.26
360 0.81 0.24 1.71 0.65 1.17 0.36 2.04 0.55 0.83 0.28 2.81 0.79
420 0.20 0.09 0.72 1.07 0.71 0.15 1.89 0.54 0.70 0.24 2.27 0.53
480 0.32 0.08 0.68 0.43 0.68 0.24 1.23 0.66 0.97 0.33 1.01 0.45
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Table 5 Mean {SD) levels of non
active and inactive subjects with 7
-esterified fatty acids (mmol/1) measured in plasma in 
subjects in each group.
Time Low Fat Medium fat High fat
(min) Active Inactive Active Inactive Active Inactive
-10 0.62 0.37 0.65 0.34 0.53 0.53 0.67 0.28 0.56 0.29 0.64 0.22
0 0.61 0.42 0.55 0.16 0.58 0.44 0.64 0.27 0.51 0.09 0.55 0.28
30 0.36 0.24 0.31 0.17 0.40 0.42 0.42 0.32 0.24 0.12 0.40 0.12
60 0.22 0.15 0.19 0.10 0.23 0.17 0.33 0.20 0.23 0.17 0.31 0.09
120 0.15 0.09 0.13 0.09 0.19 0.13 0.22 0.14 0.34 0.21 0.37 0.13
180 0.13 0.08 0.22 0.17 0.16 0.12 0.24 0.17 0.26 0.21 0.49 0.20
240 0.13 0.09 0.26 0.16 0.17 0.11 0.33 0.23 0.37 0.28 0.43 0.30
300 0 .2 1  0.11 0.23 0.16 0 .2 2  0.12 0.23 0.09 0.31 0.17 0.38 0.29
360 0.40 0.22 0.34 0.24 0.32 0.21 0.34 0.13 0.41 0.14 0.37 0.29
420 0.74 0.28 0.48 0.38 0.69 0.47 0.47 0.26 0.54 0.27 0.40 0.20
480 0.67 0.42 0.72 0.34 0.68 0.46 0.67 0.33 0.58 0.26 0.46 0.18
Table 6. Mean {SD) levels of insulin (U/ml) measured in the plasma of inactive and 
active subjects with 5 subjects in each group
Time Low Fat Medium fat High fat
(min) Active Inactive Active Inactive Active Inactive
-10 10.9 4.1 12.3 3.7 1 1 .1  2.6 15.4 6.4 9.8 3.0 9.4 4.2
0 9.2 3.2 15.8 4.5 9.8 4.9 14.4 5.5 9.9 1.8 9.3 3.8
30 118.8 74.2 112.4 92.5 120.3 35.5 160.9 53.5 107.8 72.1 45.5 74.7
60 98.1 71.4 166.9 122.6 147.1 36.3 138.3 50.5 113.6 86.6 91.7 77.0
120 99.2 47.9 87.9 59.3 107.2 26.2 115.1 70.7 70.0 27.3 107.5 27.8
180 46.2 16.5 87.2 57.2 89.2 20.8 84.4 55.6 87.2 63.7 84.3 40.1
240 28.0 15.3 51.4 31.1 69.1 29.5 12.2 52.9 37.8 24.7 87.5 56.3
300 1 0 .2  7 .2 25.6 15.1 16.7 7.4 45.2 44.9 22.5 22.5 36.0 16.4
360 6.9 5.0 16.3 6.5 10.0 3.5 38.5 38.2 9.5 6.9 24.8 7.3
420 10.4 4.6 13.4 4.8 12.3 4.6 14.6 5.88 7.4 4.1 17.2 4.7
480 8.1 4.0 14.2 3.7 19.8 14.1 13.7 7.2 10.1 5.5 18.8 12.3
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Table 7 Mean (SD) levels of GIP (pmol/1) in the plasma in inactive and active subjects
with 5 subjects in each group.
Time
(min)
Low Fat Medium fat High fat 1
Active Inactive Active Inactive Active Inactive |
-10 108.9 103.6 95.6 17.5 81.8 55.7 116.5 59.5 115.6 56.0 126.9 63.4 1
0 107.1 93.7 85.0 12.2 82,9 55.4 78.3 36.0 93.9 74.4 96.5 26.7
30 240.6 200.9 181.4 60.8 219.3 93.3 197.9 38.7 315.2 178.4 317.8 360.4\
60 310.4 292.4 270.9 61.6 323.2 75.0 343.6 85.5 483.3 131.8 423.4 2 79.2
120 440.4 299.0 400.9 61.7 403.5 129.0 397.9 66.8 457.5 104.2 336.9 505.2
180 433.1 300.4 432.6 87.5 400.4 82.4 335.1 52.4 407.5 90.3 558.2 188.7\
240 338.4 153.5 334.5 50.1 : 37401 72.9 302.1 26.7 343.1 57.2 455.6 720.71
300 236.9 148.5 201.8 14.9 296.7 70.6 271.5 70.4 272.6 89.5 338.1 76.8
360 188.8 155.1 223.4 78.0 182.0 13.6 203.7 49.6 251.2 86.2 312.1 88.3
420 89.7 47.6 156.9 89.6 141.1 46.5 170.9 37.9 172.5 39.7 255.5 73.6 |
480 88.7 57.7 177.6 67.8 129.6 66.4 122.7 35.0 172.6 66.0 175.7 82.5 1
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APPENDIX IV: MEAN DATA FOR MEAL FREQUENCY STUDY-CHAPTER 5.
Table 8 Mean (SD) levels of triacylglycerol (mmol/1) measured in plasma in 11 healthy 
female subjects
Time (min) Normal diet Nibbling^diet Gorging diet-10 1.12 0.37 1.11 0.40 1.12 0.290 1.03 0.37 1.09 0.35 1.06 0.2130 1.07 0.34 1.28 0.44 1.14 0.2560 1.36 0.42 1.51 0.61 1.47 0.38120 1.86 0.73 2.11 0.92 2.17 0.82180 2.12 0.96 2.30 1.41 2.52 1.11240 2.09 1.12 2.32 0.96 2.39 0.95300 1.80 0.70 1.98 0.69 1.90 0.64360 1.33 0.53 1.36 0.35 1.39 0.40420 1.08 0.37 0.97 0.18 1.12 0.39480 0.87 0.22 0.85 0.18 1.00 0.38
Table 9 Mean (SD) levels of triacylglycerol (mmol/1) measured in the CM-enriched 
fraction in 11  healthy female subjects
Time (min) Normal diet Nibbling diet Gorging diet-10 0.22 0.09 0.25 0.10 0.23 0.120 0.25 0.13 0.25 0.13 0.27 0.19-30 0.35 0.17 0.33 0.23 0.30 0.1860 0.62 0.34 0.62 0.47 0.57 0.30120 1.09 0.46 1 .1 2  0.76 1.24 0.83180 1.33 0.92 1.41 1.41 1.25 0.66240 1.04 0.79 1.38 0.86 1.44 0.90300 0.87 0.59 0.99 0.54 0.92 0.62360 0.59 0.42 0.53 0.28 0.65 0.35420 0.41 0.31 0.32 0.15 0.34 0.20480 0.24 0.15 0.20 0.13 0.28 0.27
Table 10 Mean (SD) levels of triacylglycerol (mmol/1) measured in the infranatant 
fraction in 11  healthy female subjects
Time (min) Normal diet Nibbling diet Gorging diet-10 0.91 0.21 1.00 0.30 0.99 0.300 0.77 0.20 0.91 0.22 0.84 0.2330 0.79 0.17 0.98 0.29 0.87 0.2460 0.81 0.21 1.05 0.36 0.98 0.29120 0.77 0.22 1.17 0.40 1.03 0.28180 0.95 0.26 1.24 0.38 1.11 0.45240 1.03 0.11 1.08 0.27 1.05 0.35300 0.93 0.39 1.14 0.32 0.96 0.33360 0.86 0.19 0.94 0.21 0.81 0.31420 0.70 0.16 0.74 0.16 0.81 0.21480 0.71 0.16 0.67 0.14 0.74 0.18
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Table 11 Mean (SD) levels of apolipoprotein B-48 (M-g/ml) measured in the plasma in 11
healthy female subjects
Time (min) Normal diet Nibbling diet Gorging diet-10 3.46 0.72 3.33 0.64 3.45 0.650 3.29 0.84 3.73 0.58 3.52 0.7830 4.87 1.81 3.85 1.09 4.04 0.8960 4.88 1.90 4.66 1.13 4.54 0.96120 4.83 1.59 5.17 1.76 5.91 1.98180 5.18 2.01 5.36 2.06 5.90 1.27240 4.97 1.58 5.76 2.40 5.82 1.76300 4.5 1.29 5.95 1.78 5.52 1.86360 4.59 1.10 4.59 1.21 4.40 0.68420 3.68 0.62 3.82 0.55 4.23 0.77480 3.40 0.76 3.53 0.77 4.33 0.93
Table 12 Mean (SD) levels of apolipoprotein B-48 (|ig/ml) measured in the CM-
Time (min) Normal diet Nibbling diet Gorging diet-10 0.27 0.11 0.31 0.14 0.33 0.170 0.31 0.18 0.26 0.15 0.30 0.1430 0.46 0.24 0.30 0.11 0.32 0.1660 0.59 0.24 0.39 0.11 0.41 0.15120 0.80 0.41 0.52 0.25 0.68 0.63180 0.72 0.41 0.57 0.27 0.64 0.21240 0.69 0.47 0.95 0.70 1.01 0.56300 0.80 0.47 0.94 0.83 0.80 0.54360 0.62 0.27 0.55 0.13 0.68 0.36420 0.53 0.34 0.44 0.10 0.38 0.15480 0.51 0.30 0.59 0.58 0.37 0.17
Table 13 Mean (SD) levels of apolipoprotein B-48 (p.g/ml) measured in the infranatant
in 11 healthy female subjects
Time (min) Normal diet Nibbling diet Gorging diet-10 3.47 0.72 3.92 0.75 3.42 0.930 3,16 1.33 3.73 1.40 3.11 1.2530 4.96 1.24 4.82 1.04 4.42 1.1160 4.66 1.32 4.66 0.91 4.11 1.62120 4.67 1.32 5.18 1.47 4.73 1.00180 4.57 1.37 5.21 1.58 5.49 1.40240 4.13 1.72 4.78 1.57 3.99 0.95300 4.73 1.92 5.34 1.35 4.45 1.41360 5.18 1.31 5.12 1.28 4.51 1.03420 4.63 1.08 4.37 0.92 4.46 1.03480 4.40 0.79 4.40 0.95 4.04 1.23
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Table 14 Mean (SD) levels of retinyl ester (|ig/ml) measured in plasma in 11 healthy
female subjects
Time (min) Normal diet Nibbling diet Gorging diet-10 0 0 00 0 0 030 0.07 0.06 0.09 0.07 0.09 0.1460 0.10 0.05 0.13 0.10 0.14 0.07120 0.17 0.12 0.21 0.13 0.28 0.21180 0.57 0.73 0.41 0.32 0.74 0.79240 1.03 1.01 0.96 0.85 1.77 1.92300 1.90 1.99 2.05 2.35 2.70 3.55360 2.17 1.47 3.12 2.61 3.29 3.80420 2.15 0.90 2.89 1.35 2.41 1.50480 1.68 0.67 2.15 0.76 2.14 0.90
Table 15 Mean (SD) levels of retinyl ester (jig/ml) measured in the CM-enriched 
fraction in 11 healthy female subjects
Time (min) Normal diet Nibbling diet Gorging diet-10 0 0 00 0 0 030 0.03 0.03 0 .0 1  0.02 0 .0 2  0.0260 0.07 0.05 0.06 0.06 0.06 0.03120 0.22 0.17 0.18 0.18 0.35 0.38180 0.66 0.73 0.50 0.57 1.30 1.49240 1.49 1.83 1.45 1.92 2 .0 1  2.02300 2.61 2.77 2.23 2.95 3.22 4.44360 2.98 2.91 3.11 4.68 3.57 4.68420 2.87 1.68 2.24 2.09 2.32 2.35480 1.55 1.18 1.22 1.29 1.29 0.88
Table 16 Mean (SD) levels of retinyl ester (p.g/ml) measured in the infranatant fraction
in 11  healthy female subjects
Time (min) Normal diet Nibbling diet Gorging diet-10 0 0 00 0 0 030 0.06 0.03 0.08 0.04 0.06 0.0360 0.07 0.04 0.09 0.05 0.09 0.04120 0.06 0.03 0.10 0.05 0 .1 1  0.02180 0.10 0.04 0.13 0.05 0.19 0.13240 0.15 0.09 0.16 0.08 0.20 0.14300 0.37 0.44 0.31 0.21 0.28 0.19360 0.36 0.28 0.57 0.44 0.50 0.52420 0.37 0.24 0.47 0.30 0.72 0.40480 0.51 0.25 0.48 0.20 0.58 0.25
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Table 17 Mean (SD) levels of non-esterified fatty acids (mmol/1) measured in plasma in 
11 healthy female subjects
Time (min) Normal diet Nibbling diet Gorging diet
- 1 0 0.83 0.34 0.47 0.15 0.56 0.27
0 0.70 0.21 0.47 0.25 0.48 0.1730 0.45 0.18 0.39 0.16 0.43 0.1860 0.32 0.14 0 .2 2  0.06 0 .2 2  0.07
1 2 0 0.44 0.19 0.29 0.14 0.37 0.18180 0.56 0.18 0.43 0.15 0.45 0.21240 0.59 0.21 0.61 0.19 0.60 0.19300 0.79 0.25 0.79 0.28 0.71 0.25360 0.89 0.24 0.82 0.26 0 .6 6  0.26420 0.85 0.26 0 .6 8  0.18 0.66 0.23480 0.73 0.20 0.75 0.26 0.65 0.23
Table 18 Mean (SD) levels of insulin (pmol/1) measured in plasma in 11 healthy female 
subjects
Time (min) Normal diet Nibbling diet Gorging diet
- 1 0 47.1 18.9 52.3 13.5 49.0 8.9
0 54.7 20.2 61.9 34.7 53.7 11.230 324.6 142.4 338.9 214.1 257.6 163.760 306.7 156.4 303.9 195.0 360.4 223.8
1 2 0 355.9 257.4 315.3 145.6 287.4 201.3180 315.7 199.0 274.8 145.4 335.8 159.4240 192.9 85.5 233.7 127.7 185.2 18.7300 124.0 68.8 127.2 50.9 120.6 61.7360 64.2 23.0 80.8 50.3 130.9 161420 55.3 22.9 80.0 101.1 68.9 40.9480 43.4 16.5 47.2 30.7 47.6 20.5
Table 19 Mean (SD) levels of paracetamol (mmol/1) measured in plasma in 10 healthy 
female subjects
Time (min) Normal diet Nibbling diet Gorging diet
- 1 0 0 0 0
0 0 0 030 0.07 0.03 0.08 0.03 0.08 0.0260 0.10 0.03 0.10 0.03 0.09 0.03
1 2 0 0 .1 2  0.02 0.13 0.02 0.12 0.03
180 0 .1 2  0.02 0 .1 2  0.02 0.12 0.03
240 0.10 0.03 0 .1 0  0.02 0.11 0.03300 0.08 0.02 0.08 0.03 0.08 0.02360 0.06 0.02 0.06 0.01 0.06 0.01420 0.04 0.01 0.05 0.01 0.05 0.01480 0.04 0.01 0.04 0.01 0.05 0.04
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